data_2kyb_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2kyb _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 61.2 tttp . . . . . 0 CA--C 1.531 0.238 0 CA-C-O 121.141 0.496 . . . . 1.0 110.131 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 65.8 p -96.03 162.69 13.44 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.953 0.883 . . . . 1.0 109.759 179.738 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -101.6 155.89 18.89 Favored Glycine 0 N--CA 1.47 0.961 0 N-CA-C 110.454 -1.058 . . . . 1.0 110.454 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 69.0 mt -111.55 128.09 68.29 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.088 0 CA-C-O 121.502 0.668 . . . . 1.0 109.559 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 24.4 t -68.48 132.05 33.13 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 CA-C-N 115.571 -0.741 . . . . 1.0 109.883 179.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 10.5 p-10 -55.77 109.18 0.53 Allowed 'General case' 0 CA--C 1.54 0.572 0 CA-C-N 116.112 -0.494 . . . . 1.0 110.411 179.659 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 15.1 t -66.4 72.28 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-N 116.155 -0.475 . . . . 1.0 110.207 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 30.4 t -85.39 -104.59 0.06 Allowed 'General case' 0 CA--C 1.54 0.564 0 CA-C-N 115.92 -0.582 . . . . 1.0 109.916 179.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 97.0 p -157.29 -28.02 0.09 Allowed 'General case' 0 N--CA 1.478 0.967 0 CA-C-O 121.471 0.653 . . . . 1.0 111.11 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 44.4 t -153.87 145.31 23.13 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 115.539 -0.755 . . . . 1.0 110.703 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -155.16 121.55 5.28 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 120.773 -0.371 . . . . 1.0 110.536 178.319 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 74.7 m-20 -89.23 134.09 34.18 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 121.856 0.836 . . . . 1.0 109.809 179.453 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 33.9 t -103.84 128.36 57.18 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 CA-C-N 115.154 -0.93 . . . . 1.0 109.559 179.71 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 83.1 mtt-85 -97.43 179.75 4.76 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-O 121.56 0.695 . . . . 1.0 110.046 179.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.4 p -104.86 -7.15 19.58 Favored 'General case' 0 N--CA 1.484 1.238 0 CA-C-N 115.373 -0.83 . . . . 1.0 110.36 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.483 ' C ' ' H ' ' A' ' 19' ' ' SER . 42.0 t -170.7 178.22 3.64 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-O 121.264 0.554 . . . . 1.0 110.745 -179.772 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -72.97 40.4 0.09 Allowed 'General case' 0 N--CA 1.475 0.793 0 CA-C-N 115.82 -0.627 . . . . 1.0 110.664 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.483 ' H ' ' C ' ' A' ' 17' ' ' SER . 78.8 p -137.49 136.82 38.06 Favored 'General case' 0 N--CA 1.48 1.033 0 CA-C-O 121.52 0.676 . . . . 1.0 110.403 179.871 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 80.4 p -73.71 -27.98 61.48 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-N 115.427 -0.806 . . . . 1.0 110.21 179.784 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 97.2 p -65.34 -21.32 66.68 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 116.335 -0.393 . . . . 1.0 110.242 -179.541 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 37.6 m -55.49 -29.36 58.66 Favored 'General case' 0 N--CA 1.472 0.639 0 CA-C-O 120.988 0.423 . . . . 1.0 110.284 179.138 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 25.5 tttm 71.14 -177.2 0.2 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.933 -0.576 . . . . 1.0 110.018 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 13.2 t -79.57 161.06 4.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 122.063 0.935 . . . . 1.0 109.512 179.335 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 35.0 pt -148.82 -22.43 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 CA-C-N 114.858 -1.065 . . . . 1.0 110.414 -179.766 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -173.52 164.62 36.33 Favored Glycine 0 CA--C 1.52 0.376 0 N-CA-C 110.673 -0.971 . . . . 1.0 110.673 -179.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 98.1 p -118.62 133.11 56.1 Favored 'General case' 0 N--CA 1.48 1.053 0 CA-C-O 121.91 0.862 . . . . 1.0 110.06 179.562 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.2 tp -101.6 155.48 18.07 Favored 'General case' 0 N--CA 1.473 0.725 0 CA-C-N 115.113 -0.948 . . . . 1.0 109.649 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 57.6 m -93.2 143.06 26.62 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.144 -0.934 . . . . 1.0 109.919 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -74.83 155.65 48.37 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.149 -1.18 . . . . 1.0 110.149 179.442 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 69.67 16.84 7.91 Favored 'General case' 0 N--CA 1.475 0.784 0 CA-C-O 120.792 0.329 . . . . 1.0 110.381 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 83.3 m -88.06 141.95 28.17 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-O 121.279 0.562 . . . . 1.0 109.957 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 37.9 ttpt -83.15 134.6 34.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.712 0.768 . . . . 1.0 110.029 179.555 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 5.2 m -140.96 123.42 15.24 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.575 0 CA-C-N 115.316 -0.856 . . . . 1.0 110.136 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.43 ' O ' ' C ' ' A' ' 36' ' ' ILE . 31.2 m -84.31 87.62 7.21 Favored 'General case' 0 N--CA 1.467 0.384 0 N-CA-C 109.661 -0.496 . . . . 1.0 109.661 179.117 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.473 ' H ' ' CD1' ' A' ' 36' ' ' ILE . 1.7 mp -34.49 145.66 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 CA-C-N 116.067 -0.515 . . . . 1.0 110.541 179.196 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -154.3 67.54 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 CA-C-N 115.974 -0.557 . . . . 1.0 109.829 -178.563 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.05 167.89 34.61 Favored Glycine 0 CA--C 1.503 -0.69 0 N-CA-C 110.567 -1.013 . . . . 1.0 110.567 178.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.3 pp20? -153.73 156.61 38.1 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.216 -0.492 . . . . 1.0 110.669 -178.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -153.61 127.61 8.96 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 116.022 -0.536 . . . . 1.0 110.505 179.229 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.426 ' C ' ' H ' ' A' ' 43' ' ' PHE . . . 59.54 -152.87 33.7 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.358 -0.697 . . . . 1.0 111.358 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -77.47 38.87 0.25 Allowed 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 109.855 -0.424 . . . . 1.0 109.855 179.443 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.426 ' H ' ' C ' ' A' ' 41' ' ' GLY . 50.6 m-85 -151.37 159.14 44.42 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-O 121.804 0.812 . . . . 1.0 110.477 -179.769 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 1.3 m-85 -118.86 157.3 27.9 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 122.199 0.999 . . . . 1.0 110.238 179.668 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 84.4 tttt -99.81 144.33 29.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 114.854 -1.067 . . . . 1.0 109.854 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 28.8 pt -149.37 172.24 1.66 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.241 -0.891 . . . . 1.0 109.952 -179.576 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 77.4 tt0 -139.86 105.13 5.04 Favored 'General case' 0 N--CA 1.472 0.673 0 CA-C-N 115.143 -0.935 . . . . 1.0 110.333 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 27.1 t80 -139.7 163.71 31.87 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 115.592 -0.731 . . . . 1.0 110.187 179.269 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . 0.427 ' C ' ' H ' ' A' ' 51' ' ' SER . 18.5 mmtm 51.77 24.87 2.64 Favored 'General case' 0 CA--C 1.544 0.741 0 CA-C-N 115.57 -0.741 . . . . 1.0 111.06 179.623 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 74.0 -8.89 10.3 Favored Glycine 0 CA--C 1.528 0.883 0 N-CA-C 110.147 -1.181 . . . . 1.0 110.147 -179.623 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' SER . . . . . 0.427 ' H ' ' C ' ' A' ' 49' ' ' LYS . 50.5 m -108.82 174.02 6.06 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-O 122.07 0.938 . . . . 1.0 110.074 179.783 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 32.7 p80 -131.01 135.12 47.32 Favored 'General case' 0 N--CA 1.48 1.044 0 CA-C-N 114.971 -1.013 . . . . 1.0 110.331 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.03 154.55 25.98 Favored Glycine 0 N--CA 1.47 0.944 0 N-CA-C 110.652 -0.979 . . . . 1.0 110.652 179.537 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 55.6 m-85 -90.76 145.09 25.08 Favored 'General case' 0 N--CA 1.472 0.651 0 CA-C-O 121.485 0.66 . . . . 1.0 109.731 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 17.1 t -141.85 145.78 23.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 CA-C-N 115.582 -0.736 . . . . 1.0 110.365 -179.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.91 138.38 58.53 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.573 -0.74 . . . . 1.0 109.967 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 12.5 pttp -89.86 -25.13 21.18 Favored 'General case' 0 N--CA 1.475 0.809 0 CA-C-N 115.541 -0.754 . . . . 1.0 110.183 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 44.7 tp10 -65.95 -37.72 86.75 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.465 0.65 . . . . 1.0 110.509 -178.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 23.0 m-85 -68.89 -31.88 71.13 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 115.527 -0.76 . . . . 1.0 110.092 179.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 72.8 mt . . . . . 0 N--CA 1.467 0.42 0 CA-C-O 118.138 -0.934 . . . . 1.0 109.193 -179.486 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 97.2 mttt . . . . . 0 N--CA 1.472 0.628 0 CA-C-O 121.512 0.672 . . . . 1.0 110.591 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 3.2 p -132.8 153.5 51.2 Favored 'General case' 0 N--CA 1.478 0.946 0 CA-C-N 115.469 -0.787 . . . . 1.0 110.166 -179.29 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -140.71 160.78 26.63 Favored Glycine 0 N--CA 1.468 0.797 0 N-CA-C 110.658 -0.977 . . . . 1.0 110.658 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 12.5 pt -106.01 135.96 42.25 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 CA-C-O 121.287 0.565 . . . . 1.0 109.737 179.542 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.485 ' O ' ' N ' ' A' ' 8' ' ' VAL . 37.7 t -53.72 111.69 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 CA-C-N 115.62 -0.718 . . . . 1.0 109.926 -179.751 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 4.7 m120 -56.31 83.42 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 115.724 -0.671 . . . . 1.0 110.593 179.601 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.485 ' N ' ' O ' ' A' ' 6' ' ' VAL . 3.2 t 47.71 -126.25 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.554 1.134 0 CA-C-N 115.579 -0.737 . . . . 1.0 110.199 -179.791 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' SER . . . . . 0.474 ' O ' ' O ' ' A' ' 8' ' ' VAL . 19.3 m 57.78 136.69 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 115.687 -0.688 . . . . 1.0 110.72 179.659 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 48.9 m -54.41 -65.73 0.52 Allowed 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 121.022 0.439 . . . . 1.0 110.652 -179.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 65.7 m -148.72 154.51 39.72 Favored 'General case' 0 N--CA 1.471 0.621 0 CA-C-O 121.798 0.809 . . . . 1.0 110.505 179.599 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -102.21 142.68 33.06 Favored 'General case' 0 N--CA 1.485 1.301 0 CA-C-N 115.233 -0.894 . . . . 1.0 109.977 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -85.18 99.53 11.14 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.072 -0.967 . . . . 1.0 109.477 -179.492 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 17.6 m -80.66 135.5 25.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 108.686 -0.857 . . . . 1.0 108.686 -179.458 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 67.2 mtm180 -117.85 -176.48 3.05 Favored 'General case' 0 N--CA 1.476 0.852 0 CA-C-N 115.13 -0.941 . . . . 1.0 110.234 -179.247 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 67.0 p -89.88 -20.61 23.19 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 115.333 -0.849 . . . . 1.0 110.519 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.653 ' C ' ' H ' ' A' ' 19' ' ' SER . 60.9 p -176.28 -173.17 0.53 Allowed 'General case' 0 N--CA 1.473 0.718 0 CA-C-O 121.681 0.753 . . . . 1.0 110.414 -179.649 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.81 17.24 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.375 0 CA-C-N 115.343 -0.844 . . . . 1.0 111.586 178.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' SER . . . . . 0.653 ' H ' ' C ' ' A' ' 17' ' ' SER . 70.0 m -100.87 97.83 8.39 Favored 'General case' 0 N--CA 1.48 1.038 0 CA-C-N 115.352 -0.84 . . . . 1.0 110.169 179.533 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.9 m -64.37 -4.29 3.72 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-N 115.685 -0.689 . . . . 1.0 110.15 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.4 ' H ' ' C ' ' A' ' 19' ' ' SER . 85.7 p -97.89 -3.53 38.39 Favored 'General case' 0 N--CA 1.473 0.699 0 CA-C-N 116.001 -0.545 . . . . 1.0 110.719 -179.826 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 78.1 p -77.36 -4.96 47.81 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 110.022 -0.362 . . . . 1.0 110.022 179.331 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 33.7 tttt 66.05 -163.27 0.24 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.094 0.473 . . . . 1.0 110.167 179.606 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 24.8 t -94.22 158.16 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 CA-C-O 122.193 0.997 . . . . 1.0 109.28 179.753 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 47.7 pt -137.67 -20.58 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.005 0 CA-C-N 114.852 -1.067 . . . . 1.0 110.496 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . 0.425 ' CA ' ' HZ3' ' A' ' 49' ' ' LYS . . . -158.44 -153.89 6.95 Favored Glycine 0 N--CA 1.466 0.64 0 N-CA-C 110.689 -0.964 . . . . 1.0 110.689 -179.441 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' SER . . . . . 0.733 ' H ' ' HZ1' ' A' ' 49' ' ' LYS . 93.2 p -159.17 148.65 18.69 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 121.322 0.582 . . . . 1.0 110.372 179.644 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.6 tp -122.3 154.43 37.6 Favored 'General case' 0 N--CA 1.481 1.106 0 CA-C-O 121.624 0.726 . . . . 1.0 110.311 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 90.9 p -103.33 159.92 15.14 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 115.39 -0.823 . . . . 1.0 110.25 179.749 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -79.65 168.11 52.31 Favored Glycine 0 N--CA 1.476 1.352 0 N-CA-C 110.537 -1.025 . . . . 1.0 110.537 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 66.2 m-20 56.32 20.87 4.94 Favored 'General case' 0 N--CA 1.477 0.877 0 CA-C-O 120.929 0.395 . . . . 1.0 110.759 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 29.6 m -89.94 150.42 22.17 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-O 121.401 0.619 . . . . 1.0 109.828 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 50.9 tttp -103.25 150.6 23.57 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 115.548 -0.751 . . . . 1.0 110.275 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.4 p -157.36 145.56 10.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.687 -0.688 . . . . 1.0 109.858 179.553 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 90.4 m -106.09 106.33 16.79 Favored 'General case' 0 N--CA 1.481 1.095 0 N-CA-C 109.428 -0.582 . . . . 1.0 109.428 178.544 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.441 ' CG2' ' CD2' ' A' ' 44' ' ' TYR . 11.7 mm -42.35 134.86 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 CA-C-N 116.502 -0.317 . . . . 1.0 111.2 179.283 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 3.2 m -159.51 90.24 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.069 0 CA-C-O 121.986 0.898 . . . . 1.0 110.518 -178.052 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 109.63 115.06 3.7 Favored Glycine 0 N--CA 1.481 1.657 0 CA-C-N 115.114 -0.948 . . . . 1.0 110.824 179.178 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.464 ' CD ' ' H ' ' A' ' 39' ' ' GLU . 0.5 OUTLIER -105.13 132.62 51.12 Favored 'General case' 0 N--CA 1.48 1.033 0 N-CA-C 109.245 -0.65 . . . . 1.0 109.245 -178.817 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 79.8 tt0 -151.31 102.85 2.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.837 -0.62 . . . . 1.0 109.883 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.468 ' C ' ' H ' ' A' ' 43' ' ' PHE . . . 57.12 -149.21 31.39 Favored Glycine 0 CA--C 1.533 1.16 0 N-CA-C 111.226 -0.749 . . . . 1.0 111.226 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -74.56 17.56 0.2 Allowed 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 120.926 -0.31 . . . . 1.0 110.455 179.082 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.468 ' H ' ' C ' ' A' ' 41' ' ' GLY . 38.3 m-85 -133.56 158.13 43.95 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-O 121.853 0.835 . . . . 1.0 110.215 -179.53 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' TYR . . . . . 0.441 ' CD2' ' CG2' ' A' ' 36' ' ' ILE . 2.8 m-85 -127.04 165.22 19.88 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 122.621 1.2 . . . . 1.0 109.839 179.618 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 23.9 ttpp -107.96 129.58 55.1 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 114.465 -1.243 . . . . 1.0 110.004 -179.736 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 45.5 pt -122.18 170.05 12.81 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-O 122.302 1.048 . . . . 1.0 110.045 179.458 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -131.1 102.2 5.91 Favored 'General case' 0 N--CA 1.482 1.164 0 CA-C-N 114.702 -1.135 . . . . 1.0 109.778 -179.441 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -138.93 160.35 39.95 Favored 'General case' 0 N--CA 1.47 0.575 0 CA-C-O 121.432 0.634 . . . . 1.0 109.829 179.561 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . 0.733 ' HZ1' ' H ' ' A' ' 27' ' ' SER . 43.3 mtmt 50.35 26.65 2.36 Favored 'General case' 0 CA--C 1.546 0.811 0 CA-C-N 115.595 -0.73 . . . . 1.0 111.369 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 67.07 6.74 40.19 Favored Glycine 0 N--CA 1.474 1.227 0 N-CA-C 110.465 -1.054 . . . . 1.0 110.465 -179.418 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 85.7 p -117.35 175.45 5.61 Favored 'General case' 0 N--CA 1.485 1.303 0 C-N-CA 124.228 1.011 . . . . 1.0 110.506 -179.631 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 27.3 p-80 -114.29 135.51 53.99 Favored 'General case' 0 N--CA 1.486 1.368 0 CA-C-N 115.18 -0.918 . . . . 1.0 110.331 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -140.08 166.08 25.8 Favored Glycine 0 N--CA 1.472 1.059 0 N-CA-C 110.988 -0.845 . . . . 1.0 110.988 179.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 58.2 m-85 -130.35 136.5 49.17 Favored 'General case' 0 N--CA 1.483 1.196 0 CA-C-O 121.904 0.859 . . . . 1.0 110.11 179.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 26.0 t -143.28 150.2 17.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 CA-C-N 115.145 -0.934 . . . . 1.0 110.175 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -67.64 127.49 32.97 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-N 115.481 -0.781 . . . . 1.0 109.812 179.424 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . 0.417 ' NZ ' ' O ' ' A' ' 41' ' ' GLY . 11.5 pttm -74.91 -20.81 59.54 Favored 'General case' 0 N--CA 1.476 0.853 0 CA-C-N 115.251 -0.886 . . . . 1.0 110.095 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 76.5 tt0 -65.41 -37.47 87.06 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 121.461 0.648 . . . . 1.0 110.399 -178.817 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 27.3 m-85 -74.08 -33.61 63.7 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 115.609 -0.723 . . . . 1.0 109.897 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 62.6 mt . . . . . 0 N--CA 1.471 0.613 0 CA-C-O 118.096 -0.954 . . . . 1.0 109.051 -179.033 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 55.1 mtpt . . . . . 0 N--CA 1.468 0.436 0 CA-C-O 121.382 0.61 . . . . 1.0 110.434 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 46.0 p -137.11 160.43 38.99 Favored 'General case' 0 N--CA 1.473 0.709 0 CA-C-O 121.719 0.771 . . . . 1.0 110.458 -179.681 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -138.01 155.51 23.33 Favored Glycine 0 N--CA 1.471 0.995 0 N-CA-C 110.659 -0.977 . . . . 1.0 110.659 -179.861 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 15.6 pt -98.24 137.26 26.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 CA-C-O 121.676 0.75 . . . . 1.0 109.209 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.571 ' O ' ' C ' ' A' ' 7' ' ' ASN . 22.0 t -83.01 142.98 12.83 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.46 0 CA-C-N 115.366 -0.834 . . . . 1.0 109.566 -179.827 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . 0.571 ' C ' ' O ' ' A' ' 6' ' ' VAL . 42.9 t30 8.72 -109.27 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.125 0 CA-C-N 116.243 -0.435 . . . . 1.0 111.859 -179.602 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 22.0 t -143.02 -52.25 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.292 0 CA-C-O 120.715 0.293 . . . . 1.0 110.434 177.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 40.7 t -170.14 77.75 0.09 Allowed 'General case' 0 N--CA 1.472 0.641 0 CA-C-O 120.855 0.359 . . . . 1.0 110.618 -179.544 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 49.3 m -160.52 168.46 25.01 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-N 116.052 -0.522 . . . . 1.0 110.679 -179.803 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 41.8 t -90.38 130.82 36.42 Favored 'General case' 0 N--CA 1.473 0.682 0 CA-C-O 121.304 0.573 . . . . 1.0 110.104 179.585 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 9.8 mp -100.94 164.35 11.86 Favored 'General case' 0 N--CA 1.479 1.002 0 CA-C-O 122.73 1.252 . . . . 1.0 109.41 179.409 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 84.9 m-20 -93.4 118.24 31.06 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-N 114.253 -1.339 . . . . 1.0 109.989 -179.614 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 20.6 t -101.9 107.58 21.94 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.308 0 N-CA-C 110.173 -0.306 . . . . 1.0 110.173 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 31.9 mtm180 -82.42 -173.14 4.41 Favored 'General case' 0 N--CA 1.478 0.971 0 CA-C-O 121.297 0.57 . . . . 1.0 110.345 179.441 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 17.6 t -95.17 -23.69 17.17 Favored 'General case' 0 N--CA 1.48 1.057 0 CA-C-N 115.675 -0.693 . . . . 1.0 111.085 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 28.7 t 175.86 38.85 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.645 0 CA-C-O 121.182 0.515 . . . . 1.0 111.214 -179.717 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . 76.07 45.39 0.12 Allowed 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 115.834 -0.621 . . . . 1.0 110.55 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 70.5 m -129.83 117.28 19.95 Favored 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 115.84 -0.618 . . . . 1.0 110.795 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 24.9 m -64.06 -29.12 70.28 Favored 'General case' 0 N--CA 1.475 0.794 0 CA-C-N 116.067 -0.515 . . . . 1.0 109.995 179.347 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 55.0 m -68.45 -22.38 64.58 Favored 'General case' 0 CA--C 1.537 0.442 0 CA-C-N 116.121 -0.49 . . . . 1.0 110.508 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 45.9 t -70.18 -39.07 75.48 Favored 'General case' 0 N--CA 1.475 0.8 0 CA-C-O 121.429 0.633 . . . . 1.0 110.528 179.128 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.451 ' HG2' ' H ' ' A' ' 24' ' ' VAL . 5.0 ttmm 80.43 -170.58 0.04 OUTLIER 'General case' 0 N--CA 1.485 1.305 0 CA-C-N 115.612 -0.722 . . . . 1.0 109.703 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.451 ' H ' ' HG2' ' A' ' 23' ' ' LYS . 24.9 t -83.76 105.51 13.35 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.494 0 CA-C-N 115.852 -0.613 . . . . 1.0 109.873 179.746 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 40.0 pt -94.12 -19.61 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 CA-C-N 115.789 -0.641 . . . . 1.0 110.489 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -145.22 -163.95 10.42 Favored Glycine 0 N--CA 1.478 1.492 0 N-CA-C 110.99 -0.844 . . . . 1.0 110.99 -179.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 45.4 t -160.87 130.24 4.84 Favored 'General case' 0 N--CA 1.47 0.549 0 C-N-CA 120.65 -0.42 . . . . 1.0 109.958 179.594 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.9 tp -109.52 153.32 24.27 Favored 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 121.342 0.591 . . . . 1.0 109.947 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 61.4 m -91.3 149.93 21.53 Favored 'General case' 0 N--CA 1.472 0.628 0 CA-C-N 115.696 -0.684 . . . . 1.0 110.037 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -74.7 148.68 38.79 Favored Glycine 0 CA--C 1.528 0.849 0 N-CA-C 110.481 -1.048 . . . . 1.0 110.481 179.612 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 12.1 t-20 64.82 41.06 5.18 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-O 121.024 0.44 . . . . 1.0 110.52 -179.763 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 34.7 m -106.96 127.43 53.44 Favored 'General case' 0 N--CA 1.489 1.484 0 CA-C-N 115.95 -0.568 . . . . 1.0 110.356 179.554 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -76.68 147.05 37.71 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-O 121.231 0.538 . . . . 1.0 109.822 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.3 p -157.28 148.08 10.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.706 -0.679 . . . . 1.0 110.35 -179.421 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 68.4 p -86.06 84.28 7.55 Favored 'General case' 0 N--CA 1.473 0.689 0 CA-C-N 116.111 -0.495 . . . . 1.0 110.031 179.228 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.427 ' CG2' ' H ' ' A' ' 37' ' ' VAL . 69.4 mt -50.53 171.57 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 CA-C-N 116.37 -0.377 . . . . 1.0 110.216 -179.862 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.427 ' H ' ' CG2' ' A' ' 36' ' ' ILE . 39.1 t -139.29 -92.42 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.298 0 CA-C-N 116.547 -0.297 . . . . 1.0 110.668 -179.482 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -118.45 -172.58 15.6 Favored Glycine 0 N--CA 1.487 2.04 0 N-CA-C 111.052 -0.819 . . . . 1.0 111.052 -179.172 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -113.86 111.84 22.38 Favored 'General case' 0 N--CA 1.483 1.19 0 CA-C-O 123.331 1.539 . . . . 1.0 109.623 179.359 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.497 ' N ' ' O ' ' A' ' 43' ' ' PHE . 3.1 tm-20 -104.07 96.41 6.64 Favored 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 113.676 -1.602 . . . . 1.0 109.214 179.026 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.408 ' C ' ' O ' ' A' ' 40' ' ' GLU . . . 30.61 56.31 0.25 Allowed Glycine 0 N--CA 1.503 3.11 0 CA-C-N 114.806 -1.088 . . . . 1.0 113.141 179.64 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . 76.46 30.41 0.65 Allowed 'General case' 0 N--CA 1.489 1.494 0 CA-C-N 115.18 -0.51 . . . . 1.0 111.188 -178.438 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.497 ' O ' ' N ' ' A' ' 40' ' ' GLU . 75.1 m-85 -153.86 159.41 41.79 Favored 'General case' 0 N--CA 1.496 1.864 0 CA-C-N 116.194 -0.457 . . . . 1.0 111.005 179.774 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' TYR . . . . . 0.428 ' CD1' ' N ' ' A' ' 44' ' ' TYR . 15.2 p90 -143.89 165.98 26.21 Favored 'General case' 0 N--CA 1.488 1.435 0 CA-C-O 120.893 0.377 . . . . 1.0 110.407 179.398 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.568 ' NZ ' ' HH ' ' A' ' 54' ' ' TYR . 68.4 mttm -88.2 159.52 18.12 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 109.551 -0.537 . . . . 1.0 109.551 -179.433 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 38.4 pt -146.97 154.38 11.91 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 CA-C-N 115.902 -0.59 . . . . 1.0 110.308 -179.367 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 72.7 mt-10 -110.33 84.28 1.9 Allowed 'General case' 0 N--CA 1.479 1.009 0 CA-C-N 115.911 -0.586 . . . . 1.0 109.67 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 7.7 t80 -119.56 137.04 54.09 Favored 'General case' 0 N--CA 1.486 1.352 0 CA-C-N 116.036 -0.529 . . . . 1.0 110.149 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 96.2 mttt 47.49 27.47 0.97 Allowed 'General case' 0 N--CA 1.481 1.09 0 CA-C-N 115.907 -0.588 . . . . 1.0 111.149 -179.297 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 67.44 23.26 73.49 Favored Glycine 0 N--CA 1.472 1.039 0 N-CA-C 110.824 -0.91 . . . . 1.0 110.824 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 92.1 p -128.4 166.02 19.5 Favored 'General case' 0 N--CA 1.482 1.136 0 CA-C-O 121.722 0.772 . . . . 1.0 110.826 -178.787 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -94.31 153.66 17.89 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-N 115.344 -0.844 . . . . 1.0 110.382 -179.407 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -158.09 166.31 34.03 Favored Glycine 0 N--CA 1.473 1.118 0 N-CA-C 110.748 -0.941 . . . . 1.0 110.748 -179.821 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' TYR . . . . . 0.568 ' HH ' ' NZ ' ' A' ' 45' ' ' LYS . 69.5 m-85 -133.38 142.1 48.22 Favored 'General case' 0 N--CA 1.484 1.233 0 CA-C-N 115.552 -0.324 . . . . 1.0 110.417 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -147.78 147.29 17.4 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 CA-C-O 121.366 0.603 . . . . 1.0 109.816 -179.167 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -69.69 143.22 53.2 Favored 'General case' 0 CA--C 1.533 0.323 0 CA-C-N 115.642 -0.708 . . . . 1.0 110.017 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 9.6 mtmp? -87.31 -32.81 19.46 Favored 'General case' 0 N--CA 1.48 1.073 0 CA-C-N 116.006 -0.543 . . . . 1.0 110.218 179.645 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -52.58 -39.77 61.92 Favored 'General case' 0 N--CA 1.472 0.634 0 N-CA-C 110.227 -0.286 . . . . 1.0 110.227 -179.412 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 7.4 m-85 -48.4 -25.09 1.46 Allowed 'General case' 0 N--CA 1.48 1.069 0 CA-C-N 116.386 -0.37 . . . . 1.0 110.591 179.152 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 69.9 mt . . . . . 0 N--CA 1.476 0.861 0 CA-C-O 117.781 -1.104 . . . . 1.0 108.656 179.739 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 68.0 mttm . . . . . 0 N--CA 1.471 0.607 0 CA-C-O 121.812 0.815 . . . . 1.0 110.678 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 51.7 p -115.73 156.89 25.16 Favored 'General case' 0 N--CA 1.479 1.003 0 CA-C-N 115.132 -0.94 . . . . 1.0 110.228 -179.8 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -91.4 148.98 19.57 Favored Glycine 0 N--CA 1.468 0.777 0 N-CA-C 110.36 -1.096 . . . . 1.0 110.36 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 65.7 mt -104.33 126.75 59.02 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 CA-C-O 121.607 0.718 . . . . 1.0 109.131 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 28.8 t -91.47 129.49 42.1 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-N 115.402 -0.817 . . . . 1.0 109.692 179.532 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 62.5 m-80 -49.27 125.64 11.31 Favored 'General case' 0 CA--C 1.545 0.762 0 CA-C-N 116.085 -0.507 . . . . 1.0 110.54 179.315 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 32.6 t -51.28 -62.27 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 CA-C-N 115.905 -0.589 . . . . 1.0 110.473 -179.451 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.9 m -62.91 153.93 31.87 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.179 0.514 . . . . 1.0 109.988 179.611 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 69.54 -171.8 0.18 Allowed 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 115.856 -0.611 . . . . 1.0 110.157 -179.873 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 42.6 t -150.32 154.17 37.38 Favored 'General case' 0 N--CA 1.473 0.697 0 CA-C-O 121.548 0.69 . . . . 1.0 110.366 179.91 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -99.68 135.28 41.33 Favored 'General case' 0 N--CA 1.478 0.94 0 CA-C-O 122.062 0.934 . . . . 1.0 109.989 -179.42 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 20.3 p-10 -90.76 129.27 36.86 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.009 -0.996 . . . . 1.0 109.674 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 41.0 t -92.02 103.38 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 CA-C-N 115.664 -0.698 . . . . 1.0 109.336 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 90.8 mtt-85 -81.97 151.57 27.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.434 0.635 . . . . 1.0 109.893 179.244 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 39.8 t -71.99 -21.63 61.54 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 115.582 -0.735 . . . . 1.0 110.433 179.535 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 48.9 m -163.73 174.94 11.02 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-N 116.014 -0.539 . . . . 1.0 110.682 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -70.6 56.48 0.17 Allowed 'General case' 0 N--CA 1.474 0.744 0 CA-C-N 115.792 -0.64 . . . . 1.0 110.42 179.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 49.1 m -140.65 130.02 23.84 Favored 'General case' 0 N--CA 1.481 1.089 0 CA-C-O 121.532 0.682 . . . . 1.0 110.577 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 3.7 t -66.31 -31.66 72.59 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 115.476 -0.784 . . . . 1.0 110.425 179.755 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 95.7 p -73.85 -4.81 37.14 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 115.976 -0.557 . . . . 1.0 110.244 -179.787 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 43.1 t -58.9 -173.82 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 120.952 0.406 . . . . 1.0 110.41 179.493 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -127.58 161.52 28.63 Favored 'General case' 0 N--CA 1.478 0.974 0 CA-C-O 121.747 0.784 . . . . 1.0 110.286 -179.768 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.2 t -89.42 108.99 19.81 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-N 115.283 -0.871 . . . . 1.0 109.694 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 45.9 pt -85.72 -17.01 9.69 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 CA-C-N 115.597 -0.729 . . . . 1.0 110.187 179.728 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 175.32 174.73 42.17 Favored Glycine 0 N--CA 1.461 0.319 0 N-CA-C 110.942 -0.863 . . . . 1.0 110.942 -179.455 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 42.6 t -142.52 137.58 30.31 Favored 'General case' 0 N--CA 1.475 0.798 0 CA-C-O 121.775 0.798 . . . . 1.0 110.528 179.604 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -99.8 171.87 7.61 Favored 'General case' 0 N--CA 1.475 0.782 0 CA-C-N 115.303 -0.862 . . . . 1.0 109.206 -179.671 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 56.7 m -89.96 155.13 19.32 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 115.085 -0.961 . . . . 1.0 110.298 -179.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -74.97 150.76 41.47 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.117 -1.193 . . . . 1.0 110.117 179.397 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 22.9 t30 74.83 17.71 2.79 Favored 'General case' 0 N--CA 1.48 1.04 0 CA-C-O 120.798 0.332 . . . . 1.0 110.572 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 59.4 m -87.86 132.39 34.21 Favored 'General case' 0 N--CA 1.478 0.975 0 CA-C-O 121.236 0.541 . . . . 1.0 110.042 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 26.9 mtpp -82.61 144.62 30.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.638 0.732 . . . . 1.0 109.677 179.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 16.9 m -147.63 130.47 7.87 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.451 0 CA-C-N 115.319 -0.855 . . . . 1.0 109.863 -179.91 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' THR . . . . . 0.411 ' O ' ' C ' ' A' ' 36' ' ' ILE . 30.7 m -86.39 89.05 7.75 Favored 'General case' 0 CA--C 1.515 -0.388 0 N-CA-C 109.098 -0.704 . . . . 1.0 109.098 179.463 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.411 ' C ' ' O ' ' A' ' 35' ' ' THR . 3.5 mp -34.47 146.94 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.504 2.253 0 CA-C-N 116.372 -0.377 . . . . 1.0 111.579 179.345 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 4.7 t -143.45 62.55 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.084 0 CA-C-O 121.05 0.452 . . . . 1.0 110.333 -178.669 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 108.61 166.57 20.94 Favored Glycine 0 N--CA 1.465 0.624 0 N-CA-C 110.462 -1.055 . . . . 1.0 110.462 179.75 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 16.4 pt-20 -142.21 147.25 36.24 Favored 'General case' 0 N--CA 1.476 0.842 0 CA-C-N 114.824 -0.688 . . . . 1.0 110.15 -179.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -154.37 125.84 7.47 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 115.704 -0.68 . . . . 1.0 110.162 179.453 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 50.33 -112.46 1.55 Allowed Glycine 0 CA--C 1.535 1.312 0 N-CA-C 111.398 -0.681 . . . . 1.0 111.398 179.442 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -115.37 22.63 13.08 Favored 'General case' 0 N--CA 1.482 1.143 0 N-CA-C 109.911 -0.403 . . . . 1.0 109.911 179.151 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.407 ' C ' ' NZ ' ' A' ' 57' ' ' LYS . 54.5 m-85 -143.37 153.88 43.15 Favored 'General case' 0 N--CA 1.477 0.884 0 CA-C-O 122.012 0.91 . . . . 1.0 110.365 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' TYR . . . . . 0.43 ' N ' ' CD1' ' A' ' 44' ' ' TYR . 11.8 p90 -134.67 169.17 17.72 Favored 'General case' 0 N--CA 1.473 0.687 0 CA-C-O 122.146 0.974 . . . . 1.0 110.04 -179.481 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.462 ' NZ ' ' CD2' ' A' ' 52' ' ' HIS . 63.3 tttm -95.58 151.85 18.96 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 114.902 -1.045 . . . . 1.0 109.918 -179.328 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 18.1 pt -143.91 162.05 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 CA-C-O 122.156 0.979 . . . . 1.0 110.021 179.39 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -125.25 96.78 4.96 Favored 'General case' 0 N--CA 1.479 1.017 0 CA-C-N 114.818 -1.083 . . . . 1.0 110.108 179.276 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 39.2 t80 -135.73 152.79 51.5 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 115.718 -0.674 . . . . 1.0 109.968 179.287 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 63.5 mttt 56.69 10.86 0.78 Allowed 'General case' 0 N--CA 1.475 0.819 0 CA-C-N 115.812 -0.631 . . . . 1.0 110.84 179.629 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 81.35 0.03 88.44 Favored Glycine 0 N--CA 1.472 1.1 0 N-CA-C 110.264 -1.134 . . . . 1.0 110.264 -179.573 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 49.4 m -110.98 172.97 6.56 Favored 'General case' 0 N--CA 1.482 1.153 0 C-N-CA 123.902 0.881 . . . . 1.0 110.167 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' HIS . . . . . 0.462 ' CD2' ' NZ ' ' A' ' 45' ' ' LYS . 30.7 m170 -107.16 145.54 32.43 Favored 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 115.35 -0.841 . . . . 1.0 110.023 -179.747 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -152.06 170.92 31.42 Favored Glycine 0 N--CA 1.464 0.501 0 N-CA-C 110.9 -0.88 . . . . 1.0 110.9 -179.382 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 80.1 m-85 -132.38 146.23 51.81 Favored 'General case' 0 N--CA 1.482 1.13 0 CA-C-O 121.518 0.675 . . . . 1.0 110.258 179.219 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 36.4 t -143.64 147.59 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 CA-C-N 115.451 -0.795 . . . . 1.0 110.277 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -68.75 153.12 44.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.547 -0.751 . . . . 1.0 110.216 179.641 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . 0.407 ' NZ ' ' C ' ' A' ' 43' ' ' PHE . 65.4 mttp -89.99 -22.82 21.73 Favored 'General case' 0 N--CA 1.478 0.961 0 CA-C-N 115.709 -0.678 . . . . 1.0 110.586 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -52.38 -35.99 52.83 Favored 'General case' 0 CA--C 1.537 0.478 0 CA-C-O 121.068 0.461 . . . . 1.0 110.488 -179.146 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 24.4 m-85 -64.04 -30.18 71.27 Favored 'General case' 0 N--CA 1.475 0.823 0 CA-C-N 115.905 -0.589 . . . . 1.0 110.477 178.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 63.5 mt . . . . . 0 N--CA 1.47 0.542 0 CA-C-O 118.119 -0.943 . . . . 1.0 108.609 -179.577 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 25.9 ttpp . . . . . 0 N--CA 1.461 0.108 0 CA-C-O 121.369 0.604 . . . . 1.0 110.112 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 53.9 p -118.31 144.79 45.58 Favored 'General case' 0 N--CA 1.474 0.727 0 CA-C-O 121.695 0.76 . . . . 1.0 110.475 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -97.58 154.25 20.31 Favored Glycine 0 N--CA 1.476 1.322 0 N-CA-C 110.038 -1.225 . . . . 1.0 110.038 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 65.7 mt -106.07 125.26 61.66 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.086 0 CA-C-O 121.239 0.543 . . . . 1.0 109.555 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 45.0 t -74.55 133.48 31.45 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.324 0 CA-C-N 115.788 -0.642 . . . . 1.0 109.479 179.61 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 9.4 m120 -62.13 109.27 1.25 Allowed 'General case' 0 CA--C 1.537 0.444 0 CA-C-N 115.735 -0.666 . . . . 1.0 110.113 179.363 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.3 p -55.61 -19.33 5.91 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 CA-C-N 116.035 -0.529 . . . . 1.0 110.435 179.515 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' SER . . . . . 0.476 ' O ' ' OG ' ' A' ' 10' ' ' SER . 49.5 m -52.08 105.97 0.13 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.158 -0.473 . . . . 1.0 110.422 -179.373 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' SER . . . . . 0.476 ' OG ' ' O ' ' A' ' 9' ' ' SER . 80.9 p 60.42 -122.38 0.97 Allowed 'General case' 0 CA--C 1.548 0.882 0 CA-C-N 116.062 -0.517 . . . . 1.0 110.448 -180.0 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 47.7 t -151.98 156.57 40.29 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-O 121.379 0.609 . . . . 1.0 110.083 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -104.24 136.46 43.8 Favored 'General case' 0 N--CA 1.479 1.016 0 CA-C-O 121.817 0.818 . . . . 1.0 110.323 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 72.5 m-80 -92.31 133.97 35.35 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.199 -0.909 . . . . 1.0 109.269 -179.623 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 59.3 t -93.19 105.75 17.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-N 115.104 -0.953 . . . . 1.0 109.37 -179.658 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 88.9 mtt-85 -81.32 148.55 29.33 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.487 0.661 . . . . 1.0 109.922 179.305 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 87.6 p -73.14 -19.41 61.14 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 115.606 -0.724 . . . . 1.0 110.019 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 87.1 p -162.17 172.85 15.13 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-O 121.179 0.514 . . . . 1.0 110.798 -179.585 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -71.47 57.45 0.26 Allowed 'General case' 0 N--CA 1.474 0.767 0 CA-C-N 115.789 -0.641 . . . . 1.0 110.49 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 55.8 m -143.93 130.43 20.01 Favored 'General case' 0 N--CA 1.481 1.105 0 CA-C-N 115.71 -0.677 . . . . 1.0 110.492 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 57.8 p -65.72 -26.61 67.83 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 115.827 -0.624 . . . . 1.0 110.226 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 49.4 m -71.07 -8.02 50.49 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 116.063 -0.517 . . . . 1.0 110.256 179.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 61.2 m -67.0 132.08 47.17 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 121.388 0.614 . . . . 1.0 110.01 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -72.48 169.58 16.13 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.615 -0.72 . . . . 1.0 110.123 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.7 t -90.16 112.58 24.95 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 CA-C-O 121.807 0.813 . . . . 1.0 109.754 179.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 2.1 pp -85.18 -27.19 6.54 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 CA-C-N 115.146 -0.934 . . . . 1.0 109.761 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 173.15 -171.84 44.73 Favored Glycine 0 N--CA 1.465 0.583 0 N-CA-C 111.398 -0.681 . . . . 1.0 111.398 -179.423 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 95.4 p -151.92 145.23 24.73 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-O 121.895 0.855 . . . . 1.0 110.449 179.208 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -102.31 -179.11 3.89 Favored 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 115.166 -0.925 . . . . 1.0 109.28 -179.662 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 96.8 p -91.66 144.63 25.33 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 115.145 -0.934 . . . . 1.0 110.197 -179.646 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -75.13 157.96 50.5 Favored Glycine 0 N--CA 1.461 0.343 0 N-CA-C 110.212 -1.155 . . . . 1.0 110.212 179.566 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 8.7 t30 69.46 20.82 7.08 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-O 120.707 0.289 . . . . 1.0 110.485 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 85.7 m -88.99 137.16 32.57 Favored 'General case' 0 N--CA 1.478 0.962 0 CA-C-O 121.413 0.625 . . . . 1.0 110.433 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -86.93 144.51 26.92 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-O 122.069 0.938 . . . . 1.0 109.814 179.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 5.7 p -153.75 138.14 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.423 0 CA-C-N 114.898 -1.046 . . . . 1.0 109.806 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 60.9 p -82.46 84.32 7.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.784 -0.644 . . . . 1.0 109.62 178.694 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 88.6 mt -43.02 160.06 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 CA-C-N 115.657 -0.701 . . . . 1.0 110.243 179.428 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 43.3 t -123.34 -92.5 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 CA-C-N 115.882 -0.599 . . . . 1.0 109.698 -179.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -114.89 -159.15 12.27 Favored Glycine 0 N--CA 1.466 0.653 0 CA-C-O 122.318 0.954 . . . . 1.0 110.861 -179.278 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . 0.461 ' N ' ' NZ ' ' A' ' 45' ' ' LYS . 1.0 OUTLIER -143.66 147.93 35.04 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 114.707 -0.747 . . . . 1.0 110.61 -179.524 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -154.64 124.5 6.65 Favored 'General case' 0 N--CA 1.47 0.558 0 CA-C-N 115.929 -0.578 . . . . 1.0 110.345 179.319 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 53.3 -150.15 11.71 Favored Glycine 0 CA--C 1.532 1.149 0 N-CA-C 111.139 -0.784 . . . . 1.0 111.139 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -84.9 30.37 0.58 Allowed 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 110.151 -0.314 . . . . 1.0 110.151 179.431 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 -145.69 153.37 40.92 Favored 'General case' 0 N--CA 1.477 0.909 0 CA-C-O 121.784 0.802 . . . . 1.0 110.529 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 1.7 m-85 -109.68 148.87 30.59 Favored 'General case' 0 N--CA 1.48 1.032 0 CA-C-O 122.556 1.169 . . . . 1.0 110.099 179.468 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.461 ' NZ ' ' N ' ' A' ' 39' ' ' GLU . 35.4 mtmm -87.98 140.73 29.2 Favored 'General case' 0 CA--C 1.518 -0.281 0 CA-C-N 114.485 -1.234 . . . . 1.0 109.508 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 39.9 pt -149.86 173.41 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.358 0 CA-C-N 114.594 -1.185 . . . . 1.0 109.688 -179.128 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -146.61 108.14 4.29 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 115.74 -0.664 . . . . 1.0 110.225 178.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 54.6 t80 -139.08 162.35 35.15 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.739 -0.664 . . . . 1.0 110.054 179.76 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 19.2 tttp 59.18 16.49 4.91 Favored 'General case' 0 CA--C 1.546 0.818 0 CA-C-N 115.55 -0.75 . . . . 1.0 110.9 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 77.85 -2.1 65.64 Favored Glycine 0 N--CA 1.477 1.403 0 N-CA-C 110.171 -1.171 . . . . 1.0 110.171 -179.357 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 49.2 m -114.95 176.29 5.12 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 124.278 1.031 . . . . 1.0 110.486 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 25.9 p80 -105.36 141.01 37.62 Favored 'General case' 0 N--CA 1.482 1.15 0 CA-C-N 115.464 -0.789 . . . . 1.0 110.064 -179.447 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.68 165.8 27.92 Favored Glycine 0 N--CA 1.463 0.435 0 N-CA-C 110.525 -1.03 . . . . 1.0 110.525 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -130.37 145.43 51.8 Favored 'General case' 0 N--CA 1.483 1.217 0 CA-C-O 121.527 0.68 . . . . 1.0 110.001 179.538 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 41.3 t -145.92 149.75 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 CA-C-O 121.904 0.859 . . . . 1.0 109.427 -179.723 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.402 ' O ' ' CD1' ' A' ' 59' ' ' TYR . . . -60.71 153.44 24.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 114.986 -1.006 . . . . 1.0 110.164 178.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 15.8 pttp -102.89 -31.34 10.31 Favored 'General case' 0 N--CA 1.482 1.167 0 CA-C-N 115.442 -0.799 . . . . 1.0 111.763 178.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' GLU . . . . . 0.407 ' C ' ' H ' ' A' ' 60' ' ' ILE . 14.6 pt-20 -64.53 -31.82 73.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.444 0.64 . . . . 1.0 111.022 -179.176 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . 0.402 ' CD1' ' O ' ' A' ' 56' ' ' ALA . 0.6 OUTLIER -62.7 -4.12 1.88 Allowed 'General case' 0 CA--C 1.549 0.918 0 CA-C-N 115.476 -0.783 . . . . 1.0 110.138 -179.888 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . 0.407 ' H ' ' C ' ' A' ' 58' ' ' GLU . 85.1 mt . . . . . 0 N--CA 1.477 0.888 0 N-CA-C 108.13 -1.063 . . . . 1.0 108.13 -179.163 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 98.5 mttt . . . . . 0 N--CA 1.475 0.785 0 CA-C-O 121.432 0.634 . . . . 1.0 110.563 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 20.2 p -137.78 151.26 47.96 Favored 'General case' 0 N--CA 1.489 1.479 0 CA-C-N 115.549 -0.75 . . . . 1.0 110.353 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -96.8 142.78 16.36 Favored Glycine 0 N--CA 1.474 1.217 0 N-CA-C 110.625 -0.99 . . . . 1.0 110.625 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 75.1 mt -109.24 141.56 24.18 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.177 0 CA-C-O 121.224 0.535 . . . . 1.0 109.95 -179.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 2.8 t -116.56 115.86 50.39 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 CA-C-O 116.812 -1.566 . . . . 1.0 110.682 178.083 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -82.48 146.3 29.33 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 120.098 1.317 . . . . 1.0 109.06 177.638 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.9 p -50.14 139.01 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 CA-C-N 116.314 -0.403 . . . . 1.0 111.126 179.289 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 79.2 p -168.59 -78.88 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.844 0 CA-C-O 120.843 0.354 . . . . 1.0 111.141 -179.26 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 97.6 p -131.15 -133.74 0.2 Allowed 'General case' 0 N--CA 1.485 1.287 0 CA-C-N 116.068 -0.515 . . . . 1.0 110.516 -179.105 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 98.3 p -138.85 153.76 48.36 Favored 'General case' 0 N--CA 1.477 0.925 0 CA-C-O 121.312 0.577 . . . . 1.0 110.238 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -140.3 128.27 22.09 Favored 'General case' 0 N--CA 1.49 1.553 0 CA-C-O 121.733 0.778 . . . . 1.0 109.715 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 19.3 p30 -92.96 144.08 25.61 Favored 'General case' 0 N--CA 1.473 0.704 0 CA-C-N 115.298 -0.865 . . . . 1.0 110.06 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 93.9 t -97.79 128.45 49.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 CA-C-O 121.879 0.847 . . . . 1.0 108.894 179.173 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 89.5 mtt-85 -99.55 -167.74 1.51 Allowed 'General case' 0 N--CA 1.473 0.702 0 CA-C-N 115.187 -0.915 . . . . 1.0 110.162 -179.744 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 60.1 p -130.8 33.16 4.26 Favored 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 123.017 0.527 . . . . 1.0 110.611 -179.413 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.48 ' OG ' ' N ' ' A' ' 18' ' ' ALA . 6.9 t 175.8 -177.95 0.13 Allowed 'General case' 0 N--CA 1.48 1.027 0 CA-C-O 121.632 0.729 . . . . 1.0 110.507 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.48 ' N ' ' OG ' ' A' ' 17' ' ' SER . . . -97.11 42.97 1.08 Allowed 'General case' 0 N--CA 1.488 1.448 0 CA-C-N 115.285 -0.87 . . . . 1.0 110.182 179.511 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 44.3 t -130.63 138.18 49.97 Favored 'General case' 0 N--CA 1.489 1.477 0 CA-C-N 115.106 -0.952 . . . . 1.0 110.902 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 80.1 p -74.73 -8.75 57.37 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-N 116.227 -0.442 . . . . 1.0 110.569 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 66.7 m -99.36 -6.58 27.57 Favored 'General case' 0 N--CA 1.486 1.333 0 CA-C-N 116.201 -0.454 . . . . 1.0 111.069 -179.072 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 13.9 t -66.48 133.95 51.46 Favored 'General case' 0 N--CA 1.473 0.72 0 CA-C-N 115.962 -0.563 . . . . 1.0 110.843 -179.414 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 38.3 ttmt -59.89 155.67 15.99 Favored 'General case' 0 N--CA 1.475 0.793 0 CA-C-N 116.031 -0.531 . . . . 1.0 110.622 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 6.8 p -83.94 144.56 9.68 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.193 0 CA-C-O 121.176 0.513 . . . . 1.0 110.503 -179.68 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 40.1 pt -121.87 -10.26 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 CA-C-N 115.813 -0.631 . . . . 1.0 110.34 179.266 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 179.35 -171.56 43.42 Favored Glycine 0 N--CA 1.467 0.759 0 N-CA-C 111.111 -0.796 . . . . 1.0 111.111 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 96.7 p -157.25 151.0 24.33 Favored 'General case' 0 N--CA 1.475 0.797 0 CA-C-N 115.642 -0.279 . . . . 1.0 110.559 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 2.2 pp -117.23 167.78 10.9 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 123.076 0.55 . . . . 1.0 110.507 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 90.9 p -112.74 160.02 18.37 Favored 'General case' 0 N--CA 1.482 1.17 0 CA-C-N 115.718 -0.673 . . . . 1.0 110.537 -179.491 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.421 ' O ' ' HB2' ' A' ' 31' ' ' ASN . . . -83.75 76.06 2.29 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 110.901 -0.88 . . . . 1.0 110.901 179.41 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.421 ' HB2' ' O ' ' A' ' 30' ' ' GLY . 22.1 t-20 164.61 16.3 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.843 0 C-N-CA 123.287 0.635 . . . . 1.0 110.242 -179.566 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 36.4 m -109.84 147.47 33.27 Favored 'General case' 0 N--CA 1.486 1.337 0 C-N-CA 123.424 0.69 . . . . 1.0 111.046 -179.458 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 22.2 pttp -90.25 148.77 22.7 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 122.602 0.361 . . . . 1.0 110.209 178.532 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.6 m -143.21 126.04 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 CA-C-O 120.829 0.347 . . . . 1.0 110.296 179.587 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 9.8 t -82.79 85.47 7.07 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 121.445 0.641 . . . . 1.0 110.619 179.674 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 85.6 mt -51.16 157.23 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 CA-C-N 115.546 -0.752 . . . . 1.0 110.165 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 39.6 t -127.4 -97.86 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 CA-C-N 115.947 -0.569 . . . . 1.0 110.003 -179.076 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -99.49 -178.42 31.2 Favored Glycine 0 N--CA 1.472 1.036 0 N-CA-C 110.937 -0.865 . . . . 1.0 110.937 -179.773 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -135.16 141.8 46.0 Favored 'General case' 0 N--CA 1.483 1.193 0 CA-C-O 120.984 0.421 . . . . 1.0 110.204 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -155.38 134.84 12.48 Favored 'General case' 0 CA--C 1.539 0.524 0 CA-C-N 116.001 -0.545 . . . . 1.0 110.378 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 48.56 -113.14 1.4 Allowed Glycine 0 CA--C 1.547 2.051 0 CA-C-N 115.947 -0.57 . . . . 1.0 111.707 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -122.49 24.7 9.16 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 110.049 -0.352 . . . . 1.0 110.049 179.23 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -145.07 156.18 43.76 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-O 121.301 0.572 . . . . 1.0 110.296 -179.474 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 22.6 p90 -131.67 162.87 29.38 Favored 'General case' 0 N--CA 1.488 1.458 0 CA-C-N 115.684 -0.689 . . . . 1.0 110.452 179.712 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -88.58 160.39 17.45 Favored 'General case' 0 N--CA 1.476 0.829 0 CA-C-N 116.037 -0.528 . . . . 1.0 110.159 -179.372 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 34.4 pt -145.75 153.17 13.74 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 CA-C-O 121.312 0.577 . . . . 1.0 110.504 -179.632 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 80.8 mm-40 -95.75 58.73 1.99 Allowed 'General case' 0 N--CA 1.481 1.113 0 CA-C-N 115.668 -0.696 . . . . 1.0 110.069 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 77.8 t80 -78.94 117.54 20.11 Favored 'General case' 0 N--CA 1.474 0.727 0 CA-C-N 115.603 -0.726 . . . . 1.0 109.915 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm 45.58 33.21 1.32 Allowed 'General case' 0 CA--C 1.557 1.24 0 CA-C-O 121.276 0.56 . . . . 1.0 111.415 -179.629 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 68.19 21.74 74.03 Favored Glycine 0 N--CA 1.482 1.736 0 N-CA-C 111.373 -0.691 . . . . 1.0 111.373 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 28.9 t -115.98 171.65 7.65 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 123.332 0.653 . . . . 1.0 110.878 -179.186 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -96.77 136.85 36.73 Favored 'General case' 0 N--CA 1.479 0.995 0 CA-C-N 115.942 -0.572 . . . . 1.0 110.229 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -148.2 163.13 28.9 Favored Glycine 0 N--CA 1.479 1.522 0 N-CA-C 110.993 -0.843 . . . . 1.0 110.993 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' TYR . . . . . 0.451 ' CD1' ' N ' ' A' ' 17' ' ' SER . 82.2 m-85 -133.83 138.01 45.39 Favored 'General case' 0 N--CA 1.483 1.184 0 CA-C-O 121.483 0.659 . . . . 1.0 110.544 -179.744 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 42.8 t -144.23 151.22 16.16 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.291 0 CA-C-N 115.501 -0.772 . . . . 1.0 110.1 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -79.55 113.53 17.77 Favored 'General case' 0 N--CA 1.474 0.747 0 CA-C-N 115.785 -0.643 . . . . 1.0 110.502 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 19.3 pttp -74.23 -28.44 61.24 Favored 'General case' 0 N--CA 1.476 0.871 0 CA-C-O 120.812 0.339 . . . . 1.0 110.512 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -55.11 -45.18 75.5 Favored 'General case' 0 N--CA 1.477 0.876 0 CA-C-N 116.234 -0.439 . . . . 1.0 111.014 -179.297 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 22.9 m-85 -63.0 -35.02 78.81 Favored 'General case' 0 N--CA 1.477 0.893 0 N-CA-C 110.003 -0.369 . . . . 1.0 110.003 178.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 74.4 mt . . . . . 0 N--CA 1.479 1.01 0 CA-C-O 118.133 -0.937 . . . . 1.0 109.253 -179.48 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 98.9 mttt . . . . . 0 N--CA 1.479 1.006 0 CA-C-O 121.817 0.818 . . . . 1.0 110.181 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 73.3 p -123.14 144.59 49.24 Favored 'General case' 0 N--CA 1.48 1.054 0 CA-C-N 115.161 -0.927 . . . . 1.0 110.314 -179.796 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -95.64 151.77 20.11 Favored Glycine 0 CA--C 1.527 0.838 0 N-CA-C 110.229 -1.149 . . . . 1.0 110.229 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 4.0 mp -103.56 124.89 58.11 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 N-CA-C 109.493 -0.558 . . . . 1.0 109.493 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.3 t -66.67 120.09 13.24 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.554 0 CA-C-N 115.7 -0.682 . . . . 1.0 109.845 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . 0.421 ' C ' ' H ' ' A' ' 9' ' ' SER . 18.2 p-10 -59.63 102.28 0.14 Allowed 'General case' 0 CA--C 1.539 0.537 0 CA-C-O 121.029 0.443 . . . . 1.0 110.479 179.492 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 8.2 p -64.27 -2.85 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-N 115.951 -0.568 . . . . 1.0 110.721 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' SER . . . . . 0.421 ' H ' ' C ' ' A' ' 7' ' ' ASN . 41.3 m -45.89 -56.71 5.08 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-N 115.743 -0.662 . . . . 1.0 111.445 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 50.0 m -148.56 179.41 7.83 Favored 'General case' 0 N--CA 1.477 0.907 0 CA-C-N 115.61 -0.723 . . . . 1.0 110.277 179.216 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 45.1 t -84.75 140.31 31.35 Favored 'General case' 0 N--CA 1.473 0.712 0 CA-C-N 115.479 -0.782 . . . . 1.0 110.249 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -111.6 140.65 46.04 Favored 'General case' 0 N--CA 1.485 1.29 0 CA-C-O 122.232 1.015 . . . . 1.0 109.935 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 72.6 m-80 -82.67 126.7 32.65 Favored 'General case' 0 N--CA 1.451 -0.407 0 CA-C-N 114.805 -1.089 . . . . 1.0 109.476 179.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.4 t -102.09 125.86 56.21 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 CA-C-N 115.229 -0.896 . . . . 1.0 110.181 -179.763 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -91.83 179.62 5.57 Favored 'General case' 0 N--CA 1.486 1.348 0 CA-C-O 121.582 0.706 . . . . 1.0 110.238 179.039 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 1.4 m -92.65 -22.61 19.35 Favored 'General case' 0 N--CA 1.489 1.508 0 CA-C-N 115.435 -0.802 . . . . 1.0 110.282 179.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 45.5 p -176.74 -178.13 0.85 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 122.175 0.988 . . . . 1.0 110.032 -179.162 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -82.15 82.27 7.76 Favored 'General case' 0 N--CA 1.47 0.562 0 CA-C-N 114.852 -1.067 . . . . 1.0 109.689 179.182 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 65.5 p -167.25 154.68 8.92 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 121.565 0.698 . . . . 1.0 110.332 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 26.3 m -75.1 -25.32 58.44 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.398 -0.819 . . . . 1.0 110.639 179.311 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 99.5 p -63.08 -22.93 67.19 Favored 'General case' 0 N--CA 1.471 0.602 0 C-N-CA 120.597 -0.441 . . . . 1.0 110.408 -178.423 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 26.5 t -96.96 141.79 29.7 Favored 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 109.652 -0.499 . . . . 1.0 109.652 178.41 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 24.9 tttm -163.24 109.9 1.16 Allowed 'General case' 0 N--CA 1.474 0.754 0 CA-C-O 122.077 0.942 . . . . 1.0 110.029 179.638 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.3 t 62.06 135.92 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.519 0 CA-C-N 115.032 -0.986 . . . . 1.0 110.24 -179.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 1.3 pp -152.57 -17.14 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.963 0 CA-C-N 115.93 -0.577 . . . . 1.0 110.326 -179.387 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 163.27 -166.91 37.32 Favored Glycine 0 CA--C 1.522 0.469 0 N-CA-C 110.359 -1.096 . . . . 1.0 110.359 -178.247 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 93.9 p -145.11 140.44 28.03 Favored 'General case' 0 N--CA 1.481 1.121 0 CA-C-N 114.882 -0.659 . . . . 1.0 110.591 179.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.9 pp -102.17 122.41 44.1 Favored 'General case' 0 N--CA 1.491 1.58 0 CA-C-O 121.587 0.708 . . . . 1.0 109.392 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 51.0 m -44.69 131.62 6.75 Favored 'General case' 0 N--CA 1.484 1.233 0 CA-C-N 115.476 -0.784 . . . . 1.0 111.082 -178.654 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -68.08 165.87 45.14 Favored Glycine 0 CA--C 1.521 0.449 0 N-CA-C 111.354 -0.699 . . . . 1.0 111.354 -178.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 13.8 m-80 65.1 20.66 12.08 Favored 'General case' 0 N--CA 1.471 0.624 0 CA-C-O 120.954 0.407 . . . . 1.0 110.455 179.654 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 91.8 m -97.67 145.54 26.21 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-N 115.994 -0.548 . . . . 1.0 109.735 179.48 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -86.27 139.3 31.14 Favored 'General case' 0 N--CA 1.473 0.682 0 CA-C-N 115.77 -0.65 . . . . 1.0 110.143 179.428 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 9.8 m -142.49 124.99 13.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 CA-C-N 115.675 -0.693 . . . . 1.0 110.118 179.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 60.0 p -89.93 90.78 8.31 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 115.917 -0.583 . . . . 1.0 109.813 179.185 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 3.5 mp -36.75 147.17 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.498 1.94 0 CA-C-N 115.768 -0.651 . . . . 1.0 111.517 179.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 4.7 t -141.68 61.47 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.37 0 CA-C-O 121.239 0.543 . . . . 1.0 110.522 -178.485 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 107.83 160.55 20.83 Favored Glycine 0 N--CA 1.471 1.005 0 N-CA-C 110.711 -0.956 . . . . 1.0 110.711 179.435 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 74.7 mt-10 -135.46 140.72 45.08 Favored 'General case' 0 N--CA 1.487 1.383 0 CA-C-O 121.161 0.505 . . . . 1.0 110.261 179.703 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.7 tm-20 -148.95 121.87 8.77 Favored 'General case' 0 N--CA 1.477 0.875 0 CA-C-N 115.837 -0.619 . . . . 1.0 110.346 -179.595 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 50.41 -114.17 2.44 Favored Glycine 0 CA--C 1.543 1.783 0 N-CA-C 111.16 -0.776 . . . . 1.0 111.16 179.651 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -113.62 26.82 10.05 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 122.609 0.364 . . . . 1.0 110.724 179.431 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 -146.9 156.34 43.0 Favored 'General case' 0 N--CA 1.476 0.841 0 CA-C-O 121.721 0.772 . . . . 1.0 110.487 179.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' TYR . . . . . 0.4 ' CD1' ' N ' ' A' ' 44' ' ' TYR . 15.0 p90 -140.45 172.67 12.4 Favored 'General case' 0 N--CA 1.473 0.72 0 CA-C-N 115.336 -0.847 . . . . 1.0 110.121 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 24.0 mtpp -101.32 151.83 21.42 Favored 'General case' 0 N--CA 1.478 0.944 0 CA-C-N 115.225 -0.898 . . . . 1.0 110.281 -179.282 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 38.9 pt -139.55 152.97 23.29 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 CA-C-N 115.59 -0.732 . . . . 1.0 110.596 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 4.3 tm-20 -113.45 86.82 2.47 Favored 'General case' 0 N--CA 1.485 1.288 0 CA-C-N 115.323 -0.853 . . . . 1.0 109.872 179.236 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 22.6 t80 -139.65 158.46 44.08 Favored 'General case' 0 N--CA 1.469 0.505 0 CA-C-O 121.209 0.528 . . . . 1.0 110.566 179.391 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 33.8 mtmt 50.29 20.83 0.7 Allowed 'General case' 0 N--CA 1.476 0.859 0 CA-C-N 115.847 -0.615 . . . . 1.0 110.447 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 71.55 -3.32 18.04 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.799 -0.92 . . . . 1.0 110.799 -179.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 44.0 t -117.38 173.97 6.4 Favored 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 124.119 0.968 . . . . 1.0 110.644 -179.431 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' HIS . . . . . 0.445 ' CD2' ' H ' ' A' ' 52' ' ' HIS . 6.8 p80 -112.37 153.54 27.11 Favored 'General case' 0 N--CA 1.481 1.094 0 CA-C-N 115.467 -0.788 . . . . 1.0 109.955 -179.587 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.06 165.55 27.71 Favored Glycine 0 N--CA 1.471 0.994 0 N-CA-C 110.711 -0.956 . . . . 1.0 110.711 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 77.0 m-85 -130.54 139.67 50.48 Favored 'General case' 0 N--CA 1.486 1.351 0 CA-C-O 121.119 0.485 . . . . 1.0 110.268 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 4.2 p -158.91 158.84 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.001 0 CA-C-N 115.92 -0.582 . . . . 1.0 110.25 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.66 134.13 56.74 Favored 'General case' 0 CA--C 1.541 0.609 0 CA-C-O 121.191 0.519 . . . . 1.0 110.397 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -91.06 -35.97 14.31 Favored 'General case' 0 N--CA 1.483 1.198 0 CA-C-N 115.712 -0.676 . . . . 1.0 110.258 -179.831 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -56.73 -28.47 61.09 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-O 121.099 0.476 . . . . 1.0 110.633 -179.454 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 2.2 m-85 -63.21 -39.24 94.08 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-N 115.88 -0.6 . . . . 1.0 110.17 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 70.2 mt . . . . . 0 N--CA 1.472 0.628 0 CA-C-O 117.698 -1.144 . . . . 1.0 109.338 -179.32 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 7.0 mtpm? . . . . . 0 N--CA 1.47 0.565 0 CA-C-O 120.722 0.296 . . . . 1.0 110.994 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 68.6 p -125.89 163.07 23.74 Favored 'General case' 0 N--CA 1.48 1.045 0 CA-C-O 121.786 0.803 . . . . 1.0 110.353 -179.259 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -122.13 153.17 16.81 Favored Glycine 0 N--CA 1.479 1.565 0 CA-C-N 115.147 -0.933 . . . . 1.0 110.883 -179.696 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 28.2 pt -114.45 140.47 35.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 CA-C-O 121.869 0.842 . . . . 1.0 110.076 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.444 ' H ' ' HA ' ' A' ' 31' ' ' ASN . 2.2 t -90.82 132.04 36.41 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 CA-C-N 115.083 -0.962 . . . . 1.0 109.315 -179.666 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 31.9 m120 -59.53 114.66 2.82 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 120.397 -0.521 . . . . 1.0 110.35 179.329 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 40.6 t -53.49 -19.51 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 CA-C-O 121.397 0.618 . . . . 1.0 110.448 -179.676 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.5 m -49.42 109.28 0.25 Allowed 'General case' 0 CA--C 1.545 0.769 0 CA-C-N 115.642 -0.708 . . . . 1.0 110.873 179.339 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 7.9 m 61.67 -125.42 0.81 Allowed 'General case' 0 CA--C 1.543 0.699 0 CA-C-N 116.582 -0.281 . . . . 1.0 110.606 -179.18 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 89.0 p -152.28 158.68 43.13 Favored 'General case' 0 N--CA 1.478 0.936 0 CA-C-O 120.97 0.414 . . . . 1.0 110.666 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 51.5 tp -123.05 133.44 54.32 Favored 'General case' 0 N--CA 1.486 1.345 0 CA-C-O 121.578 0.704 . . . . 1.0 110.212 179.596 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 14.9 p-10 -84.63 143.48 29.22 Favored 'General case' 0 CA--C 1.535 0.394 0 CA-C-N 115.432 -0.804 . . . . 1.0 109.982 179.404 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 45.2 t -96.4 117.54 40.95 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 N-CA-C 109.424 -0.584 . . . . 1.0 109.424 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 81.3 mtt85 -84.97 165.63 17.44 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 109.774 -0.454 . . . . 1.0 109.774 179.675 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' SER . . . . . 0.555 ' H ' ' HG ' ' A' ' 22' ' ' SER . 38.0 t -95.85 -18.28 20.48 Favored 'General case' 0 N--CA 1.483 1.184 0 CA-C-N 115.972 -0.558 . . . . 1.0 110.516 179.468 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' SER . . . . . 0.631 ' HG ' ' H ' ' A' ' 18' ' ' ALA . 32.9 t -153.36 -164.63 1.95 Allowed 'General case' 0 N--CA 1.479 0.986 0 CA-C-N 116.246 -0.434 . . . . 1.0 111.089 -179.806 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.631 ' H ' ' HG ' ' A' ' 17' ' ' SER . . . -83.72 47.33 1.27 Allowed 'General case' 0 N--CA 1.477 0.919 0 CA-C-O 121.458 0.647 . . . . 1.0 110.234 -179.776 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 53.6 m -157.74 137.1 11.88 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-N 115.562 -0.745 . . . . 1.0 110.851 179.748 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.1 t -70.38 -32.09 69.62 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 115.939 -0.573 . . . . 1.0 110.448 179.701 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' SER . . . . . 0.465 ' C ' ' H ' ' A' ' 23' ' ' LYS . 51.1 m -70.81 -2.58 15.31 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 116.42 -0.354 . . . . 1.0 110.683 -179.78 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' SER . . . . . 0.555 ' HG ' ' H ' ' A' ' 16' ' ' SER . 59.8 p -76.71 21.07 0.21 Allowed 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 121.362 0.601 . . . . 1.0 110.563 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.535 ' O ' ' O ' ' A' ' 22' ' ' SER . 98.2 mttt 48.13 167.25 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.443 0 CA-C-N 115.653 -0.703 . . . . 1.0 111.565 -179.147 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 25.9 t -89.56 168.92 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-O 121.563 0.697 . . . . 1.0 109.56 179.36 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 43.5 pt -135.58 -22.64 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 CA-C-N 115.472 -0.785 . . . . 1.0 110.497 179.565 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.72 179.87 43.0 Favored Glycine 0 N--CA 1.462 0.419 0 N-CA-C 110.52 -1.032 . . . . 1.0 110.52 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 88.7 p -132.56 133.44 43.72 Favored 'General case' 0 N--CA 1.478 0.933 0 CA-C-O 121.282 0.563 . . . . 1.0 109.873 179.664 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -98.62 174.19 6.55 Favored 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 108.959 -0.756 . . . . 1.0 108.959 -179.468 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' SER . . . . . 0.533 ' O ' ' O ' ' A' ' 30' ' ' GLY . 42.0 t -79.16 137.19 37.35 Favored 'General case' 0 CA--C 1.515 -0.367 0 CA-C-N 115.964 -0.562 . . . . 1.0 109.901 -179.189 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.533 ' O ' ' O ' ' A' ' 29' ' ' SER . . . -13.24 -107.45 0.0 OUTLIER Glycine 0 N--CA 1.512 3.715 0 CA-C-O 119.473 -0.626 . . . . 1.0 113.017 179.82 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . 0.444 ' HA ' ' H ' ' A' ' 6' ' ' VAL . 19.5 p-10 -77.73 79.22 4.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 117.569 0.684 . . . . 1.0 109.781 177.775 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' THR . . . . . 0.529 ' OG1' ' O ' ' A' ' 29' ' ' SER . 45.6 m -84.84 146.24 27.42 Favored 'General case' 0 N--CA 1.494 1.769 0 CA-C-N 115.961 -0.563 . . . . 1.0 109.82 179.293 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 55.8 mtpt -82.62 128.47 34.36 Favored 'General case' 0 N--CA 1.474 0.761 0 CA-C-N 116.035 -0.529 . . . . 1.0 110.116 179.157 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.9 m -144.48 127.0 10.72 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 CA-C-N 116.323 -0.399 . . . . 1.0 110.368 179.361 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 68.6 p -80.81 83.82 6.47 Favored 'General case' 0 N--CA 1.47 0.559 0 CA-C-O 121.289 0.566 . . . . 1.0 109.86 179.485 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 81.3 mt -47.23 163.83 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.063 0 CA-C-N 115.641 -0.708 . . . . 1.0 110.54 179.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 42.7 t -129.25 -94.18 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 N-CA-C 110.045 -0.354 . . . . 1.0 110.045 -179.229 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -102.12 -168.12 27.0 Favored Glycine 0 N--CA 1.474 1.227 0 N-CA-C 110.912 -0.875 . . . . 1.0 110.912 -179.568 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -130.29 140.68 50.65 Favored 'General case' 0 N--CA 1.485 1.275 0 CA-C-N 115.293 -0.453 . . . . 1.0 110.541 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 -153.21 114.02 4.09 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 116.084 -0.507 . . . . 1.0 110.207 -179.845 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 51.22 -116.4 4.54 Favored Glycine 0 CA--C 1.542 1.772 0 N-CA-C 111.634 -0.586 . . . . 1.0 111.634 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -117.41 25.07 10.7 Favored 'General case' 0 N--CA 1.488 1.453 0 C-N-CA 122.401 0.28 . . . . 1.0 110.429 179.493 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -145.64 157.08 44.01 Favored 'General case' 0 N--CA 1.48 1.074 0 CA-C-O 121.232 0.539 . . . . 1.0 110.405 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 13.8 p90 -141.72 176.18 9.12 Favored 'General case' 0 N--CA 1.482 1.131 0 CA-C-N 115.76 -0.654 . . . . 1.0 110.376 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 34.3 mtmm -97.06 149.35 22.05 Favored 'General case' 0 N--CA 1.479 0.987 0 CA-C-N 115.786 -0.643 . . . . 1.0 110.327 -179.117 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 26.3 pt -142.95 160.48 18.02 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 CA-C-O 121.949 0.88 . . . . 1.0 110.119 179.487 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -121.7 92.1 3.66 Favored 'General case' 0 N--CA 1.487 1.385 0 CA-C-N 115.084 -0.962 . . . . 1.0 109.608 -179.68 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 21.8 t80 -136.32 151.86 50.05 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-O 121.239 0.542 . . . . 1.0 110.398 179.82 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 46.9 mmtt 53.53 17.55 1.18 Allowed 'General case' 0 N--CA 1.479 1.02 0 CA-C-N 115.763 -0.653 . . . . 1.0 110.619 -179.586 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 72.81 -2.25 33.97 Favored Glycine 0 N--CA 1.467 0.713 0 N-CA-C 110.63 -0.988 . . . . 1.0 110.63 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 41.9 t -107.89 172.47 6.81 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 124.009 0.924 . . . . 1.0 110.489 -179.672 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 25.8 p-80 -106.77 142.26 36.69 Favored 'General case' 0 N--CA 1.482 1.125 0 CA-C-N 115.803 -0.635 . . . . 1.0 110.133 179.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -150.83 169.79 30.62 Favored Glycine 0 N--CA 1.472 1.08 0 N-CA-C 111.094 -0.802 . . . . 1.0 111.094 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 58.5 m-85 -133.53 145.81 50.47 Favored 'General case' 0 N--CA 1.48 1.04 0 CA-C-O 121.673 0.749 . . . . 1.0 110.33 179.655 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 3.5 m -146.16 147.98 17.63 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 CA-C-N 115.319 -0.855 . . . . 1.0 109.892 -179.7 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -66.44 147.21 53.62 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 115.204 -0.907 . . . . 1.0 110.477 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -82.4 -25.74 33.45 Favored 'General case' 0 N--CA 1.477 0.879 0 CA-C-N 116.166 -0.47 . . . . 1.0 110.44 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 4.2 tm-20 -56.68 -34.58 67.54 Favored 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 121.293 0.568 . . . . 1.0 110.738 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 26.1 m-85 -78.46 -4.92 50.87 Favored 'General case' 0 N--CA 1.483 1.188 0 CA-C-N 115.629 -0.714 . . . . 1.0 110.1 179.81 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 34.2 mm . . . . . 0 N--CA 1.487 1.393 0 CA-C-O 118.17 -0.919 . . . . 1.0 109.507 180.0 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 24.3 pttm . . . . . 0 N--CA 1.479 0.978 0 CA-C-O 121.298 0.57 . . . . 1.0 110.716 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 62.7 p -131.84 154.74 48.85 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-O 121.955 0.883 . . . . 1.0 109.84 -179.649 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -143.11 161.22 27.6 Favored Glycine 0 N--CA 1.461 0.341 0 N-CA-C 110.317 -1.113 . . . . 1.0 110.317 -179.663 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 74.1 mt -109.97 135.86 47.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 CA-C-O 121.691 0.758 . . . . 1.0 109.503 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 47.4 t -82.49 131.02 34.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.282 -0.872 . . . . 1.0 109.44 179.575 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 -60.09 109.64 1.02 Allowed 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 115.628 -0.715 . . . . 1.0 110.404 179.751 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 14.7 p -65.79 133.3 31.0 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 CA-C-N 116.028 -0.533 . . . . 1.0 110.234 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 88.0 p -170.51 -55.98 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 121.191 0.52 . . . . 1.0 110.138 179.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 68.5 m -148.79 -110.98 0.07 Allowed 'General case' 0 N--CA 1.477 0.891 0 CA-C-N 115.863 -0.608 . . . . 1.0 110.718 -179.471 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 39.7 t -135.29 142.95 45.97 Favored 'General case' 0 N--CA 1.473 0.713 0 CA-C-O 121.9 0.857 . . . . 1.0 110.51 -179.55 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -101.39 141.66 33.93 Favored 'General case' 0 N--CA 1.474 0.742 0 CA-C-O 122.21 1.005 . . . . 1.0 110.029 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 79.8 m-20 -93.13 123.17 36.21 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 114.708 -1.133 . . . . 1.0 109.523 -179.672 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 64.3 t -96.67 114.97 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 CA-C-N 115.603 -0.726 . . . . 1.0 109.089 -179.808 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -87.65 173.19 9.18 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-O 122.07 0.938 . . . . 1.0 109.585 179.095 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 88.8 p -97.52 -19.25 18.5 Favored 'General case' 0 N--CA 1.478 0.969 0 CA-C-N 114.974 -1.012 . . . . 1.0 110.292 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 88.9 p -149.41 -163.58 1.82 Allowed 'General case' 0 N--CA 1.475 0.823 0 CA-C-O 121.47 0.653 . . . . 1.0 110.824 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -101.3 53.61 0.83 Allowed 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 115.58 -0.736 . . . . 1.0 110.165 -179.79 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 46.4 t -138.89 137.34 36.42 Favored 'General case' 0 N--CA 1.479 1.023 0 CA-C-O 121.55 0.691 . . . . 1.0 110.744 179.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.2 t -67.42 -27.14 66.82 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 115.391 -0.822 . . . . 1.0 110.702 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 50.0 m -77.41 -7.51 56.24 Favored 'General case' 0 N--CA 1.469 0.508 0 CA-C-N 115.656 -0.702 . . . . 1.0 110.19 -179.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 34.8 t -65.77 124.89 23.65 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-O 120.987 0.422 . . . . 1.0 110.341 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -67.88 166.57 15.3 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.89 -0.595 . . . . 1.0 110.208 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 19.5 t -76.9 114.38 17.19 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.658 0 CA-C-O 121.662 0.744 . . . . 1.0 110.023 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 5.4 tt -96.88 -17.35 6.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.195 -0.911 . . . . 1.0 109.846 179.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -166.81 -162.12 17.62 Favored Glycine 0 N--CA 1.463 0.456 0 N-CA-C 110.721 -0.952 . . . . 1.0 110.721 -179.537 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 50.4 m -158.71 132.51 7.63 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.278 0.561 . . . . 1.0 109.936 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.2 tp -110.31 149.06 30.74 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-O 121.567 0.699 . . . . 1.0 109.907 179.614 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 45.7 p -91.15 159.89 15.85 Favored 'General case' 0 N--CA 1.469 0.483 0 CA-C-N 115.327 -0.851 . . . . 1.0 109.604 179.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -78.75 152.17 36.74 Favored Glycine 0 CA--C 1.529 0.934 0 N-CA-C 110.443 -1.063 . . . . 1.0 110.443 179.526 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 70.14 19.08 6.84 Favored 'General case' 0 N--CA 1.474 0.772 0 CA-C-O 120.887 0.375 . . . . 1.0 110.449 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 32.0 m -88.67 139.75 30.15 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-N 116.119 -0.491 . . . . 1.0 109.878 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 63.3 tttm -86.3 139.25 31.17 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.893 -0.594 . . . . 1.0 109.963 179.547 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 14.4 m -142.99 124.46 11.77 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.879 0 CA-C-N 115.687 -0.688 . . . . 1.0 110.2 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 62.1 p -79.89 87.76 5.32 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-O 121.355 0.598 . . . . 1.0 109.709 179.636 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . 0.421 ' CG2' ' H ' ' A' ' 37' ' ' VAL . 63.0 mt -55.81 169.43 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.504 0 CA-C-O 121.66 0.743 . . . . 1.0 109.498 179.844 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.421 ' H ' ' CG2' ' A' ' 36' ' ' ILE . 0.2 OUTLIER -131.91 -96.0 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.055 0 CA-C-N 115.348 -0.842 . . . . 1.0 109.885 -179.156 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -99.4 -170.07 30.46 Favored Glycine 0 N--CA 1.465 0.62 0 N-CA-C 110.631 -0.987 . . . . 1.0 110.631 -179.566 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 13.5 mp0 -128.85 132.95 47.81 Favored 'General case' 0 N--CA 1.478 0.943 0 CA-C-N 114.651 -0.775 . . . . 1.0 110.224 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.41 ' O ' ' O ' ' A' ' 43' ' ' PHE . 44.3 tp10 -150.32 120.68 7.35 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-N 115.497 -0.774 . . . . 1.0 110.041 179.527 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 47.08 -122.65 7.17 Favored Glycine 0 CA--C 1.543 1.805 0 N-CA-C 111.509 -0.636 . . . . 1.0 111.509 179.779 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -114.03 22.32 14.0 Favored 'General case' 0 N--CA 1.481 1.106 0 C-N-CA 122.546 0.338 . . . . 1.0 110.251 178.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . 0.41 ' O ' ' O ' ' A' ' 40' ' ' GLU . 77.7 m-85 -149.13 157.42 43.37 Favored 'General case' 0 N--CA 1.484 1.264 0 CA-C-O 121.6 0.714 . . . . 1.0 110.74 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' TYR . . . . . 0.458 ' N ' ' CD1' ' A' ' 44' ' ' TYR . 10.1 p90 -140.39 172.99 11.95 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 122.077 0.942 . . . . 1.0 109.939 -179.712 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -97.52 156.56 16.44 Favored 'General case' 0 N--CA 1.474 0.751 0 CA-C-N 114.905 -1.043 . . . . 1.0 109.97 -179.434 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 32.2 pt -147.41 161.7 7.9 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 CA-C-O 122.215 1.007 . . . . 1.0 109.884 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 18.6 mp0 -121.54 87.36 2.74 Favored 'General case' 0 N--CA 1.481 1.088 0 CA-C-N 114.748 -1.115 . . . . 1.0 109.844 -179.768 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -138.68 158.86 43.45 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-N 115.576 -0.738 . . . . 1.0 110.019 179.86 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . 0.417 ' C ' ' H ' ' A' ' 51' ' ' SER . 48.7 mtmt 52.92 18.47 1.08 Allowed 'General case' 0 CA--C 1.541 0.611 0 CA-C-N 115.626 -0.715 . . . . 1.0 110.811 179.801 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 67.97 -1.52 8.11 Favored Glycine 0 CA--C 1.532 1.1 0 N-CA-C 110.429 -1.068 . . . . 1.0 110.429 -179.181 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' SER . . . . . 0.417 ' H ' ' C ' ' A' ' 49' ' ' LYS . 97.6 p -116.12 171.96 7.47 Favored 'General case' 0 N--CA 1.484 1.265 0 CA-C-O 121.994 0.902 . . . . 1.0 110.317 -179.859 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 96.3 m-70 -101.75 146.12 28.2 Favored 'General case' 0 N--CA 1.478 0.932 0 CA-C-N 115.006 -0.997 . . . . 1.0 110.09 -179.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -152.9 168.32 31.78 Favored Glycine 0 CA--C 1.531 1.041 0 N-CA-C 110.673 -0.971 . . . . 1.0 110.673 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 66.2 m-85 -134.61 150.16 50.66 Favored 'General case' 0 N--CA 1.486 1.37 0 CA-C-O 121.018 0.437 . . . . 1.0 110.608 179.601 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -155.19 155.84 5.45 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 CA-C-N 115.967 -0.561 . . . . 1.0 110.348 -179.808 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.69 130.38 44.02 Favored 'General case' 0 CA--C 1.545 0.78 0 CA-C-O 122.173 0.987 . . . . 1.0 109.861 179.049 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.46 -35.1 17.23 Favored 'General case' 0 N--CA 1.483 1.191 0 CA-C-N 114.86 -1.064 . . . . 1.0 110.177 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -58.33 -30.39 66.66 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.656 0.741 . . . . 1.0 110.371 -179.674 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 1.2 t80 -52.52 -19.8 2.51 Favored 'General case' 0 CA--C 1.537 0.465 0 CA-C-N 115.362 -0.835 . . . . 1.0 110.792 -179.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 69.8 mt . . . . . 0 C--O 1.221 -0.436 0 CA-C-O 118.0 -1.0 . . . . 1.0 108.761 -179.834 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 74.6 mmtt . . . . . 0 N--CA 1.471 0.593 0 CA-C-O 121.267 0.556 . . . . 1.0 110.753 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 69.8 p -131.55 158.59 40.55 Favored 'General case' 0 N--CA 1.472 0.659 0 CA-C-O 121.825 0.821 . . . . 1.0 110.136 -179.48 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -145.57 163.94 28.15 Favored Glycine 0 N--CA 1.468 0.812 0 N-CA-C 110.495 -1.042 . . . . 1.0 110.495 -179.556 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 3.7 mp -110.13 129.68 64.69 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 CA-C-O 121.287 0.565 . . . . 1.0 109.97 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 55.9 t -73.42 133.34 31.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.648 -0.706 . . . . 1.0 109.491 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ASN . . . . . 0.544 HD21 ' N ' ' A' ' 7' ' ' ASN . 1.0 OUTLIER -49.2 96.83 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.707 0 CA-C-N 115.768 -0.651 . . . . 1.0 110.694 179.604 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.5 t -63.37 -6.55 2.26 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.539 0 CA-C-N 115.749 -0.66 . . . . 1.0 110.008 -179.221 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.0 m -52.71 -49.87 64.5 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.087 -0.506 . . . . 1.0 110.69 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 93.0 p -149.96 169.37 21.33 Favored 'General case' 0 N--CA 1.472 0.652 0 CA-C-O 121.461 0.648 . . . . 1.0 110.524 179.385 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 89.1 p -78.93 150.34 32.11 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 115.523 -0.762 . . . . 1.0 109.707 -179.331 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.9 mp -118.96 145.48 45.76 Favored 'General case' 0 N--CA 1.49 1.543 0 CA-C-O 122.287 1.042 . . . . 1.0 110.08 -179.426 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 73.8 m-80 -96.49 146.62 24.64 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 114.701 -1.136 . . . . 1.0 110.003 179.693 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 22.4 t -94.57 104.78 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.936 0 CA-C-N 115.529 -0.76 . . . . 1.0 109.684 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 88.8 mtm180 -79.41 135.64 36.74 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.341 0.591 . . . . 1.0 109.761 179.821 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 38.9 t -63.43 -27.17 69.1 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 115.581 -0.736 . . . . 1.0 110.442 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 47.2 t -144.85 -176.66 5.16 Favored 'General case' 0 N--CA 1.479 0.998 0 CA-C-N 115.97 -0.559 . . . . 1.0 110.927 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -81.83 57.17 3.33 Favored 'General case' 0 N--CA 1.476 0.843 0 CA-C-N 115.774 -0.648 . . . . 1.0 110.235 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 47.3 t -156.92 137.67 13.29 Favored 'General case' 0 N--CA 1.472 0.64 0 CA-C-O 121.203 0.525 . . . . 1.0 110.686 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.8 t -67.12 -32.97 74.46 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 115.756 -0.656 . . . . 1.0 110.629 179.62 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 89.4 p -69.35 -4.31 17.72 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 116.029 -0.532 . . . . 1.0 110.303 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 90.2 p -60.47 -172.02 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.539 0 CA-C-O 120.995 0.426 . . . . 1.0 110.25 179.53 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 5.5 mptt -116.57 148.16 41.15 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-O 121.234 0.54 . . . . 1.0 110.749 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 20.1 t -82.16 115.46 24.73 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 115.778 -0.646 . . . . 1.0 109.537 179.79 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 34.2 pt -96.43 -16.79 7.09 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.896 0 CA-C-N 115.706 -0.679 . . . . 1.0 109.891 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 179.53 165.77 34.17 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.71 -0.956 . . . . 1.0 110.71 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 50.7 m -117.54 135.55 53.87 Favored 'General case' 0 N--CA 1.484 1.268 0 CA-C-O 121.289 0.566 . . . . 1.0 109.918 179.61 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 3.5 tp -100.04 159.02 15.42 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-O 121.875 0.845 . . . . 1.0 109.141 -179.414 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 49.1 m -101.48 145.95 28.29 Favored 'General case' 0 N--CA 1.473 0.677 0 CA-C-N 115.208 -0.906 . . . . 1.0 110.106 -179.132 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -73.85 151.86 44.93 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.353 -1.099 . . . . 1.0 110.353 179.285 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 74.78 13.77 3.43 Favored 'General case' 0 N--CA 1.482 1.159 0 CA-C-O 120.525 0.202 . . . . 1.0 110.518 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 89.0 m -83.05 137.15 34.23 Favored 'General case' 0 N--CA 1.477 0.912 0 CA-C-O 121.12 0.486 . . . . 1.0 110.32 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -92.81 144.04 25.68 Favored 'General case' 0 N--CA 1.473 0.721 0 CA-C-N 115.806 -0.634 . . . . 1.0 109.989 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.4 p -154.77 139.81 10.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.748 -0.66 . . . . 1.0 109.91 179.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 68.9 p -83.4 83.36 7.9 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.877 -0.601 . . . . 1.0 109.637 179.217 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 74.5 mt -48.49 167.0 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 CA-C-N 115.818 -0.628 . . . . 1.0 110.066 179.801 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 40.8 t -128.07 -91.86 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 CA-C-N 116.22 -0.445 . . . . 1.0 110.087 -179.61 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -118.03 -155.54 10.06 Favored Glycine 0 N--CA 1.474 1.215 0 N-CA-C 110.863 -0.895 . . . . 1.0 110.863 -179.471 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -142.19 144.71 33.54 Favored 'General case' 0 N--CA 1.478 0.971 0 CA-C-N 115.059 -0.57 . . . . 1.0 110.281 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 38.3 tp10 -147.36 122.39 10.09 Favored 'General case' 0 N--CA 1.473 0.713 0 CA-C-N 115.74 -0.664 . . . . 1.0 109.986 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 54.71 -129.43 44.63 Favored Glycine 0 CA--C 1.53 0.995 0 N-CA-C 111.398 -0.681 . . . . 1.0 111.398 179.595 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -100.18 33.92 2.5 Favored 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 110.068 -0.345 . . . . 1.0 110.068 179.406 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -159.04 168.96 25.35 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-O 122.152 0.977 . . . . 1.0 110.083 179.321 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' TYR . . . . . 0.483 ' N ' ' CD1' ' A' ' 44' ' ' TYR . 3.3 p90 -129.63 163.92 25.01 Favored 'General case' 0 N--CA 1.481 1.107 0 CA-C-N 114.79 -1.095 . . . . 1.0 110.448 179.779 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 62.8 tttp -86.88 142.31 28.13 Favored 'General case' 0 N--CA 1.473 0.717 0 CA-C-N 115.341 -0.845 . . . . 1.0 109.771 -179.049 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 19.7 pt -141.32 156.51 21.54 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-O 122.083 0.944 . . . . 1.0 110.22 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -124.88 94.08 4.08 Favored 'General case' 0 N--CA 1.48 1.053 0 CA-C-N 114.844 -1.071 . . . . 1.0 109.971 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 22.8 t80 -128.47 147.5 50.67 Favored 'General case' 0 N--CA 1.476 0.875 0 CA-C-N 115.974 -0.557 . . . . 1.0 110.058 179.517 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 46.4 mtpt 54.11 17.56 1.47 Allowed 'General case' 0 CA--C 1.547 0.832 0 CA-C-N 115.908 -0.587 . . . . 1.0 110.497 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 72.18 1.78 51.01 Favored Glycine 0 N--CA 1.468 0.805 0 N-CA-C 110.6 -1.0 . . . . 1.0 110.6 -179.489 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 47.4 t -104.99 171.13 7.48 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 123.517 0.727 . . . . 1.0 110.2 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 49.4 p-80 -103.67 138.5 40.23 Favored 'General case' 0 N--CA 1.482 1.137 0 CA-C-N 115.618 -0.719 . . . . 1.0 110.484 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -150.75 166.76 30.36 Favored Glycine 0 N--CA 1.472 1.058 0 N-CA-C 110.782 -0.927 . . . . 1.0 110.782 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 33.4 m-85 -135.5 152.16 51.06 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-O 121.539 0.685 . . . . 1.0 110.194 179.456 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -150.39 151.16 12.91 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.953 0 CA-C-N 115.455 -0.793 . . . . 1.0 109.768 -179.089 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.56 125.64 24.61 Favored 'General case' 0 CA--C 1.54 0.561 0 CA-C-N 115.222 -0.899 . . . . 1.0 110.2 179.405 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 7.7 pttm -78.55 -31.18 47.32 Favored 'General case' 0 N--CA 1.473 0.681 0 CA-C-N 115.259 -0.882 . . . . 1.0 110.183 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -55.57 -35.45 65.76 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.061 -0.518 . . . . 1.0 110.401 -179.14 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.7 m-85 -60.47 -42.01 95.36 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 115.866 -0.606 . . . . 1.0 109.868 179.486 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 65.6 mt . . . . . 0 N--CA 1.476 0.831 0 CA-C-O 118.199 -0.905 . . . . 1.0 109.268 -179.359 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 41.1 ttp . . . . . 0 N--CA 1.489 1.499 0 N-CA-C 108.795 -0.817 . . . . 1.0 108.795 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 61.2 tttp -64.42 124.64 22.32 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.141 0.496 . . . . 1.0 110.131 -179.219 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 65.8 p -96.03 162.69 13.44 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.953 0.883 . . . . 1.0 109.759 179.738 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -101.6 155.89 18.89 Favored Glycine 0 N--CA 1.47 0.961 0 N-CA-C 110.454 -1.058 . . . . 1.0 110.454 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 69.0 mt -111.55 128.09 68.29 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.088 0 CA-C-O 121.502 0.668 . . . . 1.0 109.559 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 24.4 t -68.48 132.05 33.13 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 CA-C-N 115.571 -0.741 . . . . 1.0 109.883 179.807 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 10.5 p-10 -55.77 109.18 0.53 Allowed 'General case' 0 CA--C 1.54 0.572 0 CA-C-N 116.112 -0.494 . . . . 1.0 110.411 179.659 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 15.1 t -66.4 72.28 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-N 116.155 -0.475 . . . . 1.0 110.207 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 30.4 t -85.39 -104.59 0.06 Allowed 'General case' 0 CA--C 1.54 0.564 0 CA-C-N 115.92 -0.582 . . . . 1.0 109.916 179.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 97.0 p -157.29 -28.02 0.09 Allowed 'General case' 0 N--CA 1.478 0.967 0 CA-C-O 121.471 0.653 . . . . 1.0 111.11 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 44.4 t -153.87 145.31 23.13 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 115.539 -0.755 . . . . 1.0 110.703 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -155.16 121.55 5.28 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 120.773 -0.371 . . . . 1.0 110.536 178.319 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 74.7 m-20 -89.23 134.09 34.18 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 121.856 0.836 . . . . 1.0 109.809 179.453 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 33.9 t -103.84 128.36 57.18 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 CA-C-N 115.154 -0.93 . . . . 1.0 109.559 179.71 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 83.1 mtt-85 -97.43 179.75 4.76 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-O 121.56 0.695 . . . . 1.0 110.046 179.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.4 p -104.86 -7.15 19.58 Favored 'General case' 0 N--CA 1.484 1.238 0 CA-C-N 115.373 -0.83 . . . . 1.0 110.36 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.483 ' C ' ' H ' ' A' ' 19' ' ' SER . 42.0 t -170.7 178.22 3.64 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-O 121.264 0.554 . . . . 1.0 110.745 -179.772 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -72.97 40.4 0.09 Allowed 'General case' 0 N--CA 1.475 0.793 0 CA-C-N 115.82 -0.627 . . . . 1.0 110.664 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.483 ' H ' ' C ' ' A' ' 17' ' ' SER . 78.8 p -137.49 136.82 38.06 Favored 'General case' 0 N--CA 1.48 1.033 0 CA-C-O 121.52 0.676 . . . . 1.0 110.403 179.871 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 80.4 p -73.71 -27.98 61.48 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-N 115.427 -0.806 . . . . 1.0 110.21 179.784 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 97.2 p -65.34 -21.32 66.68 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 116.335 -0.393 . . . . 1.0 110.242 -179.541 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 37.6 m -55.49 -29.36 58.66 Favored 'General case' 0 N--CA 1.472 0.639 0 CA-C-O 120.988 0.423 . . . . 1.0 110.284 179.138 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 25.5 tttm 71.14 -177.2 0.2 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.933 -0.576 . . . . 1.0 110.018 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 13.2 t -79.57 161.06 4.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 122.063 0.935 . . . . 1.0 109.512 179.335 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 35.0 pt -148.82 -22.43 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 CA-C-N 114.858 -1.065 . . . . 1.0 110.414 -179.766 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -173.52 164.62 36.33 Favored Glycine 0 CA--C 1.52 0.376 0 N-CA-C 110.673 -0.971 . . . . 1.0 110.673 -179.752 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 98.1 p -118.62 133.11 56.1 Favored 'General case' 0 N--CA 1.48 1.053 0 CA-C-O 121.91 0.862 . . . . 1.0 110.06 179.562 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.2 tp -101.6 155.48 18.07 Favored 'General case' 0 N--CA 1.473 0.725 0 CA-C-N 115.113 -0.948 . . . . 1.0 109.649 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 57.6 m -93.2 143.06 26.62 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.144 -0.934 . . . . 1.0 109.919 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -74.83 155.65 48.37 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.149 -1.18 . . . . 1.0 110.149 179.442 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 69.67 16.84 7.91 Favored 'General case' 0 N--CA 1.475 0.784 0 CA-C-O 120.792 0.329 . . . . 1.0 110.381 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 83.3 m -88.06 141.95 28.17 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-O 121.279 0.562 . . . . 1.0 109.957 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 37.9 ttpt -83.15 134.6 34.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.712 0.768 . . . . 1.0 110.029 179.555 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 5.2 m -140.96 123.42 15.24 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.575 0 CA-C-N 115.316 -0.856 . . . . 1.0 110.136 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.43 ' O ' ' C ' ' A' ' 36' ' ' ILE . 31.2 m -84.31 87.62 7.21 Favored 'General case' 0 N--CA 1.467 0.384 0 N-CA-C 109.661 -0.496 . . . . 1.0 109.661 179.117 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.473 ' H ' ' CD1' ' A' ' 36' ' ' ILE . 1.7 mp -34.49 145.66 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 CA-C-N 116.067 -0.515 . . . . 1.0 110.541 179.196 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -154.3 67.54 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 CA-C-N 115.974 -0.557 . . . . 1.0 109.829 -178.563 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.05 167.89 34.61 Favored Glycine 0 CA--C 1.503 -0.69 0 N-CA-C 110.567 -1.013 . . . . 1.0 110.567 178.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.3 pp20? -153.73 156.61 38.1 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.216 -0.492 . . . . 1.0 110.669 -178.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -153.61 127.61 8.96 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 116.022 -0.536 . . . . 1.0 110.505 179.229 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.426 ' C ' ' H ' ' A' ' 43' ' ' PHE . . . 59.54 -152.87 33.7 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.358 -0.697 . . . . 1.0 111.358 179.602 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -77.47 38.87 0.25 Allowed 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 109.855 -0.424 . . . . 1.0 109.855 179.443 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.426 ' H ' ' C ' ' A' ' 41' ' ' GLY . 50.6 m-85 -151.37 159.14 44.42 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-O 121.804 0.812 . . . . 1.0 110.477 -179.769 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 1.3 m-85 -118.86 157.3 27.9 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 122.199 0.999 . . . . 1.0 110.238 179.668 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 84.4 tttt -99.81 144.33 29.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 114.854 -1.067 . . . . 1.0 109.854 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 28.8 pt -149.37 172.24 1.66 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.241 -0.891 . . . . 1.0 109.952 -179.576 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 77.4 tt0 -139.86 105.13 5.04 Favored 'General case' 0 N--CA 1.472 0.673 0 CA-C-N 115.143 -0.935 . . . . 1.0 110.333 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 27.1 t80 -139.7 163.71 31.87 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 115.592 -0.731 . . . . 1.0 110.187 179.269 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . 0.427 ' C ' ' H ' ' A' ' 51' ' ' SER . 18.5 mmtm 51.77 24.87 2.64 Favored 'General case' 0 CA--C 1.544 0.741 0 CA-C-N 115.57 -0.741 . . . . 1.0 111.06 179.623 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 74.0 -8.89 10.3 Favored Glycine 0 CA--C 1.528 0.883 0 N-CA-C 110.147 -1.181 . . . . 1.0 110.147 -179.623 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' SER . . . . . 0.427 ' H ' ' C ' ' A' ' 49' ' ' LYS . 50.5 m -108.82 174.02 6.06 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-O 122.07 0.938 . . . . 1.0 110.074 179.783 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 32.7 p80 -131.01 135.12 47.32 Favored 'General case' 0 N--CA 1.48 1.044 0 CA-C-N 114.971 -1.013 . . . . 1.0 110.331 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.03 154.55 25.98 Favored Glycine 0 N--CA 1.47 0.944 0 N-CA-C 110.652 -0.979 . . . . 1.0 110.652 179.537 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 55.6 m-85 -90.76 145.09 25.08 Favored 'General case' 0 N--CA 1.472 0.651 0 CA-C-O 121.485 0.66 . . . . 1.0 109.731 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 17.1 t -141.85 145.78 23.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 CA-C-N 115.582 -0.736 . . . . 1.0 110.365 -179.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.91 138.38 58.53 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.573 -0.74 . . . . 1.0 109.967 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 12.5 pttp -89.86 -25.13 21.18 Favored 'General case' 0 N--CA 1.475 0.809 0 CA-C-N 115.541 -0.754 . . . . 1.0 110.183 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 44.7 tp10 -65.95 -37.72 86.75 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.465 0.65 . . . . 1.0 110.509 -178.85 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 23.0 m-85 -68.89 -31.88 71.13 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 115.527 -0.76 . . . . 1.0 110.092 179.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 72.8 mt . . . . . 0 N--CA 1.467 0.42 0 CA-C-O 118.138 -0.934 . . . . 1.0 109.193 -179.486 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.5 mtt . . . . . 0 N--CA 1.488 1.443 0 N-CA-C 108.967 -0.753 . . . . 1.0 108.967 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -66.24 -20.23 66.05 Favored 'General case' 0 N--CA 1.472 0.628 0 CA-C-O 121.512 0.672 . . . . 1.0 110.591 -179.6 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 3.2 p -132.8 153.5 51.2 Favored 'General case' 0 N--CA 1.478 0.946 0 CA-C-N 115.469 -0.787 . . . . 1.0 110.166 -179.29 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -140.71 160.78 26.63 Favored Glycine 0 N--CA 1.468 0.797 0 N-CA-C 110.658 -0.977 . . . . 1.0 110.658 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 12.5 pt -106.01 135.96 42.25 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 CA-C-O 121.287 0.565 . . . . 1.0 109.737 179.542 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.485 ' O ' ' N ' ' A' ' 8' ' ' VAL . 37.7 t -53.72 111.69 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 CA-C-N 115.62 -0.718 . . . . 1.0 109.926 -179.751 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 4.7 m120 -56.31 83.42 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 115.724 -0.671 . . . . 1.0 110.593 179.601 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.485 ' N ' ' O ' ' A' ' 6' ' ' VAL . 3.2 t 47.71 -126.25 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.554 1.134 0 CA-C-N 115.579 -0.737 . . . . 1.0 110.199 -179.791 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' SER . . . . . 0.474 ' O ' ' O ' ' A' ' 8' ' ' VAL . 19.3 m 57.78 136.69 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 115.687 -0.688 . . . . 1.0 110.72 179.659 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 48.9 m -54.41 -65.73 0.52 Allowed 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 121.022 0.439 . . . . 1.0 110.652 -179.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 65.7 m -148.72 154.51 39.72 Favored 'General case' 0 N--CA 1.471 0.621 0 CA-C-O 121.798 0.809 . . . . 1.0 110.505 179.599 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -102.21 142.68 33.06 Favored 'General case' 0 N--CA 1.485 1.301 0 CA-C-N 115.233 -0.894 . . . . 1.0 109.977 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -85.18 99.53 11.14 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.072 -0.967 . . . . 1.0 109.477 -179.492 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 17.6 m -80.66 135.5 25.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 108.686 -0.857 . . . . 1.0 108.686 -179.458 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 67.2 mtm180 -117.85 -176.48 3.05 Favored 'General case' 0 N--CA 1.476 0.852 0 CA-C-N 115.13 -0.941 . . . . 1.0 110.234 -179.247 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 67.0 p -89.88 -20.61 23.19 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 115.333 -0.849 . . . . 1.0 110.519 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.653 ' C ' ' H ' ' A' ' 19' ' ' SER . 60.9 p -176.28 -173.17 0.53 Allowed 'General case' 0 N--CA 1.473 0.718 0 CA-C-O 121.681 0.753 . . . . 1.0 110.414 -179.649 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.81 17.24 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.375 0 CA-C-N 115.343 -0.844 . . . . 1.0 111.586 178.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' SER . . . . . 0.653 ' H ' ' C ' ' A' ' 17' ' ' SER . 70.0 m -100.87 97.83 8.39 Favored 'General case' 0 N--CA 1.48 1.038 0 CA-C-N 115.352 -0.84 . . . . 1.0 110.169 179.533 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.9 m -64.37 -4.29 3.72 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-N 115.685 -0.689 . . . . 1.0 110.15 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.4 ' H ' ' C ' ' A' ' 19' ' ' SER . 85.7 p -97.89 -3.53 38.39 Favored 'General case' 0 N--CA 1.473 0.699 0 CA-C-N 116.001 -0.545 . . . . 1.0 110.719 -179.826 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 78.1 p -77.36 -4.96 47.81 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 110.022 -0.362 . . . . 1.0 110.022 179.331 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 33.7 tttt 66.05 -163.27 0.24 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.094 0.473 . . . . 1.0 110.167 179.606 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 24.8 t -94.22 158.16 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 CA-C-O 122.193 0.997 . . . . 1.0 109.28 179.753 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 47.7 pt -137.67 -20.58 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.005 0 CA-C-N 114.852 -1.067 . . . . 1.0 110.496 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.425 ' CA ' ' HZ3' ' A' ' 49' ' ' LYS . . . -158.44 -153.89 6.95 Favored Glycine 0 N--CA 1.466 0.64 0 N-CA-C 110.689 -0.964 . . . . 1.0 110.689 -179.441 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' SER . . . . . 0.733 ' H ' ' HZ1' ' A' ' 49' ' ' LYS . 93.2 p -159.17 148.65 18.69 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 121.322 0.582 . . . . 1.0 110.372 179.644 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.6 tp -122.3 154.43 37.6 Favored 'General case' 0 N--CA 1.481 1.106 0 CA-C-O 121.624 0.726 . . . . 1.0 110.311 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 90.9 p -103.33 159.92 15.14 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 115.39 -0.823 . . . . 1.0 110.25 179.749 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -79.65 168.11 52.31 Favored Glycine 0 N--CA 1.476 1.352 0 N-CA-C 110.537 -1.025 . . . . 1.0 110.537 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 66.2 m-20 56.32 20.87 4.94 Favored 'General case' 0 N--CA 1.477 0.877 0 CA-C-O 120.929 0.395 . . . . 1.0 110.759 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 29.6 m -89.94 150.42 22.17 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-O 121.401 0.619 . . . . 1.0 109.828 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 50.9 tttp -103.25 150.6 23.57 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 115.548 -0.751 . . . . 1.0 110.275 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.4 p -157.36 145.56 10.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.687 -0.688 . . . . 1.0 109.858 179.553 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 90.4 m -106.09 106.33 16.79 Favored 'General case' 0 N--CA 1.481 1.095 0 N-CA-C 109.428 -0.582 . . . . 1.0 109.428 178.544 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.441 ' CG2' ' CD2' ' A' ' 44' ' ' TYR . 11.7 mm -42.35 134.86 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 CA-C-N 116.502 -0.317 . . . . 1.0 111.2 179.283 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 3.2 m -159.51 90.24 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.069 0 CA-C-O 121.986 0.898 . . . . 1.0 110.518 -178.052 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 109.63 115.06 3.7 Favored Glycine 0 N--CA 1.481 1.657 0 CA-C-N 115.114 -0.948 . . . . 1.0 110.824 179.178 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.464 ' CD ' ' H ' ' A' ' 39' ' ' GLU . 0.5 OUTLIER -105.13 132.62 51.12 Favored 'General case' 0 N--CA 1.48 1.033 0 N-CA-C 109.245 -0.65 . . . . 1.0 109.245 -178.817 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 79.8 tt0 -151.31 102.85 2.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.837 -0.62 . . . . 1.0 109.883 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.468 ' C ' ' H ' ' A' ' 43' ' ' PHE . . . 57.12 -149.21 31.39 Favored Glycine 0 CA--C 1.533 1.16 0 N-CA-C 111.226 -0.749 . . . . 1.0 111.226 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -74.56 17.56 0.2 Allowed 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 120.926 -0.31 . . . . 1.0 110.455 179.082 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.468 ' H ' ' C ' ' A' ' 41' ' ' GLY . 38.3 m-85 -133.56 158.13 43.95 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-O 121.853 0.835 . . . . 1.0 110.215 -179.53 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' TYR . . . . . 0.441 ' CD2' ' CG2' ' A' ' 36' ' ' ILE . 2.8 m-85 -127.04 165.22 19.88 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 122.621 1.2 . . . . 1.0 109.839 179.618 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 23.9 ttpp -107.96 129.58 55.1 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 114.465 -1.243 . . . . 1.0 110.004 -179.736 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 45.5 pt -122.18 170.05 12.81 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-O 122.302 1.048 . . . . 1.0 110.045 179.458 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -131.1 102.2 5.91 Favored 'General case' 0 N--CA 1.482 1.164 0 CA-C-N 114.702 -1.135 . . . . 1.0 109.778 -179.441 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -138.93 160.35 39.95 Favored 'General case' 0 N--CA 1.47 0.575 0 CA-C-O 121.432 0.634 . . . . 1.0 109.829 179.561 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . 0.733 ' HZ1' ' H ' ' A' ' 27' ' ' SER . 43.3 mtmt 50.35 26.65 2.36 Favored 'General case' 0 CA--C 1.546 0.811 0 CA-C-N 115.595 -0.73 . . . . 1.0 111.369 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 67.07 6.74 40.19 Favored Glycine 0 N--CA 1.474 1.227 0 N-CA-C 110.465 -1.054 . . . . 1.0 110.465 -179.418 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 85.7 p -117.35 175.45 5.61 Favored 'General case' 0 N--CA 1.485 1.303 0 C-N-CA 124.228 1.011 . . . . 1.0 110.506 -179.631 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 27.3 p-80 -114.29 135.51 53.99 Favored 'General case' 0 N--CA 1.486 1.368 0 CA-C-N 115.18 -0.918 . . . . 1.0 110.331 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -140.08 166.08 25.8 Favored Glycine 0 N--CA 1.472 1.059 0 N-CA-C 110.988 -0.845 . . . . 1.0 110.988 179.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 58.2 m-85 -130.35 136.5 49.17 Favored 'General case' 0 N--CA 1.483 1.196 0 CA-C-O 121.904 0.859 . . . . 1.0 110.11 179.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 26.0 t -143.28 150.2 17.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 CA-C-N 115.145 -0.934 . . . . 1.0 110.175 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -67.64 127.49 32.97 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-N 115.481 -0.781 . . . . 1.0 109.812 179.424 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . 0.417 ' NZ ' ' O ' ' A' ' 41' ' ' GLY . 11.5 pttm -74.91 -20.81 59.54 Favored 'General case' 0 N--CA 1.476 0.853 0 CA-C-N 115.251 -0.886 . . . . 1.0 110.095 179.95 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 76.5 tt0 -65.41 -37.47 87.06 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 121.461 0.648 . . . . 1.0 110.399 -178.817 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 27.3 m-85 -74.08 -33.61 63.7 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 115.609 -0.723 . . . . 1.0 109.897 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 62.6 mt . . . . . 0 N--CA 1.471 0.613 0 CA-C-O 118.096 -0.954 . . . . 1.0 109.051 -179.033 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.9 mtm . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 108.706 -0.85 . . . . 1.0 108.706 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 55.1 mtpt -63.69 -23.53 67.41 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-O 121.382 0.61 . . . . 1.0 110.434 -179.647 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 46.0 p -137.11 160.43 38.99 Favored 'General case' 0 N--CA 1.473 0.709 0 CA-C-O 121.719 0.771 . . . . 1.0 110.458 -179.681 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -138.01 155.51 23.33 Favored Glycine 0 N--CA 1.471 0.995 0 N-CA-C 110.659 -0.977 . . . . 1.0 110.659 -179.861 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 15.6 pt -98.24 137.26 26.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 CA-C-O 121.676 0.75 . . . . 1.0 109.209 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.571 ' O ' ' C ' ' A' ' 7' ' ' ASN . 22.0 t -83.01 142.98 12.83 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.46 0 CA-C-N 115.366 -0.834 . . . . 1.0 109.566 -179.827 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . 0.571 ' C ' ' O ' ' A' ' 6' ' ' VAL . 42.9 t30 8.72 -109.27 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.125 0 CA-C-N 116.243 -0.435 . . . . 1.0 111.859 -179.602 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 22.0 t -143.02 -52.25 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.292 0 CA-C-O 120.715 0.293 . . . . 1.0 110.434 177.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 40.7 t -170.14 77.75 0.09 Allowed 'General case' 0 N--CA 1.472 0.641 0 CA-C-O 120.855 0.359 . . . . 1.0 110.618 -179.544 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 49.3 m -160.52 168.46 25.01 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-N 116.052 -0.522 . . . . 1.0 110.679 -179.803 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 41.8 t -90.38 130.82 36.42 Favored 'General case' 0 N--CA 1.473 0.682 0 CA-C-O 121.304 0.573 . . . . 1.0 110.104 179.585 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 9.8 mp -100.94 164.35 11.86 Favored 'General case' 0 N--CA 1.479 1.002 0 CA-C-O 122.73 1.252 . . . . 1.0 109.41 179.409 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 84.9 m-20 -93.4 118.24 31.06 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-N 114.253 -1.339 . . . . 1.0 109.989 -179.614 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 20.6 t -101.9 107.58 21.94 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.308 0 N-CA-C 110.173 -0.306 . . . . 1.0 110.173 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 31.9 mtm180 -82.42 -173.14 4.41 Favored 'General case' 0 N--CA 1.478 0.971 0 CA-C-O 121.297 0.57 . . . . 1.0 110.345 179.441 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 17.6 t -95.17 -23.69 17.17 Favored 'General case' 0 N--CA 1.48 1.057 0 CA-C-N 115.675 -0.693 . . . . 1.0 111.085 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 28.7 t 175.86 38.85 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.645 0 CA-C-O 121.182 0.515 . . . . 1.0 111.214 -179.717 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . 76.07 45.39 0.12 Allowed 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 115.834 -0.621 . . . . 1.0 110.55 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 70.5 m -129.83 117.28 19.95 Favored 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 115.84 -0.618 . . . . 1.0 110.795 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 24.9 m -64.06 -29.12 70.28 Favored 'General case' 0 N--CA 1.475 0.794 0 CA-C-N 116.067 -0.515 . . . . 1.0 109.995 179.347 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 55.0 m -68.45 -22.38 64.58 Favored 'General case' 0 CA--C 1.537 0.442 0 CA-C-N 116.121 -0.49 . . . . 1.0 110.508 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 45.9 t -70.18 -39.07 75.48 Favored 'General case' 0 N--CA 1.475 0.8 0 CA-C-O 121.429 0.633 . . . . 1.0 110.528 179.128 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.451 ' HG2' ' H ' ' A' ' 24' ' ' VAL . 5.0 ttmm 80.43 -170.58 0.04 OUTLIER 'General case' 0 N--CA 1.485 1.305 0 CA-C-N 115.612 -0.722 . . . . 1.0 109.703 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.451 ' H ' ' HG2' ' A' ' 23' ' ' LYS . 24.9 t -83.76 105.51 13.35 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.494 0 CA-C-N 115.852 -0.613 . . . . 1.0 109.873 179.746 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 40.0 pt -94.12 -19.61 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 CA-C-N 115.789 -0.641 . . . . 1.0 110.489 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -145.22 -163.95 10.42 Favored Glycine 0 N--CA 1.478 1.492 0 N-CA-C 110.99 -0.844 . . . . 1.0 110.99 -179.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 45.4 t -160.87 130.24 4.84 Favored 'General case' 0 N--CA 1.47 0.549 0 C-N-CA 120.65 -0.42 . . . . 1.0 109.958 179.594 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.9 tp -109.52 153.32 24.27 Favored 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 121.342 0.591 . . . . 1.0 109.947 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 61.4 m -91.3 149.93 21.53 Favored 'General case' 0 N--CA 1.472 0.628 0 CA-C-N 115.696 -0.684 . . . . 1.0 110.037 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -74.7 148.68 38.79 Favored Glycine 0 CA--C 1.528 0.849 0 N-CA-C 110.481 -1.048 . . . . 1.0 110.481 179.612 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 12.1 t-20 64.82 41.06 5.18 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-O 121.024 0.44 . . . . 1.0 110.52 -179.763 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 34.7 m -106.96 127.43 53.44 Favored 'General case' 0 N--CA 1.489 1.484 0 CA-C-N 115.95 -0.568 . . . . 1.0 110.356 179.554 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -76.68 147.05 37.71 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-O 121.231 0.538 . . . . 1.0 109.822 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.3 p -157.28 148.08 10.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.706 -0.679 . . . . 1.0 110.35 -179.421 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 68.4 p -86.06 84.28 7.55 Favored 'General case' 0 N--CA 1.473 0.689 0 CA-C-N 116.111 -0.495 . . . . 1.0 110.031 179.228 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.427 ' CG2' ' H ' ' A' ' 37' ' ' VAL . 69.4 mt -50.53 171.57 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 CA-C-N 116.37 -0.377 . . . . 1.0 110.216 -179.862 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.427 ' H ' ' CG2' ' A' ' 36' ' ' ILE . 39.1 t -139.29 -92.42 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.298 0 CA-C-N 116.547 -0.297 . . . . 1.0 110.668 -179.482 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -118.45 -172.58 15.6 Favored Glycine 0 N--CA 1.487 2.04 0 N-CA-C 111.052 -0.819 . . . . 1.0 111.052 -179.172 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -113.86 111.84 22.38 Favored 'General case' 0 N--CA 1.483 1.19 0 CA-C-O 123.331 1.539 . . . . 1.0 109.623 179.359 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.497 ' N ' ' O ' ' A' ' 43' ' ' PHE . 3.1 tm-20 -104.07 96.41 6.64 Favored 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 113.676 -1.602 . . . . 1.0 109.214 179.026 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.408 ' C ' ' O ' ' A' ' 40' ' ' GLU . . . 30.61 56.31 0.25 Allowed Glycine 0 N--CA 1.503 3.11 0 CA-C-N 114.806 -1.088 . . . . 1.0 113.141 179.64 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . 76.46 30.41 0.65 Allowed 'General case' 0 N--CA 1.489 1.494 0 CA-C-N 115.18 -0.51 . . . . 1.0 111.188 -178.438 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.497 ' O ' ' N ' ' A' ' 40' ' ' GLU . 75.1 m-85 -153.86 159.41 41.79 Favored 'General case' 0 N--CA 1.496 1.864 0 CA-C-N 116.194 -0.457 . . . . 1.0 111.005 179.774 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' TYR . . . . . 0.428 ' CD1' ' N ' ' A' ' 44' ' ' TYR . 15.2 p90 -143.89 165.98 26.21 Favored 'General case' 0 N--CA 1.488 1.435 0 CA-C-O 120.893 0.377 . . . . 1.0 110.407 179.398 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.568 ' NZ ' ' HH ' ' A' ' 54' ' ' TYR . 68.4 mttm -88.2 159.52 18.12 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 109.551 -0.537 . . . . 1.0 109.551 -179.433 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 38.4 pt -146.97 154.38 11.91 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 CA-C-N 115.902 -0.59 . . . . 1.0 110.308 -179.367 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 72.7 mt-10 -110.33 84.28 1.9 Allowed 'General case' 0 N--CA 1.479 1.009 0 CA-C-N 115.911 -0.586 . . . . 1.0 109.67 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 7.7 t80 -119.56 137.04 54.09 Favored 'General case' 0 N--CA 1.486 1.352 0 CA-C-N 116.036 -0.529 . . . . 1.0 110.149 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 96.2 mttt 47.49 27.47 0.97 Allowed 'General case' 0 N--CA 1.481 1.09 0 CA-C-N 115.907 -0.588 . . . . 1.0 111.149 -179.297 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 67.44 23.26 73.49 Favored Glycine 0 N--CA 1.472 1.039 0 N-CA-C 110.824 -0.91 . . . . 1.0 110.824 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 92.1 p -128.4 166.02 19.5 Favored 'General case' 0 N--CA 1.482 1.136 0 CA-C-O 121.722 0.772 . . . . 1.0 110.826 -178.787 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -94.31 153.66 17.89 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-N 115.344 -0.844 . . . . 1.0 110.382 -179.407 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -158.09 166.31 34.03 Favored Glycine 0 N--CA 1.473 1.118 0 N-CA-C 110.748 -0.941 . . . . 1.0 110.748 -179.821 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . 0.568 ' HH ' ' NZ ' ' A' ' 45' ' ' LYS . 69.5 m-85 -133.38 142.1 48.22 Favored 'General case' 0 N--CA 1.484 1.233 0 CA-C-N 115.552 -0.324 . . . . 1.0 110.417 -179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -147.78 147.29 17.4 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 CA-C-O 121.366 0.603 . . . . 1.0 109.816 -179.167 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -69.69 143.22 53.2 Favored 'General case' 0 CA--C 1.533 0.323 0 CA-C-N 115.642 -0.708 . . . . 1.0 110.017 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 9.6 mtmp? -87.31 -32.81 19.46 Favored 'General case' 0 N--CA 1.48 1.073 0 CA-C-N 116.006 -0.543 . . . . 1.0 110.218 179.645 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -52.58 -39.77 61.92 Favored 'General case' 0 N--CA 1.472 0.634 0 N-CA-C 110.227 -0.286 . . . . 1.0 110.227 -179.412 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 7.4 m-85 -48.4 -25.09 1.46 Allowed 'General case' 0 N--CA 1.48 1.069 0 CA-C-N 116.386 -0.37 . . . . 1.0 110.591 179.152 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 69.9 mt . . . . . 0 N--CA 1.476 0.861 0 CA-C-O 117.781 -1.104 . . . . 1.0 108.656 179.739 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 71.3 mtp . . . . . 0 N--CA 1.494 1.731 0 N-CA-C 109.391 -0.596 . . . . 1.0 109.391 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -62.88 -40.93 99.05 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-O 121.812 0.815 . . . . 1.0 110.678 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 51.7 p -115.73 156.89 25.16 Favored 'General case' 0 N--CA 1.479 1.003 0 CA-C-N 115.132 -0.94 . . . . 1.0 110.228 -179.8 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -91.4 148.98 19.57 Favored Glycine 0 N--CA 1.468 0.777 0 N-CA-C 110.36 -1.096 . . . . 1.0 110.36 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 65.7 mt -104.33 126.75 59.02 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 CA-C-O 121.607 0.718 . . . . 1.0 109.131 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 28.8 t -91.47 129.49 42.1 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-N 115.402 -0.817 . . . . 1.0 109.692 179.532 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 62.5 m-80 -49.27 125.64 11.31 Favored 'General case' 0 CA--C 1.545 0.762 0 CA-C-N 116.085 -0.507 . . . . 1.0 110.54 179.315 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 32.6 t -51.28 -62.27 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 CA-C-N 115.905 -0.589 . . . . 1.0 110.473 -179.451 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.9 m -62.91 153.93 31.87 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.179 0.514 . . . . 1.0 109.988 179.611 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 69.54 -171.8 0.18 Allowed 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 115.856 -0.611 . . . . 1.0 110.157 -179.873 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 42.6 t -150.32 154.17 37.38 Favored 'General case' 0 N--CA 1.473 0.697 0 CA-C-O 121.548 0.69 . . . . 1.0 110.366 179.91 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -99.68 135.28 41.33 Favored 'General case' 0 N--CA 1.478 0.94 0 CA-C-O 122.062 0.934 . . . . 1.0 109.989 -179.42 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 20.3 p-10 -90.76 129.27 36.86 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.009 -0.996 . . . . 1.0 109.674 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 41.0 t -92.02 103.38 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 CA-C-N 115.664 -0.698 . . . . 1.0 109.336 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 90.8 mtt-85 -81.97 151.57 27.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.434 0.635 . . . . 1.0 109.893 179.244 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 39.8 t -71.99 -21.63 61.54 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 115.582 -0.735 . . . . 1.0 110.433 179.535 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 48.9 m -163.73 174.94 11.02 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-N 116.014 -0.539 . . . . 1.0 110.682 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -70.6 56.48 0.17 Allowed 'General case' 0 N--CA 1.474 0.744 0 CA-C-N 115.792 -0.64 . . . . 1.0 110.42 179.502 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 49.1 m -140.65 130.02 23.84 Favored 'General case' 0 N--CA 1.481 1.089 0 CA-C-O 121.532 0.682 . . . . 1.0 110.577 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 3.7 t -66.31 -31.66 72.59 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 115.476 -0.784 . . . . 1.0 110.425 179.755 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 95.7 p -73.85 -4.81 37.14 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 115.976 -0.557 . . . . 1.0 110.244 -179.787 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 43.1 t -58.9 -173.82 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 120.952 0.406 . . . . 1.0 110.41 179.493 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -127.58 161.52 28.63 Favored 'General case' 0 N--CA 1.478 0.974 0 CA-C-O 121.747 0.784 . . . . 1.0 110.286 -179.768 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.2 t -89.42 108.99 19.81 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-N 115.283 -0.871 . . . . 1.0 109.694 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 45.9 pt -85.72 -17.01 9.69 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 CA-C-N 115.597 -0.729 . . . . 1.0 110.187 179.728 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 175.32 174.73 42.17 Favored Glycine 0 N--CA 1.461 0.319 0 N-CA-C 110.942 -0.863 . . . . 1.0 110.942 -179.455 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 42.6 t -142.52 137.58 30.31 Favored 'General case' 0 N--CA 1.475 0.798 0 CA-C-O 121.775 0.798 . . . . 1.0 110.528 179.604 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -99.8 171.87 7.61 Favored 'General case' 0 N--CA 1.475 0.782 0 CA-C-N 115.303 -0.862 . . . . 1.0 109.206 -179.671 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 56.7 m -89.96 155.13 19.32 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 115.085 -0.961 . . . . 1.0 110.298 -179.225 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -74.97 150.76 41.47 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.117 -1.193 . . . . 1.0 110.117 179.397 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 22.9 t30 74.83 17.71 2.79 Favored 'General case' 0 N--CA 1.48 1.04 0 CA-C-O 120.798 0.332 . . . . 1.0 110.572 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 59.4 m -87.86 132.39 34.21 Favored 'General case' 0 N--CA 1.478 0.975 0 CA-C-O 121.236 0.541 . . . . 1.0 110.042 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 26.9 mtpp -82.61 144.62 30.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.638 0.732 . . . . 1.0 109.677 179.738 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 16.9 m -147.63 130.47 7.87 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.451 0 CA-C-N 115.319 -0.855 . . . . 1.0 109.863 -179.91 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' THR . . . . . 0.411 ' O ' ' C ' ' A' ' 36' ' ' ILE . 30.7 m -86.39 89.05 7.75 Favored 'General case' 0 CA--C 1.515 -0.388 0 N-CA-C 109.098 -0.704 . . . . 1.0 109.098 179.463 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.411 ' C ' ' O ' ' A' ' 35' ' ' THR . 3.5 mp -34.47 146.94 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.504 2.253 0 CA-C-N 116.372 -0.377 . . . . 1.0 111.579 179.345 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 4.7 t -143.45 62.55 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.084 0 CA-C-O 121.05 0.452 . . . . 1.0 110.333 -178.669 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 108.61 166.57 20.94 Favored Glycine 0 N--CA 1.465 0.624 0 N-CA-C 110.462 -1.055 . . . . 1.0 110.462 179.75 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 16.4 pt-20 -142.21 147.25 36.24 Favored 'General case' 0 N--CA 1.476 0.842 0 CA-C-N 114.824 -0.688 . . . . 1.0 110.15 -179.747 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -154.37 125.84 7.47 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 115.704 -0.68 . . . . 1.0 110.162 179.453 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 50.33 -112.46 1.55 Allowed Glycine 0 CA--C 1.535 1.312 0 N-CA-C 111.398 -0.681 . . . . 1.0 111.398 179.442 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -115.37 22.63 13.08 Favored 'General case' 0 N--CA 1.482 1.143 0 N-CA-C 109.911 -0.403 . . . . 1.0 109.911 179.151 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.407 ' C ' ' NZ ' ' A' ' 57' ' ' LYS . 54.5 m-85 -143.37 153.88 43.15 Favored 'General case' 0 N--CA 1.477 0.884 0 CA-C-O 122.012 0.91 . . . . 1.0 110.365 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' TYR . . . . . 0.43 ' N ' ' CD1' ' A' ' 44' ' ' TYR . 11.8 p90 -134.67 169.17 17.72 Favored 'General case' 0 N--CA 1.473 0.687 0 CA-C-O 122.146 0.974 . . . . 1.0 110.04 -179.481 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.462 ' NZ ' ' CD2' ' A' ' 52' ' ' HIS . 63.3 tttm -95.58 151.85 18.96 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 114.902 -1.045 . . . . 1.0 109.918 -179.328 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 18.1 pt -143.91 162.05 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 CA-C-O 122.156 0.979 . . . . 1.0 110.021 179.39 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -125.25 96.78 4.96 Favored 'General case' 0 N--CA 1.479 1.017 0 CA-C-N 114.818 -1.083 . . . . 1.0 110.108 179.276 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 39.2 t80 -135.73 152.79 51.5 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 115.718 -0.674 . . . . 1.0 109.968 179.287 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 63.5 mttt 56.69 10.86 0.78 Allowed 'General case' 0 N--CA 1.475 0.819 0 CA-C-N 115.812 -0.631 . . . . 1.0 110.84 179.629 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 81.35 0.03 88.44 Favored Glycine 0 N--CA 1.472 1.1 0 N-CA-C 110.264 -1.134 . . . . 1.0 110.264 -179.573 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 49.4 m -110.98 172.97 6.56 Favored 'General case' 0 N--CA 1.482 1.153 0 C-N-CA 123.902 0.881 . . . . 1.0 110.167 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' HIS . . . . . 0.462 ' CD2' ' NZ ' ' A' ' 45' ' ' LYS . 30.7 m170 -107.16 145.54 32.43 Favored 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 115.35 -0.841 . . . . 1.0 110.023 -179.747 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -152.06 170.92 31.42 Favored Glycine 0 N--CA 1.464 0.501 0 N-CA-C 110.9 -0.88 . . . . 1.0 110.9 -179.382 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 80.1 m-85 -132.38 146.23 51.81 Favored 'General case' 0 N--CA 1.482 1.13 0 CA-C-O 121.518 0.675 . . . . 1.0 110.258 179.219 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 36.4 t -143.64 147.59 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 CA-C-N 115.451 -0.795 . . . . 1.0 110.277 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -68.75 153.12 44.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.547 -0.751 . . . . 1.0 110.216 179.641 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . 0.407 ' NZ ' ' C ' ' A' ' 43' ' ' PHE . 65.4 mttp -89.99 -22.82 21.73 Favored 'General case' 0 N--CA 1.478 0.961 0 CA-C-N 115.709 -0.678 . . . . 1.0 110.586 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -52.38 -35.99 52.83 Favored 'General case' 0 CA--C 1.537 0.478 0 CA-C-O 121.068 0.461 . . . . 1.0 110.488 -179.146 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 24.4 m-85 -64.04 -30.18 71.27 Favored 'General case' 0 N--CA 1.475 0.823 0 CA-C-N 115.905 -0.589 . . . . 1.0 110.477 178.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 63.5 mt . . . . . 0 N--CA 1.47 0.542 0 CA-C-O 118.119 -0.943 . . . . 1.0 108.609 -179.577 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 65.8 mtt . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 108.807 -0.812 . . . . 1.0 108.807 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 25.9 ttpp -65.04 148.91 50.79 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.531 -0.759 . . . . 1.0 110.112 -179.551 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 53.9 p -118.31 144.79 45.58 Favored 'General case' 0 N--CA 1.474 0.727 0 CA-C-O 121.695 0.76 . . . . 1.0 110.475 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -97.58 154.25 20.31 Favored Glycine 0 N--CA 1.476 1.322 0 N-CA-C 110.038 -1.225 . . . . 1.0 110.038 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 65.7 mt -106.07 125.26 61.66 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.086 0 CA-C-O 121.239 0.543 . . . . 1.0 109.555 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 45.0 t -74.55 133.48 31.45 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.324 0 CA-C-N 115.788 -0.642 . . . . 1.0 109.479 179.61 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 9.4 m120 -62.13 109.27 1.25 Allowed 'General case' 0 CA--C 1.537 0.444 0 CA-C-N 115.735 -0.666 . . . . 1.0 110.113 179.363 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.3 p -55.61 -19.33 5.91 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 CA-C-N 116.035 -0.529 . . . . 1.0 110.435 179.515 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' SER . . . . . 0.476 ' O ' ' OG ' ' A' ' 10' ' ' SER . 49.5 m -52.08 105.97 0.13 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.158 -0.473 . . . . 1.0 110.422 -179.373 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' SER . . . . . 0.476 ' OG ' ' O ' ' A' ' 9' ' ' SER . 80.9 p 60.42 -122.38 0.97 Allowed 'General case' 0 CA--C 1.548 0.882 0 CA-C-N 116.062 -0.517 . . . . 1.0 110.448 -180.0 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 47.7 t -151.98 156.57 40.29 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-O 121.379 0.609 . . . . 1.0 110.083 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -104.24 136.46 43.8 Favored 'General case' 0 N--CA 1.479 1.016 0 CA-C-O 121.817 0.818 . . . . 1.0 110.323 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 72.5 m-80 -92.31 133.97 35.35 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.199 -0.909 . . . . 1.0 109.269 -179.623 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 59.3 t -93.19 105.75 17.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-N 115.104 -0.953 . . . . 1.0 109.37 -179.658 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 88.9 mtt-85 -81.32 148.55 29.33 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.487 0.661 . . . . 1.0 109.922 179.305 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 87.6 p -73.14 -19.41 61.14 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 115.606 -0.724 . . . . 1.0 110.019 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 87.1 p -162.17 172.85 15.13 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-O 121.179 0.514 . . . . 1.0 110.798 -179.585 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -71.47 57.45 0.26 Allowed 'General case' 0 N--CA 1.474 0.767 0 CA-C-N 115.789 -0.641 . . . . 1.0 110.49 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 55.8 m -143.93 130.43 20.01 Favored 'General case' 0 N--CA 1.481 1.105 0 CA-C-N 115.71 -0.677 . . . . 1.0 110.492 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 57.8 p -65.72 -26.61 67.83 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 115.827 -0.624 . . . . 1.0 110.226 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 49.4 m -71.07 -8.02 50.49 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 116.063 -0.517 . . . . 1.0 110.256 179.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 61.2 m -67.0 132.08 47.17 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 121.388 0.614 . . . . 1.0 110.01 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -72.48 169.58 16.13 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.615 -0.72 . . . . 1.0 110.123 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.7 t -90.16 112.58 24.95 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 CA-C-O 121.807 0.813 . . . . 1.0 109.754 179.751 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 2.1 pp -85.18 -27.19 6.54 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 CA-C-N 115.146 -0.934 . . . . 1.0 109.761 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 173.15 -171.84 44.73 Favored Glycine 0 N--CA 1.465 0.583 0 N-CA-C 111.398 -0.681 . . . . 1.0 111.398 -179.423 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 95.4 p -151.92 145.23 24.73 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-O 121.895 0.855 . . . . 1.0 110.449 179.208 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -102.31 -179.11 3.89 Favored 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 115.166 -0.925 . . . . 1.0 109.28 -179.662 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 96.8 p -91.66 144.63 25.33 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 115.145 -0.934 . . . . 1.0 110.197 -179.646 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -75.13 157.96 50.5 Favored Glycine 0 N--CA 1.461 0.343 0 N-CA-C 110.212 -1.155 . . . . 1.0 110.212 179.566 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 8.7 t30 69.46 20.82 7.08 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-O 120.707 0.289 . . . . 1.0 110.485 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 85.7 m -88.99 137.16 32.57 Favored 'General case' 0 N--CA 1.478 0.962 0 CA-C-O 121.413 0.625 . . . . 1.0 110.433 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -86.93 144.51 26.92 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-O 122.069 0.938 . . . . 1.0 109.814 179.771 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 5.7 p -153.75 138.14 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.423 0 CA-C-N 114.898 -1.046 . . . . 1.0 109.806 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 60.9 p -82.46 84.32 7.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.784 -0.644 . . . . 1.0 109.62 178.694 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 88.6 mt -43.02 160.06 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 CA-C-N 115.657 -0.701 . . . . 1.0 110.243 179.428 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 43.3 t -123.34 -92.5 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 CA-C-N 115.882 -0.599 . . . . 1.0 109.698 -179.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -114.89 -159.15 12.27 Favored Glycine 0 N--CA 1.466 0.653 0 CA-C-O 122.318 0.954 . . . . 1.0 110.861 -179.278 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . 0.461 ' N ' ' NZ ' ' A' ' 45' ' ' LYS . 1.0 OUTLIER -143.66 147.93 35.04 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 114.707 -0.747 . . . . 1.0 110.61 -179.524 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -154.64 124.5 6.65 Favored 'General case' 0 N--CA 1.47 0.558 0 CA-C-N 115.929 -0.578 . . . . 1.0 110.345 179.319 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 53.3 -150.15 11.71 Favored Glycine 0 CA--C 1.532 1.149 0 N-CA-C 111.139 -0.784 . . . . 1.0 111.139 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -84.9 30.37 0.58 Allowed 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 110.151 -0.314 . . . . 1.0 110.151 179.431 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 -145.69 153.37 40.92 Favored 'General case' 0 N--CA 1.477 0.909 0 CA-C-O 121.784 0.802 . . . . 1.0 110.529 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 1.7 m-85 -109.68 148.87 30.59 Favored 'General case' 0 N--CA 1.48 1.032 0 CA-C-O 122.556 1.169 . . . . 1.0 110.099 179.468 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.461 ' NZ ' ' N ' ' A' ' 39' ' ' GLU . 35.4 mtmm -87.98 140.73 29.2 Favored 'General case' 0 CA--C 1.518 -0.281 0 CA-C-N 114.485 -1.234 . . . . 1.0 109.508 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 39.9 pt -149.86 173.41 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.358 0 CA-C-N 114.594 -1.185 . . . . 1.0 109.688 -179.128 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -146.61 108.14 4.29 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 115.74 -0.664 . . . . 1.0 110.225 178.94 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 54.6 t80 -139.08 162.35 35.15 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.739 -0.664 . . . . 1.0 110.054 179.76 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 19.2 tttp 59.18 16.49 4.91 Favored 'General case' 0 CA--C 1.546 0.818 0 CA-C-N 115.55 -0.75 . . . . 1.0 110.9 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 77.85 -2.1 65.64 Favored Glycine 0 N--CA 1.477 1.403 0 N-CA-C 110.171 -1.171 . . . . 1.0 110.171 -179.357 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 49.2 m -114.95 176.29 5.12 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 124.278 1.031 . . . . 1.0 110.486 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 25.9 p80 -105.36 141.01 37.62 Favored 'General case' 0 N--CA 1.482 1.15 0 CA-C-N 115.464 -0.789 . . . . 1.0 110.064 -179.447 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.68 165.8 27.92 Favored Glycine 0 N--CA 1.463 0.435 0 N-CA-C 110.525 -1.03 . . . . 1.0 110.525 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -130.37 145.43 51.8 Favored 'General case' 0 N--CA 1.483 1.217 0 CA-C-O 121.527 0.68 . . . . 1.0 110.001 179.538 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 41.3 t -145.92 149.75 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 CA-C-O 121.904 0.859 . . . . 1.0 109.427 -179.723 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.402 ' O ' ' CD1' ' A' ' 59' ' ' TYR . . . -60.71 153.44 24.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 114.986 -1.006 . . . . 1.0 110.164 178.952 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 15.8 pttp -102.89 -31.34 10.31 Favored 'General case' 0 N--CA 1.482 1.167 0 CA-C-N 115.442 -0.799 . . . . 1.0 111.763 178.9 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' GLU . . . . . 0.407 ' C ' ' H ' ' A' ' 60' ' ' ILE . 14.6 pt-20 -64.53 -31.82 73.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.444 0.64 . . . . 1.0 111.022 -179.176 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . 0.402 ' CD1' ' O ' ' A' ' 56' ' ' ALA . 0.6 OUTLIER -62.7 -4.12 1.88 Allowed 'General case' 0 CA--C 1.549 0.918 0 CA-C-N 115.476 -0.783 . . . . 1.0 110.138 -179.888 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . 0.407 ' H ' ' C ' ' A' ' 58' ' ' GLU . 85.1 mt . . . . . 0 N--CA 1.477 0.888 0 N-CA-C 108.13 -1.063 . . . . 1.0 108.13 -179.163 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 15.5 ptp . . . . . 0 N--CA 1.492 1.642 0 N-CA-C 109.435 -0.58 . . . . 1.0 109.435 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -63.84 -79.8 0.03 OUTLIER 'General case' 0 N--CA 1.475 0.785 0 CA-C-O 121.432 0.634 . . . . 1.0 110.563 -179.759 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 20.2 p -137.78 151.26 47.96 Favored 'General case' 0 N--CA 1.489 1.479 0 CA-C-N 115.549 -0.75 . . . . 1.0 110.353 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -96.8 142.78 16.36 Favored Glycine 0 N--CA 1.474 1.217 0 N-CA-C 110.625 -0.99 . . . . 1.0 110.625 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 75.1 mt -109.24 141.56 24.18 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.177 0 CA-C-O 121.224 0.535 . . . . 1.0 109.95 -179.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 2.8 t -116.56 115.86 50.39 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 CA-C-O 116.812 -1.566 . . . . 1.0 110.682 178.083 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -82.48 146.3 29.33 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 120.098 1.317 . . . . 1.0 109.06 177.638 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.9 p -50.14 139.01 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 CA-C-N 116.314 -0.403 . . . . 1.0 111.126 179.289 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 79.2 p -168.59 -78.88 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.844 0 CA-C-O 120.843 0.354 . . . . 1.0 111.141 -179.26 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 97.6 p -131.15 -133.74 0.2 Allowed 'General case' 0 N--CA 1.485 1.287 0 CA-C-N 116.068 -0.515 . . . . 1.0 110.516 -179.105 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 98.3 p -138.85 153.76 48.36 Favored 'General case' 0 N--CA 1.477 0.925 0 CA-C-O 121.312 0.577 . . . . 1.0 110.238 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -140.3 128.27 22.09 Favored 'General case' 0 N--CA 1.49 1.553 0 CA-C-O 121.733 0.778 . . . . 1.0 109.715 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 19.3 p30 -92.96 144.08 25.61 Favored 'General case' 0 N--CA 1.473 0.704 0 CA-C-N 115.298 -0.865 . . . . 1.0 110.06 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 93.9 t -97.79 128.45 49.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 CA-C-O 121.879 0.847 . . . . 1.0 108.894 179.173 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 89.5 mtt-85 -99.55 -167.74 1.51 Allowed 'General case' 0 N--CA 1.473 0.702 0 CA-C-N 115.187 -0.915 . . . . 1.0 110.162 -179.744 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 60.1 p -130.8 33.16 4.26 Favored 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 123.017 0.527 . . . . 1.0 110.611 -179.413 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.48 ' OG ' ' N ' ' A' ' 18' ' ' ALA . 6.9 t 175.8 -177.95 0.13 Allowed 'General case' 0 N--CA 1.48 1.027 0 CA-C-O 121.632 0.729 . . . . 1.0 110.507 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.48 ' N ' ' OG ' ' A' ' 17' ' ' SER . . . -97.11 42.97 1.08 Allowed 'General case' 0 N--CA 1.488 1.448 0 CA-C-N 115.285 -0.87 . . . . 1.0 110.182 179.511 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 44.3 t -130.63 138.18 49.97 Favored 'General case' 0 N--CA 1.489 1.477 0 CA-C-N 115.106 -0.952 . . . . 1.0 110.902 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 80.1 p -74.73 -8.75 57.37 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-N 116.227 -0.442 . . . . 1.0 110.569 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 66.7 m -99.36 -6.58 27.57 Favored 'General case' 0 N--CA 1.486 1.333 0 CA-C-N 116.201 -0.454 . . . . 1.0 111.069 -179.072 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 13.9 t -66.48 133.95 51.46 Favored 'General case' 0 N--CA 1.473 0.72 0 CA-C-N 115.962 -0.563 . . . . 1.0 110.843 -179.414 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 38.3 ttmt -59.89 155.67 15.99 Favored 'General case' 0 N--CA 1.475 0.793 0 CA-C-N 116.031 -0.531 . . . . 1.0 110.622 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 6.8 p -83.94 144.56 9.68 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.193 0 CA-C-O 121.176 0.513 . . . . 1.0 110.503 -179.68 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 40.1 pt -121.87 -10.26 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 CA-C-N 115.813 -0.631 . . . . 1.0 110.34 179.266 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 179.35 -171.56 43.42 Favored Glycine 0 N--CA 1.467 0.759 0 N-CA-C 111.111 -0.796 . . . . 1.0 111.111 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 96.7 p -157.25 151.0 24.33 Favored 'General case' 0 N--CA 1.475 0.797 0 CA-C-N 115.642 -0.279 . . . . 1.0 110.559 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 2.2 pp -117.23 167.78 10.9 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 123.076 0.55 . . . . 1.0 110.507 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 90.9 p -112.74 160.02 18.37 Favored 'General case' 0 N--CA 1.482 1.17 0 CA-C-N 115.718 -0.673 . . . . 1.0 110.537 -179.491 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.421 ' O ' ' HB2' ' A' ' 31' ' ' ASN . . . -83.75 76.06 2.29 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 110.901 -0.88 . . . . 1.0 110.901 179.41 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.421 ' HB2' ' O ' ' A' ' 30' ' ' GLY . 22.1 t-20 164.61 16.3 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.843 0 C-N-CA 123.287 0.635 . . . . 1.0 110.242 -179.566 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 36.4 m -109.84 147.47 33.27 Favored 'General case' 0 N--CA 1.486 1.337 0 C-N-CA 123.424 0.69 . . . . 1.0 111.046 -179.458 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 22.2 pttp -90.25 148.77 22.7 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 122.602 0.361 . . . . 1.0 110.209 178.532 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.6 m -143.21 126.04 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 CA-C-O 120.829 0.347 . . . . 1.0 110.296 179.587 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 9.8 t -82.79 85.47 7.07 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 121.445 0.641 . . . . 1.0 110.619 179.674 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 85.6 mt -51.16 157.23 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 CA-C-N 115.546 -0.752 . . . . 1.0 110.165 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 39.6 t -127.4 -97.86 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 CA-C-N 115.947 -0.569 . . . . 1.0 110.003 -179.076 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -99.49 -178.42 31.2 Favored Glycine 0 N--CA 1.472 1.036 0 N-CA-C 110.937 -0.865 . . . . 1.0 110.937 -179.773 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -135.16 141.8 46.0 Favored 'General case' 0 N--CA 1.483 1.193 0 CA-C-O 120.984 0.421 . . . . 1.0 110.204 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -155.38 134.84 12.48 Favored 'General case' 0 CA--C 1.539 0.524 0 CA-C-N 116.001 -0.545 . . . . 1.0 110.378 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 48.56 -113.14 1.4 Allowed Glycine 0 CA--C 1.547 2.051 0 CA-C-N 115.947 -0.57 . . . . 1.0 111.707 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -122.49 24.7 9.16 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 110.049 -0.352 . . . . 1.0 110.049 179.23 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -145.07 156.18 43.76 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-O 121.301 0.572 . . . . 1.0 110.296 -179.474 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 22.6 p90 -131.67 162.87 29.38 Favored 'General case' 0 N--CA 1.488 1.458 0 CA-C-N 115.684 -0.689 . . . . 1.0 110.452 179.712 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -88.58 160.39 17.45 Favored 'General case' 0 N--CA 1.476 0.829 0 CA-C-N 116.037 -0.528 . . . . 1.0 110.159 -179.372 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 34.4 pt -145.75 153.17 13.74 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 CA-C-O 121.312 0.577 . . . . 1.0 110.504 -179.632 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 80.8 mm-40 -95.75 58.73 1.99 Allowed 'General case' 0 N--CA 1.481 1.113 0 CA-C-N 115.668 -0.696 . . . . 1.0 110.069 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 77.8 t80 -78.94 117.54 20.11 Favored 'General case' 0 N--CA 1.474 0.727 0 CA-C-N 115.603 -0.726 . . . . 1.0 109.915 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm 45.58 33.21 1.32 Allowed 'General case' 0 CA--C 1.557 1.24 0 CA-C-O 121.276 0.56 . . . . 1.0 111.415 -179.629 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 68.19 21.74 74.03 Favored Glycine 0 N--CA 1.482 1.736 0 N-CA-C 111.373 -0.691 . . . . 1.0 111.373 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 28.9 t -115.98 171.65 7.65 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 123.332 0.653 . . . . 1.0 110.878 -179.186 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -96.77 136.85 36.73 Favored 'General case' 0 N--CA 1.479 0.995 0 CA-C-N 115.942 -0.572 . . . . 1.0 110.229 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -148.2 163.13 28.9 Favored Glycine 0 N--CA 1.479 1.522 0 N-CA-C 110.993 -0.843 . . . . 1.0 110.993 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . 0.451 ' CD1' ' N ' ' A' ' 17' ' ' SER . 82.2 m-85 -133.83 138.01 45.39 Favored 'General case' 0 N--CA 1.483 1.184 0 CA-C-O 121.483 0.659 . . . . 1.0 110.544 -179.744 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 42.8 t -144.23 151.22 16.16 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.291 0 CA-C-N 115.501 -0.772 . . . . 1.0 110.1 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -79.55 113.53 17.77 Favored 'General case' 0 N--CA 1.474 0.747 0 CA-C-N 115.785 -0.643 . . . . 1.0 110.502 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 19.3 pttp -74.23 -28.44 61.24 Favored 'General case' 0 N--CA 1.476 0.871 0 CA-C-O 120.812 0.339 . . . . 1.0 110.512 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -55.11 -45.18 75.5 Favored 'General case' 0 N--CA 1.477 0.876 0 CA-C-N 116.234 -0.439 . . . . 1.0 111.014 -179.297 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 22.9 m-85 -63.0 -35.02 78.81 Favored 'General case' 0 N--CA 1.477 0.893 0 N-CA-C 110.003 -0.369 . . . . 1.0 110.003 178.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 74.4 mt . . . . . 0 N--CA 1.479 1.01 0 CA-C-O 118.133 -0.937 . . . . 1.0 109.253 -179.48 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 21.2 ptt? . . . . . 0 N--CA 1.484 1.229 0 N-CA-C 108.835 -0.802 . . . . 1.0 108.835 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -134.3 153.45 51.87 Favored 'General case' 0 N--CA 1.479 1.006 0 CA-C-O 121.817 0.818 . . . . 1.0 110.181 179.776 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 73.3 p -123.14 144.59 49.24 Favored 'General case' 0 N--CA 1.48 1.054 0 CA-C-N 115.161 -0.927 . . . . 1.0 110.314 -179.796 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -95.64 151.77 20.11 Favored Glycine 0 CA--C 1.527 0.838 0 N-CA-C 110.229 -1.149 . . . . 1.0 110.229 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 4.0 mp -103.56 124.89 58.11 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 N-CA-C 109.493 -0.558 . . . . 1.0 109.493 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.3 t -66.67 120.09 13.24 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.554 0 CA-C-N 115.7 -0.682 . . . . 1.0 109.845 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . 0.421 ' C ' ' H ' ' A' ' 9' ' ' SER . 18.2 p-10 -59.63 102.28 0.14 Allowed 'General case' 0 CA--C 1.539 0.537 0 CA-C-O 121.029 0.443 . . . . 1.0 110.479 179.492 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 8.2 p -64.27 -2.85 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-N 115.951 -0.568 . . . . 1.0 110.721 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' SER . . . . . 0.421 ' H ' ' C ' ' A' ' 7' ' ' ASN . 41.3 m -45.89 -56.71 5.08 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-N 115.743 -0.662 . . . . 1.0 111.445 -179.87 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 50.0 m -148.56 179.41 7.83 Favored 'General case' 0 N--CA 1.477 0.907 0 CA-C-N 115.61 -0.723 . . . . 1.0 110.277 179.216 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 45.1 t -84.75 140.31 31.35 Favored 'General case' 0 N--CA 1.473 0.712 0 CA-C-N 115.479 -0.782 . . . . 1.0 110.249 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -111.6 140.65 46.04 Favored 'General case' 0 N--CA 1.485 1.29 0 CA-C-O 122.232 1.015 . . . . 1.0 109.935 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 72.6 m-80 -82.67 126.7 32.65 Favored 'General case' 0 N--CA 1.451 -0.407 0 CA-C-N 114.805 -1.089 . . . . 1.0 109.476 179.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.4 t -102.09 125.86 56.21 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 CA-C-N 115.229 -0.896 . . . . 1.0 110.181 -179.763 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -91.83 179.62 5.57 Favored 'General case' 0 N--CA 1.486 1.348 0 CA-C-O 121.582 0.706 . . . . 1.0 110.238 179.039 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 1.4 m -92.65 -22.61 19.35 Favored 'General case' 0 N--CA 1.489 1.508 0 CA-C-N 115.435 -0.802 . . . . 1.0 110.282 179.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 45.5 p -176.74 -178.13 0.85 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 122.175 0.988 . . . . 1.0 110.032 -179.162 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -82.15 82.27 7.76 Favored 'General case' 0 N--CA 1.47 0.562 0 CA-C-N 114.852 -1.067 . . . . 1.0 109.689 179.182 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 65.5 p -167.25 154.68 8.92 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 121.565 0.698 . . . . 1.0 110.332 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 26.3 m -75.1 -25.32 58.44 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.398 -0.819 . . . . 1.0 110.639 179.311 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 99.5 p -63.08 -22.93 67.19 Favored 'General case' 0 N--CA 1.471 0.602 0 C-N-CA 120.597 -0.441 . . . . 1.0 110.408 -178.423 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 26.5 t -96.96 141.79 29.7 Favored 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 109.652 -0.499 . . . . 1.0 109.652 178.41 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 24.9 tttm -163.24 109.9 1.16 Allowed 'General case' 0 N--CA 1.474 0.754 0 CA-C-O 122.077 0.942 . . . . 1.0 110.029 179.638 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.3 t 62.06 135.92 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.519 0 CA-C-N 115.032 -0.986 . . . . 1.0 110.24 -179.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 1.3 pp -152.57 -17.14 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.963 0 CA-C-N 115.93 -0.577 . . . . 1.0 110.326 -179.387 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 163.27 -166.91 37.32 Favored Glycine 0 CA--C 1.522 0.469 0 N-CA-C 110.359 -1.096 . . . . 1.0 110.359 -178.247 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 93.9 p -145.11 140.44 28.03 Favored 'General case' 0 N--CA 1.481 1.121 0 CA-C-N 114.882 -0.659 . . . . 1.0 110.591 179.782 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.9 pp -102.17 122.41 44.1 Favored 'General case' 0 N--CA 1.491 1.58 0 CA-C-O 121.587 0.708 . . . . 1.0 109.392 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 51.0 m -44.69 131.62 6.75 Favored 'General case' 0 N--CA 1.484 1.233 0 CA-C-N 115.476 -0.784 . . . . 1.0 111.082 -178.654 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -68.08 165.87 45.14 Favored Glycine 0 CA--C 1.521 0.449 0 N-CA-C 111.354 -0.699 . . . . 1.0 111.354 -178.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 13.8 m-80 65.1 20.66 12.08 Favored 'General case' 0 N--CA 1.471 0.624 0 CA-C-O 120.954 0.407 . . . . 1.0 110.455 179.654 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 91.8 m -97.67 145.54 26.21 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-N 115.994 -0.548 . . . . 1.0 109.735 179.48 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -86.27 139.3 31.14 Favored 'General case' 0 N--CA 1.473 0.682 0 CA-C-N 115.77 -0.65 . . . . 1.0 110.143 179.428 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 9.8 m -142.49 124.99 13.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 CA-C-N 115.675 -0.693 . . . . 1.0 110.118 179.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 60.0 p -89.93 90.78 8.31 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 115.917 -0.583 . . . . 1.0 109.813 179.185 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 3.5 mp -36.75 147.17 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.498 1.94 0 CA-C-N 115.768 -0.651 . . . . 1.0 111.517 179.669 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 4.7 t -141.68 61.47 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.37 0 CA-C-O 121.239 0.543 . . . . 1.0 110.522 -178.485 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 107.83 160.55 20.83 Favored Glycine 0 N--CA 1.471 1.005 0 N-CA-C 110.711 -0.956 . . . . 1.0 110.711 179.435 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 74.7 mt-10 -135.46 140.72 45.08 Favored 'General case' 0 N--CA 1.487 1.383 0 CA-C-O 121.161 0.505 . . . . 1.0 110.261 179.703 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.7 tm-20 -148.95 121.87 8.77 Favored 'General case' 0 N--CA 1.477 0.875 0 CA-C-N 115.837 -0.619 . . . . 1.0 110.346 -179.595 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 50.41 -114.17 2.44 Favored Glycine 0 CA--C 1.543 1.783 0 N-CA-C 111.16 -0.776 . . . . 1.0 111.16 179.651 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -113.62 26.82 10.05 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 122.609 0.364 . . . . 1.0 110.724 179.431 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 -146.9 156.34 43.0 Favored 'General case' 0 N--CA 1.476 0.841 0 CA-C-O 121.721 0.772 . . . . 1.0 110.487 179.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' TYR . . . . . 0.4 ' CD1' ' N ' ' A' ' 44' ' ' TYR . 15.0 p90 -140.45 172.67 12.4 Favored 'General case' 0 N--CA 1.473 0.72 0 CA-C-N 115.336 -0.847 . . . . 1.0 110.121 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 24.0 mtpp -101.32 151.83 21.42 Favored 'General case' 0 N--CA 1.478 0.944 0 CA-C-N 115.225 -0.898 . . . . 1.0 110.281 -179.282 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 38.9 pt -139.55 152.97 23.29 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 CA-C-N 115.59 -0.732 . . . . 1.0 110.596 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 4.3 tm-20 -113.45 86.82 2.47 Favored 'General case' 0 N--CA 1.485 1.288 0 CA-C-N 115.323 -0.853 . . . . 1.0 109.872 179.236 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 22.6 t80 -139.65 158.46 44.08 Favored 'General case' 0 N--CA 1.469 0.505 0 CA-C-O 121.209 0.528 . . . . 1.0 110.566 179.391 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 33.8 mtmt 50.29 20.83 0.7 Allowed 'General case' 0 N--CA 1.476 0.859 0 CA-C-N 115.847 -0.615 . . . . 1.0 110.447 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 71.55 -3.32 18.04 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.799 -0.92 . . . . 1.0 110.799 -179.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 44.0 t -117.38 173.97 6.4 Favored 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 124.119 0.968 . . . . 1.0 110.644 -179.431 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' HIS . . . . . 0.445 ' CD2' ' H ' ' A' ' 52' ' ' HIS . 6.8 p80 -112.37 153.54 27.11 Favored 'General case' 0 N--CA 1.481 1.094 0 CA-C-N 115.467 -0.788 . . . . 1.0 109.955 -179.587 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.06 165.55 27.71 Favored Glycine 0 N--CA 1.471 0.994 0 N-CA-C 110.711 -0.956 . . . . 1.0 110.711 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 77.0 m-85 -130.54 139.67 50.48 Favored 'General case' 0 N--CA 1.486 1.351 0 CA-C-O 121.119 0.485 . . . . 1.0 110.268 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 4.2 p -158.91 158.84 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.001 0 CA-C-N 115.92 -0.582 . . . . 1.0 110.25 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.66 134.13 56.74 Favored 'General case' 0 CA--C 1.541 0.609 0 CA-C-O 121.191 0.519 . . . . 1.0 110.397 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -91.06 -35.97 14.31 Favored 'General case' 0 N--CA 1.483 1.198 0 CA-C-N 115.712 -0.676 . . . . 1.0 110.258 -179.831 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -56.73 -28.47 61.09 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-O 121.099 0.476 . . . . 1.0 110.633 -179.454 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 2.2 m-85 -63.21 -39.24 94.08 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-N 115.88 -0.6 . . . . 1.0 110.17 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 70.2 mt . . . . . 0 N--CA 1.472 0.628 0 CA-C-O 117.698 -1.144 . . . . 1.0 109.338 -179.32 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.7 mmt . . . . . 0 N--CA 1.492 1.638 0 N-CA-C 108.938 -0.764 . . . . 1.0 108.938 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 7.0 mtpm? 52.43 98.09 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 115.897 -0.592 . . . . 1.0 110.994 -179.553 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 68.6 p -125.89 163.07 23.74 Favored 'General case' 0 N--CA 1.48 1.045 0 CA-C-O 121.786 0.803 . . . . 1.0 110.353 -179.259 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -122.13 153.17 16.81 Favored Glycine 0 N--CA 1.479 1.565 0 CA-C-N 115.147 -0.933 . . . . 1.0 110.883 -179.696 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 28.2 pt -114.45 140.47 35.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 CA-C-O 121.869 0.842 . . . . 1.0 110.076 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.444 ' H ' ' HA ' ' A' ' 31' ' ' ASN . 2.2 t -90.82 132.04 36.41 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 CA-C-N 115.083 -0.962 . . . . 1.0 109.315 -179.666 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 31.9 m120 -59.53 114.66 2.82 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 120.397 -0.521 . . . . 1.0 110.35 179.329 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 40.6 t -53.49 -19.51 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 CA-C-O 121.397 0.618 . . . . 1.0 110.448 -179.676 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.5 m -49.42 109.28 0.25 Allowed 'General case' 0 CA--C 1.545 0.769 0 CA-C-N 115.642 -0.708 . . . . 1.0 110.873 179.339 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 7.9 m 61.67 -125.42 0.81 Allowed 'General case' 0 CA--C 1.543 0.699 0 CA-C-N 116.582 -0.281 . . . . 1.0 110.606 -179.18 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 89.0 p -152.28 158.68 43.13 Favored 'General case' 0 N--CA 1.478 0.936 0 CA-C-O 120.97 0.414 . . . . 1.0 110.666 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 51.5 tp -123.05 133.44 54.32 Favored 'General case' 0 N--CA 1.486 1.345 0 CA-C-O 121.578 0.704 . . . . 1.0 110.212 179.596 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 14.9 p-10 -84.63 143.48 29.22 Favored 'General case' 0 CA--C 1.535 0.394 0 CA-C-N 115.432 -0.804 . . . . 1.0 109.982 179.404 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 45.2 t -96.4 117.54 40.95 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 N-CA-C 109.424 -0.584 . . . . 1.0 109.424 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 81.3 mtt85 -84.97 165.63 17.44 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 109.774 -0.454 . . . . 1.0 109.774 179.675 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' SER . . . . . 0.555 ' H ' ' HG ' ' A' ' 22' ' ' SER . 38.0 t -95.85 -18.28 20.48 Favored 'General case' 0 N--CA 1.483 1.184 0 CA-C-N 115.972 -0.558 . . . . 1.0 110.516 179.468 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' SER . . . . . 0.631 ' HG ' ' H ' ' A' ' 18' ' ' ALA . 32.9 t -153.36 -164.63 1.95 Allowed 'General case' 0 N--CA 1.479 0.986 0 CA-C-N 116.246 -0.434 . . . . 1.0 111.089 -179.806 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.631 ' H ' ' HG ' ' A' ' 17' ' ' SER . . . -83.72 47.33 1.27 Allowed 'General case' 0 N--CA 1.477 0.919 0 CA-C-O 121.458 0.647 . . . . 1.0 110.234 -179.776 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 53.6 m -157.74 137.1 11.88 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-N 115.562 -0.745 . . . . 1.0 110.851 179.748 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.1 t -70.38 -32.09 69.62 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 115.939 -0.573 . . . . 1.0 110.448 179.701 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' SER . . . . . 0.465 ' C ' ' H ' ' A' ' 23' ' ' LYS . 51.1 m -70.81 -2.58 15.31 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 116.42 -0.354 . . . . 1.0 110.683 -179.78 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' SER . . . . . 0.555 ' HG ' ' H ' ' A' ' 16' ' ' SER . 59.8 p -76.71 21.07 0.21 Allowed 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 121.362 0.601 . . . . 1.0 110.563 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.535 ' O ' ' O ' ' A' ' 22' ' ' SER . 98.2 mttt 48.13 167.25 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.443 0 CA-C-N 115.653 -0.703 . . . . 1.0 111.565 -179.147 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 25.9 t -89.56 168.92 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-O 121.563 0.697 . . . . 1.0 109.56 179.36 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 43.5 pt -135.58 -22.64 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 CA-C-N 115.472 -0.785 . . . . 1.0 110.497 179.565 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.72 179.87 43.0 Favored Glycine 0 N--CA 1.462 0.419 0 N-CA-C 110.52 -1.032 . . . . 1.0 110.52 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 88.7 p -132.56 133.44 43.72 Favored 'General case' 0 N--CA 1.478 0.933 0 CA-C-O 121.282 0.563 . . . . 1.0 109.873 179.664 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -98.62 174.19 6.55 Favored 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 108.959 -0.756 . . . . 1.0 108.959 -179.468 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' SER . . . . . 0.533 ' O ' ' O ' ' A' ' 30' ' ' GLY . 42.0 t -79.16 137.19 37.35 Favored 'General case' 0 CA--C 1.515 -0.367 0 CA-C-N 115.964 -0.562 . . . . 1.0 109.901 -179.189 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.533 ' O ' ' O ' ' A' ' 29' ' ' SER . . . -13.24 -107.45 0.0 OUTLIER Glycine 0 N--CA 1.512 3.715 0 CA-C-O 119.473 -0.626 . . . . 1.0 113.017 179.82 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . 0.444 ' HA ' ' H ' ' A' ' 6' ' ' VAL . 19.5 p-10 -77.73 79.22 4.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 117.569 0.684 . . . . 1.0 109.781 177.775 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' THR . . . . . 0.529 ' OG1' ' O ' ' A' ' 29' ' ' SER . 45.6 m -84.84 146.24 27.42 Favored 'General case' 0 N--CA 1.494 1.769 0 CA-C-N 115.961 -0.563 . . . . 1.0 109.82 179.293 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 55.8 mtpt -82.62 128.47 34.36 Favored 'General case' 0 N--CA 1.474 0.761 0 CA-C-N 116.035 -0.529 . . . . 1.0 110.116 179.157 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.9 m -144.48 127.0 10.72 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 CA-C-N 116.323 -0.399 . . . . 1.0 110.368 179.361 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 68.6 p -80.81 83.82 6.47 Favored 'General case' 0 N--CA 1.47 0.559 0 CA-C-O 121.289 0.566 . . . . 1.0 109.86 179.485 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 81.3 mt -47.23 163.83 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.063 0 CA-C-N 115.641 -0.708 . . . . 1.0 110.54 179.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 42.7 t -129.25 -94.18 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 N-CA-C 110.045 -0.354 . . . . 1.0 110.045 -179.229 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -102.12 -168.12 27.0 Favored Glycine 0 N--CA 1.474 1.227 0 N-CA-C 110.912 -0.875 . . . . 1.0 110.912 -179.568 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -130.29 140.68 50.65 Favored 'General case' 0 N--CA 1.485 1.275 0 CA-C-N 115.293 -0.453 . . . . 1.0 110.541 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 -153.21 114.02 4.09 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 116.084 -0.507 . . . . 1.0 110.207 -179.845 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 51.22 -116.4 4.54 Favored Glycine 0 CA--C 1.542 1.772 0 N-CA-C 111.634 -0.586 . . . . 1.0 111.634 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -117.41 25.07 10.7 Favored 'General case' 0 N--CA 1.488 1.453 0 C-N-CA 122.401 0.28 . . . . 1.0 110.429 179.493 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -145.64 157.08 44.01 Favored 'General case' 0 N--CA 1.48 1.074 0 CA-C-O 121.232 0.539 . . . . 1.0 110.405 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 13.8 p90 -141.72 176.18 9.12 Favored 'General case' 0 N--CA 1.482 1.131 0 CA-C-N 115.76 -0.654 . . . . 1.0 110.376 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 34.3 mtmm -97.06 149.35 22.05 Favored 'General case' 0 N--CA 1.479 0.987 0 CA-C-N 115.786 -0.643 . . . . 1.0 110.327 -179.117 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 26.3 pt -142.95 160.48 18.02 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 CA-C-O 121.949 0.88 . . . . 1.0 110.119 179.487 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -121.7 92.1 3.66 Favored 'General case' 0 N--CA 1.487 1.385 0 CA-C-N 115.084 -0.962 . . . . 1.0 109.608 -179.68 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 21.8 t80 -136.32 151.86 50.05 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-O 121.239 0.542 . . . . 1.0 110.398 179.82 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 46.9 mmtt 53.53 17.55 1.18 Allowed 'General case' 0 N--CA 1.479 1.02 0 CA-C-N 115.763 -0.653 . . . . 1.0 110.619 -179.586 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 72.81 -2.25 33.97 Favored Glycine 0 N--CA 1.467 0.713 0 N-CA-C 110.63 -0.988 . . . . 1.0 110.63 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 41.9 t -107.89 172.47 6.81 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 124.009 0.924 . . . . 1.0 110.489 -179.672 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 25.8 p-80 -106.77 142.26 36.69 Favored 'General case' 0 N--CA 1.482 1.125 0 CA-C-N 115.803 -0.635 . . . . 1.0 110.133 179.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -150.83 169.79 30.62 Favored Glycine 0 N--CA 1.472 1.08 0 N-CA-C 111.094 -0.802 . . . . 1.0 111.094 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 58.5 m-85 -133.53 145.81 50.47 Favored 'General case' 0 N--CA 1.48 1.04 0 CA-C-O 121.673 0.749 . . . . 1.0 110.33 179.655 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 3.5 m -146.16 147.98 17.63 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 CA-C-N 115.319 -0.855 . . . . 1.0 109.892 -179.7 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -66.44 147.21 53.62 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 115.204 -0.907 . . . . 1.0 110.477 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -82.4 -25.74 33.45 Favored 'General case' 0 N--CA 1.477 0.879 0 CA-C-N 116.166 -0.47 . . . . 1.0 110.44 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 4.2 tm-20 -56.68 -34.58 67.54 Favored 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 121.293 0.568 . . . . 1.0 110.738 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 26.1 m-85 -78.46 -4.92 50.87 Favored 'General case' 0 N--CA 1.483 1.188 0 CA-C-N 115.629 -0.714 . . . . 1.0 110.1 179.81 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 34.2 mm . . . . . 0 N--CA 1.487 1.393 0 CA-C-O 118.17 -0.919 . . . . 1.0 109.507 180.0 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.474 ' C ' ' H ' ' A' ' 3' ' ' THR . 28.4 ttt . . . . . 0 N--CA 1.499 2.011 0 CA-C-O 121.554 0.692 . . . . 1.0 109.297 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 24.3 pttm -77.44 26.81 0.16 Allowed 'General case' 0 N--CA 1.479 0.978 0 CA-C-N 115.45 -0.795 . . . . 1.0 110.716 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' THR . . . . . 0.474 ' H ' ' C ' ' A' ' 1' ' ' MET . 62.7 p -131.84 154.74 48.85 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-O 121.955 0.883 . . . . 1.0 109.84 -179.649 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -143.11 161.22 27.6 Favored Glycine 0 N--CA 1.461 0.341 0 N-CA-C 110.317 -1.113 . . . . 1.0 110.317 -179.663 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 74.1 mt -109.97 135.86 47.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 CA-C-O 121.691 0.758 . . . . 1.0 109.503 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 47.4 t -82.49 131.02 34.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.282 -0.872 . . . . 1.0 109.44 179.575 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 -60.09 109.64 1.02 Allowed 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 115.628 -0.715 . . . . 1.0 110.404 179.751 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 14.7 p -65.79 133.3 31.0 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 CA-C-N 116.028 -0.533 . . . . 1.0 110.234 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 88.0 p -170.51 -55.98 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 121.191 0.52 . . . . 1.0 110.138 179.599 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 68.5 m -148.79 -110.98 0.07 Allowed 'General case' 0 N--CA 1.477 0.891 0 CA-C-N 115.863 -0.608 . . . . 1.0 110.718 -179.471 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 39.7 t -135.29 142.95 45.97 Favored 'General case' 0 N--CA 1.473 0.713 0 CA-C-O 121.9 0.857 . . . . 1.0 110.51 -179.55 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -101.39 141.66 33.93 Favored 'General case' 0 N--CA 1.474 0.742 0 CA-C-O 122.21 1.005 . . . . 1.0 110.029 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 79.8 m-20 -93.13 123.17 36.21 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 114.708 -1.133 . . . . 1.0 109.523 -179.672 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 64.3 t -96.67 114.97 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 CA-C-N 115.603 -0.726 . . . . 1.0 109.089 -179.808 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -87.65 173.19 9.18 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-O 122.07 0.938 . . . . 1.0 109.585 179.095 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 88.8 p -97.52 -19.25 18.5 Favored 'General case' 0 N--CA 1.478 0.969 0 CA-C-N 114.974 -1.012 . . . . 1.0 110.292 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 88.9 p -149.41 -163.58 1.82 Allowed 'General case' 0 N--CA 1.475 0.823 0 CA-C-O 121.47 0.653 . . . . 1.0 110.824 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -101.3 53.61 0.83 Allowed 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 115.58 -0.736 . . . . 1.0 110.165 -179.79 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 46.4 t -138.89 137.34 36.42 Favored 'General case' 0 N--CA 1.479 1.023 0 CA-C-O 121.55 0.691 . . . . 1.0 110.744 179.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.2 t -67.42 -27.14 66.82 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 115.391 -0.822 . . . . 1.0 110.702 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 50.0 m -77.41 -7.51 56.24 Favored 'General case' 0 N--CA 1.469 0.508 0 CA-C-N 115.656 -0.702 . . . . 1.0 110.19 -179.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 34.8 t -65.77 124.89 23.65 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-O 120.987 0.422 . . . . 1.0 110.341 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -67.88 166.57 15.3 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.89 -0.595 . . . . 1.0 110.208 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 19.5 t -76.9 114.38 17.19 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.658 0 CA-C-O 121.662 0.744 . . . . 1.0 110.023 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 5.4 tt -96.88 -17.35 6.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.195 -0.911 . . . . 1.0 109.846 179.763 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -166.81 -162.12 17.62 Favored Glycine 0 N--CA 1.463 0.456 0 N-CA-C 110.721 -0.952 . . . . 1.0 110.721 -179.537 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 50.4 m -158.71 132.51 7.63 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.278 0.561 . . . . 1.0 109.936 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.2 tp -110.31 149.06 30.74 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-O 121.567 0.699 . . . . 1.0 109.907 179.614 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 45.7 p -91.15 159.89 15.85 Favored 'General case' 0 N--CA 1.469 0.483 0 CA-C-N 115.327 -0.851 . . . . 1.0 109.604 179.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -78.75 152.17 36.74 Favored Glycine 0 CA--C 1.529 0.934 0 N-CA-C 110.443 -1.063 . . . . 1.0 110.443 179.526 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 70.14 19.08 6.84 Favored 'General case' 0 N--CA 1.474 0.772 0 CA-C-O 120.887 0.375 . . . . 1.0 110.449 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 32.0 m -88.67 139.75 30.15 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-N 116.119 -0.491 . . . . 1.0 109.878 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 63.3 tttm -86.3 139.25 31.17 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.893 -0.594 . . . . 1.0 109.963 179.547 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 14.4 m -142.99 124.46 11.77 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.879 0 CA-C-N 115.687 -0.688 . . . . 1.0 110.2 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 62.1 p -79.89 87.76 5.32 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-O 121.355 0.598 . . . . 1.0 109.709 179.636 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . 0.421 ' CG2' ' H ' ' A' ' 37' ' ' VAL . 63.0 mt -55.81 169.43 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.504 0 CA-C-O 121.66 0.743 . . . . 1.0 109.498 179.844 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.421 ' H ' ' CG2' ' A' ' 36' ' ' ILE . 0.2 OUTLIER -131.91 -96.0 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.055 0 CA-C-N 115.348 -0.842 . . . . 1.0 109.885 -179.156 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -99.4 -170.07 30.46 Favored Glycine 0 N--CA 1.465 0.62 0 N-CA-C 110.631 -0.987 . . . . 1.0 110.631 -179.566 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 13.5 mp0 -128.85 132.95 47.81 Favored 'General case' 0 N--CA 1.478 0.943 0 CA-C-N 114.651 -0.775 . . . . 1.0 110.224 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.41 ' O ' ' O ' ' A' ' 43' ' ' PHE . 44.3 tp10 -150.32 120.68 7.35 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-N 115.497 -0.774 . . . . 1.0 110.041 179.527 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 47.08 -122.65 7.17 Favored Glycine 0 CA--C 1.543 1.805 0 N-CA-C 111.509 -0.636 . . . . 1.0 111.509 179.779 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -114.03 22.32 14.0 Favored 'General case' 0 N--CA 1.481 1.106 0 C-N-CA 122.546 0.338 . . . . 1.0 110.251 178.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . 0.41 ' O ' ' O ' ' A' ' 40' ' ' GLU . 77.7 m-85 -149.13 157.42 43.37 Favored 'General case' 0 N--CA 1.484 1.264 0 CA-C-O 121.6 0.714 . . . . 1.0 110.74 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' TYR . . . . . 0.458 ' N ' ' CD1' ' A' ' 44' ' ' TYR . 10.1 p90 -140.39 172.99 11.95 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 122.077 0.942 . . . . 1.0 109.939 -179.712 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -97.52 156.56 16.44 Favored 'General case' 0 N--CA 1.474 0.751 0 CA-C-N 114.905 -1.043 . . . . 1.0 109.97 -179.434 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 32.2 pt -147.41 161.7 7.9 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 CA-C-O 122.215 1.007 . . . . 1.0 109.884 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 18.6 mp0 -121.54 87.36 2.74 Favored 'General case' 0 N--CA 1.481 1.088 0 CA-C-N 114.748 -1.115 . . . . 1.0 109.844 -179.768 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -138.68 158.86 43.45 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-N 115.576 -0.738 . . . . 1.0 110.019 179.86 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . 0.417 ' C ' ' H ' ' A' ' 51' ' ' SER . 48.7 mtmt 52.92 18.47 1.08 Allowed 'General case' 0 CA--C 1.541 0.611 0 CA-C-N 115.626 -0.715 . . . . 1.0 110.811 179.801 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 67.97 -1.52 8.11 Favored Glycine 0 CA--C 1.532 1.1 0 N-CA-C 110.429 -1.068 . . . . 1.0 110.429 -179.181 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' SER . . . . . 0.417 ' H ' ' C ' ' A' ' 49' ' ' LYS . 97.6 p -116.12 171.96 7.47 Favored 'General case' 0 N--CA 1.484 1.265 0 CA-C-O 121.994 0.902 . . . . 1.0 110.317 -179.859 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 96.3 m-70 -101.75 146.12 28.2 Favored 'General case' 0 N--CA 1.478 0.932 0 CA-C-N 115.006 -0.997 . . . . 1.0 110.09 -179.828 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -152.9 168.32 31.78 Favored Glycine 0 CA--C 1.531 1.041 0 N-CA-C 110.673 -0.971 . . . . 1.0 110.673 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 66.2 m-85 -134.61 150.16 50.66 Favored 'General case' 0 N--CA 1.486 1.37 0 CA-C-O 121.018 0.437 . . . . 1.0 110.608 179.601 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -155.19 155.84 5.45 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 CA-C-N 115.967 -0.561 . . . . 1.0 110.348 -179.808 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.69 130.38 44.02 Favored 'General case' 0 CA--C 1.545 0.78 0 CA-C-O 122.173 0.987 . . . . 1.0 109.861 179.049 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.46 -35.1 17.23 Favored 'General case' 0 N--CA 1.483 1.191 0 CA-C-N 114.86 -1.064 . . . . 1.0 110.177 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -58.33 -30.39 66.66 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.656 0.741 . . . . 1.0 110.371 -179.674 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 1.2 t80 -52.52 -19.8 2.51 Favored 'General case' 0 CA--C 1.537 0.465 0 CA-C-N 115.362 -0.835 . . . . 1.0 110.792 -179.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 69.8 mt . . . . . 0 C--O 1.221 -0.436 0 CA-C-O 118.0 -1.0 . . . . 1.0 108.761 -179.834 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 28.0 ttt . . . . . 0 N--CA 1.492 1.63 0 N-CA-C 109.218 -0.66 . . . . 1.0 109.218 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 74.6 mmtt 51.76 92.09 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.593 0 CA-C-O 121.267 0.556 . . . . 1.0 110.753 179.466 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 69.8 p -131.55 158.59 40.55 Favored 'General case' 0 N--CA 1.472 0.659 0 CA-C-O 121.825 0.821 . . . . 1.0 110.136 -179.48 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -145.57 163.94 28.15 Favored Glycine 0 N--CA 1.468 0.812 0 N-CA-C 110.495 -1.042 . . . . 1.0 110.495 -179.556 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 3.7 mp -110.13 129.68 64.69 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 CA-C-O 121.287 0.565 . . . . 1.0 109.97 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 55.9 t -73.42 133.34 31.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.648 -0.706 . . . . 1.0 109.491 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ASN . . . . . 0.544 HD21 ' N ' ' A' ' 7' ' ' ASN . 1.0 OUTLIER -49.2 96.83 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.707 0 CA-C-N 115.768 -0.651 . . . . 1.0 110.694 179.604 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.5 t -63.37 -6.55 2.26 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.539 0 CA-C-N 115.749 -0.66 . . . . 1.0 110.008 -179.221 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.0 m -52.71 -49.87 64.5 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.087 -0.506 . . . . 1.0 110.69 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 93.0 p -149.96 169.37 21.33 Favored 'General case' 0 N--CA 1.472 0.652 0 CA-C-O 121.461 0.648 . . . . 1.0 110.524 179.385 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 89.1 p -78.93 150.34 32.11 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 115.523 -0.762 . . . . 1.0 109.707 -179.331 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.9 mp -118.96 145.48 45.76 Favored 'General case' 0 N--CA 1.49 1.543 0 CA-C-O 122.287 1.042 . . . . 1.0 110.08 -179.426 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 73.8 m-80 -96.49 146.62 24.64 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 114.701 -1.136 . . . . 1.0 110.003 179.693 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 22.4 t -94.57 104.78 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.936 0 CA-C-N 115.529 -0.76 . . . . 1.0 109.684 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 88.8 mtm180 -79.41 135.64 36.74 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.341 0.591 . . . . 1.0 109.761 179.821 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 38.9 t -63.43 -27.17 69.1 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 115.581 -0.736 . . . . 1.0 110.442 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 47.2 t -144.85 -176.66 5.16 Favored 'General case' 0 N--CA 1.479 0.998 0 CA-C-N 115.97 -0.559 . . . . 1.0 110.927 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -81.83 57.17 3.33 Favored 'General case' 0 N--CA 1.476 0.843 0 CA-C-N 115.774 -0.648 . . . . 1.0 110.235 -179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 47.3 t -156.92 137.67 13.29 Favored 'General case' 0 N--CA 1.472 0.64 0 CA-C-O 121.203 0.525 . . . . 1.0 110.686 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.8 t -67.12 -32.97 74.46 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 115.756 -0.656 . . . . 1.0 110.629 179.62 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 89.4 p -69.35 -4.31 17.72 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 116.029 -0.532 . . . . 1.0 110.303 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 90.2 p -60.47 -172.02 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.539 0 CA-C-O 120.995 0.426 . . . . 1.0 110.25 179.53 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 5.5 mptt -116.57 148.16 41.15 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-O 121.234 0.54 . . . . 1.0 110.749 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 20.1 t -82.16 115.46 24.73 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 115.778 -0.646 . . . . 1.0 109.537 179.79 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 34.2 pt -96.43 -16.79 7.09 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.896 0 CA-C-N 115.706 -0.679 . . . . 1.0 109.891 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 179.53 165.77 34.17 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.71 -0.956 . . . . 1.0 110.71 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 50.7 m -117.54 135.55 53.87 Favored 'General case' 0 N--CA 1.484 1.268 0 CA-C-O 121.289 0.566 . . . . 1.0 109.918 179.61 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 3.5 tp -100.04 159.02 15.42 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-O 121.875 0.845 . . . . 1.0 109.141 -179.414 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 49.1 m -101.48 145.95 28.29 Favored 'General case' 0 N--CA 1.473 0.677 0 CA-C-N 115.208 -0.906 . . . . 1.0 110.106 -179.132 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -73.85 151.86 44.93 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.353 -1.099 . . . . 1.0 110.353 179.285 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 74.78 13.77 3.43 Favored 'General case' 0 N--CA 1.482 1.159 0 CA-C-O 120.525 0.202 . . . . 1.0 110.518 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 89.0 m -83.05 137.15 34.23 Favored 'General case' 0 N--CA 1.477 0.912 0 CA-C-O 121.12 0.486 . . . . 1.0 110.32 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -92.81 144.04 25.68 Favored 'General case' 0 N--CA 1.473 0.721 0 CA-C-N 115.806 -0.634 . . . . 1.0 109.989 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.4 p -154.77 139.81 10.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.748 -0.66 . . . . 1.0 109.91 179.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 68.9 p -83.4 83.36 7.9 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.877 -0.601 . . . . 1.0 109.637 179.217 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 74.5 mt -48.49 167.0 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 CA-C-N 115.818 -0.628 . . . . 1.0 110.066 179.801 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 40.8 t -128.07 -91.86 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 CA-C-N 116.22 -0.445 . . . . 1.0 110.087 -179.61 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -118.03 -155.54 10.06 Favored Glycine 0 N--CA 1.474 1.215 0 N-CA-C 110.863 -0.895 . . . . 1.0 110.863 -179.471 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -142.19 144.71 33.54 Favored 'General case' 0 N--CA 1.478 0.971 0 CA-C-N 115.059 -0.57 . . . . 1.0 110.281 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 38.3 tp10 -147.36 122.39 10.09 Favored 'General case' 0 N--CA 1.473 0.713 0 CA-C-N 115.74 -0.664 . . . . 1.0 109.986 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 54.71 -129.43 44.63 Favored Glycine 0 CA--C 1.53 0.995 0 N-CA-C 111.398 -0.681 . . . . 1.0 111.398 179.595 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -100.18 33.92 2.5 Favored 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 110.068 -0.345 . . . . 1.0 110.068 179.406 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 26.9 p90 -159.04 168.96 25.35 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-O 122.152 0.977 . . . . 1.0 110.083 179.321 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' TYR . . . . . 0.483 ' N ' ' CD1' ' A' ' 44' ' ' TYR . 3.3 p90 -129.63 163.92 25.01 Favored 'General case' 0 N--CA 1.481 1.107 0 CA-C-N 114.79 -1.095 . . . . 1.0 110.448 179.779 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 62.8 tttp -86.88 142.31 28.13 Favored 'General case' 0 N--CA 1.473 0.717 0 CA-C-N 115.341 -0.845 . . . . 1.0 109.771 -179.049 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 19.7 pt -141.32 156.51 21.54 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-O 122.083 0.944 . . . . 1.0 110.22 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -124.88 94.08 4.08 Favored 'General case' 0 N--CA 1.48 1.053 0 CA-C-N 114.844 -1.071 . . . . 1.0 109.971 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 22.8 t80 -128.47 147.5 50.67 Favored 'General case' 0 N--CA 1.476 0.875 0 CA-C-N 115.974 -0.557 . . . . 1.0 110.058 179.517 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 46.4 mtpt 54.11 17.56 1.47 Allowed 'General case' 0 CA--C 1.547 0.832 0 CA-C-N 115.908 -0.587 . . . . 1.0 110.497 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 72.18 1.78 51.01 Favored Glycine 0 N--CA 1.468 0.805 0 N-CA-C 110.6 -1.0 . . . . 1.0 110.6 -179.489 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 47.4 t -104.99 171.13 7.48 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 123.517 0.727 . . . . 1.0 110.2 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 49.4 p-80 -103.67 138.5 40.23 Favored 'General case' 0 N--CA 1.482 1.137 0 CA-C-N 115.618 -0.719 . . . . 1.0 110.484 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -150.75 166.76 30.36 Favored Glycine 0 N--CA 1.472 1.058 0 N-CA-C 110.782 -0.927 . . . . 1.0 110.782 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 33.4 m-85 -135.5 152.16 51.06 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-O 121.539 0.685 . . . . 1.0 110.194 179.456 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -150.39 151.16 12.91 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.953 0 CA-C-N 115.455 -0.793 . . . . 1.0 109.768 -179.089 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.56 125.64 24.61 Favored 'General case' 0 CA--C 1.54 0.561 0 CA-C-N 115.222 -0.899 . . . . 1.0 110.2 179.405 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 7.7 pttm -78.55 -31.18 47.32 Favored 'General case' 0 N--CA 1.473 0.681 0 CA-C-N 115.259 -0.882 . . . . 1.0 110.183 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -55.57 -35.45 65.76 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.061 -0.518 . . . . 1.0 110.401 -179.14 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.7 m-85 -60.47 -42.01 95.36 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 115.866 -0.606 . . . . 1.0 109.868 179.486 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 65.6 mt . . . . . 0 N--CA 1.476 0.831 0 CA-C-O 118.199 -0.905 . . . . 1.0 109.268 -179.359 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 61.2 tttp . . . . . 0 CA--C 1.531 0.238 0 CA-C-O 121.141 0.496 . . . . 1.0 110.131 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 65.8 p -96.03 162.69 13.44 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.953 0.883 . . . . 1.0 109.759 179.738 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -101.6 155.89 18.89 Favored Glycine 0 N--CA 1.47 0.961 0 N-CA-C 110.454 -1.058 . . . . 1.0 110.454 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 69.0 mt -111.55 128.09 68.29 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.088 0 CA-C-O 121.502 0.668 . . . . 1.0 109.559 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 24.4 t -68.48 132.05 33.13 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 CA-C-N 115.571 -0.741 . . . . 1.0 109.883 179.807 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ASN . . . . . 0.418 ' O ' ' N ' ' A' ' 9' ' ' SER . 10.5 p-10 -55.77 109.18 0.53 Allowed 'General case' 0 CA--C 1.54 0.572 0 CA-C-N 116.112 -0.494 . . . . 1.0 110.411 179.659 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 15.1 t -66.4 72.28 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-N 116.155 -0.475 . . . . 1.0 110.207 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' SER . . . . . 0.418 ' N ' ' O ' ' A' ' 7' ' ' ASN . 30.4 t -85.39 -104.59 0.06 Allowed 'General case' 0 CA--C 1.54 0.564 0 CA-C-N 115.92 -0.582 . . . . 1.0 109.916 179.798 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 97.0 p -157.29 -28.02 0.09 Allowed 'General case' 0 N--CA 1.478 0.967 0 CA-C-O 121.471 0.653 . . . . 1.0 111.11 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 44.4 t -153.87 145.31 23.13 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 115.539 -0.755 . . . . 1.0 110.703 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.424 HD13 ' N ' ' A' ' 13' ' ' ASN . 0.2 OUTLIER -155.16 121.55 5.28 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 120.773 -0.371 . . . . 1.0 110.536 178.319 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ASN . . . . . 0.424 ' N ' HD13 ' A' ' 12' ' ' LEU . 74.7 m-20 -89.23 134.09 34.18 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 121.856 0.836 . . . . 1.0 109.809 179.453 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 33.9 t -103.84 128.36 57.18 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 CA-C-N 115.154 -0.93 . . . . 1.0 109.559 179.71 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 83.1 mtt-85 -97.43 179.75 4.76 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-O 121.56 0.695 . . . . 1.0 110.046 179.426 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.4 p -104.86 -7.15 19.58 Favored 'General case' 0 N--CA 1.484 1.238 0 CA-C-N 115.373 -0.83 . . . . 1.0 110.36 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.447 ' C ' ' H ' ' A' ' 19' ' ' SER . 42.0 t -170.7 178.22 3.64 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-O 121.264 0.554 . . . . 1.0 110.745 -179.772 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -72.97 40.4 0.09 Allowed 'General case' 0 N--CA 1.475 0.793 0 CA-C-N 115.82 -0.627 . . . . 1.0 110.664 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.447 ' H ' ' C ' ' A' ' 17' ' ' SER . 78.8 p -137.49 136.82 38.06 Favored 'General case' 0 N--CA 1.48 1.033 0 CA-C-O 121.52 0.676 . . . . 1.0 110.403 179.871 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 80.4 p -73.71 -27.98 61.48 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-N 115.427 -0.806 . . . . 1.0 110.21 179.784 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 97.2 p -65.34 -21.32 66.68 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 116.335 -0.393 . . . . 1.0 110.242 -179.541 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 37.6 m -55.49 -29.36 58.66 Favored 'General case' 0 N--CA 1.472 0.639 0 CA-C-O 120.988 0.423 . . . . 1.0 110.284 179.138 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 25.5 tttm 71.14 -177.2 0.2 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.933 -0.576 . . . . 1.0 110.018 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 13.2 t -79.57 161.06 4.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 122.063 0.935 . . . . 1.0 109.512 179.335 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 35.0 pt -148.82 -22.43 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 CA-C-N 114.858 -1.065 . . . . 1.0 110.414 -179.766 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -173.52 164.62 36.33 Favored Glycine 0 CA--C 1.52 0.376 0 N-CA-C 110.673 -0.971 . . . . 1.0 110.673 -179.752 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 98.1 p -118.62 133.11 56.1 Favored 'General case' 0 N--CA 1.48 1.053 0 CA-C-O 121.91 0.862 . . . . 1.0 110.06 179.562 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.2 tp -101.6 155.48 18.07 Favored 'General case' 0 N--CA 1.473 0.725 0 CA-C-N 115.113 -0.948 . . . . 1.0 109.649 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 57.6 m -93.2 143.06 26.62 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.144 -0.934 . . . . 1.0 109.919 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -74.83 155.65 48.37 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.149 -1.18 . . . . 1.0 110.149 179.442 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 69.67 16.84 7.91 Favored 'General case' 0 N--CA 1.475 0.784 0 CA-C-O 120.792 0.329 . . . . 1.0 110.381 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 83.3 m -88.06 141.95 28.17 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-O 121.279 0.562 . . . . 1.0 109.957 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 37.9 ttpt -83.15 134.6 34.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.712 0.768 . . . . 1.0 110.029 179.555 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 5.2 m -140.96 123.42 15.24 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.575 0 CA-C-N 115.316 -0.856 . . . . 1.0 110.136 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.43 ' O ' ' C ' ' A' ' 36' ' ' ILE . 31.2 m -84.31 87.62 7.21 Favored 'General case' 0 N--CA 1.467 0.384 0 N-CA-C 109.661 -0.496 . . . . 1.0 109.661 179.117 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.614 ' H ' HD12 ' A' ' 36' ' ' ILE . 1.7 mp -34.49 145.66 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 CA-C-N 116.067 -0.515 . . . . 1.0 110.541 179.196 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -154.3 67.54 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 CA-C-N 115.974 -0.557 . . . . 1.0 109.829 -178.563 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.05 167.89 34.61 Favored Glycine 0 CA--C 1.503 -0.69 0 N-CA-C 110.567 -1.013 . . . . 1.0 110.567 178.731 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.3 pp20? -153.73 156.61 38.1 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.216 -0.492 . . . . 1.0 110.669 -178.991 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -153.61 127.61 8.96 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 116.022 -0.536 . . . . 1.0 110.505 179.229 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 59.54 -152.87 33.7 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.358 -0.697 . . . . 1.0 111.358 179.602 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -77.47 38.87 0.25 Allowed 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 109.855 -0.424 . . . . 1.0 109.855 179.443 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 -151.37 159.14 44.42 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-O 121.804 0.812 . . . . 1.0 110.477 -179.769 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 1.3 m-85 -118.86 157.3 27.9 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 122.199 0.999 . . . . 1.0 110.238 179.668 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 84.4 tttt -99.81 144.33 29.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 114.854 -1.067 . . . . 1.0 109.854 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 28.8 pt -149.37 172.24 1.66 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.241 -0.891 . . . . 1.0 109.952 -179.576 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 77.4 tt0 -139.86 105.13 5.04 Favored 'General case' 0 N--CA 1.472 0.673 0 CA-C-N 115.143 -0.935 . . . . 1.0 110.333 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 27.1 t80 -139.7 163.71 31.87 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 115.592 -0.731 . . . . 1.0 110.187 179.269 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' LYS . . . . . 0.414 ' C ' ' H ' ' A' ' 51' ' ' SER . 18.5 mmtm 51.77 24.87 2.64 Favored 'General case' 0 CA--C 1.544 0.741 0 CA-C-N 115.57 -0.741 . . . . 1.0 111.06 179.623 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 74.0 -8.89 10.3 Favored Glycine 0 CA--C 1.528 0.883 0 N-CA-C 110.147 -1.181 . . . . 1.0 110.147 -179.623 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' SER . . . . . 0.414 ' H ' ' C ' ' A' ' 49' ' ' LYS . 50.5 m -108.82 174.02 6.06 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-O 122.07 0.938 . . . . 1.0 110.074 179.783 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 32.7 p80 -131.01 135.12 47.32 Favored 'General case' 0 N--CA 1.48 1.044 0 CA-C-N 114.971 -1.013 . . . . 1.0 110.331 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.03 154.55 25.98 Favored Glycine 0 N--CA 1.47 0.944 0 N-CA-C 110.652 -0.979 . . . . 1.0 110.652 179.537 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 55.6 m-85 -90.76 145.09 25.08 Favored 'General case' 0 N--CA 1.472 0.651 0 CA-C-O 121.485 0.66 . . . . 1.0 109.731 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 17.1 t -141.85 145.78 23.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 CA-C-N 115.582 -0.736 . . . . 1.0 110.365 -179.844 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.91 138.38 58.53 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.573 -0.74 . . . . 1.0 109.967 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 12.5 pttp -89.86 -25.13 21.18 Favored 'General case' 0 N--CA 1.475 0.809 0 CA-C-N 115.541 -0.754 . . . . 1.0 110.183 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 44.7 tp10 -65.95 -37.72 86.75 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.465 0.65 . . . . 1.0 110.509 -178.85 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 23.0 m-85 -68.89 -31.88 71.13 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 115.527 -0.76 . . . . 1.0 110.092 179.82 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 72.8 mt . . . . . 0 N--CA 1.467 0.42 0 CA-C-O 118.138 -0.934 . . . . 1.0 109.193 -179.486 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 97.2 mttt . . . . . 0 N--CA 1.472 0.628 0 CA-C-O 121.512 0.672 . . . . 1.0 110.591 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 3.2 p -132.8 153.5 51.2 Favored 'General case' 0 N--CA 1.478 0.946 0 CA-C-N 115.469 -0.787 . . . . 1.0 110.166 -179.29 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -140.71 160.78 26.63 Favored Glycine 0 N--CA 1.468 0.797 0 N-CA-C 110.658 -0.977 . . . . 1.0 110.658 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 12.5 pt -106.01 135.96 42.25 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 CA-C-O 121.287 0.565 . . . . 1.0 109.737 179.542 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.485 ' O ' ' N ' ' A' ' 8' ' ' VAL . 37.7 t -53.72 111.69 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 CA-C-N 115.62 -0.718 . . . . 1.0 109.926 -179.751 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 4.7 m120 -56.31 83.42 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 115.724 -0.671 . . . . 1.0 110.593 179.601 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.485 ' N ' ' O ' ' A' ' 6' ' ' VAL . 3.2 t 47.71 -126.25 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.554 1.134 0 CA-C-N 115.579 -0.737 . . . . 1.0 110.199 -179.791 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' SER . . . . . 0.474 ' O ' ' O ' ' A' ' 8' ' ' VAL . 19.3 m 57.78 136.69 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 115.687 -0.688 . . . . 1.0 110.72 179.659 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 48.9 m -54.41 -65.73 0.52 Allowed 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 121.022 0.439 . . . . 1.0 110.652 -179.68 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 65.7 m -148.72 154.51 39.72 Favored 'General case' 0 N--CA 1.471 0.621 0 CA-C-O 121.798 0.809 . . . . 1.0 110.505 179.599 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -102.21 142.68 33.06 Favored 'General case' 0 N--CA 1.485 1.301 0 CA-C-N 115.233 -0.894 . . . . 1.0 109.977 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -85.18 99.53 11.14 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.072 -0.967 . . . . 1.0 109.477 -179.492 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 17.6 m -80.66 135.5 25.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 108.686 -0.857 . . . . 1.0 108.686 -179.458 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 67.2 mtm180 -117.85 -176.48 3.05 Favored 'General case' 0 N--CA 1.476 0.852 0 CA-C-N 115.13 -0.941 . . . . 1.0 110.234 -179.247 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 67.0 p -89.88 -20.61 23.19 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 115.333 -0.849 . . . . 1.0 110.519 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.645 ' C ' ' H ' ' A' ' 19' ' ' SER . 60.9 p -176.28 -173.17 0.53 Allowed 'General case' 0 N--CA 1.473 0.718 0 CA-C-O 121.681 0.753 . . . . 1.0 110.414 -179.649 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.81 17.24 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.375 0 CA-C-N 115.343 -0.844 . . . . 1.0 111.586 178.654 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' SER . . . . . 0.645 ' H ' ' C ' ' A' ' 17' ' ' SER . 70.0 m -100.87 97.83 8.39 Favored 'General case' 0 N--CA 1.48 1.038 0 CA-C-N 115.352 -0.84 . . . . 1.0 110.169 179.533 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.9 m -64.37 -4.29 3.72 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-N 115.685 -0.689 . . . . 1.0 110.15 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 85.7 p -97.89 -3.53 38.39 Favored 'General case' 0 N--CA 1.473 0.699 0 CA-C-N 116.001 -0.545 . . . . 1.0 110.719 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 78.1 p -77.36 -4.96 47.81 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 110.022 -0.362 . . . . 1.0 110.022 179.331 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 33.7 tttt 66.05 -163.27 0.24 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.094 0.473 . . . . 1.0 110.167 179.606 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 24.8 t -94.22 158.16 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 CA-C-O 122.193 0.997 . . . . 1.0 109.28 179.753 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 47.7 pt -137.67 -20.58 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.005 0 CA-C-N 114.852 -1.067 . . . . 1.0 110.496 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' GLY . . . . . 0.471 ' CA ' ' HZ1' ' A' ' 49' ' ' LYS . . . -158.44 -153.89 6.95 Favored Glycine 0 N--CA 1.466 0.64 0 N-CA-C 110.689 -0.964 . . . . 1.0 110.689 -179.441 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' SER . . . . . 0.681 ' H ' ' HZ3' ' A' ' 49' ' ' LYS . 93.2 p -159.17 148.65 18.69 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 121.322 0.582 . . . . 1.0 110.372 179.644 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.6 tp -122.3 154.43 37.6 Favored 'General case' 0 N--CA 1.481 1.106 0 CA-C-O 121.624 0.726 . . . . 1.0 110.311 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 90.9 p -103.33 159.92 15.14 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 115.39 -0.823 . . . . 1.0 110.25 179.749 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -79.65 168.11 52.31 Favored Glycine 0 N--CA 1.476 1.352 0 N-CA-C 110.537 -1.025 . . . . 1.0 110.537 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 66.2 m-20 56.32 20.87 4.94 Favored 'General case' 0 N--CA 1.477 0.877 0 CA-C-O 120.929 0.395 . . . . 1.0 110.759 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 29.6 m -89.94 150.42 22.17 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-O 121.401 0.619 . . . . 1.0 109.828 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 50.9 tttp -103.25 150.6 23.57 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 115.548 -0.751 . . . . 1.0 110.275 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.4 p -157.36 145.56 10.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.687 -0.688 . . . . 1.0 109.858 179.553 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 90.4 m -106.09 106.33 16.79 Favored 'General case' 0 N--CA 1.481 1.095 0 N-CA-C 109.428 -0.582 . . . . 1.0 109.428 178.544 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.459 ' O ' HG13 ' A' ' 37' ' ' VAL . 11.7 mm -42.35 134.86 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 CA-C-N 116.502 -0.317 . . . . 1.0 111.2 179.283 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.459 HG13 ' O ' ' A' ' 36' ' ' ILE . 3.2 m -159.51 90.24 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.069 0 CA-C-O 121.986 0.898 . . . . 1.0 110.518 -178.052 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 109.63 115.06 3.7 Favored Glycine 0 N--CA 1.481 1.657 0 CA-C-N 115.114 -0.948 . . . . 1.0 110.824 179.178 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.546 ' H ' ' CD ' ' A' ' 39' ' ' GLU . 0.5 OUTLIER -105.13 132.62 51.12 Favored 'General case' 0 N--CA 1.48 1.033 0 N-CA-C 109.245 -0.65 . . . . 1.0 109.245 -178.817 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 79.8 tt0 -151.31 102.85 2.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.837 -0.62 . . . . 1.0 109.883 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.432 ' C ' ' H ' ' A' ' 43' ' ' PHE . . . 57.12 -149.21 31.39 Favored Glycine 0 CA--C 1.533 1.16 0 N-CA-C 111.226 -0.749 . . . . 1.0 111.226 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -74.56 17.56 0.2 Allowed 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 120.926 -0.31 . . . . 1.0 110.455 179.082 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.432 ' H ' ' C ' ' A' ' 41' ' ' GLY . 38.3 m-85 -133.56 158.13 43.95 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-O 121.853 0.835 . . . . 1.0 110.215 -179.53 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' TYR . . . . . 0.441 ' CD2' ' CG2' ' A' ' 36' ' ' ILE . 2.8 m-85 -127.04 165.22 19.88 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 122.621 1.2 . . . . 1.0 109.839 179.618 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 23.9 ttpp -107.96 129.58 55.1 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 114.465 -1.243 . . . . 1.0 110.004 -179.736 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 45.5 pt -122.18 170.05 12.81 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-O 122.302 1.048 . . . . 1.0 110.045 179.458 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -131.1 102.2 5.91 Favored 'General case' 0 N--CA 1.482 1.164 0 CA-C-N 114.702 -1.135 . . . . 1.0 109.778 -179.441 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -138.93 160.35 39.95 Favored 'General case' 0 N--CA 1.47 0.575 0 CA-C-O 121.432 0.634 . . . . 1.0 109.829 179.561 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' LYS . . . . . 0.681 ' HZ3' ' H ' ' A' ' 27' ' ' SER . 43.3 mtmt 50.35 26.65 2.36 Favored 'General case' 0 CA--C 1.546 0.811 0 CA-C-N 115.595 -0.73 . . . . 1.0 111.369 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 67.07 6.74 40.19 Favored Glycine 0 N--CA 1.474 1.227 0 N-CA-C 110.465 -1.054 . . . . 1.0 110.465 -179.418 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 85.7 p -117.35 175.45 5.61 Favored 'General case' 0 N--CA 1.485 1.303 0 C-N-CA 124.228 1.011 . . . . 1.0 110.506 -179.631 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 27.3 p-80 -114.29 135.51 53.99 Favored 'General case' 0 N--CA 1.486 1.368 0 CA-C-N 115.18 -0.918 . . . . 1.0 110.331 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -140.08 166.08 25.8 Favored Glycine 0 N--CA 1.472 1.059 0 N-CA-C 110.988 -0.845 . . . . 1.0 110.988 179.724 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 58.2 m-85 -130.35 136.5 49.17 Favored 'General case' 0 N--CA 1.483 1.196 0 CA-C-O 121.904 0.859 . . . . 1.0 110.11 179.692 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 26.0 t -143.28 150.2 17.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 CA-C-N 115.145 -0.934 . . . . 1.0 110.175 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -67.64 127.49 32.97 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-N 115.481 -0.781 . . . . 1.0 109.812 179.424 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 11.5 pttm -74.91 -20.81 59.54 Favored 'General case' 0 N--CA 1.476 0.853 0 CA-C-N 115.251 -0.886 . . . . 1.0 110.095 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 76.5 tt0 -65.41 -37.47 87.06 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 121.461 0.648 . . . . 1.0 110.399 -178.817 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 27.3 m-85 -74.08 -33.61 63.7 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 115.609 -0.723 . . . . 1.0 109.897 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 62.6 mt . . . . . 0 N--CA 1.471 0.613 0 CA-C-O 118.096 -0.954 . . . . 1.0 109.051 -179.033 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 55.1 mtpt . . . . . 0 N--CA 1.468 0.436 0 CA-C-O 121.382 0.61 . . . . 1.0 110.434 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 46.0 p -137.11 160.43 38.99 Favored 'General case' 0 N--CA 1.473 0.709 0 CA-C-O 121.719 0.771 . . . . 1.0 110.458 -179.681 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -138.01 155.51 23.33 Favored Glycine 0 N--CA 1.471 0.995 0 N-CA-C 110.659 -0.977 . . . . 1.0 110.659 -179.861 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 15.6 pt -98.24 137.26 26.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 CA-C-O 121.676 0.75 . . . . 1.0 109.209 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.571 ' O ' ' C ' ' A' ' 7' ' ' ASN . 22.0 t -83.01 142.98 12.83 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.46 0 CA-C-N 115.366 -0.834 . . . . 1.0 109.566 -179.827 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ASN . . . . . 0.571 ' C ' ' O ' ' A' ' 6' ' ' VAL . 42.9 t30 8.72 -109.27 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.125 0 CA-C-N 116.243 -0.435 . . . . 1.0 111.859 -179.602 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 22.0 t -143.02 -52.25 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.292 0 CA-C-O 120.715 0.293 . . . . 1.0 110.434 177.781 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 40.7 t -170.14 77.75 0.09 Allowed 'General case' 0 N--CA 1.472 0.641 0 CA-C-O 120.855 0.359 . . . . 1.0 110.618 -179.544 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 49.3 m -160.52 168.46 25.01 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-N 116.052 -0.522 . . . . 1.0 110.679 -179.803 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 41.8 t -90.38 130.82 36.42 Favored 'General case' 0 N--CA 1.473 0.682 0 CA-C-O 121.304 0.573 . . . . 1.0 110.104 179.585 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 9.8 mp -100.94 164.35 11.86 Favored 'General case' 0 N--CA 1.479 1.002 0 CA-C-O 122.73 1.252 . . . . 1.0 109.41 179.409 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 84.9 m-20 -93.4 118.24 31.06 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-N 114.253 -1.339 . . . . 1.0 109.989 -179.614 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 20.6 t -101.9 107.58 21.94 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.308 0 N-CA-C 110.173 -0.306 . . . . 1.0 110.173 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 31.9 mtm180 -82.42 -173.14 4.41 Favored 'General case' 0 N--CA 1.478 0.971 0 CA-C-O 121.297 0.57 . . . . 1.0 110.345 179.441 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 17.6 t -95.17 -23.69 17.17 Favored 'General case' 0 N--CA 1.48 1.057 0 CA-C-N 115.675 -0.693 . . . . 1.0 111.085 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.401 ' O ' ' HB3' ' A' ' 18' ' ' ALA . 28.7 t 175.86 38.85 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.645 0 CA-C-O 121.182 0.515 . . . . 1.0 111.214 -179.717 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.401 ' HB3' ' O ' ' A' ' 17' ' ' SER . . . 76.07 45.39 0.12 Allowed 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 115.834 -0.621 . . . . 1.0 110.55 -179.782 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 70.5 m -129.83 117.28 19.95 Favored 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 115.84 -0.618 . . . . 1.0 110.795 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 24.9 m -64.06 -29.12 70.28 Favored 'General case' 0 N--CA 1.475 0.794 0 CA-C-N 116.067 -0.515 . . . . 1.0 109.995 179.347 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 55.0 m -68.45 -22.38 64.58 Favored 'General case' 0 CA--C 1.537 0.442 0 CA-C-N 116.121 -0.49 . . . . 1.0 110.508 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 45.9 t -70.18 -39.07 75.48 Favored 'General case' 0 N--CA 1.475 0.8 0 CA-C-O 121.429 0.633 . . . . 1.0 110.528 179.128 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.451 ' HG2' ' H ' ' A' ' 24' ' ' VAL . 5.0 ttmm 80.43 -170.58 0.04 OUTLIER 'General case' 0 N--CA 1.485 1.305 0 CA-C-N 115.612 -0.722 . . . . 1.0 109.703 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.451 ' H ' ' HG2' ' A' ' 23' ' ' LYS . 24.9 t -83.76 105.51 13.35 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.494 0 CA-C-N 115.852 -0.613 . . . . 1.0 109.873 179.746 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 40.0 pt -94.12 -19.61 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 CA-C-N 115.789 -0.641 . . . . 1.0 110.489 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -145.22 -163.95 10.42 Favored Glycine 0 N--CA 1.478 1.492 0 N-CA-C 110.99 -0.844 . . . . 1.0 110.99 -179.634 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 45.4 t -160.87 130.24 4.84 Favored 'General case' 0 N--CA 1.47 0.549 0 C-N-CA 120.65 -0.42 . . . . 1.0 109.958 179.594 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.9 tp -109.52 153.32 24.27 Favored 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 121.342 0.591 . . . . 1.0 109.947 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 61.4 m -91.3 149.93 21.53 Favored 'General case' 0 N--CA 1.472 0.628 0 CA-C-N 115.696 -0.684 . . . . 1.0 110.037 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -74.7 148.68 38.79 Favored Glycine 0 CA--C 1.528 0.849 0 N-CA-C 110.481 -1.048 . . . . 1.0 110.481 179.612 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 12.1 t-20 64.82 41.06 5.18 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-O 121.024 0.44 . . . . 1.0 110.52 -179.763 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 34.7 m -106.96 127.43 53.44 Favored 'General case' 0 N--CA 1.489 1.484 0 CA-C-N 115.95 -0.568 . . . . 1.0 110.356 179.554 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -76.68 147.05 37.71 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-O 121.231 0.538 . . . . 1.0 109.822 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.3 p -157.28 148.08 10.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.706 -0.679 . . . . 1.0 110.35 -179.421 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 68.4 p -86.06 84.28 7.55 Favored 'General case' 0 N--CA 1.473 0.689 0 CA-C-N 116.111 -0.495 . . . . 1.0 110.031 179.228 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.577 HG22 ' N ' ' A' ' 37' ' ' VAL . 69.4 mt -50.53 171.57 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 CA-C-N 116.37 -0.377 . . . . 1.0 110.216 -179.862 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.577 ' N ' HG22 ' A' ' 36' ' ' ILE . 39.1 t -139.29 -92.42 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.298 0 CA-C-N 116.547 -0.297 . . . . 1.0 110.668 -179.482 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -118.45 -172.58 15.6 Favored Glycine 0 N--CA 1.487 2.04 0 N-CA-C 111.052 -0.819 . . . . 1.0 111.052 -179.172 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -113.86 111.84 22.38 Favored 'General case' 0 N--CA 1.483 1.19 0 CA-C-O 123.331 1.539 . . . . 1.0 109.623 179.359 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.497 ' N ' ' O ' ' A' ' 43' ' ' PHE . 3.1 tm-20 -104.07 96.41 6.64 Favored 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 113.676 -1.602 . . . . 1.0 109.214 179.026 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.423 ' O ' ' HB3' ' A' ' 42' ' ' ALA . . . 30.61 56.31 0.25 Allowed Glycine 0 N--CA 1.503 3.11 0 CA-C-N 114.806 -1.088 . . . . 1.0 113.141 179.64 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 42' ' ' ALA . . . . . 0.423 ' HB3' ' O ' ' A' ' 41' ' ' GLY . . . 76.46 30.41 0.65 Allowed 'General case' 0 N--CA 1.489 1.494 0 CA-C-N 115.18 -0.51 . . . . 1.0 111.188 -178.438 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.497 ' O ' ' N ' ' A' ' 40' ' ' GLU . 75.1 m-85 -153.86 159.41 41.79 Favored 'General case' 0 N--CA 1.496 1.864 0 CA-C-N 116.194 -0.457 . . . . 1.0 111.005 179.774 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' TYR . . . . . 0.428 ' CD1' ' N ' ' A' ' 44' ' ' TYR . 15.2 p90 -143.89 165.98 26.21 Favored 'General case' 0 N--CA 1.488 1.435 0 CA-C-O 120.893 0.377 . . . . 1.0 110.407 179.398 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -88.2 159.52 18.12 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 109.551 -0.537 . . . . 1.0 109.551 -179.433 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 38.4 pt -146.97 154.38 11.91 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 CA-C-N 115.902 -0.59 . . . . 1.0 110.308 -179.367 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 72.7 mt-10 -110.33 84.28 1.9 Allowed 'General case' 0 N--CA 1.479 1.009 0 CA-C-N 115.911 -0.586 . . . . 1.0 109.67 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 7.7 t80 -119.56 137.04 54.09 Favored 'General case' 0 N--CA 1.486 1.352 0 CA-C-N 116.036 -0.529 . . . . 1.0 110.149 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 96.2 mttt 47.49 27.47 0.97 Allowed 'General case' 0 N--CA 1.481 1.09 0 CA-C-N 115.907 -0.588 . . . . 1.0 111.149 -179.297 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 67.44 23.26 73.49 Favored Glycine 0 N--CA 1.472 1.039 0 N-CA-C 110.824 -0.91 . . . . 1.0 110.824 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 92.1 p -128.4 166.02 19.5 Favored 'General case' 0 N--CA 1.482 1.136 0 CA-C-O 121.722 0.772 . . . . 1.0 110.826 -178.787 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -94.31 153.66 17.89 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-N 115.344 -0.844 . . . . 1.0 110.382 -179.407 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -158.09 166.31 34.03 Favored Glycine 0 N--CA 1.473 1.118 0 N-CA-C 110.748 -0.941 . . . . 1.0 110.748 -179.821 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -133.38 142.1 48.22 Favored 'General case' 0 N--CA 1.484 1.233 0 CA-C-N 115.552 -0.324 . . . . 1.0 110.417 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -147.78 147.29 17.4 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 CA-C-O 121.366 0.603 . . . . 1.0 109.816 -179.167 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -69.69 143.22 53.2 Favored 'General case' 0 CA--C 1.533 0.323 0 CA-C-N 115.642 -0.708 . . . . 1.0 110.017 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 9.6 mtmp? -87.31 -32.81 19.46 Favored 'General case' 0 N--CA 1.48 1.073 0 CA-C-N 116.006 -0.543 . . . . 1.0 110.218 179.645 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -52.58 -39.77 61.92 Favored 'General case' 0 N--CA 1.472 0.634 0 N-CA-C 110.227 -0.286 . . . . 1.0 110.227 -179.412 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 7.4 m-85 -48.4 -25.09 1.46 Allowed 'General case' 0 N--CA 1.48 1.069 0 CA-C-N 116.386 -0.37 . . . . 1.0 110.591 179.152 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 69.9 mt . . . . . 0 N--CA 1.476 0.861 0 CA-C-O 117.781 -1.104 . . . . 1.0 108.656 179.739 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 68.0 mttm . . . . . 0 N--CA 1.471 0.607 0 CA-C-O 121.812 0.815 . . . . 1.0 110.678 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 51.7 p -115.73 156.89 25.16 Favored 'General case' 0 N--CA 1.479 1.003 0 CA-C-N 115.132 -0.94 . . . . 1.0 110.228 -179.8 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -91.4 148.98 19.57 Favored Glycine 0 N--CA 1.468 0.777 0 N-CA-C 110.36 -1.096 . . . . 1.0 110.36 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 65.7 mt -104.33 126.75 59.02 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 CA-C-O 121.607 0.718 . . . . 1.0 109.131 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 28.8 t -91.47 129.49 42.1 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-N 115.402 -0.817 . . . . 1.0 109.692 179.532 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 62.5 m-80 -49.27 125.64 11.31 Favored 'General case' 0 CA--C 1.545 0.762 0 CA-C-N 116.085 -0.507 . . . . 1.0 110.54 179.315 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 32.6 t -51.28 -62.27 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 CA-C-N 115.905 -0.589 . . . . 1.0 110.473 -179.451 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.9 m -62.91 153.93 31.87 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.179 0.514 . . . . 1.0 109.988 179.611 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 69.54 -171.8 0.18 Allowed 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 115.856 -0.611 . . . . 1.0 110.157 -179.873 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 42.6 t -150.32 154.17 37.38 Favored 'General case' 0 N--CA 1.473 0.697 0 CA-C-O 121.548 0.69 . . . . 1.0 110.366 179.91 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.584 HD11 ' CG ' ' A' ' 59' ' ' TYR . 4.5 mm? -99.68 135.28 41.33 Favored 'General case' 0 N--CA 1.478 0.94 0 CA-C-O 122.062 0.934 . . . . 1.0 109.989 -179.42 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 20.3 p-10 -90.76 129.27 36.86 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.009 -0.996 . . . . 1.0 109.674 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 41.0 t -92.02 103.38 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 CA-C-N 115.664 -0.698 . . . . 1.0 109.336 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 90.8 mtt-85 -81.97 151.57 27.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.434 0.635 . . . . 1.0 109.893 179.244 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 39.8 t -71.99 -21.63 61.54 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 115.582 -0.735 . . . . 1.0 110.433 179.535 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 48.9 m -163.73 174.94 11.02 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-N 116.014 -0.539 . . . . 1.0 110.682 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -70.6 56.48 0.17 Allowed 'General case' 0 N--CA 1.474 0.744 0 CA-C-N 115.792 -0.64 . . . . 1.0 110.42 179.502 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 49.1 m -140.65 130.02 23.84 Favored 'General case' 0 N--CA 1.481 1.089 0 CA-C-O 121.532 0.682 . . . . 1.0 110.577 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 3.7 t -66.31 -31.66 72.59 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 115.476 -0.784 . . . . 1.0 110.425 179.755 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 95.7 p -73.85 -4.81 37.14 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 115.976 -0.557 . . . . 1.0 110.244 -179.787 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 43.1 t -58.9 -173.82 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 120.952 0.406 . . . . 1.0 110.41 179.493 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -127.58 161.52 28.63 Favored 'General case' 0 N--CA 1.478 0.974 0 CA-C-O 121.747 0.784 . . . . 1.0 110.286 -179.768 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.2 t -89.42 108.99 19.81 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-N 115.283 -0.871 . . . . 1.0 109.694 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 45.9 pt -85.72 -17.01 9.69 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 CA-C-N 115.597 -0.729 . . . . 1.0 110.187 179.728 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 175.32 174.73 42.17 Favored Glycine 0 N--CA 1.461 0.319 0 N-CA-C 110.942 -0.863 . . . . 1.0 110.942 -179.455 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 42.6 t -142.52 137.58 30.31 Favored 'General case' 0 N--CA 1.475 0.798 0 CA-C-O 121.775 0.798 . . . . 1.0 110.528 179.604 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -99.8 171.87 7.61 Favored 'General case' 0 N--CA 1.475 0.782 0 CA-C-N 115.303 -0.862 . . . . 1.0 109.206 -179.671 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 56.7 m -89.96 155.13 19.32 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 115.085 -0.961 . . . . 1.0 110.298 -179.225 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -74.97 150.76 41.47 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.117 -1.193 . . . . 1.0 110.117 179.397 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 22.9 t30 74.83 17.71 2.79 Favored 'General case' 0 N--CA 1.48 1.04 0 CA-C-O 120.798 0.332 . . . . 1.0 110.572 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 59.4 m -87.86 132.39 34.21 Favored 'General case' 0 N--CA 1.478 0.975 0 CA-C-O 121.236 0.541 . . . . 1.0 110.042 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 26.9 mtpp -82.61 144.62 30.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.638 0.732 . . . . 1.0 109.677 179.738 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 16.9 m -147.63 130.47 7.87 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.451 0 CA-C-N 115.319 -0.855 . . . . 1.0 109.863 -179.91 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.411 ' O ' ' C ' ' A' ' 36' ' ' ILE . 30.7 m -86.39 89.05 7.75 Favored 'General case' 0 CA--C 1.515 -0.388 0 N-CA-C 109.098 -0.704 . . . . 1.0 109.098 179.463 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.438 ' H ' HD12 ' A' ' 36' ' ' ILE . 3.5 mp -34.47 146.94 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.504 2.253 0 CA-C-N 116.372 -0.377 . . . . 1.0 111.579 179.345 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 4.7 t -143.45 62.55 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.084 0 CA-C-O 121.05 0.452 . . . . 1.0 110.333 -178.669 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 108.61 166.57 20.94 Favored Glycine 0 N--CA 1.465 0.624 0 N-CA-C 110.462 -1.055 . . . . 1.0 110.462 179.75 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 16.4 pt-20 -142.21 147.25 36.24 Favored 'General case' 0 N--CA 1.476 0.842 0 CA-C-N 114.824 -0.688 . . . . 1.0 110.15 -179.747 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -154.37 125.84 7.47 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 115.704 -0.68 . . . . 1.0 110.162 179.453 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 50.33 -112.46 1.55 Allowed Glycine 0 CA--C 1.535 1.312 0 N-CA-C 111.398 -0.681 . . . . 1.0 111.398 179.442 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -115.37 22.63 13.08 Favored 'General case' 0 N--CA 1.482 1.143 0 N-CA-C 109.911 -0.403 . . . . 1.0 109.911 179.151 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.407 ' C ' ' NZ ' ' A' ' 57' ' ' LYS . 54.5 m-85 -143.37 153.88 43.15 Favored 'General case' 0 N--CA 1.477 0.884 0 CA-C-O 122.012 0.91 . . . . 1.0 110.365 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' TYR . . . . . 0.43 ' N ' ' CD1' ' A' ' 44' ' ' TYR . 11.8 p90 -134.67 169.17 17.72 Favored 'General case' 0 N--CA 1.473 0.687 0 CA-C-O 122.146 0.974 . . . . 1.0 110.04 -179.481 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 63.3 tttm -95.58 151.85 18.96 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 114.902 -1.045 . . . . 1.0 109.918 -179.328 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 18.1 pt -143.91 162.05 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 CA-C-O 122.156 0.979 . . . . 1.0 110.021 179.39 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -125.25 96.78 4.96 Favored 'General case' 0 N--CA 1.479 1.017 0 CA-C-N 114.818 -1.083 . . . . 1.0 110.108 179.276 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 39.2 t80 -135.73 152.79 51.5 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 115.718 -0.674 . . . . 1.0 109.968 179.287 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 63.5 mttt 56.69 10.86 0.78 Allowed 'General case' 0 N--CA 1.475 0.819 0 CA-C-N 115.812 -0.631 . . . . 1.0 110.84 179.629 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 81.35 0.03 88.44 Favored Glycine 0 N--CA 1.472 1.1 0 N-CA-C 110.264 -1.134 . . . . 1.0 110.264 -179.573 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 49.4 m -110.98 172.97 6.56 Favored 'General case' 0 N--CA 1.482 1.153 0 C-N-CA 123.902 0.881 . . . . 1.0 110.167 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 47.8 m-70 -107.16 145.54 32.43 Favored 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 115.35 -0.841 . . . . 1.0 110.023 -179.747 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -152.06 170.92 31.42 Favored Glycine 0 N--CA 1.464 0.501 0 N-CA-C 110.9 -0.88 . . . . 1.0 110.9 -179.382 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 80.1 m-85 -132.38 146.23 51.81 Favored 'General case' 0 N--CA 1.482 1.13 0 CA-C-O 121.518 0.675 . . . . 1.0 110.258 179.219 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 36.4 t -143.64 147.59 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 CA-C-N 115.451 -0.795 . . . . 1.0 110.277 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -68.75 153.12 44.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.547 -0.751 . . . . 1.0 110.216 179.641 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' LYS . . . . . 0.407 ' NZ ' ' C ' ' A' ' 43' ' ' PHE . 65.4 mttp -89.99 -22.82 21.73 Favored 'General case' 0 N--CA 1.478 0.961 0 CA-C-N 115.709 -0.678 . . . . 1.0 110.586 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -52.38 -35.99 52.83 Favored 'General case' 0 CA--C 1.537 0.478 0 CA-C-O 121.068 0.461 . . . . 1.0 110.488 -179.146 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.584 ' CG ' HD11 ' A' ' 12' ' ' LEU . 24.4 m-85 -64.04 -30.18 71.27 Favored 'General case' 0 N--CA 1.475 0.823 0 CA-C-N 115.905 -0.589 . . . . 1.0 110.477 178.941 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 63.5 mt . . . . . 0 N--CA 1.47 0.542 0 CA-C-O 118.119 -0.943 . . . . 1.0 108.609 -179.577 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 25.9 ttpp . . . . . 0 N--CA 1.461 0.108 0 CA-C-O 121.369 0.604 . . . . 1.0 110.112 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 53.9 p -118.31 144.79 45.58 Favored 'General case' 0 N--CA 1.474 0.727 0 CA-C-O 121.695 0.76 . . . . 1.0 110.475 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -97.58 154.25 20.31 Favored Glycine 0 N--CA 1.476 1.322 0 N-CA-C 110.038 -1.225 . . . . 1.0 110.038 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 65.7 mt -106.07 125.26 61.66 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.086 0 CA-C-O 121.239 0.543 . . . . 1.0 109.555 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 45.0 t -74.55 133.48 31.45 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.324 0 CA-C-N 115.788 -0.642 . . . . 1.0 109.479 179.61 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 9.4 m120 -62.13 109.27 1.25 Allowed 'General case' 0 CA--C 1.537 0.444 0 CA-C-N 115.735 -0.666 . . . . 1.0 110.113 179.363 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.3 p -55.61 -19.33 5.91 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 CA-C-N 116.035 -0.529 . . . . 1.0 110.435 179.515 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 49.5 m -52.08 105.97 0.13 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.158 -0.473 . . . . 1.0 110.422 -179.373 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 80.9 p 60.42 -122.38 0.97 Allowed 'General case' 0 CA--C 1.548 0.882 0 CA-C-N 116.062 -0.517 . . . . 1.0 110.448 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 47.7 t -151.98 156.57 40.29 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-O 121.379 0.609 . . . . 1.0 110.083 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -104.24 136.46 43.8 Favored 'General case' 0 N--CA 1.479 1.016 0 CA-C-O 121.817 0.818 . . . . 1.0 110.323 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 72.5 m-80 -92.31 133.97 35.35 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.199 -0.909 . . . . 1.0 109.269 -179.623 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 59.3 t -93.19 105.75 17.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-N 115.104 -0.953 . . . . 1.0 109.37 -179.658 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 88.9 mtt-85 -81.32 148.55 29.33 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.487 0.661 . . . . 1.0 109.922 179.305 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 87.6 p -73.14 -19.41 61.14 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 115.606 -0.724 . . . . 1.0 110.019 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 87.1 p -162.17 172.85 15.13 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-O 121.179 0.514 . . . . 1.0 110.798 -179.585 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -71.47 57.45 0.26 Allowed 'General case' 0 N--CA 1.474 0.767 0 CA-C-N 115.789 -0.641 . . . . 1.0 110.49 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 55.8 m -143.93 130.43 20.01 Favored 'General case' 0 N--CA 1.481 1.105 0 CA-C-N 115.71 -0.677 . . . . 1.0 110.492 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 57.8 p -65.72 -26.61 67.83 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 115.827 -0.624 . . . . 1.0 110.226 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 49.4 m -71.07 -8.02 50.49 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 116.063 -0.517 . . . . 1.0 110.256 179.685 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 61.2 m -67.0 132.08 47.17 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 121.388 0.614 . . . . 1.0 110.01 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -72.48 169.58 16.13 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.615 -0.72 . . . . 1.0 110.123 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.7 t -90.16 112.58 24.95 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 CA-C-O 121.807 0.813 . . . . 1.0 109.754 179.751 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 2.1 pp -85.18 -27.19 6.54 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 CA-C-N 115.146 -0.934 . . . . 1.0 109.761 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 173.15 -171.84 44.73 Favored Glycine 0 N--CA 1.465 0.583 0 N-CA-C 111.398 -0.681 . . . . 1.0 111.398 -179.423 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 95.4 p -151.92 145.23 24.73 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-O 121.895 0.855 . . . . 1.0 110.449 179.208 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -102.31 -179.11 3.89 Favored 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 115.166 -0.925 . . . . 1.0 109.28 -179.662 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 96.8 p -91.66 144.63 25.33 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 115.145 -0.934 . . . . 1.0 110.197 -179.646 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -75.13 157.96 50.5 Favored Glycine 0 N--CA 1.461 0.343 0 N-CA-C 110.212 -1.155 . . . . 1.0 110.212 179.566 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 13.0 t-20 69.46 20.82 7.08 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-O 120.707 0.289 . . . . 1.0 110.485 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 85.7 m -88.99 137.16 32.57 Favored 'General case' 0 N--CA 1.478 0.962 0 CA-C-O 121.413 0.625 . . . . 1.0 110.433 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -86.93 144.51 26.92 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-O 122.069 0.938 . . . . 1.0 109.814 179.771 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 5.7 p -153.75 138.14 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.423 0 CA-C-N 114.898 -1.046 . . . . 1.0 109.806 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 60.9 p -82.46 84.32 7.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.784 -0.644 . . . . 1.0 109.62 178.694 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.432 HG22 ' N ' ' A' ' 37' ' ' VAL . 88.6 mt -43.02 160.06 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 CA-C-N 115.657 -0.701 . . . . 1.0 110.243 179.428 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.432 ' N ' HG22 ' A' ' 36' ' ' ILE . 43.3 t -123.34 -92.5 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 CA-C-N 115.882 -0.599 . . . . 1.0 109.698 -179.745 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -114.89 -159.15 12.27 Favored Glycine 0 N--CA 1.466 0.653 0 CA-C-O 122.318 0.954 . . . . 1.0 110.861 -179.278 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' GLU . . . . . 0.461 ' N ' ' NZ ' ' A' ' 45' ' ' LYS . 1.0 OUTLIER -143.66 147.93 35.04 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 114.707 -0.747 . . . . 1.0 110.61 -179.524 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -154.64 124.5 6.65 Favored 'General case' 0 N--CA 1.47 0.558 0 CA-C-N 115.929 -0.578 . . . . 1.0 110.345 179.319 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 53.3 -150.15 11.71 Favored Glycine 0 CA--C 1.532 1.149 0 N-CA-C 111.139 -0.784 . . . . 1.0 111.139 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -84.9 30.37 0.58 Allowed 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 110.151 -0.314 . . . . 1.0 110.151 179.431 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 -145.69 153.37 40.92 Favored 'General case' 0 N--CA 1.477 0.909 0 CA-C-O 121.784 0.802 . . . . 1.0 110.529 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 1.7 m-85 -109.68 148.87 30.59 Favored 'General case' 0 N--CA 1.48 1.032 0 CA-C-O 122.556 1.169 . . . . 1.0 110.099 179.468 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.461 ' NZ ' ' N ' ' A' ' 39' ' ' GLU . 35.4 mtmm -87.98 140.73 29.2 Favored 'General case' 0 CA--C 1.518 -0.281 0 CA-C-N 114.485 -1.234 . . . . 1.0 109.508 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 39.9 pt -149.86 173.41 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.358 0 CA-C-N 114.594 -1.185 . . . . 1.0 109.688 -179.128 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -146.61 108.14 4.29 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 115.74 -0.664 . . . . 1.0 110.225 178.94 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 54.6 t80 -139.08 162.35 35.15 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.739 -0.664 . . . . 1.0 110.054 179.76 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 19.2 tttp 59.18 16.49 4.91 Favored 'General case' 0 CA--C 1.546 0.818 0 CA-C-N 115.55 -0.75 . . . . 1.0 110.9 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 77.85 -2.1 65.64 Favored Glycine 0 N--CA 1.477 1.403 0 N-CA-C 110.171 -1.171 . . . . 1.0 110.171 -179.357 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 49.2 m -114.95 176.29 5.12 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 124.278 1.031 . . . . 1.0 110.486 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 25.9 p80 -105.36 141.01 37.62 Favored 'General case' 0 N--CA 1.482 1.15 0 CA-C-N 115.464 -0.789 . . . . 1.0 110.064 -179.447 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.68 165.8 27.92 Favored Glycine 0 N--CA 1.463 0.435 0 N-CA-C 110.525 -1.03 . . . . 1.0 110.525 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -130.37 145.43 51.8 Favored 'General case' 0 N--CA 1.483 1.217 0 CA-C-O 121.527 0.68 . . . . 1.0 110.001 179.538 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 41.3 t -145.92 149.75 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 CA-C-O 121.904 0.859 . . . . 1.0 109.427 -179.723 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.402 ' O ' ' CD1' ' A' ' 59' ' ' TYR . . . -60.71 153.44 24.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 114.986 -1.006 . . . . 1.0 110.164 178.952 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 15.8 pttp -102.89 -31.34 10.31 Favored 'General case' 0 N--CA 1.482 1.167 0 CA-C-N 115.442 -0.799 . . . . 1.0 111.763 178.9 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 14.6 pt-20 -64.53 -31.82 73.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.444 0.64 . . . . 1.0 111.022 -179.176 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.402 ' CD1' ' O ' ' A' ' 56' ' ' ALA . 0.6 OUTLIER -62.7 -4.12 1.88 Allowed 'General case' 0 CA--C 1.549 0.918 0 CA-C-N 115.476 -0.783 . . . . 1.0 110.138 -179.888 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 85.1 mt . . . . . 0 N--CA 1.477 0.888 0 N-CA-C 108.13 -1.063 . . . . 1.0 108.13 -179.163 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 98.5 mttt . . . . . 0 N--CA 1.475 0.785 0 CA-C-O 121.432 0.634 . . . . 1.0 110.563 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 20.2 p -137.78 151.26 47.96 Favored 'General case' 0 N--CA 1.489 1.479 0 CA-C-N 115.549 -0.75 . . . . 1.0 110.353 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -96.8 142.78 16.36 Favored Glycine 0 N--CA 1.474 1.217 0 N-CA-C 110.625 -0.99 . . . . 1.0 110.625 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 75.1 mt -109.24 141.56 24.18 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.177 0 CA-C-O 121.224 0.535 . . . . 1.0 109.95 -179.618 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 2.8 t -116.56 115.86 50.39 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 CA-C-O 116.812 -1.566 . . . . 1.0 110.682 178.083 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -82.48 146.3 29.33 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 120.098 1.317 . . . . 1.0 109.06 177.638 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.9 p -50.14 139.01 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 CA-C-N 116.314 -0.403 . . . . 1.0 111.126 179.289 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 79.2 p -168.59 -78.88 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.844 0 CA-C-O 120.843 0.354 . . . . 1.0 111.141 -179.26 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 97.6 p -131.15 -133.74 0.2 Allowed 'General case' 0 N--CA 1.485 1.287 0 CA-C-N 116.068 -0.515 . . . . 1.0 110.516 -179.105 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 98.3 p -138.85 153.76 48.36 Favored 'General case' 0 N--CA 1.477 0.925 0 CA-C-O 121.312 0.577 . . . . 1.0 110.238 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -140.3 128.27 22.09 Favored 'General case' 0 N--CA 1.49 1.553 0 CA-C-O 121.733 0.778 . . . . 1.0 109.715 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 19.3 p30 -92.96 144.08 25.61 Favored 'General case' 0 N--CA 1.473 0.704 0 CA-C-N 115.298 -0.865 . . . . 1.0 110.06 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 93.9 t -97.79 128.45 49.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 CA-C-O 121.879 0.847 . . . . 1.0 108.894 179.173 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 89.5 mtt-85 -99.55 -167.74 1.51 Allowed 'General case' 0 N--CA 1.473 0.702 0 CA-C-N 115.187 -0.915 . . . . 1.0 110.162 -179.744 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 60.1 p -130.8 33.16 4.26 Favored 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 123.017 0.527 . . . . 1.0 110.611 -179.413 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' SER . . . . . 0.48 ' OG ' ' N ' ' A' ' 18' ' ' ALA . 6.9 t 175.8 -177.95 0.13 Allowed 'General case' 0 N--CA 1.48 1.027 0 CA-C-O 121.632 0.729 . . . . 1.0 110.507 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.48 ' N ' ' OG ' ' A' ' 17' ' ' SER . . . -97.11 42.97 1.08 Allowed 'General case' 0 N--CA 1.488 1.448 0 CA-C-N 115.285 -0.87 . . . . 1.0 110.182 179.511 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 44.3 t -130.63 138.18 49.97 Favored 'General case' 0 N--CA 1.489 1.477 0 CA-C-N 115.106 -0.952 . . . . 1.0 110.902 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 80.1 p -74.73 -8.75 57.37 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-N 116.227 -0.442 . . . . 1.0 110.569 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 66.7 m -99.36 -6.58 27.57 Favored 'General case' 0 N--CA 1.486 1.333 0 CA-C-N 116.201 -0.454 . . . . 1.0 111.069 -179.072 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 13.9 t -66.48 133.95 51.46 Favored 'General case' 0 N--CA 1.473 0.72 0 CA-C-N 115.962 -0.563 . . . . 1.0 110.843 -179.414 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 38.3 ttmt -59.89 155.67 15.99 Favored 'General case' 0 N--CA 1.475 0.793 0 CA-C-N 116.031 -0.531 . . . . 1.0 110.622 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 6.8 p -83.94 144.56 9.68 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.193 0 CA-C-O 121.176 0.513 . . . . 1.0 110.503 -179.68 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 40.1 pt -121.87 -10.26 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 CA-C-N 115.813 -0.631 . . . . 1.0 110.34 179.266 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 179.35 -171.56 43.42 Favored Glycine 0 N--CA 1.467 0.759 0 N-CA-C 111.111 -0.796 . . . . 1.0 111.111 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 96.7 p -157.25 151.0 24.33 Favored 'General case' 0 N--CA 1.475 0.797 0 CA-C-N 115.642 -0.279 . . . . 1.0 110.559 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 2.2 pp -117.23 167.78 10.9 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 123.076 0.55 . . . . 1.0 110.507 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 90.9 p -112.74 160.02 18.37 Favored 'General case' 0 N--CA 1.482 1.17 0 CA-C-N 115.718 -0.673 . . . . 1.0 110.537 -179.491 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.467 ' O ' ' HB2' ' A' ' 31' ' ' ASN . . . -83.75 76.06 2.29 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 110.901 -0.88 . . . . 1.0 110.901 179.41 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.467 ' HB2' ' O ' ' A' ' 30' ' ' GLY . 22.1 t-20 164.61 16.3 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.843 0 C-N-CA 123.287 0.635 . . . . 1.0 110.242 -179.566 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 36.4 m -109.84 147.47 33.27 Favored 'General case' 0 N--CA 1.486 1.337 0 C-N-CA 123.424 0.69 . . . . 1.0 111.046 -179.458 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 22.2 pttp -90.25 148.77 22.7 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 122.602 0.361 . . . . 1.0 110.209 178.532 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.6 m -143.21 126.04 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 CA-C-O 120.829 0.347 . . . . 1.0 110.296 179.587 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' THR . . . . . 0.542 ' O ' HG23 ' A' ' 35' ' ' THR . 9.8 t -82.79 85.47 7.07 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 121.445 0.641 . . . . 1.0 110.619 179.674 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 85.6 mt -51.16 157.23 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 CA-C-N 115.546 -0.752 . . . . 1.0 110.165 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 39.6 t -127.4 -97.86 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 CA-C-N 115.947 -0.569 . . . . 1.0 110.003 -179.076 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -99.49 -178.42 31.2 Favored Glycine 0 N--CA 1.472 1.036 0 N-CA-C 110.937 -0.865 . . . . 1.0 110.937 -179.773 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -135.16 141.8 46.0 Favored 'General case' 0 N--CA 1.483 1.193 0 CA-C-O 120.984 0.421 . . . . 1.0 110.204 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -155.38 134.84 12.48 Favored 'General case' 0 CA--C 1.539 0.524 0 CA-C-N 116.001 -0.545 . . . . 1.0 110.378 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 48.56 -113.14 1.4 Allowed Glycine 0 CA--C 1.547 2.051 0 CA-C-N 115.947 -0.57 . . . . 1.0 111.707 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -122.49 24.7 9.16 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 110.049 -0.352 . . . . 1.0 110.049 179.23 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -145.07 156.18 43.76 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-O 121.301 0.572 . . . . 1.0 110.296 -179.474 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 22.6 p90 -131.67 162.87 29.38 Favored 'General case' 0 N--CA 1.488 1.458 0 CA-C-N 115.684 -0.689 . . . . 1.0 110.452 179.712 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -88.58 160.39 17.45 Favored 'General case' 0 N--CA 1.476 0.829 0 CA-C-N 116.037 -0.528 . . . . 1.0 110.159 -179.372 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 34.4 pt -145.75 153.17 13.74 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 CA-C-O 121.312 0.577 . . . . 1.0 110.504 -179.632 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 80.8 mm-40 -95.75 58.73 1.99 Allowed 'General case' 0 N--CA 1.481 1.113 0 CA-C-N 115.668 -0.696 . . . . 1.0 110.069 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 77.8 t80 -78.94 117.54 20.11 Favored 'General case' 0 N--CA 1.474 0.727 0 CA-C-N 115.603 -0.726 . . . . 1.0 109.915 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm 45.58 33.21 1.32 Allowed 'General case' 0 CA--C 1.557 1.24 0 CA-C-O 121.276 0.56 . . . . 1.0 111.415 -179.629 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 68.19 21.74 74.03 Favored Glycine 0 N--CA 1.482 1.736 0 N-CA-C 111.373 -0.691 . . . . 1.0 111.373 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 28.9 t -115.98 171.65 7.65 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 123.332 0.653 . . . . 1.0 110.878 -179.186 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -96.77 136.85 36.73 Favored 'General case' 0 N--CA 1.479 0.995 0 CA-C-N 115.942 -0.572 . . . . 1.0 110.229 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -148.2 163.13 28.9 Favored Glycine 0 N--CA 1.479 1.522 0 N-CA-C 110.993 -0.843 . . . . 1.0 110.993 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' TYR . . . . . 0.451 ' CD1' ' N ' ' A' ' 17' ' ' SER . 82.2 m-85 -133.83 138.01 45.39 Favored 'General case' 0 N--CA 1.483 1.184 0 CA-C-O 121.483 0.659 . . . . 1.0 110.544 -179.744 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 42.8 t -144.23 151.22 16.16 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.291 0 CA-C-N 115.501 -0.772 . . . . 1.0 110.1 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -79.55 113.53 17.77 Favored 'General case' 0 N--CA 1.474 0.747 0 CA-C-N 115.785 -0.643 . . . . 1.0 110.502 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 19.3 pttp -74.23 -28.44 61.24 Favored 'General case' 0 N--CA 1.476 0.871 0 CA-C-O 120.812 0.339 . . . . 1.0 110.512 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -55.11 -45.18 75.5 Favored 'General case' 0 N--CA 1.477 0.876 0 CA-C-N 116.234 -0.439 . . . . 1.0 111.014 -179.297 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 22.9 m-85 -63.0 -35.02 78.81 Favored 'General case' 0 N--CA 1.477 0.893 0 N-CA-C 110.003 -0.369 . . . . 1.0 110.003 178.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 74.4 mt . . . . . 0 N--CA 1.479 1.01 0 CA-C-O 118.133 -0.937 . . . . 1.0 109.253 -179.48 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 98.9 mttt . . . . . 0 N--CA 1.479 1.006 0 CA-C-O 121.817 0.818 . . . . 1.0 110.181 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 73.3 p -123.14 144.59 49.24 Favored 'General case' 0 N--CA 1.48 1.054 0 CA-C-N 115.161 -0.927 . . . . 1.0 110.314 -179.796 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -95.64 151.77 20.11 Favored Glycine 0 CA--C 1.527 0.838 0 N-CA-C 110.229 -1.149 . . . . 1.0 110.229 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 4.0 mp -103.56 124.89 58.11 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 N-CA-C 109.493 -0.558 . . . . 1.0 109.493 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.3 t -66.67 120.09 13.24 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.554 0 CA-C-N 115.7 -0.682 . . . . 1.0 109.845 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 18.2 p-10 -59.63 102.28 0.14 Allowed 'General case' 0 CA--C 1.539 0.537 0 CA-C-O 121.029 0.443 . . . . 1.0 110.479 179.492 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 8.2 p -64.27 -2.85 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-N 115.951 -0.568 . . . . 1.0 110.721 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 41.3 m -45.89 -56.71 5.08 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-N 115.743 -0.662 . . . . 1.0 111.445 -179.87 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 50.0 m -148.56 179.41 7.83 Favored 'General case' 0 N--CA 1.477 0.907 0 CA-C-N 115.61 -0.723 . . . . 1.0 110.277 179.216 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 45.1 t -84.75 140.31 31.35 Favored 'General case' 0 N--CA 1.473 0.712 0 CA-C-N 115.479 -0.782 . . . . 1.0 110.249 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -111.6 140.65 46.04 Favored 'General case' 0 N--CA 1.485 1.29 0 CA-C-O 122.232 1.015 . . . . 1.0 109.935 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 72.6 m-80 -82.67 126.7 32.65 Favored 'General case' 0 N--CA 1.451 -0.407 0 CA-C-N 114.805 -1.089 . . . . 1.0 109.476 179.663 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.4 t -102.09 125.86 56.21 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 CA-C-N 115.229 -0.896 . . . . 1.0 110.181 -179.763 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -91.83 179.62 5.57 Favored 'General case' 0 N--CA 1.486 1.348 0 CA-C-O 121.582 0.706 . . . . 1.0 110.238 179.039 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 1.4 m -92.65 -22.61 19.35 Favored 'General case' 0 N--CA 1.489 1.508 0 CA-C-N 115.435 -0.802 . . . . 1.0 110.282 179.837 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 45.5 p -176.74 -178.13 0.85 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 122.175 0.988 . . . . 1.0 110.032 -179.162 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -82.15 82.27 7.76 Favored 'General case' 0 N--CA 1.47 0.562 0 CA-C-N 114.852 -1.067 . . . . 1.0 109.689 179.182 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 65.5 p -167.25 154.68 8.92 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 121.565 0.698 . . . . 1.0 110.332 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 26.3 m -75.1 -25.32 58.44 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.398 -0.819 . . . . 1.0 110.639 179.311 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 99.5 p -63.08 -22.93 67.19 Favored 'General case' 0 N--CA 1.471 0.602 0 C-N-CA 120.597 -0.441 . . . . 1.0 110.408 -178.423 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 26.5 t -96.96 141.79 29.7 Favored 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 109.652 -0.499 . . . . 1.0 109.652 178.41 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 24.9 tttm -163.24 109.9 1.16 Allowed 'General case' 0 N--CA 1.474 0.754 0 CA-C-O 122.077 0.942 . . . . 1.0 110.029 179.638 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.3 t 62.06 135.92 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.519 0 CA-C-N 115.032 -0.986 . . . . 1.0 110.24 -179.82 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 1.3 pp -152.57 -17.14 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.963 0 CA-C-N 115.93 -0.577 . . . . 1.0 110.326 -179.387 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 163.27 -166.91 37.32 Favored Glycine 0 CA--C 1.522 0.469 0 N-CA-C 110.359 -1.096 . . . . 1.0 110.359 -178.247 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 93.9 p -145.11 140.44 28.03 Favored 'General case' 0 N--CA 1.481 1.121 0 CA-C-N 114.882 -0.659 . . . . 1.0 110.591 179.782 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.9 pp -102.17 122.41 44.1 Favored 'General case' 0 N--CA 1.491 1.58 0 CA-C-O 121.587 0.708 . . . . 1.0 109.392 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 51.0 m -44.69 131.62 6.75 Favored 'General case' 0 N--CA 1.484 1.233 0 CA-C-N 115.476 -0.784 . . . . 1.0 111.082 -178.654 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -68.08 165.87 45.14 Favored Glycine 0 CA--C 1.521 0.449 0 N-CA-C 111.354 -0.699 . . . . 1.0 111.354 -178.972 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 13.8 m-80 65.1 20.66 12.08 Favored 'General case' 0 N--CA 1.471 0.624 0 CA-C-O 120.954 0.407 . . . . 1.0 110.455 179.654 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 91.8 m -97.67 145.54 26.21 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-N 115.994 -0.548 . . . . 1.0 109.735 179.48 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -86.27 139.3 31.14 Favored 'General case' 0 N--CA 1.473 0.682 0 CA-C-N 115.77 -0.65 . . . . 1.0 110.143 179.428 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 9.8 m -142.49 124.99 13.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 CA-C-N 115.675 -0.693 . . . . 1.0 110.118 179.808 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 60.0 p -89.93 90.78 8.31 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 115.917 -0.583 . . . . 1.0 109.813 179.185 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 3.5 mp -36.75 147.17 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.498 1.94 0 CA-C-N 115.768 -0.651 . . . . 1.0 111.517 179.669 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 4.7 t -141.68 61.47 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.37 0 CA-C-O 121.239 0.543 . . . . 1.0 110.522 -178.485 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 107.83 160.55 20.83 Favored Glycine 0 N--CA 1.471 1.005 0 N-CA-C 110.711 -0.956 . . . . 1.0 110.711 179.435 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 74.7 mt-10 -135.46 140.72 45.08 Favored 'General case' 0 N--CA 1.487 1.383 0 CA-C-O 121.161 0.505 . . . . 1.0 110.261 179.703 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.7 tm-20 -148.95 121.87 8.77 Favored 'General case' 0 N--CA 1.477 0.875 0 CA-C-N 115.837 -0.619 . . . . 1.0 110.346 -179.595 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 50.41 -114.17 2.44 Favored Glycine 0 CA--C 1.543 1.783 0 N-CA-C 111.16 -0.776 . . . . 1.0 111.16 179.651 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -113.62 26.82 10.05 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 122.609 0.364 . . . . 1.0 110.724 179.431 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 -146.9 156.34 43.0 Favored 'General case' 0 N--CA 1.476 0.841 0 CA-C-O 121.721 0.772 . . . . 1.0 110.487 179.857 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' TYR . . . . . 0.4 ' CD1' ' N ' ' A' ' 44' ' ' TYR . 15.0 p90 -140.45 172.67 12.4 Favored 'General case' 0 N--CA 1.473 0.72 0 CA-C-N 115.336 -0.847 . . . . 1.0 110.121 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 24.0 mtpp -101.32 151.83 21.42 Favored 'General case' 0 N--CA 1.478 0.944 0 CA-C-N 115.225 -0.898 . . . . 1.0 110.281 -179.282 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 38.9 pt -139.55 152.97 23.29 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 CA-C-N 115.59 -0.732 . . . . 1.0 110.596 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 4.3 tm-20 -113.45 86.82 2.47 Favored 'General case' 0 N--CA 1.485 1.288 0 CA-C-N 115.323 -0.853 . . . . 1.0 109.872 179.236 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 22.6 t80 -139.65 158.46 44.08 Favored 'General case' 0 N--CA 1.469 0.505 0 CA-C-O 121.209 0.528 . . . . 1.0 110.566 179.391 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 33.8 mtmt 50.29 20.83 0.7 Allowed 'General case' 0 N--CA 1.476 0.859 0 CA-C-N 115.847 -0.615 . . . . 1.0 110.447 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 71.55 -3.32 18.04 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.799 -0.92 . . . . 1.0 110.799 -179.533 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 44.0 t -117.38 173.97 6.4 Favored 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 124.119 0.968 . . . . 1.0 110.644 -179.431 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 26.7 p-80 -112.37 153.54 27.11 Favored 'General case' 0 N--CA 1.481 1.094 0 CA-C-N 115.467 -0.788 . . . . 1.0 109.955 -179.587 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.06 165.55 27.71 Favored Glycine 0 N--CA 1.471 0.994 0 N-CA-C 110.711 -0.956 . . . . 1.0 110.711 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 77.0 m-85 -130.54 139.67 50.48 Favored 'General case' 0 N--CA 1.486 1.351 0 CA-C-O 121.119 0.485 . . . . 1.0 110.268 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 4.2 p -158.91 158.84 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.001 0 CA-C-N 115.92 -0.582 . . . . 1.0 110.25 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.66 134.13 56.74 Favored 'General case' 0 CA--C 1.541 0.609 0 CA-C-O 121.191 0.519 . . . . 1.0 110.397 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -91.06 -35.97 14.31 Favored 'General case' 0 N--CA 1.483 1.198 0 CA-C-N 115.712 -0.676 . . . . 1.0 110.258 -179.831 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -56.73 -28.47 61.09 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-O 121.099 0.476 . . . . 1.0 110.633 -179.454 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 2.2 m-85 -63.21 -39.24 94.08 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-N 115.88 -0.6 . . . . 1.0 110.17 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 70.2 mt . . . . . 0 N--CA 1.472 0.628 0 CA-C-O 117.698 -1.144 . . . . 1.0 109.338 -179.32 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 7.0 mtpm? . . . . . 0 N--CA 1.47 0.565 0 CA-C-O 120.722 0.296 . . . . 1.0 110.994 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 68.6 p -125.89 163.07 23.74 Favored 'General case' 0 N--CA 1.48 1.045 0 CA-C-O 121.786 0.803 . . . . 1.0 110.353 -179.259 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -122.13 153.17 16.81 Favored Glycine 0 N--CA 1.479 1.565 0 CA-C-N 115.147 -0.933 . . . . 1.0 110.883 -179.696 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 28.2 pt -114.45 140.47 35.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 CA-C-O 121.869 0.842 . . . . 1.0 110.076 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.511 ' H ' ' HA ' ' A' ' 31' ' ' ASN . 2.2 t -90.82 132.04 36.41 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 CA-C-N 115.083 -0.962 . . . . 1.0 109.315 -179.666 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 31.9 m120 -59.53 114.66 2.82 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 120.397 -0.521 . . . . 1.0 110.35 179.329 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 40.6 t -53.49 -19.51 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 CA-C-O 121.397 0.618 . . . . 1.0 110.448 -179.676 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.5 m -49.42 109.28 0.25 Allowed 'General case' 0 CA--C 1.545 0.769 0 CA-C-N 115.642 -0.708 . . . . 1.0 110.873 179.339 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 7.9 m 61.67 -125.42 0.81 Allowed 'General case' 0 CA--C 1.543 0.699 0 CA-C-N 116.582 -0.281 . . . . 1.0 110.606 -179.18 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 89.0 p -152.28 158.68 43.13 Favored 'General case' 0 N--CA 1.478 0.936 0 CA-C-O 120.97 0.414 . . . . 1.0 110.666 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 51.5 tp -123.05 133.44 54.32 Favored 'General case' 0 N--CA 1.486 1.345 0 CA-C-O 121.578 0.704 . . . . 1.0 110.212 179.596 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 14.9 p-10 -84.63 143.48 29.22 Favored 'General case' 0 CA--C 1.535 0.394 0 CA-C-N 115.432 -0.804 . . . . 1.0 109.982 179.404 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 45.2 t -96.4 117.54 40.95 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 N-CA-C 109.424 -0.584 . . . . 1.0 109.424 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 81.3 mtt85 -84.97 165.63 17.44 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 109.774 -0.454 . . . . 1.0 109.774 179.675 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 38.0 t -95.85 -18.28 20.48 Favored 'General case' 0 N--CA 1.483 1.184 0 CA-C-N 115.972 -0.558 . . . . 1.0 110.516 179.468 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 32.9 t -153.36 -164.63 1.95 Allowed 'General case' 0 N--CA 1.479 0.986 0 CA-C-N 116.246 -0.434 . . . . 1.0 111.089 -179.806 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -83.72 47.33 1.27 Allowed 'General case' 0 N--CA 1.477 0.919 0 CA-C-O 121.458 0.647 . . . . 1.0 110.234 -179.776 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 53.6 m -157.74 137.1 11.88 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-N 115.562 -0.745 . . . . 1.0 110.851 179.748 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.1 t -70.38 -32.09 69.62 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 115.939 -0.573 . . . . 1.0 110.448 179.701 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' SER . . . . . 0.45 ' C ' ' H ' ' A' ' 23' ' ' LYS . 51.1 m -70.81 -2.58 15.31 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 116.42 -0.354 . . . . 1.0 110.683 -179.78 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' SER . . . . . 0.535 ' O ' ' O ' ' A' ' 23' ' ' LYS . 59.8 p -76.71 21.07 0.21 Allowed 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 121.362 0.601 . . . . 1.0 110.563 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.535 ' O ' ' O ' ' A' ' 22' ' ' SER . 98.2 mttt 48.13 167.25 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.443 0 CA-C-N 115.653 -0.703 . . . . 1.0 111.565 -179.147 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.456 HG12 ' N ' ' A' ' 25' ' ' ILE . 25.9 t -89.56 168.92 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-O 121.563 0.697 . . . . 1.0 109.56 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.456 ' N ' HG12 ' A' ' 24' ' ' VAL . 43.5 pt -135.58 -22.64 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 CA-C-N 115.472 -0.785 . . . . 1.0 110.497 179.565 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.72 179.87 43.0 Favored Glycine 0 N--CA 1.462 0.419 0 N-CA-C 110.52 -1.032 . . . . 1.0 110.52 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 88.7 p -132.56 133.44 43.72 Favored 'General case' 0 N--CA 1.478 0.933 0 CA-C-O 121.282 0.563 . . . . 1.0 109.873 179.664 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -98.62 174.19 6.55 Favored 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 108.959 -0.756 . . . . 1.0 108.959 -179.468 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' SER . . . . . 0.533 ' O ' ' O ' ' A' ' 30' ' ' GLY . 42.0 t -79.16 137.19 37.35 Favored 'General case' 0 CA--C 1.515 -0.367 0 CA-C-N 115.964 -0.562 . . . . 1.0 109.901 -179.189 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.533 ' O ' ' O ' ' A' ' 29' ' ' SER . . . -13.24 -107.45 0.0 OUTLIER Glycine 0 N--CA 1.512 3.715 0 CA-C-O 119.473 -0.626 . . . . 1.0 113.017 179.82 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ASN . . . . . 0.511 ' HA ' ' H ' ' A' ' 6' ' ' VAL . 19.5 p-10 -77.73 79.22 4.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 117.569 0.684 . . . . 1.0 109.781 177.775 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 45.6 m -84.84 146.24 27.42 Favored 'General case' 0 N--CA 1.494 1.769 0 CA-C-N 115.961 -0.563 . . . . 1.0 109.82 179.293 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 55.8 mtpt -82.62 128.47 34.36 Favored 'General case' 0 N--CA 1.474 0.761 0 CA-C-N 116.035 -0.529 . . . . 1.0 110.116 179.157 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.9 m -144.48 127.0 10.72 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 CA-C-N 116.323 -0.399 . . . . 1.0 110.368 179.361 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 68.6 p -80.81 83.82 6.47 Favored 'General case' 0 N--CA 1.47 0.559 0 CA-C-O 121.289 0.566 . . . . 1.0 109.86 179.485 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.475 HG22 ' N ' ' A' ' 37' ' ' VAL . 81.3 mt -47.23 163.83 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.063 0 CA-C-N 115.641 -0.708 . . . . 1.0 110.54 179.787 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.475 ' N ' HG22 ' A' ' 36' ' ' ILE . 42.7 t -129.25 -94.18 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 N-CA-C 110.045 -0.354 . . . . 1.0 110.045 -179.229 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -102.12 -168.12 27.0 Favored Glycine 0 N--CA 1.474 1.227 0 N-CA-C 110.912 -0.875 . . . . 1.0 110.912 -179.568 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -130.29 140.68 50.65 Favored 'General case' 0 N--CA 1.485 1.275 0 CA-C-N 115.293 -0.453 . . . . 1.0 110.541 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 -153.21 114.02 4.09 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 116.084 -0.507 . . . . 1.0 110.207 -179.845 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 51.22 -116.4 4.54 Favored Glycine 0 CA--C 1.542 1.772 0 N-CA-C 111.634 -0.586 . . . . 1.0 111.634 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -117.41 25.07 10.7 Favored 'General case' 0 N--CA 1.488 1.453 0 C-N-CA 122.401 0.28 . . . . 1.0 110.429 179.493 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -145.64 157.08 44.01 Favored 'General case' 0 N--CA 1.48 1.074 0 CA-C-O 121.232 0.539 . . . . 1.0 110.405 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 13.8 p90 -141.72 176.18 9.12 Favored 'General case' 0 N--CA 1.482 1.131 0 CA-C-N 115.76 -0.654 . . . . 1.0 110.376 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 34.3 mtmm -97.06 149.35 22.05 Favored 'General case' 0 N--CA 1.479 0.987 0 CA-C-N 115.786 -0.643 . . . . 1.0 110.327 -179.117 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 26.3 pt -142.95 160.48 18.02 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 CA-C-O 121.949 0.88 . . . . 1.0 110.119 179.487 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -121.7 92.1 3.66 Favored 'General case' 0 N--CA 1.487 1.385 0 CA-C-N 115.084 -0.962 . . . . 1.0 109.608 -179.68 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 21.8 t80 -136.32 151.86 50.05 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-O 121.239 0.542 . . . . 1.0 110.398 179.82 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 46.9 mmtt 53.53 17.55 1.18 Allowed 'General case' 0 N--CA 1.479 1.02 0 CA-C-N 115.763 -0.653 . . . . 1.0 110.619 -179.586 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 72.81 -2.25 33.97 Favored Glycine 0 N--CA 1.467 0.713 0 N-CA-C 110.63 -0.988 . . . . 1.0 110.63 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 41.9 t -107.89 172.47 6.81 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 124.009 0.924 . . . . 1.0 110.489 -179.672 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 25.8 p-80 -106.77 142.26 36.69 Favored 'General case' 0 N--CA 1.482 1.125 0 CA-C-N 115.803 -0.635 . . . . 1.0 110.133 179.882 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -150.83 169.79 30.62 Favored Glycine 0 N--CA 1.472 1.08 0 N-CA-C 111.094 -0.802 . . . . 1.0 111.094 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 58.5 m-85 -133.53 145.81 50.47 Favored 'General case' 0 N--CA 1.48 1.04 0 CA-C-O 121.673 0.749 . . . . 1.0 110.33 179.655 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 3.5 m -146.16 147.98 17.63 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 CA-C-N 115.319 -0.855 . . . . 1.0 109.892 -179.7 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -66.44 147.21 53.62 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 115.204 -0.907 . . . . 1.0 110.477 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -82.4 -25.74 33.45 Favored 'General case' 0 N--CA 1.477 0.879 0 CA-C-N 116.166 -0.47 . . . . 1.0 110.44 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 4.2 tm-20 -56.68 -34.58 67.54 Favored 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 121.293 0.568 . . . . 1.0 110.738 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 26.1 m-85 -78.46 -4.92 50.87 Favored 'General case' 0 N--CA 1.483 1.188 0 CA-C-N 115.629 -0.714 . . . . 1.0 110.1 179.81 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 34.2 mm . . . . . 0 N--CA 1.487 1.393 0 CA-C-O 118.17 -0.919 . . . . 1.0 109.507 180.0 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 24.3 pttm . . . . . 0 N--CA 1.479 0.978 0 CA-C-O 121.298 0.57 . . . . 1.0 110.716 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 62.7 p -131.84 154.74 48.85 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-O 121.955 0.883 . . . . 1.0 109.84 -179.649 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -143.11 161.22 27.6 Favored Glycine 0 N--CA 1.461 0.341 0 N-CA-C 110.317 -1.113 . . . . 1.0 110.317 -179.663 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 74.1 mt -109.97 135.86 47.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 CA-C-O 121.691 0.758 . . . . 1.0 109.503 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 47.4 t -82.49 131.02 34.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.282 -0.872 . . . . 1.0 109.44 179.575 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 -60.09 109.64 1.02 Allowed 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 115.628 -0.715 . . . . 1.0 110.404 179.751 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 14.7 p -65.79 133.3 31.0 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 CA-C-N 116.028 -0.533 . . . . 1.0 110.234 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 88.0 p -170.51 -55.98 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 121.191 0.52 . . . . 1.0 110.138 179.599 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 68.5 m -148.79 -110.98 0.07 Allowed 'General case' 0 N--CA 1.477 0.891 0 CA-C-N 115.863 -0.608 . . . . 1.0 110.718 -179.471 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 39.7 t -135.29 142.95 45.97 Favored 'General case' 0 N--CA 1.473 0.713 0 CA-C-O 121.9 0.857 . . . . 1.0 110.51 -179.55 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -101.39 141.66 33.93 Favored 'General case' 0 N--CA 1.474 0.742 0 CA-C-O 122.21 1.005 . . . . 1.0 110.029 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 79.8 m-20 -93.13 123.17 36.21 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 114.708 -1.133 . . . . 1.0 109.523 -179.672 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 64.3 t -96.67 114.97 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 CA-C-N 115.603 -0.726 . . . . 1.0 109.089 -179.808 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -87.65 173.19 9.18 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-O 122.07 0.938 . . . . 1.0 109.585 179.095 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 88.8 p -97.52 -19.25 18.5 Favored 'General case' 0 N--CA 1.478 0.969 0 CA-C-N 114.974 -1.012 . . . . 1.0 110.292 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 88.9 p -149.41 -163.58 1.82 Allowed 'General case' 0 N--CA 1.475 0.823 0 CA-C-O 121.47 0.653 . . . . 1.0 110.824 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -101.3 53.61 0.83 Allowed 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 115.58 -0.736 . . . . 1.0 110.165 -179.79 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 46.4 t -138.89 137.34 36.42 Favored 'General case' 0 N--CA 1.479 1.023 0 CA-C-O 121.55 0.691 . . . . 1.0 110.744 179.655 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.2 t -67.42 -27.14 66.82 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 115.391 -0.822 . . . . 1.0 110.702 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 50.0 m -77.41 -7.51 56.24 Favored 'General case' 0 N--CA 1.469 0.508 0 CA-C-N 115.656 -0.702 . . . . 1.0 110.19 -179.854 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 34.8 t -65.77 124.89 23.65 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-O 120.987 0.422 . . . . 1.0 110.341 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -67.88 166.57 15.3 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.89 -0.595 . . . . 1.0 110.208 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 19.5 t -76.9 114.38 17.19 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.658 0 CA-C-O 121.662 0.744 . . . . 1.0 110.023 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 5.4 tt -96.88 -17.35 6.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.195 -0.911 . . . . 1.0 109.846 179.763 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -166.81 -162.12 17.62 Favored Glycine 0 N--CA 1.463 0.456 0 N-CA-C 110.721 -0.952 . . . . 1.0 110.721 -179.537 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 50.4 m -158.71 132.51 7.63 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.278 0.561 . . . . 1.0 109.936 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.2 tp -110.31 149.06 30.74 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-O 121.567 0.699 . . . . 1.0 109.907 179.614 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 45.7 p -91.15 159.89 15.85 Favored 'General case' 0 N--CA 1.469 0.483 0 CA-C-N 115.327 -0.851 . . . . 1.0 109.604 179.608 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -78.75 152.17 36.74 Favored Glycine 0 CA--C 1.529 0.934 0 N-CA-C 110.443 -1.063 . . . . 1.0 110.443 179.526 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 70.14 19.08 6.84 Favored 'General case' 0 N--CA 1.474 0.772 0 CA-C-O 120.887 0.375 . . . . 1.0 110.449 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 32.0 m -88.67 139.75 30.15 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-N 116.119 -0.491 . . . . 1.0 109.878 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 63.3 tttm -86.3 139.25 31.17 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.893 -0.594 . . . . 1.0 109.963 179.547 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 14.4 m -142.99 124.46 11.77 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.879 0 CA-C-N 115.687 -0.688 . . . . 1.0 110.2 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 62.1 p -79.89 87.76 5.32 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-O 121.355 0.598 . . . . 1.0 109.709 179.636 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.577 HG22 ' N ' ' A' ' 37' ' ' VAL . 63.0 mt -55.81 169.43 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.504 0 CA-C-O 121.66 0.743 . . . . 1.0 109.498 179.844 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.577 ' N ' HG22 ' A' ' 36' ' ' ILE . 0.2 OUTLIER -131.91 -96.0 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.055 0 CA-C-N 115.348 -0.842 . . . . 1.0 109.885 -179.156 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 38' ' ' GLY . . . . . 0.408 ' H ' HG23 ' A' ' 37' ' ' VAL . . . -99.4 -170.07 30.46 Favored Glycine 0 N--CA 1.465 0.62 0 N-CA-C 110.631 -0.987 . . . . 1.0 110.631 -179.566 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 13.5 mp0 -128.85 132.95 47.81 Favored 'General case' 0 N--CA 1.478 0.943 0 CA-C-N 114.651 -0.775 . . . . 1.0 110.224 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.41 ' O ' ' O ' ' A' ' 43' ' ' PHE . 44.3 tp10 -150.32 120.68 7.35 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-N 115.497 -0.774 . . . . 1.0 110.041 179.527 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 47.08 -122.65 7.17 Favored Glycine 0 CA--C 1.543 1.805 0 N-CA-C 111.509 -0.636 . . . . 1.0 111.509 179.779 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -114.03 22.32 14.0 Favored 'General case' 0 N--CA 1.481 1.106 0 C-N-CA 122.546 0.338 . . . . 1.0 110.251 178.862 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.41 ' O ' ' O ' ' A' ' 40' ' ' GLU . 77.7 m-85 -149.13 157.42 43.37 Favored 'General case' 0 N--CA 1.484 1.264 0 CA-C-O 121.6 0.714 . . . . 1.0 110.74 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' TYR . . . . . 0.458 ' N ' ' CD1' ' A' ' 44' ' ' TYR . 10.1 p90 -140.39 172.99 11.95 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 122.077 0.942 . . . . 1.0 109.939 -179.712 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -97.52 156.56 16.44 Favored 'General case' 0 N--CA 1.474 0.751 0 CA-C-N 114.905 -1.043 . . . . 1.0 109.97 -179.434 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 32.2 pt -147.41 161.7 7.9 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 CA-C-O 122.215 1.007 . . . . 1.0 109.884 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 18.6 mp0 -121.54 87.36 2.74 Favored 'General case' 0 N--CA 1.481 1.088 0 CA-C-N 114.748 -1.115 . . . . 1.0 109.844 -179.768 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -138.68 158.86 43.45 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-N 115.576 -0.738 . . . . 1.0 110.019 179.86 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' LYS . . . . . 0.404 ' C ' ' H ' ' A' ' 51' ' ' SER . 48.7 mtmt 52.92 18.47 1.08 Allowed 'General case' 0 CA--C 1.541 0.611 0 CA-C-N 115.626 -0.715 . . . . 1.0 110.811 179.801 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 67.97 -1.52 8.11 Favored Glycine 0 CA--C 1.532 1.1 0 N-CA-C 110.429 -1.068 . . . . 1.0 110.429 -179.181 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' SER . . . . . 0.404 ' H ' ' C ' ' A' ' 49' ' ' LYS . 97.6 p -116.12 171.96 7.47 Favored 'General case' 0 N--CA 1.484 1.265 0 CA-C-O 121.994 0.902 . . . . 1.0 110.317 -179.859 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 96.3 m-70 -101.75 146.12 28.2 Favored 'General case' 0 N--CA 1.478 0.932 0 CA-C-N 115.006 -0.997 . . . . 1.0 110.09 -179.828 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -152.9 168.32 31.78 Favored Glycine 0 CA--C 1.531 1.041 0 N-CA-C 110.673 -0.971 . . . . 1.0 110.673 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 66.2 m-85 -134.61 150.16 50.66 Favored 'General case' 0 N--CA 1.486 1.37 0 CA-C-O 121.018 0.437 . . . . 1.0 110.608 179.601 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -155.19 155.84 5.45 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 CA-C-N 115.967 -0.561 . . . . 1.0 110.348 -179.808 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.69 130.38 44.02 Favored 'General case' 0 CA--C 1.545 0.78 0 CA-C-O 122.173 0.987 . . . . 1.0 109.861 179.049 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.46 -35.1 17.23 Favored 'General case' 0 N--CA 1.483 1.191 0 CA-C-N 114.86 -1.064 . . . . 1.0 110.177 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -58.33 -30.39 66.66 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.656 0.741 . . . . 1.0 110.371 -179.674 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 1.2 t80 -52.52 -19.8 2.51 Favored 'General case' 0 CA--C 1.537 0.465 0 CA-C-N 115.362 -0.835 . . . . 1.0 110.792 -179.806 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 69.8 mt . . . . . 0 C--O 1.221 -0.436 0 CA-C-O 118.0 -1.0 . . . . 1.0 108.761 -179.834 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 74.6 mmtt . . . . . 0 N--CA 1.471 0.593 0 CA-C-O 121.267 0.556 . . . . 1.0 110.753 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 69.8 p -131.55 158.59 40.55 Favored 'General case' 0 N--CA 1.472 0.659 0 CA-C-O 121.825 0.821 . . . . 1.0 110.136 -179.48 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -145.57 163.94 28.15 Favored Glycine 0 N--CA 1.468 0.812 0 N-CA-C 110.495 -1.042 . . . . 1.0 110.495 -179.556 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 3.7 mp -110.13 129.68 64.69 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 CA-C-O 121.287 0.565 . . . . 1.0 109.97 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 55.9 t -73.42 133.34 31.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.648 -0.706 . . . . 1.0 109.491 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ASN . . . . . 0.508 ' ND2' ' O ' ' A' ' 59' ' ' TYR . 8.1 m-20 -49.2 96.83 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.707 0 CA-C-N 115.768 -0.651 . . . . 1.0 110.694 179.604 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.5 t -63.37 -6.55 2.26 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.539 0 CA-C-N 115.749 -0.66 . . . . 1.0 110.008 -179.221 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.0 m -52.71 -49.87 64.5 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.087 -0.506 . . . . 1.0 110.69 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 93.0 p -149.96 169.37 21.33 Favored 'General case' 0 N--CA 1.472 0.652 0 CA-C-O 121.461 0.648 . . . . 1.0 110.524 179.385 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 89.1 p -78.93 150.34 32.11 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 115.523 -0.762 . . . . 1.0 109.707 -179.331 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.9 mp -118.96 145.48 45.76 Favored 'General case' 0 N--CA 1.49 1.543 0 CA-C-O 122.287 1.042 . . . . 1.0 110.08 -179.426 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 73.8 m-80 -96.49 146.62 24.64 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 114.701 -1.136 . . . . 1.0 110.003 179.693 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 22.4 t -94.57 104.78 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.936 0 CA-C-N 115.529 -0.76 . . . . 1.0 109.684 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 88.8 mtm180 -79.41 135.64 36.74 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.341 0.591 . . . . 1.0 109.761 179.821 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 38.9 t -63.43 -27.17 69.1 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 115.581 -0.736 . . . . 1.0 110.442 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 47.2 t -144.85 -176.66 5.16 Favored 'General case' 0 N--CA 1.479 0.998 0 CA-C-N 115.97 -0.559 . . . . 1.0 110.927 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.425 ' HB2' ' CD1' ' A' ' 43' ' ' PHE . . . -81.83 57.17 3.33 Favored 'General case' 0 N--CA 1.476 0.843 0 CA-C-N 115.774 -0.648 . . . . 1.0 110.235 -179.898 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 47.3 t -156.92 137.67 13.29 Favored 'General case' 0 N--CA 1.472 0.64 0 CA-C-O 121.203 0.525 . . . . 1.0 110.686 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.8 t -67.12 -32.97 74.46 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 115.756 -0.656 . . . . 1.0 110.629 179.62 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 89.4 p -69.35 -4.31 17.72 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 116.029 -0.532 . . . . 1.0 110.303 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 90.2 p -60.47 -172.02 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.539 0 CA-C-O 120.995 0.426 . . . . 1.0 110.25 179.53 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 5.5 mptt -116.57 148.16 41.15 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-O 121.234 0.54 . . . . 1.0 110.749 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 20.1 t -82.16 115.46 24.73 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 115.778 -0.646 . . . . 1.0 109.537 179.79 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 34.2 pt -96.43 -16.79 7.09 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.896 0 CA-C-N 115.706 -0.679 . . . . 1.0 109.891 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 179.53 165.77 34.17 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.71 -0.956 . . . . 1.0 110.71 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 50.7 m -117.54 135.55 53.87 Favored 'General case' 0 N--CA 1.484 1.268 0 CA-C-O 121.289 0.566 . . . . 1.0 109.918 179.61 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 3.5 tp -100.04 159.02 15.42 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-O 121.875 0.845 . . . . 1.0 109.141 -179.414 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 49.1 m -101.48 145.95 28.29 Favored 'General case' 0 N--CA 1.473 0.677 0 CA-C-N 115.208 -0.906 . . . . 1.0 110.106 -179.132 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -73.85 151.86 44.93 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.353 -1.099 . . . . 1.0 110.353 179.285 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 12.8 t30 74.78 13.77 3.43 Favored 'General case' 0 N--CA 1.482 1.159 0 CA-C-O 120.525 0.202 . . . . 1.0 110.518 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 89.0 m -83.05 137.15 34.23 Favored 'General case' 0 N--CA 1.477 0.912 0 CA-C-O 121.12 0.486 . . . . 1.0 110.32 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -92.81 144.04 25.68 Favored 'General case' 0 N--CA 1.473 0.721 0 CA-C-N 115.806 -0.634 . . . . 1.0 109.989 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.4 p -154.77 139.81 10.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.748 -0.66 . . . . 1.0 109.91 179.872 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 68.9 p -83.4 83.36 7.9 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.877 -0.601 . . . . 1.0 109.637 179.217 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.539 HG22 ' N ' ' A' ' 37' ' ' VAL . 74.5 mt -48.49 167.0 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 CA-C-N 115.818 -0.628 . . . . 1.0 110.066 179.801 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.539 ' N ' HG22 ' A' ' 36' ' ' ILE . 40.8 t -128.07 -91.86 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 CA-C-N 116.22 -0.445 . . . . 1.0 110.087 -179.61 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -118.03 -155.54 10.06 Favored Glycine 0 N--CA 1.474 1.215 0 N-CA-C 110.863 -0.895 . . . . 1.0 110.863 -179.471 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -142.19 144.71 33.54 Favored 'General case' 0 N--CA 1.478 0.971 0 CA-C-N 115.059 -0.57 . . . . 1.0 110.281 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 38.3 tp10 -147.36 122.39 10.09 Favored 'General case' 0 N--CA 1.473 0.713 0 CA-C-N 115.74 -0.664 . . . . 1.0 109.986 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 54.71 -129.43 44.63 Favored Glycine 0 CA--C 1.53 0.995 0 N-CA-C 111.398 -0.681 . . . . 1.0 111.398 179.595 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -100.18 33.92 2.5 Favored 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 110.068 -0.345 . . . . 1.0 110.068 179.406 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.425 ' CD1' ' HB2' ' A' ' 18' ' ' ALA . 26.9 p90 -159.04 168.96 25.35 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-O 122.152 0.977 . . . . 1.0 110.083 179.321 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' TYR . . . . . 0.483 ' N ' ' CD1' ' A' ' 44' ' ' TYR . 3.3 p90 -129.63 163.92 25.01 Favored 'General case' 0 N--CA 1.481 1.107 0 CA-C-N 114.79 -1.095 . . . . 1.0 110.448 179.779 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 62.8 tttp -86.88 142.31 28.13 Favored 'General case' 0 N--CA 1.473 0.717 0 CA-C-N 115.341 -0.845 . . . . 1.0 109.771 -179.049 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 19.7 pt -141.32 156.51 21.54 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-O 122.083 0.944 . . . . 1.0 110.22 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -124.88 94.08 4.08 Favored 'General case' 0 N--CA 1.48 1.053 0 CA-C-N 114.844 -1.071 . . . . 1.0 109.971 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 22.8 t80 -128.47 147.5 50.67 Favored 'General case' 0 N--CA 1.476 0.875 0 CA-C-N 115.974 -0.557 . . . . 1.0 110.058 179.517 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 46.4 mtpt 54.11 17.56 1.47 Allowed 'General case' 0 CA--C 1.547 0.832 0 CA-C-N 115.908 -0.587 . . . . 1.0 110.497 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 72.18 1.78 51.01 Favored Glycine 0 N--CA 1.468 0.805 0 N-CA-C 110.6 -1.0 . . . . 1.0 110.6 -179.489 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 47.4 t -104.99 171.13 7.48 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 123.517 0.727 . . . . 1.0 110.2 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 49.4 p-80 -103.67 138.5 40.23 Favored 'General case' 0 N--CA 1.482 1.137 0 CA-C-N 115.618 -0.719 . . . . 1.0 110.484 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -150.75 166.76 30.36 Favored Glycine 0 N--CA 1.472 1.058 0 N-CA-C 110.782 -0.927 . . . . 1.0 110.782 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 33.4 m-85 -135.5 152.16 51.06 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-O 121.539 0.685 . . . . 1.0 110.194 179.456 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -150.39 151.16 12.91 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.953 0 CA-C-N 115.455 -0.793 . . . . 1.0 109.768 -179.089 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.56 125.64 24.61 Favored 'General case' 0 CA--C 1.54 0.561 0 CA-C-N 115.222 -0.899 . . . . 1.0 110.2 179.405 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 7.7 pttm -78.55 -31.18 47.32 Favored 'General case' 0 N--CA 1.473 0.681 0 CA-C-N 115.259 -0.882 . . . . 1.0 110.183 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -55.57 -35.45 65.76 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.061 -0.518 . . . . 1.0 110.401 -179.14 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' TYR . . . . . 0.508 ' O ' ' ND2' ' A' ' 7' ' ' ASN . 10.7 m-85 -60.47 -42.01 95.36 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 115.866 -0.606 . . . . 1.0 109.868 179.486 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 65.6 mt . . . . . 0 N--CA 1.476 0.831 0 CA-C-O 118.199 -0.905 . . . . 1.0 109.268 -179.359 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 41.1 ttp . . . . . 0 N--CA 1.489 1.499 0 N-CA-C 108.795 -0.817 . . . . 1.0 108.795 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 61.2 tttp -64.42 124.64 22.32 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.141 0.496 . . . . 1.0 110.131 -179.219 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 65.8 p -96.03 162.69 13.44 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.953 0.883 . . . . 1.0 109.759 179.738 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -101.6 155.89 18.89 Favored Glycine 0 N--CA 1.47 0.961 0 N-CA-C 110.454 -1.058 . . . . 1.0 110.454 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 69.0 mt -111.55 128.09 68.29 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.088 0 CA-C-O 121.502 0.668 . . . . 1.0 109.559 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 24.4 t -68.48 132.05 33.13 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 CA-C-N 115.571 -0.741 . . . . 1.0 109.883 179.807 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ASN . . . . . 0.418 ' O ' ' N ' ' A' ' 9' ' ' SER . 10.5 p-10 -55.77 109.18 0.53 Allowed 'General case' 0 CA--C 1.54 0.572 0 CA-C-N 116.112 -0.494 . . . . 1.0 110.411 179.659 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 15.1 t -66.4 72.28 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-N 116.155 -0.475 . . . . 1.0 110.207 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.418 ' N ' ' O ' ' A' ' 7' ' ' ASN . 30.4 t -85.39 -104.59 0.06 Allowed 'General case' 0 CA--C 1.54 0.564 0 CA-C-N 115.92 -0.582 . . . . 1.0 109.916 179.798 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 97.0 p -157.29 -28.02 0.09 Allowed 'General case' 0 N--CA 1.478 0.967 0 CA-C-O 121.471 0.653 . . . . 1.0 111.11 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 44.4 t -153.87 145.31 23.13 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 115.539 -0.755 . . . . 1.0 110.703 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.424 HD13 ' N ' ' A' ' 13' ' ' ASN . 0.2 OUTLIER -155.16 121.55 5.28 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 120.773 -0.371 . . . . 1.0 110.536 178.319 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ASN . . . . . 0.424 ' N ' HD13 ' A' ' 12' ' ' LEU . 74.7 m-20 -89.23 134.09 34.18 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 121.856 0.836 . . . . 1.0 109.809 179.453 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 33.9 t -103.84 128.36 57.18 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 CA-C-N 115.154 -0.93 . . . . 1.0 109.559 179.71 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 83.1 mtt-85 -97.43 179.75 4.76 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-O 121.56 0.695 . . . . 1.0 110.046 179.426 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.4 p -104.86 -7.15 19.58 Favored 'General case' 0 N--CA 1.484 1.238 0 CA-C-N 115.373 -0.83 . . . . 1.0 110.36 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.447 ' C ' ' H ' ' A' ' 19' ' ' SER . 42.0 t -170.7 178.22 3.64 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-O 121.264 0.554 . . . . 1.0 110.745 -179.772 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -72.97 40.4 0.09 Allowed 'General case' 0 N--CA 1.475 0.793 0 CA-C-N 115.82 -0.627 . . . . 1.0 110.664 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.447 ' H ' ' C ' ' A' ' 17' ' ' SER . 78.8 p -137.49 136.82 38.06 Favored 'General case' 0 N--CA 1.48 1.033 0 CA-C-O 121.52 0.676 . . . . 1.0 110.403 179.871 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 80.4 p -73.71 -27.98 61.48 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-N 115.427 -0.806 . . . . 1.0 110.21 179.784 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 97.2 p -65.34 -21.32 66.68 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 116.335 -0.393 . . . . 1.0 110.242 -179.541 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 37.6 m -55.49 -29.36 58.66 Favored 'General case' 0 N--CA 1.472 0.639 0 CA-C-O 120.988 0.423 . . . . 1.0 110.284 179.138 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 25.5 tttm 71.14 -177.2 0.2 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.933 -0.576 . . . . 1.0 110.018 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 13.2 t -79.57 161.06 4.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 122.063 0.935 . . . . 1.0 109.512 179.335 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 35.0 pt -148.82 -22.43 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 CA-C-N 114.858 -1.065 . . . . 1.0 110.414 -179.766 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -173.52 164.62 36.33 Favored Glycine 0 CA--C 1.52 0.376 0 N-CA-C 110.673 -0.971 . . . . 1.0 110.673 -179.752 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 98.1 p -118.62 133.11 56.1 Favored 'General case' 0 N--CA 1.48 1.053 0 CA-C-O 121.91 0.862 . . . . 1.0 110.06 179.562 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.2 tp -101.6 155.48 18.07 Favored 'General case' 0 N--CA 1.473 0.725 0 CA-C-N 115.113 -0.948 . . . . 1.0 109.649 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 57.6 m -93.2 143.06 26.62 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.144 -0.934 . . . . 1.0 109.919 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -74.83 155.65 48.37 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.149 -1.18 . . . . 1.0 110.149 179.442 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 69.67 16.84 7.91 Favored 'General case' 0 N--CA 1.475 0.784 0 CA-C-O 120.792 0.329 . . . . 1.0 110.381 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 83.3 m -88.06 141.95 28.17 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-O 121.279 0.562 . . . . 1.0 109.957 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 37.9 ttpt -83.15 134.6 34.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.712 0.768 . . . . 1.0 110.029 179.555 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 5.2 m -140.96 123.42 15.24 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.575 0 CA-C-N 115.316 -0.856 . . . . 1.0 110.136 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.43 ' O ' ' C ' ' A' ' 36' ' ' ILE . 31.2 m -84.31 87.62 7.21 Favored 'General case' 0 N--CA 1.467 0.384 0 N-CA-C 109.661 -0.496 . . . . 1.0 109.661 179.117 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.614 ' H ' HD12 ' A' ' 36' ' ' ILE . 1.7 mp -34.49 145.66 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 CA-C-N 116.067 -0.515 . . . . 1.0 110.541 179.196 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -154.3 67.54 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 CA-C-N 115.974 -0.557 . . . . 1.0 109.829 -178.563 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.05 167.89 34.61 Favored Glycine 0 CA--C 1.503 -0.69 0 N-CA-C 110.567 -1.013 . . . . 1.0 110.567 178.731 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.3 pp20? -153.73 156.61 38.1 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.216 -0.492 . . . . 1.0 110.669 -178.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -153.61 127.61 8.96 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 116.022 -0.536 . . . . 1.0 110.505 179.229 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 59.54 -152.87 33.7 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.358 -0.697 . . . . 1.0 111.358 179.602 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -77.47 38.87 0.25 Allowed 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 109.855 -0.424 . . . . 1.0 109.855 179.443 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 -151.37 159.14 44.42 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-O 121.804 0.812 . . . . 1.0 110.477 -179.769 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 1.3 m-85 -118.86 157.3 27.9 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 122.199 0.999 . . . . 1.0 110.238 179.668 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 84.4 tttt -99.81 144.33 29.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 114.854 -1.067 . . . . 1.0 109.854 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 28.8 pt -149.37 172.24 1.66 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.241 -0.891 . . . . 1.0 109.952 -179.576 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 77.4 tt0 -139.86 105.13 5.04 Favored 'General case' 0 N--CA 1.472 0.673 0 CA-C-N 115.143 -0.935 . . . . 1.0 110.333 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 27.1 t80 -139.7 163.71 31.87 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 115.592 -0.731 . . . . 1.0 110.187 179.269 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' LYS . . . . . 0.414 ' C ' ' H ' ' A' ' 51' ' ' SER . 18.5 mmtm 51.77 24.87 2.64 Favored 'General case' 0 CA--C 1.544 0.741 0 CA-C-N 115.57 -0.741 . . . . 1.0 111.06 179.623 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 74.0 -8.89 10.3 Favored Glycine 0 CA--C 1.528 0.883 0 N-CA-C 110.147 -1.181 . . . . 1.0 110.147 -179.623 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' SER . . . . . 0.414 ' H ' ' C ' ' A' ' 49' ' ' LYS . 50.5 m -108.82 174.02 6.06 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-O 122.07 0.938 . . . . 1.0 110.074 179.783 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 32.7 p80 -131.01 135.12 47.32 Favored 'General case' 0 N--CA 1.48 1.044 0 CA-C-N 114.971 -1.013 . . . . 1.0 110.331 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.03 154.55 25.98 Favored Glycine 0 N--CA 1.47 0.944 0 N-CA-C 110.652 -0.979 . . . . 1.0 110.652 179.537 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 55.6 m-85 -90.76 145.09 25.08 Favored 'General case' 0 N--CA 1.472 0.651 0 CA-C-O 121.485 0.66 . . . . 1.0 109.731 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 17.1 t -141.85 145.78 23.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 CA-C-N 115.582 -0.736 . . . . 1.0 110.365 -179.844 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.91 138.38 58.53 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.573 -0.74 . . . . 1.0 109.967 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 12.5 pttp -89.86 -25.13 21.18 Favored 'General case' 0 N--CA 1.475 0.809 0 CA-C-N 115.541 -0.754 . . . . 1.0 110.183 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 44.7 tp10 -65.95 -37.72 86.75 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.465 0.65 . . . . 1.0 110.509 -178.85 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 23.0 m-85 -68.89 -31.88 71.13 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 115.527 -0.76 . . . . 1.0 110.092 179.82 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 72.8 mt . . . . . 0 N--CA 1.467 0.42 0 CA-C-O 118.138 -0.934 . . . . 1.0 109.193 -179.486 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.5 mtt . . . . . 0 N--CA 1.488 1.443 0 N-CA-C 108.967 -0.753 . . . . 1.0 108.967 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -66.24 -20.23 66.05 Favored 'General case' 0 N--CA 1.472 0.628 0 CA-C-O 121.512 0.672 . . . . 1.0 110.591 -179.6 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 3.2 p -132.8 153.5 51.2 Favored 'General case' 0 N--CA 1.478 0.946 0 CA-C-N 115.469 -0.787 . . . . 1.0 110.166 -179.29 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -140.71 160.78 26.63 Favored Glycine 0 N--CA 1.468 0.797 0 N-CA-C 110.658 -0.977 . . . . 1.0 110.658 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 12.5 pt -106.01 135.96 42.25 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 CA-C-O 121.287 0.565 . . . . 1.0 109.737 179.542 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.485 ' O ' ' N ' ' A' ' 8' ' ' VAL . 37.7 t -53.72 111.69 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 CA-C-N 115.62 -0.718 . . . . 1.0 109.926 -179.751 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 4.7 m120 -56.31 83.42 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 115.724 -0.671 . . . . 1.0 110.593 179.601 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.485 ' N ' ' O ' ' A' ' 6' ' ' VAL . 3.2 t 47.71 -126.25 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.554 1.134 0 CA-C-N 115.579 -0.737 . . . . 1.0 110.199 -179.791 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' SER . . . . . 0.474 ' O ' ' O ' ' A' ' 8' ' ' VAL . 19.3 m 57.78 136.69 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 115.687 -0.688 . . . . 1.0 110.72 179.659 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 48.9 m -54.41 -65.73 0.52 Allowed 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 121.022 0.439 . . . . 1.0 110.652 -179.68 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 65.7 m -148.72 154.51 39.72 Favored 'General case' 0 N--CA 1.471 0.621 0 CA-C-O 121.798 0.809 . . . . 1.0 110.505 179.599 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -102.21 142.68 33.06 Favored 'General case' 0 N--CA 1.485 1.301 0 CA-C-N 115.233 -0.894 . . . . 1.0 109.977 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -85.18 99.53 11.14 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.072 -0.967 . . . . 1.0 109.477 -179.492 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 17.6 m -80.66 135.5 25.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 108.686 -0.857 . . . . 1.0 108.686 -179.458 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 67.2 mtm180 -117.85 -176.48 3.05 Favored 'General case' 0 N--CA 1.476 0.852 0 CA-C-N 115.13 -0.941 . . . . 1.0 110.234 -179.247 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 67.0 p -89.88 -20.61 23.19 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 115.333 -0.849 . . . . 1.0 110.519 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.645 ' C ' ' H ' ' A' ' 19' ' ' SER . 60.9 p -176.28 -173.17 0.53 Allowed 'General case' 0 N--CA 1.473 0.718 0 CA-C-O 121.681 0.753 . . . . 1.0 110.414 -179.649 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.81 17.24 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.375 0 CA-C-N 115.343 -0.844 . . . . 1.0 111.586 178.654 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' SER . . . . . 0.645 ' H ' ' C ' ' A' ' 17' ' ' SER . 70.0 m -100.87 97.83 8.39 Favored 'General case' 0 N--CA 1.48 1.038 0 CA-C-N 115.352 -0.84 . . . . 1.0 110.169 179.533 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.9 m -64.37 -4.29 3.72 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-N 115.685 -0.689 . . . . 1.0 110.15 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 85.7 p -97.89 -3.53 38.39 Favored 'General case' 0 N--CA 1.473 0.699 0 CA-C-N 116.001 -0.545 . . . . 1.0 110.719 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 78.1 p -77.36 -4.96 47.81 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 110.022 -0.362 . . . . 1.0 110.022 179.331 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 33.7 tttt 66.05 -163.27 0.24 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.094 0.473 . . . . 1.0 110.167 179.606 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 24.8 t -94.22 158.16 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 CA-C-O 122.193 0.997 . . . . 1.0 109.28 179.753 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 47.7 pt -137.67 -20.58 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.005 0 CA-C-N 114.852 -1.067 . . . . 1.0 110.496 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.471 ' CA ' ' HZ1' ' A' ' 49' ' ' LYS . . . -158.44 -153.89 6.95 Favored Glycine 0 N--CA 1.466 0.64 0 N-CA-C 110.689 -0.964 . . . . 1.0 110.689 -179.441 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' SER . . . . . 0.681 ' H ' ' HZ3' ' A' ' 49' ' ' LYS . 93.2 p -159.17 148.65 18.69 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 121.322 0.582 . . . . 1.0 110.372 179.644 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.6 tp -122.3 154.43 37.6 Favored 'General case' 0 N--CA 1.481 1.106 0 CA-C-O 121.624 0.726 . . . . 1.0 110.311 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 90.9 p -103.33 159.92 15.14 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 115.39 -0.823 . . . . 1.0 110.25 179.749 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -79.65 168.11 52.31 Favored Glycine 0 N--CA 1.476 1.352 0 N-CA-C 110.537 -1.025 . . . . 1.0 110.537 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 66.2 m-20 56.32 20.87 4.94 Favored 'General case' 0 N--CA 1.477 0.877 0 CA-C-O 120.929 0.395 . . . . 1.0 110.759 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 29.6 m -89.94 150.42 22.17 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-O 121.401 0.619 . . . . 1.0 109.828 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 50.9 tttp -103.25 150.6 23.57 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 115.548 -0.751 . . . . 1.0 110.275 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.4 p -157.36 145.56 10.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.687 -0.688 . . . . 1.0 109.858 179.553 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 90.4 m -106.09 106.33 16.79 Favored 'General case' 0 N--CA 1.481 1.095 0 N-CA-C 109.428 -0.582 . . . . 1.0 109.428 178.544 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.459 ' O ' HG13 ' A' ' 37' ' ' VAL . 11.7 mm -42.35 134.86 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 CA-C-N 116.502 -0.317 . . . . 1.0 111.2 179.283 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.459 HG13 ' O ' ' A' ' 36' ' ' ILE . 3.2 m -159.51 90.24 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.069 0 CA-C-O 121.986 0.898 . . . . 1.0 110.518 -178.052 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 109.63 115.06 3.7 Favored Glycine 0 N--CA 1.481 1.657 0 CA-C-N 115.114 -0.948 . . . . 1.0 110.824 179.178 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.546 ' H ' ' CD ' ' A' ' 39' ' ' GLU . 0.5 OUTLIER -105.13 132.62 51.12 Favored 'General case' 0 N--CA 1.48 1.033 0 N-CA-C 109.245 -0.65 . . . . 1.0 109.245 -178.817 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 79.8 tt0 -151.31 102.85 2.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.837 -0.62 . . . . 1.0 109.883 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.432 ' C ' ' H ' ' A' ' 43' ' ' PHE . . . 57.12 -149.21 31.39 Favored Glycine 0 CA--C 1.533 1.16 0 N-CA-C 111.226 -0.749 . . . . 1.0 111.226 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -74.56 17.56 0.2 Allowed 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 120.926 -0.31 . . . . 1.0 110.455 179.082 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.432 ' H ' ' C ' ' A' ' 41' ' ' GLY . 38.3 m-85 -133.56 158.13 43.95 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-O 121.853 0.835 . . . . 1.0 110.215 -179.53 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' TYR . . . . . 0.441 ' CD2' ' CG2' ' A' ' 36' ' ' ILE . 2.8 m-85 -127.04 165.22 19.88 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 122.621 1.2 . . . . 1.0 109.839 179.618 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 23.9 ttpp -107.96 129.58 55.1 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 114.465 -1.243 . . . . 1.0 110.004 -179.736 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 45.5 pt -122.18 170.05 12.81 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-O 122.302 1.048 . . . . 1.0 110.045 179.458 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -131.1 102.2 5.91 Favored 'General case' 0 N--CA 1.482 1.164 0 CA-C-N 114.702 -1.135 . . . . 1.0 109.778 -179.441 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -138.93 160.35 39.95 Favored 'General case' 0 N--CA 1.47 0.575 0 CA-C-O 121.432 0.634 . . . . 1.0 109.829 179.561 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' LYS . . . . . 0.681 ' HZ3' ' H ' ' A' ' 27' ' ' SER . 43.3 mtmt 50.35 26.65 2.36 Favored 'General case' 0 CA--C 1.546 0.811 0 CA-C-N 115.595 -0.73 . . . . 1.0 111.369 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 67.07 6.74 40.19 Favored Glycine 0 N--CA 1.474 1.227 0 N-CA-C 110.465 -1.054 . . . . 1.0 110.465 -179.418 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 85.7 p -117.35 175.45 5.61 Favored 'General case' 0 N--CA 1.485 1.303 0 C-N-CA 124.228 1.011 . . . . 1.0 110.506 -179.631 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 27.3 p-80 -114.29 135.51 53.99 Favored 'General case' 0 N--CA 1.486 1.368 0 CA-C-N 115.18 -0.918 . . . . 1.0 110.331 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -140.08 166.08 25.8 Favored Glycine 0 N--CA 1.472 1.059 0 N-CA-C 110.988 -0.845 . . . . 1.0 110.988 179.724 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 58.2 m-85 -130.35 136.5 49.17 Favored 'General case' 0 N--CA 1.483 1.196 0 CA-C-O 121.904 0.859 . . . . 1.0 110.11 179.692 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 26.0 t -143.28 150.2 17.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 CA-C-N 115.145 -0.934 . . . . 1.0 110.175 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -67.64 127.49 32.97 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-N 115.481 -0.781 . . . . 1.0 109.812 179.424 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 11.5 pttm -74.91 -20.81 59.54 Favored 'General case' 0 N--CA 1.476 0.853 0 CA-C-N 115.251 -0.886 . . . . 1.0 110.095 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 76.5 tt0 -65.41 -37.47 87.06 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 121.461 0.648 . . . . 1.0 110.399 -178.817 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 27.3 m-85 -74.08 -33.61 63.7 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 115.609 -0.723 . . . . 1.0 109.897 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 62.6 mt . . . . . 0 N--CA 1.471 0.613 0 CA-C-O 118.096 -0.954 . . . . 1.0 109.051 -179.033 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.9 mtm . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 108.706 -0.85 . . . . 1.0 108.706 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 55.1 mtpt -63.69 -23.53 67.41 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-O 121.382 0.61 . . . . 1.0 110.434 -179.647 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 46.0 p -137.11 160.43 38.99 Favored 'General case' 0 N--CA 1.473 0.709 0 CA-C-O 121.719 0.771 . . . . 1.0 110.458 -179.681 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -138.01 155.51 23.33 Favored Glycine 0 N--CA 1.471 0.995 0 N-CA-C 110.659 -0.977 . . . . 1.0 110.659 -179.861 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 15.6 pt -98.24 137.26 26.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 CA-C-O 121.676 0.75 . . . . 1.0 109.209 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.571 ' O ' ' C ' ' A' ' 7' ' ' ASN . 22.0 t -83.01 142.98 12.83 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.46 0 CA-C-N 115.366 -0.834 . . . . 1.0 109.566 -179.827 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ASN . . . . . 0.571 ' C ' ' O ' ' A' ' 6' ' ' VAL . 42.9 t30 8.72 -109.27 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.125 0 CA-C-N 116.243 -0.435 . . . . 1.0 111.859 -179.602 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 22.0 t -143.02 -52.25 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.292 0 CA-C-O 120.715 0.293 . . . . 1.0 110.434 177.781 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 40.7 t -170.14 77.75 0.09 Allowed 'General case' 0 N--CA 1.472 0.641 0 CA-C-O 120.855 0.359 . . . . 1.0 110.618 -179.544 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 49.3 m -160.52 168.46 25.01 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-N 116.052 -0.522 . . . . 1.0 110.679 -179.803 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 41.8 t -90.38 130.82 36.42 Favored 'General case' 0 N--CA 1.473 0.682 0 CA-C-O 121.304 0.573 . . . . 1.0 110.104 179.585 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 9.8 mp -100.94 164.35 11.86 Favored 'General case' 0 N--CA 1.479 1.002 0 CA-C-O 122.73 1.252 . . . . 1.0 109.41 179.409 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 84.9 m-20 -93.4 118.24 31.06 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-N 114.253 -1.339 . . . . 1.0 109.989 -179.614 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 20.6 t -101.9 107.58 21.94 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.308 0 N-CA-C 110.173 -0.306 . . . . 1.0 110.173 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 31.9 mtm180 -82.42 -173.14 4.41 Favored 'General case' 0 N--CA 1.478 0.971 0 CA-C-O 121.297 0.57 . . . . 1.0 110.345 179.441 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 17.6 t -95.17 -23.69 17.17 Favored 'General case' 0 N--CA 1.48 1.057 0 CA-C-N 115.675 -0.693 . . . . 1.0 111.085 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.401 ' O ' ' HB3' ' A' ' 18' ' ' ALA . 28.7 t 175.86 38.85 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.645 0 CA-C-O 121.182 0.515 . . . . 1.0 111.214 -179.717 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.401 ' HB3' ' O ' ' A' ' 17' ' ' SER . . . 76.07 45.39 0.12 Allowed 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 115.834 -0.621 . . . . 1.0 110.55 -179.782 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 70.5 m -129.83 117.28 19.95 Favored 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 115.84 -0.618 . . . . 1.0 110.795 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 24.9 m -64.06 -29.12 70.28 Favored 'General case' 0 N--CA 1.475 0.794 0 CA-C-N 116.067 -0.515 . . . . 1.0 109.995 179.347 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 55.0 m -68.45 -22.38 64.58 Favored 'General case' 0 CA--C 1.537 0.442 0 CA-C-N 116.121 -0.49 . . . . 1.0 110.508 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 45.9 t -70.18 -39.07 75.48 Favored 'General case' 0 N--CA 1.475 0.8 0 CA-C-O 121.429 0.633 . . . . 1.0 110.528 179.128 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.451 ' HG2' ' H ' ' A' ' 24' ' ' VAL . 5.0 ttmm 80.43 -170.58 0.04 OUTLIER 'General case' 0 N--CA 1.485 1.305 0 CA-C-N 115.612 -0.722 . . . . 1.0 109.703 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.451 ' H ' ' HG2' ' A' ' 23' ' ' LYS . 24.9 t -83.76 105.51 13.35 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.494 0 CA-C-N 115.852 -0.613 . . . . 1.0 109.873 179.746 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 40.0 pt -94.12 -19.61 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 CA-C-N 115.789 -0.641 . . . . 1.0 110.489 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -145.22 -163.95 10.42 Favored Glycine 0 N--CA 1.478 1.492 0 N-CA-C 110.99 -0.844 . . . . 1.0 110.99 -179.634 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 45.4 t -160.87 130.24 4.84 Favored 'General case' 0 N--CA 1.47 0.549 0 C-N-CA 120.65 -0.42 . . . . 1.0 109.958 179.594 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.9 tp -109.52 153.32 24.27 Favored 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 121.342 0.591 . . . . 1.0 109.947 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 61.4 m -91.3 149.93 21.53 Favored 'General case' 0 N--CA 1.472 0.628 0 CA-C-N 115.696 -0.684 . . . . 1.0 110.037 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -74.7 148.68 38.79 Favored Glycine 0 CA--C 1.528 0.849 0 N-CA-C 110.481 -1.048 . . . . 1.0 110.481 179.612 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 12.1 t-20 64.82 41.06 5.18 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-O 121.024 0.44 . . . . 1.0 110.52 -179.763 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 34.7 m -106.96 127.43 53.44 Favored 'General case' 0 N--CA 1.489 1.484 0 CA-C-N 115.95 -0.568 . . . . 1.0 110.356 179.554 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -76.68 147.05 37.71 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-O 121.231 0.538 . . . . 1.0 109.822 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.3 p -157.28 148.08 10.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.706 -0.679 . . . . 1.0 110.35 -179.421 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 68.4 p -86.06 84.28 7.55 Favored 'General case' 0 N--CA 1.473 0.689 0 CA-C-N 116.111 -0.495 . . . . 1.0 110.031 179.228 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.577 HG22 ' N ' ' A' ' 37' ' ' VAL . 69.4 mt -50.53 171.57 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 CA-C-N 116.37 -0.377 . . . . 1.0 110.216 -179.862 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.577 ' N ' HG22 ' A' ' 36' ' ' ILE . 39.1 t -139.29 -92.42 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.298 0 CA-C-N 116.547 -0.297 . . . . 1.0 110.668 -179.482 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -118.45 -172.58 15.6 Favored Glycine 0 N--CA 1.487 2.04 0 N-CA-C 111.052 -0.819 . . . . 1.0 111.052 -179.172 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -113.86 111.84 22.38 Favored 'General case' 0 N--CA 1.483 1.19 0 CA-C-O 123.331 1.539 . . . . 1.0 109.623 179.359 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.497 ' N ' ' O ' ' A' ' 43' ' ' PHE . 3.1 tm-20 -104.07 96.41 6.64 Favored 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 113.676 -1.602 . . . . 1.0 109.214 179.026 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.423 ' O ' ' HB3' ' A' ' 42' ' ' ALA . . . 30.61 56.31 0.25 Allowed Glycine 0 N--CA 1.503 3.11 0 CA-C-N 114.806 -1.088 . . . . 1.0 113.141 179.64 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ALA . . . . . 0.423 ' HB3' ' O ' ' A' ' 41' ' ' GLY . . . 76.46 30.41 0.65 Allowed 'General case' 0 N--CA 1.489 1.494 0 CA-C-N 115.18 -0.51 . . . . 1.0 111.188 -178.438 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.497 ' O ' ' N ' ' A' ' 40' ' ' GLU . 75.1 m-85 -153.86 159.41 41.79 Favored 'General case' 0 N--CA 1.496 1.864 0 CA-C-N 116.194 -0.457 . . . . 1.0 111.005 179.774 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' TYR . . . . . 0.428 ' CD1' ' N ' ' A' ' 44' ' ' TYR . 15.2 p90 -143.89 165.98 26.21 Favored 'General case' 0 N--CA 1.488 1.435 0 CA-C-O 120.893 0.377 . . . . 1.0 110.407 179.398 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -88.2 159.52 18.12 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 109.551 -0.537 . . . . 1.0 109.551 -179.433 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 38.4 pt -146.97 154.38 11.91 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 CA-C-N 115.902 -0.59 . . . . 1.0 110.308 -179.367 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 72.7 mt-10 -110.33 84.28 1.9 Allowed 'General case' 0 N--CA 1.479 1.009 0 CA-C-N 115.911 -0.586 . . . . 1.0 109.67 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 7.7 t80 -119.56 137.04 54.09 Favored 'General case' 0 N--CA 1.486 1.352 0 CA-C-N 116.036 -0.529 . . . . 1.0 110.149 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 96.2 mttt 47.49 27.47 0.97 Allowed 'General case' 0 N--CA 1.481 1.09 0 CA-C-N 115.907 -0.588 . . . . 1.0 111.149 -179.297 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 67.44 23.26 73.49 Favored Glycine 0 N--CA 1.472 1.039 0 N-CA-C 110.824 -0.91 . . . . 1.0 110.824 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 92.1 p -128.4 166.02 19.5 Favored 'General case' 0 N--CA 1.482 1.136 0 CA-C-O 121.722 0.772 . . . . 1.0 110.826 -178.787 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -94.31 153.66 17.89 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-N 115.344 -0.844 . . . . 1.0 110.382 -179.407 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -158.09 166.31 34.03 Favored Glycine 0 N--CA 1.473 1.118 0 N-CA-C 110.748 -0.941 . . . . 1.0 110.748 -179.821 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -133.38 142.1 48.22 Favored 'General case' 0 N--CA 1.484 1.233 0 CA-C-N 115.552 -0.324 . . . . 1.0 110.417 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -147.78 147.29 17.4 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 CA-C-O 121.366 0.603 . . . . 1.0 109.816 -179.167 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -69.69 143.22 53.2 Favored 'General case' 0 CA--C 1.533 0.323 0 CA-C-N 115.642 -0.708 . . . . 1.0 110.017 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 9.6 mtmp? -87.31 -32.81 19.46 Favored 'General case' 0 N--CA 1.48 1.073 0 CA-C-N 116.006 -0.543 . . . . 1.0 110.218 179.645 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -52.58 -39.77 61.92 Favored 'General case' 0 N--CA 1.472 0.634 0 N-CA-C 110.227 -0.286 . . . . 1.0 110.227 -179.412 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 7.4 m-85 -48.4 -25.09 1.46 Allowed 'General case' 0 N--CA 1.48 1.069 0 CA-C-N 116.386 -0.37 . . . . 1.0 110.591 179.152 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 69.9 mt . . . . . 0 N--CA 1.476 0.861 0 CA-C-O 117.781 -1.104 . . . . 1.0 108.656 179.739 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 71.3 mtp . . . . . 0 N--CA 1.494 1.731 0 N-CA-C 109.391 -0.596 . . . . 1.0 109.391 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -62.88 -40.93 99.05 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-O 121.812 0.815 . . . . 1.0 110.678 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 51.7 p -115.73 156.89 25.16 Favored 'General case' 0 N--CA 1.479 1.003 0 CA-C-N 115.132 -0.94 . . . . 1.0 110.228 -179.8 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -91.4 148.98 19.57 Favored Glycine 0 N--CA 1.468 0.777 0 N-CA-C 110.36 -1.096 . . . . 1.0 110.36 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 65.7 mt -104.33 126.75 59.02 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 CA-C-O 121.607 0.718 . . . . 1.0 109.131 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 28.8 t -91.47 129.49 42.1 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-N 115.402 -0.817 . . . . 1.0 109.692 179.532 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 62.5 m-80 -49.27 125.64 11.31 Favored 'General case' 0 CA--C 1.545 0.762 0 CA-C-N 116.085 -0.507 . . . . 1.0 110.54 179.315 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 32.6 t -51.28 -62.27 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 CA-C-N 115.905 -0.589 . . . . 1.0 110.473 -179.451 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.9 m -62.91 153.93 31.87 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.179 0.514 . . . . 1.0 109.988 179.611 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 69.54 -171.8 0.18 Allowed 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 115.856 -0.611 . . . . 1.0 110.157 -179.873 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 42.6 t -150.32 154.17 37.38 Favored 'General case' 0 N--CA 1.473 0.697 0 CA-C-O 121.548 0.69 . . . . 1.0 110.366 179.91 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.584 HD11 ' CG ' ' A' ' 59' ' ' TYR . 4.5 mm? -99.68 135.28 41.33 Favored 'General case' 0 N--CA 1.478 0.94 0 CA-C-O 122.062 0.934 . . . . 1.0 109.989 -179.42 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 20.3 p-10 -90.76 129.27 36.86 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.009 -0.996 . . . . 1.0 109.674 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 41.0 t -92.02 103.38 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 CA-C-N 115.664 -0.698 . . . . 1.0 109.336 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 90.8 mtt-85 -81.97 151.57 27.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.434 0.635 . . . . 1.0 109.893 179.244 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 39.8 t -71.99 -21.63 61.54 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 115.582 -0.735 . . . . 1.0 110.433 179.535 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 48.9 m -163.73 174.94 11.02 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-N 116.014 -0.539 . . . . 1.0 110.682 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -70.6 56.48 0.17 Allowed 'General case' 0 N--CA 1.474 0.744 0 CA-C-N 115.792 -0.64 . . . . 1.0 110.42 179.502 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 49.1 m -140.65 130.02 23.84 Favored 'General case' 0 N--CA 1.481 1.089 0 CA-C-O 121.532 0.682 . . . . 1.0 110.577 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 3.7 t -66.31 -31.66 72.59 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 115.476 -0.784 . . . . 1.0 110.425 179.755 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 95.7 p -73.85 -4.81 37.14 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 115.976 -0.557 . . . . 1.0 110.244 -179.787 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 43.1 t -58.9 -173.82 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 120.952 0.406 . . . . 1.0 110.41 179.493 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -127.58 161.52 28.63 Favored 'General case' 0 N--CA 1.478 0.974 0 CA-C-O 121.747 0.784 . . . . 1.0 110.286 -179.768 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.2 t -89.42 108.99 19.81 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-N 115.283 -0.871 . . . . 1.0 109.694 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 45.9 pt -85.72 -17.01 9.69 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 CA-C-N 115.597 -0.729 . . . . 1.0 110.187 179.728 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 175.32 174.73 42.17 Favored Glycine 0 N--CA 1.461 0.319 0 N-CA-C 110.942 -0.863 . . . . 1.0 110.942 -179.455 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 42.6 t -142.52 137.58 30.31 Favored 'General case' 0 N--CA 1.475 0.798 0 CA-C-O 121.775 0.798 . . . . 1.0 110.528 179.604 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -99.8 171.87 7.61 Favored 'General case' 0 N--CA 1.475 0.782 0 CA-C-N 115.303 -0.862 . . . . 1.0 109.206 -179.671 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 56.7 m -89.96 155.13 19.32 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 115.085 -0.961 . . . . 1.0 110.298 -179.225 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -74.97 150.76 41.47 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.117 -1.193 . . . . 1.0 110.117 179.397 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 22.9 t30 74.83 17.71 2.79 Favored 'General case' 0 N--CA 1.48 1.04 0 CA-C-O 120.798 0.332 . . . . 1.0 110.572 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 59.4 m -87.86 132.39 34.21 Favored 'General case' 0 N--CA 1.478 0.975 0 CA-C-O 121.236 0.541 . . . . 1.0 110.042 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 26.9 mtpp -82.61 144.62 30.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.638 0.732 . . . . 1.0 109.677 179.738 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 16.9 m -147.63 130.47 7.87 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.451 0 CA-C-N 115.319 -0.855 . . . . 1.0 109.863 -179.91 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.411 ' O ' ' C ' ' A' ' 36' ' ' ILE . 30.7 m -86.39 89.05 7.75 Favored 'General case' 0 CA--C 1.515 -0.388 0 N-CA-C 109.098 -0.704 . . . . 1.0 109.098 179.463 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.438 ' H ' HD12 ' A' ' 36' ' ' ILE . 3.5 mp -34.47 146.94 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.504 2.253 0 CA-C-N 116.372 -0.377 . . . . 1.0 111.579 179.345 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 4.7 t -143.45 62.55 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.084 0 CA-C-O 121.05 0.452 . . . . 1.0 110.333 -178.669 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 108.61 166.57 20.94 Favored Glycine 0 N--CA 1.465 0.624 0 N-CA-C 110.462 -1.055 . . . . 1.0 110.462 179.75 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 16.4 pt-20 -142.21 147.25 36.24 Favored 'General case' 0 N--CA 1.476 0.842 0 CA-C-N 114.824 -0.688 . . . . 1.0 110.15 -179.747 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -154.37 125.84 7.47 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 115.704 -0.68 . . . . 1.0 110.162 179.453 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 50.33 -112.46 1.55 Allowed Glycine 0 CA--C 1.535 1.312 0 N-CA-C 111.398 -0.681 . . . . 1.0 111.398 179.442 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -115.37 22.63 13.08 Favored 'General case' 0 N--CA 1.482 1.143 0 N-CA-C 109.911 -0.403 . . . . 1.0 109.911 179.151 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.407 ' C ' ' NZ ' ' A' ' 57' ' ' LYS . 54.5 m-85 -143.37 153.88 43.15 Favored 'General case' 0 N--CA 1.477 0.884 0 CA-C-O 122.012 0.91 . . . . 1.0 110.365 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' TYR . . . . . 0.43 ' N ' ' CD1' ' A' ' 44' ' ' TYR . 11.8 p90 -134.67 169.17 17.72 Favored 'General case' 0 N--CA 1.473 0.687 0 CA-C-O 122.146 0.974 . . . . 1.0 110.04 -179.481 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 63.3 tttm -95.58 151.85 18.96 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 114.902 -1.045 . . . . 1.0 109.918 -179.328 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 18.1 pt -143.91 162.05 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 CA-C-O 122.156 0.979 . . . . 1.0 110.021 179.39 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -125.25 96.78 4.96 Favored 'General case' 0 N--CA 1.479 1.017 0 CA-C-N 114.818 -1.083 . . . . 1.0 110.108 179.276 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 39.2 t80 -135.73 152.79 51.5 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 115.718 -0.674 . . . . 1.0 109.968 179.287 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 63.5 mttt 56.69 10.86 0.78 Allowed 'General case' 0 N--CA 1.475 0.819 0 CA-C-N 115.812 -0.631 . . . . 1.0 110.84 179.629 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 81.35 0.03 88.44 Favored Glycine 0 N--CA 1.472 1.1 0 N-CA-C 110.264 -1.134 . . . . 1.0 110.264 -179.573 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 49.4 m -110.98 172.97 6.56 Favored 'General case' 0 N--CA 1.482 1.153 0 C-N-CA 123.902 0.881 . . . . 1.0 110.167 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 47.8 m-70 -107.16 145.54 32.43 Favored 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 115.35 -0.841 . . . . 1.0 110.023 -179.747 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -152.06 170.92 31.42 Favored Glycine 0 N--CA 1.464 0.501 0 N-CA-C 110.9 -0.88 . . . . 1.0 110.9 -179.382 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 80.1 m-85 -132.38 146.23 51.81 Favored 'General case' 0 N--CA 1.482 1.13 0 CA-C-O 121.518 0.675 . . . . 1.0 110.258 179.219 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 36.4 t -143.64 147.59 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 CA-C-N 115.451 -0.795 . . . . 1.0 110.277 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -68.75 153.12 44.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.547 -0.751 . . . . 1.0 110.216 179.641 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' LYS . . . . . 0.407 ' NZ ' ' C ' ' A' ' 43' ' ' PHE . 65.4 mttp -89.99 -22.82 21.73 Favored 'General case' 0 N--CA 1.478 0.961 0 CA-C-N 115.709 -0.678 . . . . 1.0 110.586 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -52.38 -35.99 52.83 Favored 'General case' 0 CA--C 1.537 0.478 0 CA-C-O 121.068 0.461 . . . . 1.0 110.488 -179.146 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.584 ' CG ' HD11 ' A' ' 12' ' ' LEU . 24.4 m-85 -64.04 -30.18 71.27 Favored 'General case' 0 N--CA 1.475 0.823 0 CA-C-N 115.905 -0.589 . . . . 1.0 110.477 178.941 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 63.5 mt . . . . . 0 N--CA 1.47 0.542 0 CA-C-O 118.119 -0.943 . . . . 1.0 108.609 -179.577 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 65.8 mtt . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 108.807 -0.812 . . . . 1.0 108.807 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 25.9 ttpp -65.04 148.91 50.79 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.531 -0.759 . . . . 1.0 110.112 -179.551 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 53.9 p -118.31 144.79 45.58 Favored 'General case' 0 N--CA 1.474 0.727 0 CA-C-O 121.695 0.76 . . . . 1.0 110.475 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -97.58 154.25 20.31 Favored Glycine 0 N--CA 1.476 1.322 0 N-CA-C 110.038 -1.225 . . . . 1.0 110.038 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 65.7 mt -106.07 125.26 61.66 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.086 0 CA-C-O 121.239 0.543 . . . . 1.0 109.555 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 45.0 t -74.55 133.48 31.45 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.324 0 CA-C-N 115.788 -0.642 . . . . 1.0 109.479 179.61 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 9.4 m120 -62.13 109.27 1.25 Allowed 'General case' 0 CA--C 1.537 0.444 0 CA-C-N 115.735 -0.666 . . . . 1.0 110.113 179.363 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.3 p -55.61 -19.33 5.91 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 CA-C-N 116.035 -0.529 . . . . 1.0 110.435 179.515 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 49.5 m -52.08 105.97 0.13 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.158 -0.473 . . . . 1.0 110.422 -179.373 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 80.9 p 60.42 -122.38 0.97 Allowed 'General case' 0 CA--C 1.548 0.882 0 CA-C-N 116.062 -0.517 . . . . 1.0 110.448 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 47.7 t -151.98 156.57 40.29 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-O 121.379 0.609 . . . . 1.0 110.083 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -104.24 136.46 43.8 Favored 'General case' 0 N--CA 1.479 1.016 0 CA-C-O 121.817 0.818 . . . . 1.0 110.323 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 72.5 m-80 -92.31 133.97 35.35 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.199 -0.909 . . . . 1.0 109.269 -179.623 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 59.3 t -93.19 105.75 17.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-N 115.104 -0.953 . . . . 1.0 109.37 -179.658 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 88.9 mtt-85 -81.32 148.55 29.33 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.487 0.661 . . . . 1.0 109.922 179.305 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 87.6 p -73.14 -19.41 61.14 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 115.606 -0.724 . . . . 1.0 110.019 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 87.1 p -162.17 172.85 15.13 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-O 121.179 0.514 . . . . 1.0 110.798 -179.585 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -71.47 57.45 0.26 Allowed 'General case' 0 N--CA 1.474 0.767 0 CA-C-N 115.789 -0.641 . . . . 1.0 110.49 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 55.8 m -143.93 130.43 20.01 Favored 'General case' 0 N--CA 1.481 1.105 0 CA-C-N 115.71 -0.677 . . . . 1.0 110.492 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 57.8 p -65.72 -26.61 67.83 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 115.827 -0.624 . . . . 1.0 110.226 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 49.4 m -71.07 -8.02 50.49 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 116.063 -0.517 . . . . 1.0 110.256 179.685 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 61.2 m -67.0 132.08 47.17 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 121.388 0.614 . . . . 1.0 110.01 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -72.48 169.58 16.13 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.615 -0.72 . . . . 1.0 110.123 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.7 t -90.16 112.58 24.95 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 CA-C-O 121.807 0.813 . . . . 1.0 109.754 179.751 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 2.1 pp -85.18 -27.19 6.54 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 CA-C-N 115.146 -0.934 . . . . 1.0 109.761 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 173.15 -171.84 44.73 Favored Glycine 0 N--CA 1.465 0.583 0 N-CA-C 111.398 -0.681 . . . . 1.0 111.398 -179.423 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 95.4 p -151.92 145.23 24.73 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-O 121.895 0.855 . . . . 1.0 110.449 179.208 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -102.31 -179.11 3.89 Favored 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 115.166 -0.925 . . . . 1.0 109.28 -179.662 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 96.8 p -91.66 144.63 25.33 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 115.145 -0.934 . . . . 1.0 110.197 -179.646 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -75.13 157.96 50.5 Favored Glycine 0 N--CA 1.461 0.343 0 N-CA-C 110.212 -1.155 . . . . 1.0 110.212 179.566 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 13.0 t-20 69.46 20.82 7.08 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-O 120.707 0.289 . . . . 1.0 110.485 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 85.7 m -88.99 137.16 32.57 Favored 'General case' 0 N--CA 1.478 0.962 0 CA-C-O 121.413 0.625 . . . . 1.0 110.433 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -86.93 144.51 26.92 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-O 122.069 0.938 . . . . 1.0 109.814 179.771 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 5.7 p -153.75 138.14 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.423 0 CA-C-N 114.898 -1.046 . . . . 1.0 109.806 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 60.9 p -82.46 84.32 7.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.784 -0.644 . . . . 1.0 109.62 178.694 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.432 HG22 ' N ' ' A' ' 37' ' ' VAL . 88.6 mt -43.02 160.06 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 CA-C-N 115.657 -0.701 . . . . 1.0 110.243 179.428 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.432 ' N ' HG22 ' A' ' 36' ' ' ILE . 43.3 t -123.34 -92.5 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 CA-C-N 115.882 -0.599 . . . . 1.0 109.698 -179.745 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -114.89 -159.15 12.27 Favored Glycine 0 N--CA 1.466 0.653 0 CA-C-O 122.318 0.954 . . . . 1.0 110.861 -179.278 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' GLU . . . . . 0.461 ' N ' ' NZ ' ' A' ' 45' ' ' LYS . 1.0 OUTLIER -143.66 147.93 35.04 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 114.707 -0.747 . . . . 1.0 110.61 -179.524 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -154.64 124.5 6.65 Favored 'General case' 0 N--CA 1.47 0.558 0 CA-C-N 115.929 -0.578 . . . . 1.0 110.345 179.319 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 53.3 -150.15 11.71 Favored Glycine 0 CA--C 1.532 1.149 0 N-CA-C 111.139 -0.784 . . . . 1.0 111.139 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -84.9 30.37 0.58 Allowed 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 110.151 -0.314 . . . . 1.0 110.151 179.431 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 -145.69 153.37 40.92 Favored 'General case' 0 N--CA 1.477 0.909 0 CA-C-O 121.784 0.802 . . . . 1.0 110.529 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 1.7 m-85 -109.68 148.87 30.59 Favored 'General case' 0 N--CA 1.48 1.032 0 CA-C-O 122.556 1.169 . . . . 1.0 110.099 179.468 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.461 ' NZ ' ' N ' ' A' ' 39' ' ' GLU . 35.4 mtmm -87.98 140.73 29.2 Favored 'General case' 0 CA--C 1.518 -0.281 0 CA-C-N 114.485 -1.234 . . . . 1.0 109.508 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 39.9 pt -149.86 173.41 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.358 0 CA-C-N 114.594 -1.185 . . . . 1.0 109.688 -179.128 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -146.61 108.14 4.29 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 115.74 -0.664 . . . . 1.0 110.225 178.94 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 54.6 t80 -139.08 162.35 35.15 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.739 -0.664 . . . . 1.0 110.054 179.76 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 19.2 tttp 59.18 16.49 4.91 Favored 'General case' 0 CA--C 1.546 0.818 0 CA-C-N 115.55 -0.75 . . . . 1.0 110.9 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 77.85 -2.1 65.64 Favored Glycine 0 N--CA 1.477 1.403 0 N-CA-C 110.171 -1.171 . . . . 1.0 110.171 -179.357 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 49.2 m -114.95 176.29 5.12 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 124.278 1.031 . . . . 1.0 110.486 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 25.9 p80 -105.36 141.01 37.62 Favored 'General case' 0 N--CA 1.482 1.15 0 CA-C-N 115.464 -0.789 . . . . 1.0 110.064 -179.447 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.68 165.8 27.92 Favored Glycine 0 N--CA 1.463 0.435 0 N-CA-C 110.525 -1.03 . . . . 1.0 110.525 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -130.37 145.43 51.8 Favored 'General case' 0 N--CA 1.483 1.217 0 CA-C-O 121.527 0.68 . . . . 1.0 110.001 179.538 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 41.3 t -145.92 149.75 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 CA-C-O 121.904 0.859 . . . . 1.0 109.427 -179.723 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.402 ' O ' ' CD1' ' A' ' 59' ' ' TYR . . . -60.71 153.44 24.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 114.986 -1.006 . . . . 1.0 110.164 178.952 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 15.8 pttp -102.89 -31.34 10.31 Favored 'General case' 0 N--CA 1.482 1.167 0 CA-C-N 115.442 -0.799 . . . . 1.0 111.763 178.9 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 14.6 pt-20 -64.53 -31.82 73.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.444 0.64 . . . . 1.0 111.022 -179.176 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.402 ' CD1' ' O ' ' A' ' 56' ' ' ALA . 0.6 OUTLIER -62.7 -4.12 1.88 Allowed 'General case' 0 CA--C 1.549 0.918 0 CA-C-N 115.476 -0.783 . . . . 1.0 110.138 -179.888 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 85.1 mt . . . . . 0 N--CA 1.477 0.888 0 N-CA-C 108.13 -1.063 . . . . 1.0 108.13 -179.163 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 15.5 ptp . . . . . 0 N--CA 1.492 1.642 0 N-CA-C 109.435 -0.58 . . . . 1.0 109.435 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -63.84 -79.8 0.03 OUTLIER 'General case' 0 N--CA 1.475 0.785 0 CA-C-O 121.432 0.634 . . . . 1.0 110.563 -179.759 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 20.2 p -137.78 151.26 47.96 Favored 'General case' 0 N--CA 1.489 1.479 0 CA-C-N 115.549 -0.75 . . . . 1.0 110.353 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -96.8 142.78 16.36 Favored Glycine 0 N--CA 1.474 1.217 0 N-CA-C 110.625 -0.99 . . . . 1.0 110.625 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 75.1 mt -109.24 141.56 24.18 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.177 0 CA-C-O 121.224 0.535 . . . . 1.0 109.95 -179.618 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 2.8 t -116.56 115.86 50.39 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 CA-C-O 116.812 -1.566 . . . . 1.0 110.682 178.083 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -82.48 146.3 29.33 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 120.098 1.317 . . . . 1.0 109.06 177.638 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.9 p -50.14 139.01 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 CA-C-N 116.314 -0.403 . . . . 1.0 111.126 179.289 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 79.2 p -168.59 -78.88 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.844 0 CA-C-O 120.843 0.354 . . . . 1.0 111.141 -179.26 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 97.6 p -131.15 -133.74 0.2 Allowed 'General case' 0 N--CA 1.485 1.287 0 CA-C-N 116.068 -0.515 . . . . 1.0 110.516 -179.105 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 98.3 p -138.85 153.76 48.36 Favored 'General case' 0 N--CA 1.477 0.925 0 CA-C-O 121.312 0.577 . . . . 1.0 110.238 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -140.3 128.27 22.09 Favored 'General case' 0 N--CA 1.49 1.553 0 CA-C-O 121.733 0.778 . . . . 1.0 109.715 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 19.3 p30 -92.96 144.08 25.61 Favored 'General case' 0 N--CA 1.473 0.704 0 CA-C-N 115.298 -0.865 . . . . 1.0 110.06 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 93.9 t -97.79 128.45 49.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 CA-C-O 121.879 0.847 . . . . 1.0 108.894 179.173 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 89.5 mtt-85 -99.55 -167.74 1.51 Allowed 'General case' 0 N--CA 1.473 0.702 0 CA-C-N 115.187 -0.915 . . . . 1.0 110.162 -179.744 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 60.1 p -130.8 33.16 4.26 Favored 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 123.017 0.527 . . . . 1.0 110.611 -179.413 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' SER . . . . . 0.48 ' OG ' ' N ' ' A' ' 18' ' ' ALA . 6.9 t 175.8 -177.95 0.13 Allowed 'General case' 0 N--CA 1.48 1.027 0 CA-C-O 121.632 0.729 . . . . 1.0 110.507 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.48 ' N ' ' OG ' ' A' ' 17' ' ' SER . . . -97.11 42.97 1.08 Allowed 'General case' 0 N--CA 1.488 1.448 0 CA-C-N 115.285 -0.87 . . . . 1.0 110.182 179.511 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 44.3 t -130.63 138.18 49.97 Favored 'General case' 0 N--CA 1.489 1.477 0 CA-C-N 115.106 -0.952 . . . . 1.0 110.902 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 80.1 p -74.73 -8.75 57.37 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-N 116.227 -0.442 . . . . 1.0 110.569 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 66.7 m -99.36 -6.58 27.57 Favored 'General case' 0 N--CA 1.486 1.333 0 CA-C-N 116.201 -0.454 . . . . 1.0 111.069 -179.072 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 13.9 t -66.48 133.95 51.46 Favored 'General case' 0 N--CA 1.473 0.72 0 CA-C-N 115.962 -0.563 . . . . 1.0 110.843 -179.414 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 38.3 ttmt -59.89 155.67 15.99 Favored 'General case' 0 N--CA 1.475 0.793 0 CA-C-N 116.031 -0.531 . . . . 1.0 110.622 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 6.8 p -83.94 144.56 9.68 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.193 0 CA-C-O 121.176 0.513 . . . . 1.0 110.503 -179.68 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 40.1 pt -121.87 -10.26 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 CA-C-N 115.813 -0.631 . . . . 1.0 110.34 179.266 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 179.35 -171.56 43.42 Favored Glycine 0 N--CA 1.467 0.759 0 N-CA-C 111.111 -0.796 . . . . 1.0 111.111 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 96.7 p -157.25 151.0 24.33 Favored 'General case' 0 N--CA 1.475 0.797 0 CA-C-N 115.642 -0.279 . . . . 1.0 110.559 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 2.2 pp -117.23 167.78 10.9 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 123.076 0.55 . . . . 1.0 110.507 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 90.9 p -112.74 160.02 18.37 Favored 'General case' 0 N--CA 1.482 1.17 0 CA-C-N 115.718 -0.673 . . . . 1.0 110.537 -179.491 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.467 ' O ' ' HB2' ' A' ' 31' ' ' ASN . . . -83.75 76.06 2.29 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 110.901 -0.88 . . . . 1.0 110.901 179.41 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.467 ' HB2' ' O ' ' A' ' 30' ' ' GLY . 22.1 t-20 164.61 16.3 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.843 0 C-N-CA 123.287 0.635 . . . . 1.0 110.242 -179.566 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 36.4 m -109.84 147.47 33.27 Favored 'General case' 0 N--CA 1.486 1.337 0 C-N-CA 123.424 0.69 . . . . 1.0 111.046 -179.458 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 22.2 pttp -90.25 148.77 22.7 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 122.602 0.361 . . . . 1.0 110.209 178.532 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.6 m -143.21 126.04 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 CA-C-O 120.829 0.347 . . . . 1.0 110.296 179.587 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' THR . . . . . 0.542 ' O ' HG23 ' A' ' 35' ' ' THR . 9.8 t -82.79 85.47 7.07 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 121.445 0.641 . . . . 1.0 110.619 179.674 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 85.6 mt -51.16 157.23 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 CA-C-N 115.546 -0.752 . . . . 1.0 110.165 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 39.6 t -127.4 -97.86 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 CA-C-N 115.947 -0.569 . . . . 1.0 110.003 -179.076 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -99.49 -178.42 31.2 Favored Glycine 0 N--CA 1.472 1.036 0 N-CA-C 110.937 -0.865 . . . . 1.0 110.937 -179.773 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -135.16 141.8 46.0 Favored 'General case' 0 N--CA 1.483 1.193 0 CA-C-O 120.984 0.421 . . . . 1.0 110.204 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -155.38 134.84 12.48 Favored 'General case' 0 CA--C 1.539 0.524 0 CA-C-N 116.001 -0.545 . . . . 1.0 110.378 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 48.56 -113.14 1.4 Allowed Glycine 0 CA--C 1.547 2.051 0 CA-C-N 115.947 -0.57 . . . . 1.0 111.707 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -122.49 24.7 9.16 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 110.049 -0.352 . . . . 1.0 110.049 179.23 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -145.07 156.18 43.76 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-O 121.301 0.572 . . . . 1.0 110.296 -179.474 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 22.6 p90 -131.67 162.87 29.38 Favored 'General case' 0 N--CA 1.488 1.458 0 CA-C-N 115.684 -0.689 . . . . 1.0 110.452 179.712 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -88.58 160.39 17.45 Favored 'General case' 0 N--CA 1.476 0.829 0 CA-C-N 116.037 -0.528 . . . . 1.0 110.159 -179.372 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 34.4 pt -145.75 153.17 13.74 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 CA-C-O 121.312 0.577 . . . . 1.0 110.504 -179.632 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 80.8 mm-40 -95.75 58.73 1.99 Allowed 'General case' 0 N--CA 1.481 1.113 0 CA-C-N 115.668 -0.696 . . . . 1.0 110.069 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 77.8 t80 -78.94 117.54 20.11 Favored 'General case' 0 N--CA 1.474 0.727 0 CA-C-N 115.603 -0.726 . . . . 1.0 109.915 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm 45.58 33.21 1.32 Allowed 'General case' 0 CA--C 1.557 1.24 0 CA-C-O 121.276 0.56 . . . . 1.0 111.415 -179.629 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 68.19 21.74 74.03 Favored Glycine 0 N--CA 1.482 1.736 0 N-CA-C 111.373 -0.691 . . . . 1.0 111.373 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 28.9 t -115.98 171.65 7.65 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 123.332 0.653 . . . . 1.0 110.878 -179.186 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -96.77 136.85 36.73 Favored 'General case' 0 N--CA 1.479 0.995 0 CA-C-N 115.942 -0.572 . . . . 1.0 110.229 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -148.2 163.13 28.9 Favored Glycine 0 N--CA 1.479 1.522 0 N-CA-C 110.993 -0.843 . . . . 1.0 110.993 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' TYR . . . . . 0.451 ' CD1' ' N ' ' A' ' 17' ' ' SER . 82.2 m-85 -133.83 138.01 45.39 Favored 'General case' 0 N--CA 1.483 1.184 0 CA-C-O 121.483 0.659 . . . . 1.0 110.544 -179.744 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 42.8 t -144.23 151.22 16.16 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.291 0 CA-C-N 115.501 -0.772 . . . . 1.0 110.1 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -79.55 113.53 17.77 Favored 'General case' 0 N--CA 1.474 0.747 0 CA-C-N 115.785 -0.643 . . . . 1.0 110.502 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 19.3 pttp -74.23 -28.44 61.24 Favored 'General case' 0 N--CA 1.476 0.871 0 CA-C-O 120.812 0.339 . . . . 1.0 110.512 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -55.11 -45.18 75.5 Favored 'General case' 0 N--CA 1.477 0.876 0 CA-C-N 116.234 -0.439 . . . . 1.0 111.014 -179.297 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 22.9 m-85 -63.0 -35.02 78.81 Favored 'General case' 0 N--CA 1.477 0.893 0 N-CA-C 110.003 -0.369 . . . . 1.0 110.003 178.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 74.4 mt . . . . . 0 N--CA 1.479 1.01 0 CA-C-O 118.133 -0.937 . . . . 1.0 109.253 -179.48 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 21.2 ptt? . . . . . 0 N--CA 1.484 1.229 0 N-CA-C 108.835 -0.802 . . . . 1.0 108.835 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -134.3 153.45 51.87 Favored 'General case' 0 N--CA 1.479 1.006 0 CA-C-O 121.817 0.818 . . . . 1.0 110.181 179.776 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 73.3 p -123.14 144.59 49.24 Favored 'General case' 0 N--CA 1.48 1.054 0 CA-C-N 115.161 -0.927 . . . . 1.0 110.314 -179.796 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -95.64 151.77 20.11 Favored Glycine 0 CA--C 1.527 0.838 0 N-CA-C 110.229 -1.149 . . . . 1.0 110.229 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 4.0 mp -103.56 124.89 58.11 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 N-CA-C 109.493 -0.558 . . . . 1.0 109.493 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.3 t -66.67 120.09 13.24 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.554 0 CA-C-N 115.7 -0.682 . . . . 1.0 109.845 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 18.2 p-10 -59.63 102.28 0.14 Allowed 'General case' 0 CA--C 1.539 0.537 0 CA-C-O 121.029 0.443 . . . . 1.0 110.479 179.492 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 8.2 p -64.27 -2.85 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-N 115.951 -0.568 . . . . 1.0 110.721 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 41.3 m -45.89 -56.71 5.08 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-N 115.743 -0.662 . . . . 1.0 111.445 -179.87 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 50.0 m -148.56 179.41 7.83 Favored 'General case' 0 N--CA 1.477 0.907 0 CA-C-N 115.61 -0.723 . . . . 1.0 110.277 179.216 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 45.1 t -84.75 140.31 31.35 Favored 'General case' 0 N--CA 1.473 0.712 0 CA-C-N 115.479 -0.782 . . . . 1.0 110.249 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -111.6 140.65 46.04 Favored 'General case' 0 N--CA 1.485 1.29 0 CA-C-O 122.232 1.015 . . . . 1.0 109.935 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 72.6 m-80 -82.67 126.7 32.65 Favored 'General case' 0 N--CA 1.451 -0.407 0 CA-C-N 114.805 -1.089 . . . . 1.0 109.476 179.663 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.4 t -102.09 125.86 56.21 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 CA-C-N 115.229 -0.896 . . . . 1.0 110.181 -179.763 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -91.83 179.62 5.57 Favored 'General case' 0 N--CA 1.486 1.348 0 CA-C-O 121.582 0.706 . . . . 1.0 110.238 179.039 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 1.4 m -92.65 -22.61 19.35 Favored 'General case' 0 N--CA 1.489 1.508 0 CA-C-N 115.435 -0.802 . . . . 1.0 110.282 179.837 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 45.5 p -176.74 -178.13 0.85 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 122.175 0.988 . . . . 1.0 110.032 -179.162 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -82.15 82.27 7.76 Favored 'General case' 0 N--CA 1.47 0.562 0 CA-C-N 114.852 -1.067 . . . . 1.0 109.689 179.182 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 65.5 p -167.25 154.68 8.92 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 121.565 0.698 . . . . 1.0 110.332 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 26.3 m -75.1 -25.32 58.44 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.398 -0.819 . . . . 1.0 110.639 179.311 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 99.5 p -63.08 -22.93 67.19 Favored 'General case' 0 N--CA 1.471 0.602 0 C-N-CA 120.597 -0.441 . . . . 1.0 110.408 -178.423 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 26.5 t -96.96 141.79 29.7 Favored 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 109.652 -0.499 . . . . 1.0 109.652 178.41 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 24.9 tttm -163.24 109.9 1.16 Allowed 'General case' 0 N--CA 1.474 0.754 0 CA-C-O 122.077 0.942 . . . . 1.0 110.029 179.638 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.3 t 62.06 135.92 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.519 0 CA-C-N 115.032 -0.986 . . . . 1.0 110.24 -179.82 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 1.3 pp -152.57 -17.14 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.963 0 CA-C-N 115.93 -0.577 . . . . 1.0 110.326 -179.387 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 163.27 -166.91 37.32 Favored Glycine 0 CA--C 1.522 0.469 0 N-CA-C 110.359 -1.096 . . . . 1.0 110.359 -178.247 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 93.9 p -145.11 140.44 28.03 Favored 'General case' 0 N--CA 1.481 1.121 0 CA-C-N 114.882 -0.659 . . . . 1.0 110.591 179.782 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.9 pp -102.17 122.41 44.1 Favored 'General case' 0 N--CA 1.491 1.58 0 CA-C-O 121.587 0.708 . . . . 1.0 109.392 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 51.0 m -44.69 131.62 6.75 Favored 'General case' 0 N--CA 1.484 1.233 0 CA-C-N 115.476 -0.784 . . . . 1.0 111.082 -178.654 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -68.08 165.87 45.14 Favored Glycine 0 CA--C 1.521 0.449 0 N-CA-C 111.354 -0.699 . . . . 1.0 111.354 -178.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 13.8 m-80 65.1 20.66 12.08 Favored 'General case' 0 N--CA 1.471 0.624 0 CA-C-O 120.954 0.407 . . . . 1.0 110.455 179.654 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 91.8 m -97.67 145.54 26.21 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-N 115.994 -0.548 . . . . 1.0 109.735 179.48 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -86.27 139.3 31.14 Favored 'General case' 0 N--CA 1.473 0.682 0 CA-C-N 115.77 -0.65 . . . . 1.0 110.143 179.428 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 9.8 m -142.49 124.99 13.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 CA-C-N 115.675 -0.693 . . . . 1.0 110.118 179.808 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 60.0 p -89.93 90.78 8.31 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 115.917 -0.583 . . . . 1.0 109.813 179.185 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 3.5 mp -36.75 147.17 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.498 1.94 0 CA-C-N 115.768 -0.651 . . . . 1.0 111.517 179.669 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 4.7 t -141.68 61.47 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.37 0 CA-C-O 121.239 0.543 . . . . 1.0 110.522 -178.485 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 107.83 160.55 20.83 Favored Glycine 0 N--CA 1.471 1.005 0 N-CA-C 110.711 -0.956 . . . . 1.0 110.711 179.435 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 74.7 mt-10 -135.46 140.72 45.08 Favored 'General case' 0 N--CA 1.487 1.383 0 CA-C-O 121.161 0.505 . . . . 1.0 110.261 179.703 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.7 tm-20 -148.95 121.87 8.77 Favored 'General case' 0 N--CA 1.477 0.875 0 CA-C-N 115.837 -0.619 . . . . 1.0 110.346 -179.595 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 50.41 -114.17 2.44 Favored Glycine 0 CA--C 1.543 1.783 0 N-CA-C 111.16 -0.776 . . . . 1.0 111.16 179.651 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -113.62 26.82 10.05 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 122.609 0.364 . . . . 1.0 110.724 179.431 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 -146.9 156.34 43.0 Favored 'General case' 0 N--CA 1.476 0.841 0 CA-C-O 121.721 0.772 . . . . 1.0 110.487 179.857 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' TYR . . . . . 0.4 ' CD1' ' N ' ' A' ' 44' ' ' TYR . 15.0 p90 -140.45 172.67 12.4 Favored 'General case' 0 N--CA 1.473 0.72 0 CA-C-N 115.336 -0.847 . . . . 1.0 110.121 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 24.0 mtpp -101.32 151.83 21.42 Favored 'General case' 0 N--CA 1.478 0.944 0 CA-C-N 115.225 -0.898 . . . . 1.0 110.281 -179.282 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 38.9 pt -139.55 152.97 23.29 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 CA-C-N 115.59 -0.732 . . . . 1.0 110.596 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 4.3 tm-20 -113.45 86.82 2.47 Favored 'General case' 0 N--CA 1.485 1.288 0 CA-C-N 115.323 -0.853 . . . . 1.0 109.872 179.236 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 22.6 t80 -139.65 158.46 44.08 Favored 'General case' 0 N--CA 1.469 0.505 0 CA-C-O 121.209 0.528 . . . . 1.0 110.566 179.391 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 33.8 mtmt 50.29 20.83 0.7 Allowed 'General case' 0 N--CA 1.476 0.859 0 CA-C-N 115.847 -0.615 . . . . 1.0 110.447 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 71.55 -3.32 18.04 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.799 -0.92 . . . . 1.0 110.799 -179.533 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 44.0 t -117.38 173.97 6.4 Favored 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 124.119 0.968 . . . . 1.0 110.644 -179.431 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 26.7 p-80 -112.37 153.54 27.11 Favored 'General case' 0 N--CA 1.481 1.094 0 CA-C-N 115.467 -0.788 . . . . 1.0 109.955 -179.587 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.06 165.55 27.71 Favored Glycine 0 N--CA 1.471 0.994 0 N-CA-C 110.711 -0.956 . . . . 1.0 110.711 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 77.0 m-85 -130.54 139.67 50.48 Favored 'General case' 0 N--CA 1.486 1.351 0 CA-C-O 121.119 0.485 . . . . 1.0 110.268 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 4.2 p -158.91 158.84 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.001 0 CA-C-N 115.92 -0.582 . . . . 1.0 110.25 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.66 134.13 56.74 Favored 'General case' 0 CA--C 1.541 0.609 0 CA-C-O 121.191 0.519 . . . . 1.0 110.397 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -91.06 -35.97 14.31 Favored 'General case' 0 N--CA 1.483 1.198 0 CA-C-N 115.712 -0.676 . . . . 1.0 110.258 -179.831 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -56.73 -28.47 61.09 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-O 121.099 0.476 . . . . 1.0 110.633 -179.454 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 2.2 m-85 -63.21 -39.24 94.08 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-N 115.88 -0.6 . . . . 1.0 110.17 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 70.2 mt . . . . . 0 N--CA 1.472 0.628 0 CA-C-O 117.698 -1.144 . . . . 1.0 109.338 -179.32 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.7 mmt . . . . . 0 N--CA 1.492 1.638 0 N-CA-C 108.938 -0.764 . . . . 1.0 108.938 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 7.0 mtpm? 52.43 98.09 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 115.897 -0.592 . . . . 1.0 110.994 -179.553 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 68.6 p -125.89 163.07 23.74 Favored 'General case' 0 N--CA 1.48 1.045 0 CA-C-O 121.786 0.803 . . . . 1.0 110.353 -179.259 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -122.13 153.17 16.81 Favored Glycine 0 N--CA 1.479 1.565 0 CA-C-N 115.147 -0.933 . . . . 1.0 110.883 -179.696 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 28.2 pt -114.45 140.47 35.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 CA-C-O 121.869 0.842 . . . . 1.0 110.076 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.511 ' H ' ' HA ' ' A' ' 31' ' ' ASN . 2.2 t -90.82 132.04 36.41 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 CA-C-N 115.083 -0.962 . . . . 1.0 109.315 -179.666 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 31.9 m120 -59.53 114.66 2.82 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 120.397 -0.521 . . . . 1.0 110.35 179.329 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 40.6 t -53.49 -19.51 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 CA-C-O 121.397 0.618 . . . . 1.0 110.448 -179.676 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.5 m -49.42 109.28 0.25 Allowed 'General case' 0 CA--C 1.545 0.769 0 CA-C-N 115.642 -0.708 . . . . 1.0 110.873 179.339 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 7.9 m 61.67 -125.42 0.81 Allowed 'General case' 0 CA--C 1.543 0.699 0 CA-C-N 116.582 -0.281 . . . . 1.0 110.606 -179.18 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 89.0 p -152.28 158.68 43.13 Favored 'General case' 0 N--CA 1.478 0.936 0 CA-C-O 120.97 0.414 . . . . 1.0 110.666 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 51.5 tp -123.05 133.44 54.32 Favored 'General case' 0 N--CA 1.486 1.345 0 CA-C-O 121.578 0.704 . . . . 1.0 110.212 179.596 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 14.9 p-10 -84.63 143.48 29.22 Favored 'General case' 0 CA--C 1.535 0.394 0 CA-C-N 115.432 -0.804 . . . . 1.0 109.982 179.404 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 45.2 t -96.4 117.54 40.95 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 N-CA-C 109.424 -0.584 . . . . 1.0 109.424 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 81.3 mtt85 -84.97 165.63 17.44 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 109.774 -0.454 . . . . 1.0 109.774 179.675 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 38.0 t -95.85 -18.28 20.48 Favored 'General case' 0 N--CA 1.483 1.184 0 CA-C-N 115.972 -0.558 . . . . 1.0 110.516 179.468 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 32.9 t -153.36 -164.63 1.95 Allowed 'General case' 0 N--CA 1.479 0.986 0 CA-C-N 116.246 -0.434 . . . . 1.0 111.089 -179.806 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -83.72 47.33 1.27 Allowed 'General case' 0 N--CA 1.477 0.919 0 CA-C-O 121.458 0.647 . . . . 1.0 110.234 -179.776 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 53.6 m -157.74 137.1 11.88 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-N 115.562 -0.745 . . . . 1.0 110.851 179.748 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.1 t -70.38 -32.09 69.62 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 115.939 -0.573 . . . . 1.0 110.448 179.701 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' SER . . . . . 0.45 ' C ' ' H ' ' A' ' 23' ' ' LYS . 51.1 m -70.81 -2.58 15.31 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 116.42 -0.354 . . . . 1.0 110.683 -179.78 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' SER . . . . . 0.535 ' O ' ' O ' ' A' ' 23' ' ' LYS . 59.8 p -76.71 21.07 0.21 Allowed 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 121.362 0.601 . . . . 1.0 110.563 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.535 ' O ' ' O ' ' A' ' 22' ' ' SER . 98.2 mttt 48.13 167.25 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.443 0 CA-C-N 115.653 -0.703 . . . . 1.0 111.565 -179.147 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.456 HG12 ' N ' ' A' ' 25' ' ' ILE . 25.9 t -89.56 168.92 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-O 121.563 0.697 . . . . 1.0 109.56 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.456 ' N ' HG12 ' A' ' 24' ' ' VAL . 43.5 pt -135.58 -22.64 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 CA-C-N 115.472 -0.785 . . . . 1.0 110.497 179.565 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.72 179.87 43.0 Favored Glycine 0 N--CA 1.462 0.419 0 N-CA-C 110.52 -1.032 . . . . 1.0 110.52 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 88.7 p -132.56 133.44 43.72 Favored 'General case' 0 N--CA 1.478 0.933 0 CA-C-O 121.282 0.563 . . . . 1.0 109.873 179.664 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -98.62 174.19 6.55 Favored 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 108.959 -0.756 . . . . 1.0 108.959 -179.468 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' SER . . . . . 0.533 ' O ' ' O ' ' A' ' 30' ' ' GLY . 42.0 t -79.16 137.19 37.35 Favored 'General case' 0 CA--C 1.515 -0.367 0 CA-C-N 115.964 -0.562 . . . . 1.0 109.901 -179.189 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.533 ' O ' ' O ' ' A' ' 29' ' ' SER . . . -13.24 -107.45 0.0 OUTLIER Glycine 0 N--CA 1.512 3.715 0 CA-C-O 119.473 -0.626 . . . . 1.0 113.017 179.82 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ASN . . . . . 0.511 ' HA ' ' H ' ' A' ' 6' ' ' VAL . 19.5 p-10 -77.73 79.22 4.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 117.569 0.684 . . . . 1.0 109.781 177.775 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 45.6 m -84.84 146.24 27.42 Favored 'General case' 0 N--CA 1.494 1.769 0 CA-C-N 115.961 -0.563 . . . . 1.0 109.82 179.293 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 55.8 mtpt -82.62 128.47 34.36 Favored 'General case' 0 N--CA 1.474 0.761 0 CA-C-N 116.035 -0.529 . . . . 1.0 110.116 179.157 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.9 m -144.48 127.0 10.72 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 CA-C-N 116.323 -0.399 . . . . 1.0 110.368 179.361 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 68.6 p -80.81 83.82 6.47 Favored 'General case' 0 N--CA 1.47 0.559 0 CA-C-O 121.289 0.566 . . . . 1.0 109.86 179.485 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.475 HG22 ' N ' ' A' ' 37' ' ' VAL . 81.3 mt -47.23 163.83 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.063 0 CA-C-N 115.641 -0.708 . . . . 1.0 110.54 179.787 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.475 ' N ' HG22 ' A' ' 36' ' ' ILE . 42.7 t -129.25 -94.18 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 N-CA-C 110.045 -0.354 . . . . 1.0 110.045 -179.229 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -102.12 -168.12 27.0 Favored Glycine 0 N--CA 1.474 1.227 0 N-CA-C 110.912 -0.875 . . . . 1.0 110.912 -179.568 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -130.29 140.68 50.65 Favored 'General case' 0 N--CA 1.485 1.275 0 CA-C-N 115.293 -0.453 . . . . 1.0 110.541 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 -153.21 114.02 4.09 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 116.084 -0.507 . . . . 1.0 110.207 -179.845 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 51.22 -116.4 4.54 Favored Glycine 0 CA--C 1.542 1.772 0 N-CA-C 111.634 -0.586 . . . . 1.0 111.634 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -117.41 25.07 10.7 Favored 'General case' 0 N--CA 1.488 1.453 0 C-N-CA 122.401 0.28 . . . . 1.0 110.429 179.493 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -145.64 157.08 44.01 Favored 'General case' 0 N--CA 1.48 1.074 0 CA-C-O 121.232 0.539 . . . . 1.0 110.405 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 13.8 p90 -141.72 176.18 9.12 Favored 'General case' 0 N--CA 1.482 1.131 0 CA-C-N 115.76 -0.654 . . . . 1.0 110.376 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 34.3 mtmm -97.06 149.35 22.05 Favored 'General case' 0 N--CA 1.479 0.987 0 CA-C-N 115.786 -0.643 . . . . 1.0 110.327 -179.117 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 26.3 pt -142.95 160.48 18.02 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 CA-C-O 121.949 0.88 . . . . 1.0 110.119 179.487 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -121.7 92.1 3.66 Favored 'General case' 0 N--CA 1.487 1.385 0 CA-C-N 115.084 -0.962 . . . . 1.0 109.608 -179.68 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 21.8 t80 -136.32 151.86 50.05 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-O 121.239 0.542 . . . . 1.0 110.398 179.82 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 46.9 mmtt 53.53 17.55 1.18 Allowed 'General case' 0 N--CA 1.479 1.02 0 CA-C-N 115.763 -0.653 . . . . 1.0 110.619 -179.586 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 72.81 -2.25 33.97 Favored Glycine 0 N--CA 1.467 0.713 0 N-CA-C 110.63 -0.988 . . . . 1.0 110.63 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 41.9 t -107.89 172.47 6.81 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 124.009 0.924 . . . . 1.0 110.489 -179.672 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 25.8 p-80 -106.77 142.26 36.69 Favored 'General case' 0 N--CA 1.482 1.125 0 CA-C-N 115.803 -0.635 . . . . 1.0 110.133 179.882 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -150.83 169.79 30.62 Favored Glycine 0 N--CA 1.472 1.08 0 N-CA-C 111.094 -0.802 . . . . 1.0 111.094 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 58.5 m-85 -133.53 145.81 50.47 Favored 'General case' 0 N--CA 1.48 1.04 0 CA-C-O 121.673 0.749 . . . . 1.0 110.33 179.655 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 3.5 m -146.16 147.98 17.63 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 CA-C-N 115.319 -0.855 . . . . 1.0 109.892 -179.7 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -66.44 147.21 53.62 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 115.204 -0.907 . . . . 1.0 110.477 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -82.4 -25.74 33.45 Favored 'General case' 0 N--CA 1.477 0.879 0 CA-C-N 116.166 -0.47 . . . . 1.0 110.44 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 4.2 tm-20 -56.68 -34.58 67.54 Favored 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 121.293 0.568 . . . . 1.0 110.738 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 26.1 m-85 -78.46 -4.92 50.87 Favored 'General case' 0 N--CA 1.483 1.188 0 CA-C-N 115.629 -0.714 . . . . 1.0 110.1 179.81 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 34.2 mm . . . . . 0 N--CA 1.487 1.393 0 CA-C-O 118.17 -0.919 . . . . 1.0 109.507 180.0 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.45 ' C ' ' H ' ' A' ' 3' ' ' THR . 28.4 ttt . . . . . 0 N--CA 1.499 2.011 0 CA-C-O 121.554 0.692 . . . . 1.0 109.297 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 24.3 pttm -77.44 26.81 0.16 Allowed 'General case' 0 N--CA 1.479 0.978 0 CA-C-N 115.45 -0.795 . . . . 1.0 110.716 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' THR . . . . . 0.45 ' H ' ' C ' ' A' ' 1' ' ' MET . 62.7 p -131.84 154.74 48.85 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-O 121.955 0.883 . . . . 1.0 109.84 -179.649 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -143.11 161.22 27.6 Favored Glycine 0 N--CA 1.461 0.341 0 N-CA-C 110.317 -1.113 . . . . 1.0 110.317 -179.663 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 74.1 mt -109.97 135.86 47.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 CA-C-O 121.691 0.758 . . . . 1.0 109.503 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 47.4 t -82.49 131.02 34.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.282 -0.872 . . . . 1.0 109.44 179.575 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 -60.09 109.64 1.02 Allowed 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 115.628 -0.715 . . . . 1.0 110.404 179.751 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 14.7 p -65.79 133.3 31.0 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 CA-C-N 116.028 -0.533 . . . . 1.0 110.234 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 88.0 p -170.51 -55.98 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 121.191 0.52 . . . . 1.0 110.138 179.599 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 68.5 m -148.79 -110.98 0.07 Allowed 'General case' 0 N--CA 1.477 0.891 0 CA-C-N 115.863 -0.608 . . . . 1.0 110.718 -179.471 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 39.7 t -135.29 142.95 45.97 Favored 'General case' 0 N--CA 1.473 0.713 0 CA-C-O 121.9 0.857 . . . . 1.0 110.51 -179.55 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -101.39 141.66 33.93 Favored 'General case' 0 N--CA 1.474 0.742 0 CA-C-O 122.21 1.005 . . . . 1.0 110.029 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 79.8 m-20 -93.13 123.17 36.21 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 114.708 -1.133 . . . . 1.0 109.523 -179.672 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 64.3 t -96.67 114.97 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 CA-C-N 115.603 -0.726 . . . . 1.0 109.089 -179.808 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -87.65 173.19 9.18 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-O 122.07 0.938 . . . . 1.0 109.585 179.095 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 88.8 p -97.52 -19.25 18.5 Favored 'General case' 0 N--CA 1.478 0.969 0 CA-C-N 114.974 -1.012 . . . . 1.0 110.292 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 88.9 p -149.41 -163.58 1.82 Allowed 'General case' 0 N--CA 1.475 0.823 0 CA-C-O 121.47 0.653 . . . . 1.0 110.824 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -101.3 53.61 0.83 Allowed 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 115.58 -0.736 . . . . 1.0 110.165 -179.79 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 46.4 t -138.89 137.34 36.42 Favored 'General case' 0 N--CA 1.479 1.023 0 CA-C-O 121.55 0.691 . . . . 1.0 110.744 179.655 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.2 t -67.42 -27.14 66.82 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 115.391 -0.822 . . . . 1.0 110.702 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 50.0 m -77.41 -7.51 56.24 Favored 'General case' 0 N--CA 1.469 0.508 0 CA-C-N 115.656 -0.702 . . . . 1.0 110.19 -179.854 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 34.8 t -65.77 124.89 23.65 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-O 120.987 0.422 . . . . 1.0 110.341 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -67.88 166.57 15.3 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.89 -0.595 . . . . 1.0 110.208 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 19.5 t -76.9 114.38 17.19 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.658 0 CA-C-O 121.662 0.744 . . . . 1.0 110.023 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 5.4 tt -96.88 -17.35 6.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.195 -0.911 . . . . 1.0 109.846 179.763 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -166.81 -162.12 17.62 Favored Glycine 0 N--CA 1.463 0.456 0 N-CA-C 110.721 -0.952 . . . . 1.0 110.721 -179.537 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 50.4 m -158.71 132.51 7.63 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.278 0.561 . . . . 1.0 109.936 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.2 tp -110.31 149.06 30.74 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-O 121.567 0.699 . . . . 1.0 109.907 179.614 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 45.7 p -91.15 159.89 15.85 Favored 'General case' 0 N--CA 1.469 0.483 0 CA-C-N 115.327 -0.851 . . . . 1.0 109.604 179.608 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -78.75 152.17 36.74 Favored Glycine 0 CA--C 1.529 0.934 0 N-CA-C 110.443 -1.063 . . . . 1.0 110.443 179.526 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 70.14 19.08 6.84 Favored 'General case' 0 N--CA 1.474 0.772 0 CA-C-O 120.887 0.375 . . . . 1.0 110.449 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 32.0 m -88.67 139.75 30.15 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-N 116.119 -0.491 . . . . 1.0 109.878 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 63.3 tttm -86.3 139.25 31.17 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.893 -0.594 . . . . 1.0 109.963 179.547 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 14.4 m -142.99 124.46 11.77 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.879 0 CA-C-N 115.687 -0.688 . . . . 1.0 110.2 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 62.1 p -79.89 87.76 5.32 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-O 121.355 0.598 . . . . 1.0 109.709 179.636 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.577 HG22 ' N ' ' A' ' 37' ' ' VAL . 63.0 mt -55.81 169.43 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.504 0 CA-C-O 121.66 0.743 . . . . 1.0 109.498 179.844 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.577 ' N ' HG22 ' A' ' 36' ' ' ILE . 0.2 OUTLIER -131.91 -96.0 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.055 0 CA-C-N 115.348 -0.842 . . . . 1.0 109.885 -179.156 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 38' ' ' GLY . . . . . 0.408 ' H ' HG23 ' A' ' 37' ' ' VAL . . . -99.4 -170.07 30.46 Favored Glycine 0 N--CA 1.465 0.62 0 N-CA-C 110.631 -0.987 . . . . 1.0 110.631 -179.566 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 13.5 mp0 -128.85 132.95 47.81 Favored 'General case' 0 N--CA 1.478 0.943 0 CA-C-N 114.651 -0.775 . . . . 1.0 110.224 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.41 ' O ' ' O ' ' A' ' 43' ' ' PHE . 44.3 tp10 -150.32 120.68 7.35 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-N 115.497 -0.774 . . . . 1.0 110.041 179.527 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 47.08 -122.65 7.17 Favored Glycine 0 CA--C 1.543 1.805 0 N-CA-C 111.509 -0.636 . . . . 1.0 111.509 179.779 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -114.03 22.32 14.0 Favored 'General case' 0 N--CA 1.481 1.106 0 C-N-CA 122.546 0.338 . . . . 1.0 110.251 178.862 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.41 ' O ' ' O ' ' A' ' 40' ' ' GLU . 77.7 m-85 -149.13 157.42 43.37 Favored 'General case' 0 N--CA 1.484 1.264 0 CA-C-O 121.6 0.714 . . . . 1.0 110.74 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' TYR . . . . . 0.458 ' N ' ' CD1' ' A' ' 44' ' ' TYR . 10.1 p90 -140.39 172.99 11.95 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 122.077 0.942 . . . . 1.0 109.939 -179.712 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -97.52 156.56 16.44 Favored 'General case' 0 N--CA 1.474 0.751 0 CA-C-N 114.905 -1.043 . . . . 1.0 109.97 -179.434 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 32.2 pt -147.41 161.7 7.9 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 CA-C-O 122.215 1.007 . . . . 1.0 109.884 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 18.6 mp0 -121.54 87.36 2.74 Favored 'General case' 0 N--CA 1.481 1.088 0 CA-C-N 114.748 -1.115 . . . . 1.0 109.844 -179.768 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -138.68 158.86 43.45 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-N 115.576 -0.738 . . . . 1.0 110.019 179.86 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' LYS . . . . . 0.404 ' C ' ' H ' ' A' ' 51' ' ' SER . 48.7 mtmt 52.92 18.47 1.08 Allowed 'General case' 0 CA--C 1.541 0.611 0 CA-C-N 115.626 -0.715 . . . . 1.0 110.811 179.801 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 67.97 -1.52 8.11 Favored Glycine 0 CA--C 1.532 1.1 0 N-CA-C 110.429 -1.068 . . . . 1.0 110.429 -179.181 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' SER . . . . . 0.404 ' H ' ' C ' ' A' ' 49' ' ' LYS . 97.6 p -116.12 171.96 7.47 Favored 'General case' 0 N--CA 1.484 1.265 0 CA-C-O 121.994 0.902 . . . . 1.0 110.317 -179.859 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 96.3 m-70 -101.75 146.12 28.2 Favored 'General case' 0 N--CA 1.478 0.932 0 CA-C-N 115.006 -0.997 . . . . 1.0 110.09 -179.828 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -152.9 168.32 31.78 Favored Glycine 0 CA--C 1.531 1.041 0 N-CA-C 110.673 -0.971 . . . . 1.0 110.673 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 66.2 m-85 -134.61 150.16 50.66 Favored 'General case' 0 N--CA 1.486 1.37 0 CA-C-O 121.018 0.437 . . . . 1.0 110.608 179.601 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -155.19 155.84 5.45 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 CA-C-N 115.967 -0.561 . . . . 1.0 110.348 -179.808 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.69 130.38 44.02 Favored 'General case' 0 CA--C 1.545 0.78 0 CA-C-O 122.173 0.987 . . . . 1.0 109.861 179.049 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.46 -35.1 17.23 Favored 'General case' 0 N--CA 1.483 1.191 0 CA-C-N 114.86 -1.064 . . . . 1.0 110.177 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -58.33 -30.39 66.66 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.656 0.741 . . . . 1.0 110.371 -179.674 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 1.2 t80 -52.52 -19.8 2.51 Favored 'General case' 0 CA--C 1.537 0.465 0 CA-C-N 115.362 -0.835 . . . . 1.0 110.792 -179.806 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 69.8 mt . . . . . 0 C--O 1.221 -0.436 0 CA-C-O 118.0 -1.0 . . . . 1.0 108.761 -179.834 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 28.0 ttt . . . . . 0 N--CA 1.492 1.63 0 N-CA-C 109.218 -0.66 . . . . 1.0 109.218 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 74.6 mmtt 51.76 92.09 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.593 0 CA-C-O 121.267 0.556 . . . . 1.0 110.753 179.466 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 69.8 p -131.55 158.59 40.55 Favored 'General case' 0 N--CA 1.472 0.659 0 CA-C-O 121.825 0.821 . . . . 1.0 110.136 -179.48 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -145.57 163.94 28.15 Favored Glycine 0 N--CA 1.468 0.812 0 N-CA-C 110.495 -1.042 . . . . 1.0 110.495 -179.556 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 3.7 mp -110.13 129.68 64.69 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 CA-C-O 121.287 0.565 . . . . 1.0 109.97 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 55.9 t -73.42 133.34 31.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.648 -0.706 . . . . 1.0 109.491 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ASN . . . . . 0.508 ' ND2' ' O ' ' A' ' 59' ' ' TYR . 8.1 m-20 -49.2 96.83 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.707 0 CA-C-N 115.768 -0.651 . . . . 1.0 110.694 179.604 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.5 t -63.37 -6.55 2.26 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.539 0 CA-C-N 115.749 -0.66 . . . . 1.0 110.008 -179.221 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.0 m -52.71 -49.87 64.5 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.087 -0.506 . . . . 1.0 110.69 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 93.0 p -149.96 169.37 21.33 Favored 'General case' 0 N--CA 1.472 0.652 0 CA-C-O 121.461 0.648 . . . . 1.0 110.524 179.385 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 89.1 p -78.93 150.34 32.11 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 115.523 -0.762 . . . . 1.0 109.707 -179.331 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.9 mp -118.96 145.48 45.76 Favored 'General case' 0 N--CA 1.49 1.543 0 CA-C-O 122.287 1.042 . . . . 1.0 110.08 -179.426 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 73.8 m-80 -96.49 146.62 24.64 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 114.701 -1.136 . . . . 1.0 110.003 179.693 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 22.4 t -94.57 104.78 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.936 0 CA-C-N 115.529 -0.76 . . . . 1.0 109.684 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 88.8 mtm180 -79.41 135.64 36.74 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.341 0.591 . . . . 1.0 109.761 179.821 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 38.9 t -63.43 -27.17 69.1 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 115.581 -0.736 . . . . 1.0 110.442 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 47.2 t -144.85 -176.66 5.16 Favored 'General case' 0 N--CA 1.479 0.998 0 CA-C-N 115.97 -0.559 . . . . 1.0 110.927 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.425 ' HB2' ' CD1' ' A' ' 43' ' ' PHE . . . -81.83 57.17 3.33 Favored 'General case' 0 N--CA 1.476 0.843 0 CA-C-N 115.774 -0.648 . . . . 1.0 110.235 -179.898 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 47.3 t -156.92 137.67 13.29 Favored 'General case' 0 N--CA 1.472 0.64 0 CA-C-O 121.203 0.525 . . . . 1.0 110.686 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.8 t -67.12 -32.97 74.46 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 115.756 -0.656 . . . . 1.0 110.629 179.62 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 89.4 p -69.35 -4.31 17.72 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 116.029 -0.532 . . . . 1.0 110.303 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 90.2 p -60.47 -172.02 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.539 0 CA-C-O 120.995 0.426 . . . . 1.0 110.25 179.53 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 5.5 mptt -116.57 148.16 41.15 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-O 121.234 0.54 . . . . 1.0 110.749 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 20.1 t -82.16 115.46 24.73 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 115.778 -0.646 . . . . 1.0 109.537 179.79 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 34.2 pt -96.43 -16.79 7.09 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.896 0 CA-C-N 115.706 -0.679 . . . . 1.0 109.891 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 179.53 165.77 34.17 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.71 -0.956 . . . . 1.0 110.71 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 50.7 m -117.54 135.55 53.87 Favored 'General case' 0 N--CA 1.484 1.268 0 CA-C-O 121.289 0.566 . . . . 1.0 109.918 179.61 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 3.5 tp -100.04 159.02 15.42 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-O 121.875 0.845 . . . . 1.0 109.141 -179.414 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 49.1 m -101.48 145.95 28.29 Favored 'General case' 0 N--CA 1.473 0.677 0 CA-C-N 115.208 -0.906 . . . . 1.0 110.106 -179.132 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -73.85 151.86 44.93 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.353 -1.099 . . . . 1.0 110.353 179.285 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 12.8 t30 74.78 13.77 3.43 Favored 'General case' 0 N--CA 1.482 1.159 0 CA-C-O 120.525 0.202 . . . . 1.0 110.518 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 89.0 m -83.05 137.15 34.23 Favored 'General case' 0 N--CA 1.477 0.912 0 CA-C-O 121.12 0.486 . . . . 1.0 110.32 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -92.81 144.04 25.68 Favored 'General case' 0 N--CA 1.473 0.721 0 CA-C-N 115.806 -0.634 . . . . 1.0 109.989 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.4 p -154.77 139.81 10.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.748 -0.66 . . . . 1.0 109.91 179.872 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 68.9 p -83.4 83.36 7.9 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.877 -0.601 . . . . 1.0 109.637 179.217 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.539 HG22 ' N ' ' A' ' 37' ' ' VAL . 74.5 mt -48.49 167.0 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 CA-C-N 115.818 -0.628 . . . . 1.0 110.066 179.801 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.539 ' N ' HG22 ' A' ' 36' ' ' ILE . 40.8 t -128.07 -91.86 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 CA-C-N 116.22 -0.445 . . . . 1.0 110.087 -179.61 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -118.03 -155.54 10.06 Favored Glycine 0 N--CA 1.474 1.215 0 N-CA-C 110.863 -0.895 . . . . 1.0 110.863 -179.471 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -142.19 144.71 33.54 Favored 'General case' 0 N--CA 1.478 0.971 0 CA-C-N 115.059 -0.57 . . . . 1.0 110.281 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 38.3 tp10 -147.36 122.39 10.09 Favored 'General case' 0 N--CA 1.473 0.713 0 CA-C-N 115.74 -0.664 . . . . 1.0 109.986 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 54.71 -129.43 44.63 Favored Glycine 0 CA--C 1.53 0.995 0 N-CA-C 111.398 -0.681 . . . . 1.0 111.398 179.595 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -100.18 33.92 2.5 Favored 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 110.068 -0.345 . . . . 1.0 110.068 179.406 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.425 ' CD1' ' HB2' ' A' ' 18' ' ' ALA . 26.9 p90 -159.04 168.96 25.35 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-O 122.152 0.977 . . . . 1.0 110.083 179.321 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' TYR . . . . . 0.483 ' N ' ' CD1' ' A' ' 44' ' ' TYR . 3.3 p90 -129.63 163.92 25.01 Favored 'General case' 0 N--CA 1.481 1.107 0 CA-C-N 114.79 -1.095 . . . . 1.0 110.448 179.779 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 62.8 tttp -86.88 142.31 28.13 Favored 'General case' 0 N--CA 1.473 0.717 0 CA-C-N 115.341 -0.845 . . . . 1.0 109.771 -179.049 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 19.7 pt -141.32 156.51 21.54 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-O 122.083 0.944 . . . . 1.0 110.22 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -124.88 94.08 4.08 Favored 'General case' 0 N--CA 1.48 1.053 0 CA-C-N 114.844 -1.071 . . . . 1.0 109.971 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 22.8 t80 -128.47 147.5 50.67 Favored 'General case' 0 N--CA 1.476 0.875 0 CA-C-N 115.974 -0.557 . . . . 1.0 110.058 179.517 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 46.4 mtpt 54.11 17.56 1.47 Allowed 'General case' 0 CA--C 1.547 0.832 0 CA-C-N 115.908 -0.587 . . . . 1.0 110.497 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 72.18 1.78 51.01 Favored Glycine 0 N--CA 1.468 0.805 0 N-CA-C 110.6 -1.0 . . . . 1.0 110.6 -179.489 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 47.4 t -104.99 171.13 7.48 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 123.517 0.727 . . . . 1.0 110.2 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 49.4 p-80 -103.67 138.5 40.23 Favored 'General case' 0 N--CA 1.482 1.137 0 CA-C-N 115.618 -0.719 . . . . 1.0 110.484 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -150.75 166.76 30.36 Favored Glycine 0 N--CA 1.472 1.058 0 N-CA-C 110.782 -0.927 . . . . 1.0 110.782 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 33.4 m-85 -135.5 152.16 51.06 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-O 121.539 0.685 . . . . 1.0 110.194 179.456 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -150.39 151.16 12.91 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.953 0 CA-C-N 115.455 -0.793 . . . . 1.0 109.768 -179.089 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.56 125.64 24.61 Favored 'General case' 0 CA--C 1.54 0.561 0 CA-C-N 115.222 -0.899 . . . . 1.0 110.2 179.405 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 7.7 pttm -78.55 -31.18 47.32 Favored 'General case' 0 N--CA 1.473 0.681 0 CA-C-N 115.259 -0.882 . . . . 1.0 110.183 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -55.57 -35.45 65.76 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.061 -0.518 . . . . 1.0 110.401 -179.14 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' TYR . . . . . 0.508 ' O ' ' ND2' ' A' ' 7' ' ' ASN . 10.7 m-85 -60.47 -42.01 95.36 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 115.866 -0.606 . . . . 1.0 109.868 179.486 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 65.6 mt . . . . . 0 N--CA 1.476 0.831 0 CA-C-O 118.199 -0.905 . . . . 1.0 109.268 -179.359 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 61.2 tttp . . . . . 0 CA--C 1.531 0.238 0 CA-C-O 121.141 0.496 . . . . 1.0 110.131 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 65.8 p -96.03 162.69 13.44 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.953 0.883 . . . . 1.0 109.759 179.738 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -101.6 155.89 18.89 Favored Glycine 0 N--CA 1.47 0.961 0 N-CA-C 110.454 -1.058 . . . . 1.0 110.454 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 69.0 mt -111.55 128.09 68.29 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.088 0 CA-C-O 121.502 0.668 . . . . 1.0 109.559 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 24.4 t -68.48 132.05 33.13 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 CA-C-N 115.571 -0.741 . . . . 1.0 109.883 179.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . 0.418 ' O ' ' N ' ' A' ' 9' ' ' SER . 10.5 p-10 -55.77 109.18 0.53 Allowed 'General case' 0 CA--C 1.54 0.572 0 CA-C-N 116.112 -0.494 . . . . 1.0 110.411 179.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 15.1 t -66.4 72.28 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-N 116.155 -0.475 . . . . 1.0 110.207 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . 0.418 ' N ' ' O ' ' A' ' 7' ' ' ASN . 30.4 t -85.39 -104.59 0.06 Allowed 'General case' 0 CA--C 1.54 0.564 0 CA-C-N 115.92 -0.582 . . . . 1.0 109.916 179.798 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 97.0 p -157.29 -28.02 0.09 Allowed 'General case' 0 N--CA 1.478 0.967 0 CA-C-O 121.471 0.653 . . . . 1.0 111.11 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 44.4 t -153.87 145.31 23.13 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 115.539 -0.755 . . . . 1.0 110.703 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.424 HD13 ' N ' ' A' ' 13' ' ' ASN . 0.2 OUTLIER -155.16 121.55 5.28 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 120.773 -0.371 . . . . 1.0 110.536 178.319 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . 0.424 ' N ' HD13 ' A' ' 12' ' ' LEU . 74.7 m-20 -89.23 134.09 34.18 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 121.856 0.836 . . . . 1.0 109.809 179.453 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 33.9 t -103.84 128.36 57.18 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 CA-C-N 115.154 -0.93 . . . . 1.0 109.559 179.71 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 83.1 mtt-85 -97.43 179.75 4.76 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-O 121.56 0.695 . . . . 1.0 110.046 179.426 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.4 p -104.86 -7.15 19.58 Favored 'General case' 0 N--CA 1.484 1.238 0 CA-C-N 115.373 -0.83 . . . . 1.0 110.36 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.447 ' C ' ' H ' ' A' ' 19' ' ' SER . 42.0 t -170.7 178.22 3.64 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-O 121.264 0.554 . . . . 1.0 110.745 -179.772 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -72.97 40.4 0.09 Allowed 'General case' 0 N--CA 1.475 0.793 0 CA-C-N 115.82 -0.627 . . . . 1.0 110.664 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.447 ' H ' ' C ' ' A' ' 17' ' ' SER . 78.8 p -137.49 136.82 38.06 Favored 'General case' 0 N--CA 1.48 1.033 0 CA-C-O 121.52 0.676 . . . . 1.0 110.403 179.871 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 80.4 p -73.71 -27.98 61.48 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-N 115.427 -0.806 . . . . 1.0 110.21 179.784 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 97.2 p -65.34 -21.32 66.68 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 116.335 -0.393 . . . . 1.0 110.242 -179.541 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 37.6 m -55.49 -29.36 58.66 Favored 'General case' 0 N--CA 1.472 0.639 0 CA-C-O 120.988 0.423 . . . . 1.0 110.284 179.138 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 25.5 tttm 71.14 -177.2 0.2 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.933 -0.576 . . . . 1.0 110.018 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 13.2 t -79.57 161.06 4.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 122.063 0.935 . . . . 1.0 109.512 179.335 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 35.0 pt -148.82 -22.43 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 CA-C-N 114.858 -1.065 . . . . 1.0 110.414 -179.766 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -173.52 164.62 36.33 Favored Glycine 0 CA--C 1.52 0.376 0 N-CA-C 110.673 -0.971 . . . . 1.0 110.673 -179.752 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 98.1 p -118.62 133.11 56.1 Favored 'General case' 0 N--CA 1.48 1.053 0 CA-C-O 121.91 0.862 . . . . 1.0 110.06 179.562 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.2 tp -101.6 155.48 18.07 Favored 'General case' 0 N--CA 1.473 0.725 0 CA-C-N 115.113 -0.948 . . . . 1.0 109.649 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 57.6 m -93.2 143.06 26.62 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.144 -0.934 . . . . 1.0 109.919 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -74.83 155.65 48.37 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.149 -1.18 . . . . 1.0 110.149 179.442 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 69.67 16.84 7.91 Favored 'General case' 0 N--CA 1.475 0.784 0 CA-C-O 120.792 0.329 . . . . 1.0 110.381 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 83.3 m -88.06 141.95 28.17 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-O 121.279 0.562 . . . . 1.0 109.957 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 37.9 ttpt -83.15 134.6 34.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.712 0.768 . . . . 1.0 110.029 179.555 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 5.2 m -140.96 123.42 15.24 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.575 0 CA-C-N 115.316 -0.856 . . . . 1.0 110.136 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.43 ' O ' ' C ' ' A' ' 36' ' ' ILE . 31.2 m -84.31 87.62 7.21 Favored 'General case' 0 N--CA 1.467 0.384 0 N-CA-C 109.661 -0.496 . . . . 1.0 109.661 179.117 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.614 HD12 ' H ' ' A' ' 36' ' ' ILE . 1.7 mp -34.49 145.66 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 CA-C-N 116.067 -0.515 . . . . 1.0 110.541 179.196 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -154.3 67.54 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 CA-C-N 115.974 -0.557 . . . . 1.0 109.829 -178.563 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.05 167.89 34.61 Favored Glycine 0 CA--C 1.503 -0.69 0 N-CA-C 110.567 -1.013 . . . . 1.0 110.567 178.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.3 pp20? -153.73 156.61 38.1 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.216 -0.492 . . . . 1.0 110.669 -178.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -153.61 127.61 8.96 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 116.022 -0.536 . . . . 1.0 110.505 179.229 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 59.54 -152.87 33.7 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.358 -0.697 . . . . 1.0 111.358 179.602 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -77.47 38.87 0.25 Allowed 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 109.855 -0.424 . . . . 1.0 109.855 179.443 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 -151.37 159.14 44.42 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-O 121.804 0.812 . . . . 1.0 110.477 -179.769 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 1.3 m-85 -118.86 157.3 27.9 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 122.199 0.999 . . . . 1.0 110.238 179.668 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 84.4 tttt -99.81 144.33 29.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 114.854 -1.067 . . . . 1.0 109.854 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 28.8 pt -149.37 172.24 1.66 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.241 -0.891 . . . . 1.0 109.952 -179.576 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 77.4 tt0 -139.86 105.13 5.04 Favored 'General case' 0 N--CA 1.472 0.673 0 CA-C-N 115.143 -0.935 . . . . 1.0 110.333 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 27.1 t80 -139.7 163.71 31.87 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 115.592 -0.731 . . . . 1.0 110.187 179.269 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . 0.414 ' C ' ' H ' ' A' ' 51' ' ' SER . 18.5 mmtm 51.77 24.87 2.64 Favored 'General case' 0 CA--C 1.544 0.741 0 CA-C-N 115.57 -0.741 . . . . 1.0 111.06 179.623 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 74.0 -8.89 10.3 Favored Glycine 0 CA--C 1.528 0.883 0 N-CA-C 110.147 -1.181 . . . . 1.0 110.147 -179.623 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . 0.414 ' H ' ' C ' ' A' ' 49' ' ' LYS . 50.5 m -108.82 174.02 6.06 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-O 122.07 0.938 . . . . 1.0 110.074 179.783 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 32.7 p80 -131.01 135.12 47.32 Favored 'General case' 0 N--CA 1.48 1.044 0 CA-C-N 114.971 -1.013 . . . . 1.0 110.331 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.03 154.55 25.98 Favored Glycine 0 N--CA 1.47 0.944 0 N-CA-C 110.652 -0.979 . . . . 1.0 110.652 179.537 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 55.6 m-85 -90.76 145.09 25.08 Favored 'General case' 0 N--CA 1.472 0.651 0 CA-C-O 121.485 0.66 . . . . 1.0 109.731 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 17.1 t -141.85 145.78 23.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 CA-C-N 115.582 -0.736 . . . . 1.0 110.365 -179.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.91 138.38 58.53 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.573 -0.74 . . . . 1.0 109.967 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 12.5 pttp -89.86 -25.13 21.18 Favored 'General case' 0 N--CA 1.475 0.809 0 CA-C-N 115.541 -0.754 . . . . 1.0 110.183 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 44.7 tp10 -65.95 -37.72 86.75 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.465 0.65 . . . . 1.0 110.509 -178.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 23.0 m-85 -68.89 -31.88 71.13 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 115.527 -0.76 . . . . 1.0 110.092 179.82 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 72.8 mt . . . . . 0 N--CA 1.467 0.42 0 CA-C-O 118.138 -0.934 . . . . 1.0 109.193 -179.486 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 97.2 mttt . . . . . 0 N--CA 1.472 0.628 0 CA-C-O 121.512 0.672 . . . . 1.0 110.591 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 3.2 p -132.8 153.5 51.2 Favored 'General case' 0 N--CA 1.478 0.946 0 CA-C-N 115.469 -0.787 . . . . 1.0 110.166 -179.29 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -140.71 160.78 26.63 Favored Glycine 0 N--CA 1.468 0.797 0 N-CA-C 110.658 -0.977 . . . . 1.0 110.658 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 12.5 pt -106.01 135.96 42.25 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 CA-C-O 121.287 0.565 . . . . 1.0 109.737 179.542 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.485 ' O ' ' N ' ' A' ' 8' ' ' VAL . 37.7 t -53.72 111.69 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 CA-C-N 115.62 -0.718 . . . . 1.0 109.926 -179.751 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 4.7 m120 -56.31 83.42 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 115.724 -0.671 . . . . 1.0 110.593 179.601 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.485 ' N ' ' O ' ' A' ' 6' ' ' VAL . 3.2 t 47.71 -126.25 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.554 1.134 0 CA-C-N 115.579 -0.737 . . . . 1.0 110.199 -179.791 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . 0.474 ' O ' ' O ' ' A' ' 8' ' ' VAL . 19.3 m 57.78 136.69 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 115.687 -0.688 . . . . 1.0 110.72 179.659 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 48.9 m -54.41 -65.73 0.52 Allowed 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 121.022 0.439 . . . . 1.0 110.652 -179.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 65.7 m -148.72 154.51 39.72 Favored 'General case' 0 N--CA 1.471 0.621 0 CA-C-O 121.798 0.809 . . . . 1.0 110.505 179.599 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -102.21 142.68 33.06 Favored 'General case' 0 N--CA 1.485 1.301 0 CA-C-N 115.233 -0.894 . . . . 1.0 109.977 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -85.18 99.53 11.14 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.072 -0.967 . . . . 1.0 109.477 -179.492 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 17.6 m -80.66 135.5 25.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 108.686 -0.857 . . . . 1.0 108.686 -179.458 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 67.2 mtm180 -117.85 -176.48 3.05 Favored 'General case' 0 N--CA 1.476 0.852 0 CA-C-N 115.13 -0.941 . . . . 1.0 110.234 -179.247 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 67.0 p -89.88 -20.61 23.19 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 115.333 -0.849 . . . . 1.0 110.519 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.645 ' C ' ' H ' ' A' ' 19' ' ' SER . 60.9 p -176.28 -173.17 0.53 Allowed 'General case' 0 N--CA 1.473 0.718 0 CA-C-O 121.681 0.753 . . . . 1.0 110.414 -179.649 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.81 17.24 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.375 0 CA-C-N 115.343 -0.844 . . . . 1.0 111.586 178.654 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . 0.645 ' H ' ' C ' ' A' ' 17' ' ' SER . 70.0 m -100.87 97.83 8.39 Favored 'General case' 0 N--CA 1.48 1.038 0 CA-C-N 115.352 -0.84 . . . . 1.0 110.169 179.533 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.9 m -64.37 -4.29 3.72 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-N 115.685 -0.689 . . . . 1.0 110.15 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 85.7 p -97.89 -3.53 38.39 Favored 'General case' 0 N--CA 1.473 0.699 0 CA-C-N 116.001 -0.545 . . . . 1.0 110.719 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 78.1 p -77.36 -4.96 47.81 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 110.022 -0.362 . . . . 1.0 110.022 179.331 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 33.7 tttt 66.05 -163.27 0.24 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.094 0.473 . . . . 1.0 110.167 179.606 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 24.8 t -94.22 158.16 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 CA-C-O 122.193 0.997 . . . . 1.0 109.28 179.753 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 47.7 pt -137.67 -20.58 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.005 0 CA-C-N 114.852 -1.067 . . . . 1.0 110.496 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . 0.471 ' CA ' ' HZ1' ' A' ' 49' ' ' LYS . . . -158.44 -153.89 6.95 Favored Glycine 0 N--CA 1.466 0.64 0 N-CA-C 110.689 -0.964 . . . . 1.0 110.689 -179.441 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . 0.681 ' H ' ' HZ3' ' A' ' 49' ' ' LYS . 93.2 p -159.17 148.65 18.69 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 121.322 0.582 . . . . 1.0 110.372 179.644 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.6 tp -122.3 154.43 37.6 Favored 'General case' 0 N--CA 1.481 1.106 0 CA-C-O 121.624 0.726 . . . . 1.0 110.311 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 90.9 p -103.33 159.92 15.14 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 115.39 -0.823 . . . . 1.0 110.25 179.749 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -79.65 168.11 52.31 Favored Glycine 0 N--CA 1.476 1.352 0 N-CA-C 110.537 -1.025 . . . . 1.0 110.537 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 66.2 m-20 56.32 20.87 4.94 Favored 'General case' 0 N--CA 1.477 0.877 0 CA-C-O 120.929 0.395 . . . . 1.0 110.759 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 29.6 m -89.94 150.42 22.17 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-O 121.401 0.619 . . . . 1.0 109.828 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 50.9 tttp -103.25 150.6 23.57 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 115.548 -0.751 . . . . 1.0 110.275 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.4 p -157.36 145.56 10.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.687 -0.688 . . . . 1.0 109.858 179.553 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 90.4 m -106.09 106.33 16.79 Favored 'General case' 0 N--CA 1.481 1.095 0 N-CA-C 109.428 -0.582 . . . . 1.0 109.428 178.544 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.459 ' O ' HG13 ' A' ' 37' ' ' VAL . 11.7 mm -42.35 134.86 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 CA-C-N 116.502 -0.317 . . . . 1.0 111.2 179.283 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.459 HG13 ' O ' ' A' ' 36' ' ' ILE . 3.2 m -159.51 90.24 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.069 0 CA-C-O 121.986 0.898 . . . . 1.0 110.518 -178.052 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 109.63 115.06 3.7 Favored Glycine 0 N--CA 1.481 1.657 0 CA-C-N 115.114 -0.948 . . . . 1.0 110.824 179.178 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.546 ' CD ' ' H ' ' A' ' 39' ' ' GLU . 0.5 OUTLIER -105.13 132.62 51.12 Favored 'General case' 0 N--CA 1.48 1.033 0 N-CA-C 109.245 -0.65 . . . . 1.0 109.245 -178.817 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 79.8 tt0 -151.31 102.85 2.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.837 -0.62 . . . . 1.0 109.883 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.432 ' C ' ' H ' ' A' ' 43' ' ' PHE . . . 57.12 -149.21 31.39 Favored Glycine 0 CA--C 1.533 1.16 0 N-CA-C 111.226 -0.749 . . . . 1.0 111.226 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -74.56 17.56 0.2 Allowed 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 120.926 -0.31 . . . . 1.0 110.455 179.082 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.432 ' H ' ' C ' ' A' ' 41' ' ' GLY . 38.3 m-85 -133.56 158.13 43.95 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-O 121.853 0.835 . . . . 1.0 110.215 -179.53 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' TYR . . . . . 0.441 ' CD2' ' CG2' ' A' ' 36' ' ' ILE . 2.8 m-85 -127.04 165.22 19.88 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 122.621 1.2 . . . . 1.0 109.839 179.618 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 23.9 ttpp -107.96 129.58 55.1 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 114.465 -1.243 . . . . 1.0 110.004 -179.736 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 45.5 pt -122.18 170.05 12.81 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-O 122.302 1.048 . . . . 1.0 110.045 179.458 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -131.1 102.2 5.91 Favored 'General case' 0 N--CA 1.482 1.164 0 CA-C-N 114.702 -1.135 . . . . 1.0 109.778 -179.441 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -138.93 160.35 39.95 Favored 'General case' 0 N--CA 1.47 0.575 0 CA-C-O 121.432 0.634 . . . . 1.0 109.829 179.561 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . 0.681 ' HZ3' ' H ' ' A' ' 27' ' ' SER . 43.3 mtmt 50.35 26.65 2.36 Favored 'General case' 0 CA--C 1.546 0.811 0 CA-C-N 115.595 -0.73 . . . . 1.0 111.369 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 67.07 6.74 40.19 Favored Glycine 0 N--CA 1.474 1.227 0 N-CA-C 110.465 -1.054 . . . . 1.0 110.465 -179.418 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 85.7 p -117.35 175.45 5.61 Favored 'General case' 0 N--CA 1.485 1.303 0 C-N-CA 124.228 1.011 . . . . 1.0 110.506 -179.631 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 27.3 p-80 -114.29 135.51 53.99 Favored 'General case' 0 N--CA 1.486 1.368 0 CA-C-N 115.18 -0.918 . . . . 1.0 110.331 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -140.08 166.08 25.8 Favored Glycine 0 N--CA 1.472 1.059 0 N-CA-C 110.988 -0.845 . . . . 1.0 110.988 179.724 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 58.2 m-85 -130.35 136.5 49.17 Favored 'General case' 0 N--CA 1.483 1.196 0 CA-C-O 121.904 0.859 . . . . 1.0 110.11 179.692 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 26.0 t -143.28 150.2 17.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 CA-C-N 115.145 -0.934 . . . . 1.0 110.175 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -67.64 127.49 32.97 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-N 115.481 -0.781 . . . . 1.0 109.812 179.424 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 11.5 pttm -74.91 -20.81 59.54 Favored 'General case' 0 N--CA 1.476 0.853 0 CA-C-N 115.251 -0.886 . . . . 1.0 110.095 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 76.5 tt0 -65.41 -37.47 87.06 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 121.461 0.648 . . . . 1.0 110.399 -178.817 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 27.3 m-85 -74.08 -33.61 63.7 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 115.609 -0.723 . . . . 1.0 109.897 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 62.6 mt . . . . . 0 N--CA 1.471 0.613 0 CA-C-O 118.096 -0.954 . . . . 1.0 109.051 -179.033 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 55.1 mtpt . . . . . 0 N--CA 1.468 0.436 0 CA-C-O 121.382 0.61 . . . . 1.0 110.434 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 46.0 p -137.11 160.43 38.99 Favored 'General case' 0 N--CA 1.473 0.709 0 CA-C-O 121.719 0.771 . . . . 1.0 110.458 -179.681 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -138.01 155.51 23.33 Favored Glycine 0 N--CA 1.471 0.995 0 N-CA-C 110.659 -0.977 . . . . 1.0 110.659 -179.861 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 15.6 pt -98.24 137.26 26.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 CA-C-O 121.676 0.75 . . . . 1.0 109.209 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.571 ' O ' ' C ' ' A' ' 7' ' ' ASN . 22.0 t -83.01 142.98 12.83 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.46 0 CA-C-N 115.366 -0.834 . . . . 1.0 109.566 -179.827 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . 0.571 ' C ' ' O ' ' A' ' 6' ' ' VAL . 42.9 t30 8.72 -109.27 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.125 0 CA-C-N 116.243 -0.435 . . . . 1.0 111.859 -179.602 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 22.0 t -143.02 -52.25 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.292 0 CA-C-O 120.715 0.293 . . . . 1.0 110.434 177.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 40.7 t -170.14 77.75 0.09 Allowed 'General case' 0 N--CA 1.472 0.641 0 CA-C-O 120.855 0.359 . . . . 1.0 110.618 -179.544 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 49.3 m -160.52 168.46 25.01 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-N 116.052 -0.522 . . . . 1.0 110.679 -179.803 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 41.8 t -90.38 130.82 36.42 Favored 'General case' 0 N--CA 1.473 0.682 0 CA-C-O 121.304 0.573 . . . . 1.0 110.104 179.585 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 9.8 mp -100.94 164.35 11.86 Favored 'General case' 0 N--CA 1.479 1.002 0 CA-C-O 122.73 1.252 . . . . 1.0 109.41 179.409 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 84.9 m-20 -93.4 118.24 31.06 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-N 114.253 -1.339 . . . . 1.0 109.989 -179.614 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 20.6 t -101.9 107.58 21.94 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.308 0 N-CA-C 110.173 -0.306 . . . . 1.0 110.173 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 31.9 mtm180 -82.42 -173.14 4.41 Favored 'General case' 0 N--CA 1.478 0.971 0 CA-C-O 121.297 0.57 . . . . 1.0 110.345 179.441 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 17.6 t -95.17 -23.69 17.17 Favored 'General case' 0 N--CA 1.48 1.057 0 CA-C-N 115.675 -0.693 . . . . 1.0 111.085 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.401 ' O ' ' HB3' ' A' ' 18' ' ' ALA . 28.7 t 175.86 38.85 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.645 0 CA-C-O 121.182 0.515 . . . . 1.0 111.214 -179.717 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.401 ' HB3' ' O ' ' A' ' 17' ' ' SER . . . 76.07 45.39 0.12 Allowed 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 115.834 -0.621 . . . . 1.0 110.55 -179.782 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 70.5 m -129.83 117.28 19.95 Favored 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 115.84 -0.618 . . . . 1.0 110.795 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 24.9 m -64.06 -29.12 70.28 Favored 'General case' 0 N--CA 1.475 0.794 0 CA-C-N 116.067 -0.515 . . . . 1.0 109.995 179.347 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 55.0 m -68.45 -22.38 64.58 Favored 'General case' 0 CA--C 1.537 0.442 0 CA-C-N 116.121 -0.49 . . . . 1.0 110.508 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 45.9 t -70.18 -39.07 75.48 Favored 'General case' 0 N--CA 1.475 0.8 0 CA-C-O 121.429 0.633 . . . . 1.0 110.528 179.128 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.451 ' HG2' ' H ' ' A' ' 24' ' ' VAL . 5.0 ttmm 80.43 -170.58 0.04 OUTLIER 'General case' 0 N--CA 1.485 1.305 0 CA-C-N 115.612 -0.722 . . . . 1.0 109.703 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.451 ' H ' ' HG2' ' A' ' 23' ' ' LYS . 24.9 t -83.76 105.51 13.35 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.494 0 CA-C-N 115.852 -0.613 . . . . 1.0 109.873 179.746 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 40.0 pt -94.12 -19.61 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 CA-C-N 115.789 -0.641 . . . . 1.0 110.489 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -145.22 -163.95 10.42 Favored Glycine 0 N--CA 1.478 1.492 0 N-CA-C 110.99 -0.844 . . . . 1.0 110.99 -179.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 45.4 t -160.87 130.24 4.84 Favored 'General case' 0 N--CA 1.47 0.549 0 C-N-CA 120.65 -0.42 . . . . 1.0 109.958 179.594 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.9 tp -109.52 153.32 24.27 Favored 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 121.342 0.591 . . . . 1.0 109.947 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 61.4 m -91.3 149.93 21.53 Favored 'General case' 0 N--CA 1.472 0.628 0 CA-C-N 115.696 -0.684 . . . . 1.0 110.037 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -74.7 148.68 38.79 Favored Glycine 0 CA--C 1.528 0.849 0 N-CA-C 110.481 -1.048 . . . . 1.0 110.481 179.612 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 12.1 t-20 64.82 41.06 5.18 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-O 121.024 0.44 . . . . 1.0 110.52 -179.763 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 34.7 m -106.96 127.43 53.44 Favored 'General case' 0 N--CA 1.489 1.484 0 CA-C-N 115.95 -0.568 . . . . 1.0 110.356 179.554 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -76.68 147.05 37.71 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-O 121.231 0.538 . . . . 1.0 109.822 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.3 p -157.28 148.08 10.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.706 -0.679 . . . . 1.0 110.35 -179.421 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 68.4 p -86.06 84.28 7.55 Favored 'General case' 0 N--CA 1.473 0.689 0 CA-C-N 116.111 -0.495 . . . . 1.0 110.031 179.228 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.577 HG22 ' N ' ' A' ' 37' ' ' VAL . 69.4 mt -50.53 171.57 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 CA-C-N 116.37 -0.377 . . . . 1.0 110.216 -179.862 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.577 ' N ' HG22 ' A' ' 36' ' ' ILE . 39.1 t -139.29 -92.42 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.298 0 CA-C-N 116.547 -0.297 . . . . 1.0 110.668 -179.482 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -118.45 -172.58 15.6 Favored Glycine 0 N--CA 1.487 2.04 0 N-CA-C 111.052 -0.819 . . . . 1.0 111.052 -179.172 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -113.86 111.84 22.38 Favored 'General case' 0 N--CA 1.483 1.19 0 CA-C-O 123.331 1.539 . . . . 1.0 109.623 179.359 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.497 ' N ' ' O ' ' A' ' 43' ' ' PHE . 3.1 tm-20 -104.07 96.41 6.64 Favored 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 113.676 -1.602 . . . . 1.0 109.214 179.026 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.423 ' O ' ' HB3' ' A' ' 42' ' ' ALA . . . 30.61 56.31 0.25 Allowed Glycine 0 N--CA 1.503 3.11 0 CA-C-N 114.806 -1.088 . . . . 1.0 113.141 179.64 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . 0.423 ' HB3' ' O ' ' A' ' 41' ' ' GLY . . . 76.46 30.41 0.65 Allowed 'General case' 0 N--CA 1.489 1.494 0 CA-C-N 115.18 -0.51 . . . . 1.0 111.188 -178.438 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.497 ' O ' ' N ' ' A' ' 40' ' ' GLU . 75.1 m-85 -153.86 159.41 41.79 Favored 'General case' 0 N--CA 1.496 1.864 0 CA-C-N 116.194 -0.457 . . . . 1.0 111.005 179.774 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' TYR . . . . . 0.428 ' CD1' ' N ' ' A' ' 44' ' ' TYR . 15.2 p90 -143.89 165.98 26.21 Favored 'General case' 0 N--CA 1.488 1.435 0 CA-C-O 120.893 0.377 . . . . 1.0 110.407 179.398 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -88.2 159.52 18.12 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 109.551 -0.537 . . . . 1.0 109.551 -179.433 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 38.4 pt -146.97 154.38 11.91 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 CA-C-N 115.902 -0.59 . . . . 1.0 110.308 -179.367 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 72.7 mt-10 -110.33 84.28 1.9 Allowed 'General case' 0 N--CA 1.479 1.009 0 CA-C-N 115.911 -0.586 . . . . 1.0 109.67 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 7.7 t80 -119.56 137.04 54.09 Favored 'General case' 0 N--CA 1.486 1.352 0 CA-C-N 116.036 -0.529 . . . . 1.0 110.149 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 96.2 mttt 47.49 27.47 0.97 Allowed 'General case' 0 N--CA 1.481 1.09 0 CA-C-N 115.907 -0.588 . . . . 1.0 111.149 -179.297 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 67.44 23.26 73.49 Favored Glycine 0 N--CA 1.472 1.039 0 N-CA-C 110.824 -0.91 . . . . 1.0 110.824 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 92.1 p -128.4 166.02 19.5 Favored 'General case' 0 N--CA 1.482 1.136 0 CA-C-O 121.722 0.772 . . . . 1.0 110.826 -178.787 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -94.31 153.66 17.89 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-N 115.344 -0.844 . . . . 1.0 110.382 -179.407 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -158.09 166.31 34.03 Favored Glycine 0 N--CA 1.473 1.118 0 N-CA-C 110.748 -0.941 . . . . 1.0 110.748 -179.821 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -133.38 142.1 48.22 Favored 'General case' 0 N--CA 1.484 1.233 0 CA-C-N 115.552 -0.324 . . . . 1.0 110.417 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -147.78 147.29 17.4 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 CA-C-O 121.366 0.603 . . . . 1.0 109.816 -179.167 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -69.69 143.22 53.2 Favored 'General case' 0 CA--C 1.533 0.323 0 CA-C-N 115.642 -0.708 . . . . 1.0 110.017 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 9.6 mtmp? -87.31 -32.81 19.46 Favored 'General case' 0 N--CA 1.48 1.073 0 CA-C-N 116.006 -0.543 . . . . 1.0 110.218 179.645 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -52.58 -39.77 61.92 Favored 'General case' 0 N--CA 1.472 0.634 0 N-CA-C 110.227 -0.286 . . . . 1.0 110.227 -179.412 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 7.4 m-85 -48.4 -25.09 1.46 Allowed 'General case' 0 N--CA 1.48 1.069 0 CA-C-N 116.386 -0.37 . . . . 1.0 110.591 179.152 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 69.9 mt . . . . . 0 N--CA 1.476 0.861 0 CA-C-O 117.781 -1.104 . . . . 1.0 108.656 179.739 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 68.0 mttm . . . . . 0 N--CA 1.471 0.607 0 CA-C-O 121.812 0.815 . . . . 1.0 110.678 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 51.7 p -115.73 156.89 25.16 Favored 'General case' 0 N--CA 1.479 1.003 0 CA-C-N 115.132 -0.94 . . . . 1.0 110.228 -179.8 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -91.4 148.98 19.57 Favored Glycine 0 N--CA 1.468 0.777 0 N-CA-C 110.36 -1.096 . . . . 1.0 110.36 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 65.7 mt -104.33 126.75 59.02 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 CA-C-O 121.607 0.718 . . . . 1.0 109.131 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 28.8 t -91.47 129.49 42.1 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-N 115.402 -0.817 . . . . 1.0 109.692 179.532 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 62.5 m-80 -49.27 125.64 11.31 Favored 'General case' 0 CA--C 1.545 0.762 0 CA-C-N 116.085 -0.507 . . . . 1.0 110.54 179.315 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 32.6 t -51.28 -62.27 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 CA-C-N 115.905 -0.589 . . . . 1.0 110.473 -179.451 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.9 m -62.91 153.93 31.87 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.179 0.514 . . . . 1.0 109.988 179.611 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 69.54 -171.8 0.18 Allowed 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 115.856 -0.611 . . . . 1.0 110.157 -179.873 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 42.6 t -150.32 154.17 37.38 Favored 'General case' 0 N--CA 1.473 0.697 0 CA-C-O 121.548 0.69 . . . . 1.0 110.366 179.91 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.584 HD11 ' CG ' ' A' ' 59' ' ' TYR . 4.5 mm? -99.68 135.28 41.33 Favored 'General case' 0 N--CA 1.478 0.94 0 CA-C-O 122.062 0.934 . . . . 1.0 109.989 -179.42 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 20.3 p-10 -90.76 129.27 36.86 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.009 -0.996 . . . . 1.0 109.674 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 41.0 t -92.02 103.38 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 CA-C-N 115.664 -0.698 . . . . 1.0 109.336 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 90.8 mtt-85 -81.97 151.57 27.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.434 0.635 . . . . 1.0 109.893 179.244 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 39.8 t -71.99 -21.63 61.54 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 115.582 -0.735 . . . . 1.0 110.433 179.535 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 48.9 m -163.73 174.94 11.02 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-N 116.014 -0.539 . . . . 1.0 110.682 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -70.6 56.48 0.17 Allowed 'General case' 0 N--CA 1.474 0.744 0 CA-C-N 115.792 -0.64 . . . . 1.0 110.42 179.502 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 49.1 m -140.65 130.02 23.84 Favored 'General case' 0 N--CA 1.481 1.089 0 CA-C-O 121.532 0.682 . . . . 1.0 110.577 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 3.7 t -66.31 -31.66 72.59 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 115.476 -0.784 . . . . 1.0 110.425 179.755 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 95.7 p -73.85 -4.81 37.14 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 115.976 -0.557 . . . . 1.0 110.244 -179.787 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 43.1 t -58.9 -173.82 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 120.952 0.406 . . . . 1.0 110.41 179.493 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -127.58 161.52 28.63 Favored 'General case' 0 N--CA 1.478 0.974 0 CA-C-O 121.747 0.784 . . . . 1.0 110.286 -179.768 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.2 t -89.42 108.99 19.81 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-N 115.283 -0.871 . . . . 1.0 109.694 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 45.9 pt -85.72 -17.01 9.69 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 CA-C-N 115.597 -0.729 . . . . 1.0 110.187 179.728 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 175.32 174.73 42.17 Favored Glycine 0 N--CA 1.461 0.319 0 N-CA-C 110.942 -0.863 . . . . 1.0 110.942 -179.455 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 42.6 t -142.52 137.58 30.31 Favored 'General case' 0 N--CA 1.475 0.798 0 CA-C-O 121.775 0.798 . . . . 1.0 110.528 179.604 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -99.8 171.87 7.61 Favored 'General case' 0 N--CA 1.475 0.782 0 CA-C-N 115.303 -0.862 . . . . 1.0 109.206 -179.671 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 56.7 m -89.96 155.13 19.32 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 115.085 -0.961 . . . . 1.0 110.298 -179.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -74.97 150.76 41.47 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.117 -1.193 . . . . 1.0 110.117 179.397 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 22.9 t30 74.83 17.71 2.79 Favored 'General case' 0 N--CA 1.48 1.04 0 CA-C-O 120.798 0.332 . . . . 1.0 110.572 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 59.4 m -87.86 132.39 34.21 Favored 'General case' 0 N--CA 1.478 0.975 0 CA-C-O 121.236 0.541 . . . . 1.0 110.042 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 26.9 mtpp -82.61 144.62 30.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.638 0.732 . . . . 1.0 109.677 179.738 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 16.9 m -147.63 130.47 7.87 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.451 0 CA-C-N 115.319 -0.855 . . . . 1.0 109.863 -179.91 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.411 ' O ' ' C ' ' A' ' 36' ' ' ILE . 30.7 m -86.39 89.05 7.75 Favored 'General case' 0 CA--C 1.515 -0.388 0 N-CA-C 109.098 -0.704 . . . . 1.0 109.098 179.463 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.438 HD12 ' H ' ' A' ' 36' ' ' ILE . 3.5 mp -34.47 146.94 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.504 2.253 0 CA-C-N 116.372 -0.377 . . . . 1.0 111.579 179.345 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 4.7 t -143.45 62.55 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.084 0 CA-C-O 121.05 0.452 . . . . 1.0 110.333 -178.669 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 108.61 166.57 20.94 Favored Glycine 0 N--CA 1.465 0.624 0 N-CA-C 110.462 -1.055 . . . . 1.0 110.462 179.75 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 16.4 pt-20 -142.21 147.25 36.24 Favored 'General case' 0 N--CA 1.476 0.842 0 CA-C-N 114.824 -0.688 . . . . 1.0 110.15 -179.747 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -154.37 125.84 7.47 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 115.704 -0.68 . . . . 1.0 110.162 179.453 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 50.33 -112.46 1.55 Allowed Glycine 0 CA--C 1.535 1.312 0 N-CA-C 111.398 -0.681 . . . . 1.0 111.398 179.442 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -115.37 22.63 13.08 Favored 'General case' 0 N--CA 1.482 1.143 0 N-CA-C 109.911 -0.403 . . . . 1.0 109.911 179.151 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.407 ' C ' ' NZ ' ' A' ' 57' ' ' LYS . 54.5 m-85 -143.37 153.88 43.15 Favored 'General case' 0 N--CA 1.477 0.884 0 CA-C-O 122.012 0.91 . . . . 1.0 110.365 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' TYR . . . . . 0.43 ' N ' ' CD1' ' A' ' 44' ' ' TYR . 11.8 p90 -134.67 169.17 17.72 Favored 'General case' 0 N--CA 1.473 0.687 0 CA-C-O 122.146 0.974 . . . . 1.0 110.04 -179.481 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.462 ' NZ ' ' CD2' ' A' ' 52' ' ' HIS . 63.3 tttm -95.58 151.85 18.96 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 114.902 -1.045 . . . . 1.0 109.918 -179.328 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 18.1 pt -143.91 162.05 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 CA-C-O 122.156 0.979 . . . . 1.0 110.021 179.39 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -125.25 96.78 4.96 Favored 'General case' 0 N--CA 1.479 1.017 0 CA-C-N 114.818 -1.083 . . . . 1.0 110.108 179.276 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 39.2 t80 -135.73 152.79 51.5 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 115.718 -0.674 . . . . 1.0 109.968 179.287 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 63.5 mttt 56.69 10.86 0.78 Allowed 'General case' 0 N--CA 1.475 0.819 0 CA-C-N 115.812 -0.631 . . . . 1.0 110.84 179.629 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 81.35 0.03 88.44 Favored Glycine 0 N--CA 1.472 1.1 0 N-CA-C 110.264 -1.134 . . . . 1.0 110.264 -179.573 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 49.4 m -110.98 172.97 6.56 Favored 'General case' 0 N--CA 1.482 1.153 0 C-N-CA 123.902 0.881 . . . . 1.0 110.167 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' HIS . . . . . 0.462 ' CD2' ' NZ ' ' A' ' 45' ' ' LYS . 30.7 m170 -107.16 145.54 32.43 Favored 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 115.35 -0.841 . . . . 1.0 110.023 -179.747 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -152.06 170.92 31.42 Favored Glycine 0 N--CA 1.464 0.501 0 N-CA-C 110.9 -0.88 . . . . 1.0 110.9 -179.382 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 80.1 m-85 -132.38 146.23 51.81 Favored 'General case' 0 N--CA 1.482 1.13 0 CA-C-O 121.518 0.675 . . . . 1.0 110.258 179.219 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 36.4 t -143.64 147.59 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 CA-C-N 115.451 -0.795 . . . . 1.0 110.277 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -68.75 153.12 44.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.547 -0.751 . . . . 1.0 110.216 179.641 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . 0.407 ' NZ ' ' C ' ' A' ' 43' ' ' PHE . 65.4 mttp -89.99 -22.82 21.73 Favored 'General case' 0 N--CA 1.478 0.961 0 CA-C-N 115.709 -0.678 . . . . 1.0 110.586 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -52.38 -35.99 52.83 Favored 'General case' 0 CA--C 1.537 0.478 0 CA-C-O 121.068 0.461 . . . . 1.0 110.488 -179.146 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.584 ' CG ' HD11 ' A' ' 12' ' ' LEU . 24.4 m-85 -64.04 -30.18 71.27 Favored 'General case' 0 N--CA 1.475 0.823 0 CA-C-N 115.905 -0.589 . . . . 1.0 110.477 178.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 63.5 mt . . . . . 0 N--CA 1.47 0.542 0 CA-C-O 118.119 -0.943 . . . . 1.0 108.609 -179.577 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 25.9 ttpp . . . . . 0 N--CA 1.461 0.108 0 CA-C-O 121.369 0.604 . . . . 1.0 110.112 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 53.9 p -118.31 144.79 45.58 Favored 'General case' 0 N--CA 1.474 0.727 0 CA-C-O 121.695 0.76 . . . . 1.0 110.475 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -97.58 154.25 20.31 Favored Glycine 0 N--CA 1.476 1.322 0 N-CA-C 110.038 -1.225 . . . . 1.0 110.038 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 65.7 mt -106.07 125.26 61.66 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.086 0 CA-C-O 121.239 0.543 . . . . 1.0 109.555 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 45.0 t -74.55 133.48 31.45 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.324 0 CA-C-N 115.788 -0.642 . . . . 1.0 109.479 179.61 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 9.4 m120 -62.13 109.27 1.25 Allowed 'General case' 0 CA--C 1.537 0.444 0 CA-C-N 115.735 -0.666 . . . . 1.0 110.113 179.363 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.3 p -55.61 -19.33 5.91 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 CA-C-N 116.035 -0.529 . . . . 1.0 110.435 179.515 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 49.5 m -52.08 105.97 0.13 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.158 -0.473 . . . . 1.0 110.422 -179.373 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 80.9 p 60.42 -122.38 0.97 Allowed 'General case' 0 CA--C 1.548 0.882 0 CA-C-N 116.062 -0.517 . . . . 1.0 110.448 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 47.7 t -151.98 156.57 40.29 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-O 121.379 0.609 . . . . 1.0 110.083 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -104.24 136.46 43.8 Favored 'General case' 0 N--CA 1.479 1.016 0 CA-C-O 121.817 0.818 . . . . 1.0 110.323 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 72.5 m-80 -92.31 133.97 35.35 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.199 -0.909 . . . . 1.0 109.269 -179.623 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 59.3 t -93.19 105.75 17.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-N 115.104 -0.953 . . . . 1.0 109.37 -179.658 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 88.9 mtt-85 -81.32 148.55 29.33 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.487 0.661 . . . . 1.0 109.922 179.305 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 87.6 p -73.14 -19.41 61.14 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 115.606 -0.724 . . . . 1.0 110.019 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 87.1 p -162.17 172.85 15.13 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-O 121.179 0.514 . . . . 1.0 110.798 -179.585 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -71.47 57.45 0.26 Allowed 'General case' 0 N--CA 1.474 0.767 0 CA-C-N 115.789 -0.641 . . . . 1.0 110.49 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 55.8 m -143.93 130.43 20.01 Favored 'General case' 0 N--CA 1.481 1.105 0 CA-C-N 115.71 -0.677 . . . . 1.0 110.492 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 57.8 p -65.72 -26.61 67.83 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 115.827 -0.624 . . . . 1.0 110.226 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 49.4 m -71.07 -8.02 50.49 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 116.063 -0.517 . . . . 1.0 110.256 179.685 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 61.2 m -67.0 132.08 47.17 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 121.388 0.614 . . . . 1.0 110.01 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -72.48 169.58 16.13 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.615 -0.72 . . . . 1.0 110.123 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.7 t -90.16 112.58 24.95 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 CA-C-O 121.807 0.813 . . . . 1.0 109.754 179.751 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 2.1 pp -85.18 -27.19 6.54 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 CA-C-N 115.146 -0.934 . . . . 1.0 109.761 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 173.15 -171.84 44.73 Favored Glycine 0 N--CA 1.465 0.583 0 N-CA-C 111.398 -0.681 . . . . 1.0 111.398 -179.423 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 95.4 p -151.92 145.23 24.73 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-O 121.895 0.855 . . . . 1.0 110.449 179.208 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -102.31 -179.11 3.89 Favored 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 115.166 -0.925 . . . . 1.0 109.28 -179.662 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 96.8 p -91.66 144.63 25.33 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 115.145 -0.934 . . . . 1.0 110.197 -179.646 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -75.13 157.96 50.5 Favored Glycine 0 N--CA 1.461 0.343 0 N-CA-C 110.212 -1.155 . . . . 1.0 110.212 179.566 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 8.7 t30 69.46 20.82 7.08 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-O 120.707 0.289 . . . . 1.0 110.485 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 85.7 m -88.99 137.16 32.57 Favored 'General case' 0 N--CA 1.478 0.962 0 CA-C-O 121.413 0.625 . . . . 1.0 110.433 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -86.93 144.51 26.92 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-O 122.069 0.938 . . . . 1.0 109.814 179.771 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 5.7 p -153.75 138.14 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.423 0 CA-C-N 114.898 -1.046 . . . . 1.0 109.806 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 60.9 p -82.46 84.32 7.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.784 -0.644 . . . . 1.0 109.62 178.694 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.432 HG22 ' N ' ' A' ' 37' ' ' VAL . 88.6 mt -43.02 160.06 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 CA-C-N 115.657 -0.701 . . . . 1.0 110.243 179.428 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.432 ' N ' HG22 ' A' ' 36' ' ' ILE . 43.3 t -123.34 -92.5 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 CA-C-N 115.882 -0.599 . . . . 1.0 109.698 -179.745 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -114.89 -159.15 12.27 Favored Glycine 0 N--CA 1.466 0.653 0 CA-C-O 122.318 0.954 . . . . 1.0 110.861 -179.278 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . 0.461 ' N ' ' NZ ' ' A' ' 45' ' ' LYS . 1.0 OUTLIER -143.66 147.93 35.04 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 114.707 -0.747 . . . . 1.0 110.61 -179.524 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -154.64 124.5 6.65 Favored 'General case' 0 N--CA 1.47 0.558 0 CA-C-N 115.929 -0.578 . . . . 1.0 110.345 179.319 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 53.3 -150.15 11.71 Favored Glycine 0 CA--C 1.532 1.149 0 N-CA-C 111.139 -0.784 . . . . 1.0 111.139 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -84.9 30.37 0.58 Allowed 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 110.151 -0.314 . . . . 1.0 110.151 179.431 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 -145.69 153.37 40.92 Favored 'General case' 0 N--CA 1.477 0.909 0 CA-C-O 121.784 0.802 . . . . 1.0 110.529 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 1.7 m-85 -109.68 148.87 30.59 Favored 'General case' 0 N--CA 1.48 1.032 0 CA-C-O 122.556 1.169 . . . . 1.0 110.099 179.468 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.461 ' NZ ' ' N ' ' A' ' 39' ' ' GLU . 35.4 mtmm -87.98 140.73 29.2 Favored 'General case' 0 CA--C 1.518 -0.281 0 CA-C-N 114.485 -1.234 . . . . 1.0 109.508 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 39.9 pt -149.86 173.41 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.358 0 CA-C-N 114.594 -1.185 . . . . 1.0 109.688 -179.128 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -146.61 108.14 4.29 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 115.74 -0.664 . . . . 1.0 110.225 178.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 54.6 t80 -139.08 162.35 35.15 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.739 -0.664 . . . . 1.0 110.054 179.76 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 19.2 tttp 59.18 16.49 4.91 Favored 'General case' 0 CA--C 1.546 0.818 0 CA-C-N 115.55 -0.75 . . . . 1.0 110.9 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 77.85 -2.1 65.64 Favored Glycine 0 N--CA 1.477 1.403 0 N-CA-C 110.171 -1.171 . . . . 1.0 110.171 -179.357 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 49.2 m -114.95 176.29 5.12 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 124.278 1.031 . . . . 1.0 110.486 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 25.9 p80 -105.36 141.01 37.62 Favored 'General case' 0 N--CA 1.482 1.15 0 CA-C-N 115.464 -0.789 . . . . 1.0 110.064 -179.447 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.68 165.8 27.92 Favored Glycine 0 N--CA 1.463 0.435 0 N-CA-C 110.525 -1.03 . . . . 1.0 110.525 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -130.37 145.43 51.8 Favored 'General case' 0 N--CA 1.483 1.217 0 CA-C-O 121.527 0.68 . . . . 1.0 110.001 179.538 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 41.3 t -145.92 149.75 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 CA-C-O 121.904 0.859 . . . . 1.0 109.427 -179.723 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.402 ' O ' ' CD1' ' A' ' 59' ' ' TYR . . . -60.71 153.44 24.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 114.986 -1.006 . . . . 1.0 110.164 178.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 15.8 pttp -102.89 -31.34 10.31 Favored 'General case' 0 N--CA 1.482 1.167 0 CA-C-N 115.442 -0.799 . . . . 1.0 111.763 178.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 14.6 pt-20 -64.53 -31.82 73.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.444 0.64 . . . . 1.0 111.022 -179.176 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . 0.402 ' CD1' ' O ' ' A' ' 56' ' ' ALA . 0.6 OUTLIER -62.7 -4.12 1.88 Allowed 'General case' 0 CA--C 1.549 0.918 0 CA-C-N 115.476 -0.783 . . . . 1.0 110.138 -179.888 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 85.1 mt . . . . . 0 N--CA 1.477 0.888 0 N-CA-C 108.13 -1.063 . . . . 1.0 108.13 -179.163 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 98.5 mttt . . . . . 0 N--CA 1.475 0.785 0 CA-C-O 121.432 0.634 . . . . 1.0 110.563 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 20.2 p -137.78 151.26 47.96 Favored 'General case' 0 N--CA 1.489 1.479 0 CA-C-N 115.549 -0.75 . . . . 1.0 110.353 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -96.8 142.78 16.36 Favored Glycine 0 N--CA 1.474 1.217 0 N-CA-C 110.625 -0.99 . . . . 1.0 110.625 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 75.1 mt -109.24 141.56 24.18 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.177 0 CA-C-O 121.224 0.535 . . . . 1.0 109.95 -179.618 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 2.8 t -116.56 115.86 50.39 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 CA-C-O 116.812 -1.566 . . . . 1.0 110.682 178.083 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -82.48 146.3 29.33 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 120.098 1.317 . . . . 1.0 109.06 177.638 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.9 p -50.14 139.01 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 CA-C-N 116.314 -0.403 . . . . 1.0 111.126 179.289 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 79.2 p -168.59 -78.88 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.844 0 CA-C-O 120.843 0.354 . . . . 1.0 111.141 -179.26 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 97.6 p -131.15 -133.74 0.2 Allowed 'General case' 0 N--CA 1.485 1.287 0 CA-C-N 116.068 -0.515 . . . . 1.0 110.516 -179.105 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 98.3 p -138.85 153.76 48.36 Favored 'General case' 0 N--CA 1.477 0.925 0 CA-C-O 121.312 0.577 . . . . 1.0 110.238 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -140.3 128.27 22.09 Favored 'General case' 0 N--CA 1.49 1.553 0 CA-C-O 121.733 0.778 . . . . 1.0 109.715 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 19.3 p30 -92.96 144.08 25.61 Favored 'General case' 0 N--CA 1.473 0.704 0 CA-C-N 115.298 -0.865 . . . . 1.0 110.06 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 93.9 t -97.79 128.45 49.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 CA-C-O 121.879 0.847 . . . . 1.0 108.894 179.173 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 89.5 mtt-85 -99.55 -167.74 1.51 Allowed 'General case' 0 N--CA 1.473 0.702 0 CA-C-N 115.187 -0.915 . . . . 1.0 110.162 -179.744 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 60.1 p -130.8 33.16 4.26 Favored 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 123.017 0.527 . . . . 1.0 110.611 -179.413 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . 0.48 ' OG ' ' N ' ' A' ' 18' ' ' ALA . 6.9 t 175.8 -177.95 0.13 Allowed 'General case' 0 N--CA 1.48 1.027 0 CA-C-O 121.632 0.729 . . . . 1.0 110.507 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.48 ' N ' ' OG ' ' A' ' 17' ' ' SER . . . -97.11 42.97 1.08 Allowed 'General case' 0 N--CA 1.488 1.448 0 CA-C-N 115.285 -0.87 . . . . 1.0 110.182 179.511 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 44.3 t -130.63 138.18 49.97 Favored 'General case' 0 N--CA 1.489 1.477 0 CA-C-N 115.106 -0.952 . . . . 1.0 110.902 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 80.1 p -74.73 -8.75 57.37 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-N 116.227 -0.442 . . . . 1.0 110.569 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 66.7 m -99.36 -6.58 27.57 Favored 'General case' 0 N--CA 1.486 1.333 0 CA-C-N 116.201 -0.454 . . . . 1.0 111.069 -179.072 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 13.9 t -66.48 133.95 51.46 Favored 'General case' 0 N--CA 1.473 0.72 0 CA-C-N 115.962 -0.563 . . . . 1.0 110.843 -179.414 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 38.3 ttmt -59.89 155.67 15.99 Favored 'General case' 0 N--CA 1.475 0.793 0 CA-C-N 116.031 -0.531 . . . . 1.0 110.622 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 6.8 p -83.94 144.56 9.68 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.193 0 CA-C-O 121.176 0.513 . . . . 1.0 110.503 -179.68 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 40.1 pt -121.87 -10.26 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 CA-C-N 115.813 -0.631 . . . . 1.0 110.34 179.266 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 179.35 -171.56 43.42 Favored Glycine 0 N--CA 1.467 0.759 0 N-CA-C 111.111 -0.796 . . . . 1.0 111.111 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 96.7 p -157.25 151.0 24.33 Favored 'General case' 0 N--CA 1.475 0.797 0 CA-C-N 115.642 -0.279 . . . . 1.0 110.559 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 2.2 pp -117.23 167.78 10.9 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 123.076 0.55 . . . . 1.0 110.507 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 90.9 p -112.74 160.02 18.37 Favored 'General case' 0 N--CA 1.482 1.17 0 CA-C-N 115.718 -0.673 . . . . 1.0 110.537 -179.491 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.467 ' O ' ' HB2' ' A' ' 31' ' ' ASN . . . -83.75 76.06 2.29 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 110.901 -0.88 . . . . 1.0 110.901 179.41 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.467 ' HB2' ' O ' ' A' ' 30' ' ' GLY . 22.1 t-20 164.61 16.3 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.843 0 C-N-CA 123.287 0.635 . . . . 1.0 110.242 -179.566 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 36.4 m -109.84 147.47 33.27 Favored 'General case' 0 N--CA 1.486 1.337 0 C-N-CA 123.424 0.69 . . . . 1.0 111.046 -179.458 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 22.2 pttp -90.25 148.77 22.7 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 122.602 0.361 . . . . 1.0 110.209 178.532 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.6 m -143.21 126.04 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 CA-C-O 120.829 0.347 . . . . 1.0 110.296 179.587 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . 0.542 ' O ' HG23 ' A' ' 35' ' ' THR . 9.8 t -82.79 85.47 7.07 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 121.445 0.641 . . . . 1.0 110.619 179.674 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 85.6 mt -51.16 157.23 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 CA-C-N 115.546 -0.752 . . . . 1.0 110.165 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 39.6 t -127.4 -97.86 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 CA-C-N 115.947 -0.569 . . . . 1.0 110.003 -179.076 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -99.49 -178.42 31.2 Favored Glycine 0 N--CA 1.472 1.036 0 N-CA-C 110.937 -0.865 . . . . 1.0 110.937 -179.773 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -135.16 141.8 46.0 Favored 'General case' 0 N--CA 1.483 1.193 0 CA-C-O 120.984 0.421 . . . . 1.0 110.204 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -155.38 134.84 12.48 Favored 'General case' 0 CA--C 1.539 0.524 0 CA-C-N 116.001 -0.545 . . . . 1.0 110.378 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 48.56 -113.14 1.4 Allowed Glycine 0 CA--C 1.547 2.051 0 CA-C-N 115.947 -0.57 . . . . 1.0 111.707 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -122.49 24.7 9.16 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 110.049 -0.352 . . . . 1.0 110.049 179.23 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -145.07 156.18 43.76 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-O 121.301 0.572 . . . . 1.0 110.296 -179.474 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 22.6 p90 -131.67 162.87 29.38 Favored 'General case' 0 N--CA 1.488 1.458 0 CA-C-N 115.684 -0.689 . . . . 1.0 110.452 179.712 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -88.58 160.39 17.45 Favored 'General case' 0 N--CA 1.476 0.829 0 CA-C-N 116.037 -0.528 . . . . 1.0 110.159 -179.372 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 34.4 pt -145.75 153.17 13.74 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 CA-C-O 121.312 0.577 . . . . 1.0 110.504 -179.632 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 80.8 mm-40 -95.75 58.73 1.99 Allowed 'General case' 0 N--CA 1.481 1.113 0 CA-C-N 115.668 -0.696 . . . . 1.0 110.069 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 77.8 t80 -78.94 117.54 20.11 Favored 'General case' 0 N--CA 1.474 0.727 0 CA-C-N 115.603 -0.726 . . . . 1.0 109.915 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm 45.58 33.21 1.32 Allowed 'General case' 0 CA--C 1.557 1.24 0 CA-C-O 121.276 0.56 . . . . 1.0 111.415 -179.629 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 68.19 21.74 74.03 Favored Glycine 0 N--CA 1.482 1.736 0 N-CA-C 111.373 -0.691 . . . . 1.0 111.373 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 28.9 t -115.98 171.65 7.65 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 123.332 0.653 . . . . 1.0 110.878 -179.186 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -96.77 136.85 36.73 Favored 'General case' 0 N--CA 1.479 0.995 0 CA-C-N 115.942 -0.572 . . . . 1.0 110.229 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -148.2 163.13 28.9 Favored Glycine 0 N--CA 1.479 1.522 0 N-CA-C 110.993 -0.843 . . . . 1.0 110.993 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' TYR . . . . . 0.451 ' CD1' ' N ' ' A' ' 17' ' ' SER . 82.2 m-85 -133.83 138.01 45.39 Favored 'General case' 0 N--CA 1.483 1.184 0 CA-C-O 121.483 0.659 . . . . 1.0 110.544 -179.744 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 42.8 t -144.23 151.22 16.16 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.291 0 CA-C-N 115.501 -0.772 . . . . 1.0 110.1 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -79.55 113.53 17.77 Favored 'General case' 0 N--CA 1.474 0.747 0 CA-C-N 115.785 -0.643 . . . . 1.0 110.502 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 19.3 pttp -74.23 -28.44 61.24 Favored 'General case' 0 N--CA 1.476 0.871 0 CA-C-O 120.812 0.339 . . . . 1.0 110.512 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -55.11 -45.18 75.5 Favored 'General case' 0 N--CA 1.477 0.876 0 CA-C-N 116.234 -0.439 . . . . 1.0 111.014 -179.297 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 22.9 m-85 -63.0 -35.02 78.81 Favored 'General case' 0 N--CA 1.477 0.893 0 N-CA-C 110.003 -0.369 . . . . 1.0 110.003 178.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 74.4 mt . . . . . 0 N--CA 1.479 1.01 0 CA-C-O 118.133 -0.937 . . . . 1.0 109.253 -179.48 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 98.9 mttt . . . . . 0 N--CA 1.479 1.006 0 CA-C-O 121.817 0.818 . . . . 1.0 110.181 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 73.3 p -123.14 144.59 49.24 Favored 'General case' 0 N--CA 1.48 1.054 0 CA-C-N 115.161 -0.927 . . . . 1.0 110.314 -179.796 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -95.64 151.77 20.11 Favored Glycine 0 CA--C 1.527 0.838 0 N-CA-C 110.229 -1.149 . . . . 1.0 110.229 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 4.0 mp -103.56 124.89 58.11 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 N-CA-C 109.493 -0.558 . . . . 1.0 109.493 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.3 t -66.67 120.09 13.24 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.554 0 CA-C-N 115.7 -0.682 . . . . 1.0 109.845 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 18.2 p-10 -59.63 102.28 0.14 Allowed 'General case' 0 CA--C 1.539 0.537 0 CA-C-O 121.029 0.443 . . . . 1.0 110.479 179.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 8.2 p -64.27 -2.85 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-N 115.951 -0.568 . . . . 1.0 110.721 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 41.3 m -45.89 -56.71 5.08 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-N 115.743 -0.662 . . . . 1.0 111.445 -179.87 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 50.0 m -148.56 179.41 7.83 Favored 'General case' 0 N--CA 1.477 0.907 0 CA-C-N 115.61 -0.723 . . . . 1.0 110.277 179.216 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 45.1 t -84.75 140.31 31.35 Favored 'General case' 0 N--CA 1.473 0.712 0 CA-C-N 115.479 -0.782 . . . . 1.0 110.249 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -111.6 140.65 46.04 Favored 'General case' 0 N--CA 1.485 1.29 0 CA-C-O 122.232 1.015 . . . . 1.0 109.935 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 72.6 m-80 -82.67 126.7 32.65 Favored 'General case' 0 N--CA 1.451 -0.407 0 CA-C-N 114.805 -1.089 . . . . 1.0 109.476 179.663 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.4 t -102.09 125.86 56.21 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 CA-C-N 115.229 -0.896 . . . . 1.0 110.181 -179.763 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -91.83 179.62 5.57 Favored 'General case' 0 N--CA 1.486 1.348 0 CA-C-O 121.582 0.706 . . . . 1.0 110.238 179.039 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 1.4 m -92.65 -22.61 19.35 Favored 'General case' 0 N--CA 1.489 1.508 0 CA-C-N 115.435 -0.802 . . . . 1.0 110.282 179.837 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 45.5 p -176.74 -178.13 0.85 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 122.175 0.988 . . . . 1.0 110.032 -179.162 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -82.15 82.27 7.76 Favored 'General case' 0 N--CA 1.47 0.562 0 CA-C-N 114.852 -1.067 . . . . 1.0 109.689 179.182 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 65.5 p -167.25 154.68 8.92 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 121.565 0.698 . . . . 1.0 110.332 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 26.3 m -75.1 -25.32 58.44 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.398 -0.819 . . . . 1.0 110.639 179.311 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 99.5 p -63.08 -22.93 67.19 Favored 'General case' 0 N--CA 1.471 0.602 0 C-N-CA 120.597 -0.441 . . . . 1.0 110.408 -178.423 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 26.5 t -96.96 141.79 29.7 Favored 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 109.652 -0.499 . . . . 1.0 109.652 178.41 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 24.9 tttm -163.24 109.9 1.16 Allowed 'General case' 0 N--CA 1.474 0.754 0 CA-C-O 122.077 0.942 . . . . 1.0 110.029 179.638 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.3 t 62.06 135.92 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.519 0 CA-C-N 115.032 -0.986 . . . . 1.0 110.24 -179.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 1.3 pp -152.57 -17.14 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.963 0 CA-C-N 115.93 -0.577 . . . . 1.0 110.326 -179.387 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 163.27 -166.91 37.32 Favored Glycine 0 CA--C 1.522 0.469 0 N-CA-C 110.359 -1.096 . . . . 1.0 110.359 -178.247 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 93.9 p -145.11 140.44 28.03 Favored 'General case' 0 N--CA 1.481 1.121 0 CA-C-N 114.882 -0.659 . . . . 1.0 110.591 179.782 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.9 pp -102.17 122.41 44.1 Favored 'General case' 0 N--CA 1.491 1.58 0 CA-C-O 121.587 0.708 . . . . 1.0 109.392 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 51.0 m -44.69 131.62 6.75 Favored 'General case' 0 N--CA 1.484 1.233 0 CA-C-N 115.476 -0.784 . . . . 1.0 111.082 -178.654 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -68.08 165.87 45.14 Favored Glycine 0 CA--C 1.521 0.449 0 N-CA-C 111.354 -0.699 . . . . 1.0 111.354 -178.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 13.8 m-80 65.1 20.66 12.08 Favored 'General case' 0 N--CA 1.471 0.624 0 CA-C-O 120.954 0.407 . . . . 1.0 110.455 179.654 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 91.8 m -97.67 145.54 26.21 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-N 115.994 -0.548 . . . . 1.0 109.735 179.48 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -86.27 139.3 31.14 Favored 'General case' 0 N--CA 1.473 0.682 0 CA-C-N 115.77 -0.65 . . . . 1.0 110.143 179.428 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 9.8 m -142.49 124.99 13.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 CA-C-N 115.675 -0.693 . . . . 1.0 110.118 179.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 60.0 p -89.93 90.78 8.31 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 115.917 -0.583 . . . . 1.0 109.813 179.185 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 3.5 mp -36.75 147.17 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.498 1.94 0 CA-C-N 115.768 -0.651 . . . . 1.0 111.517 179.669 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 4.7 t -141.68 61.47 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.37 0 CA-C-O 121.239 0.543 . . . . 1.0 110.522 -178.485 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 107.83 160.55 20.83 Favored Glycine 0 N--CA 1.471 1.005 0 N-CA-C 110.711 -0.956 . . . . 1.0 110.711 179.435 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 74.7 mt-10 -135.46 140.72 45.08 Favored 'General case' 0 N--CA 1.487 1.383 0 CA-C-O 121.161 0.505 . . . . 1.0 110.261 179.703 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.7 tm-20 -148.95 121.87 8.77 Favored 'General case' 0 N--CA 1.477 0.875 0 CA-C-N 115.837 -0.619 . . . . 1.0 110.346 -179.595 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 50.41 -114.17 2.44 Favored Glycine 0 CA--C 1.543 1.783 0 N-CA-C 111.16 -0.776 . . . . 1.0 111.16 179.651 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -113.62 26.82 10.05 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 122.609 0.364 . . . . 1.0 110.724 179.431 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 -146.9 156.34 43.0 Favored 'General case' 0 N--CA 1.476 0.841 0 CA-C-O 121.721 0.772 . . . . 1.0 110.487 179.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' TYR . . . . . 0.4 ' CD1' ' N ' ' A' ' 44' ' ' TYR . 15.0 p90 -140.45 172.67 12.4 Favored 'General case' 0 N--CA 1.473 0.72 0 CA-C-N 115.336 -0.847 . . . . 1.0 110.121 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 24.0 mtpp -101.32 151.83 21.42 Favored 'General case' 0 N--CA 1.478 0.944 0 CA-C-N 115.225 -0.898 . . . . 1.0 110.281 -179.282 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 38.9 pt -139.55 152.97 23.29 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 CA-C-N 115.59 -0.732 . . . . 1.0 110.596 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 4.3 tm-20 -113.45 86.82 2.47 Favored 'General case' 0 N--CA 1.485 1.288 0 CA-C-N 115.323 -0.853 . . . . 1.0 109.872 179.236 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 22.6 t80 -139.65 158.46 44.08 Favored 'General case' 0 N--CA 1.469 0.505 0 CA-C-O 121.209 0.528 . . . . 1.0 110.566 179.391 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 33.8 mtmt 50.29 20.83 0.7 Allowed 'General case' 0 N--CA 1.476 0.859 0 CA-C-N 115.847 -0.615 . . . . 1.0 110.447 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 71.55 -3.32 18.04 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.799 -0.92 . . . . 1.0 110.799 -179.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 44.0 t -117.38 173.97 6.4 Favored 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 124.119 0.968 . . . . 1.0 110.644 -179.431 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' HIS . . . . . 0.508 ' CD2' ' H ' ' A' ' 52' ' ' HIS . 6.8 p80 -112.37 153.54 27.11 Favored 'General case' 0 N--CA 1.481 1.094 0 CA-C-N 115.467 -0.788 . . . . 1.0 109.955 -179.587 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.06 165.55 27.71 Favored Glycine 0 N--CA 1.471 0.994 0 N-CA-C 110.711 -0.956 . . . . 1.0 110.711 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 77.0 m-85 -130.54 139.67 50.48 Favored 'General case' 0 N--CA 1.486 1.351 0 CA-C-O 121.119 0.485 . . . . 1.0 110.268 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 4.2 p -158.91 158.84 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.001 0 CA-C-N 115.92 -0.582 . . . . 1.0 110.25 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.66 134.13 56.74 Favored 'General case' 0 CA--C 1.541 0.609 0 CA-C-O 121.191 0.519 . . . . 1.0 110.397 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -91.06 -35.97 14.31 Favored 'General case' 0 N--CA 1.483 1.198 0 CA-C-N 115.712 -0.676 . . . . 1.0 110.258 -179.831 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -56.73 -28.47 61.09 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-O 121.099 0.476 . . . . 1.0 110.633 -179.454 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 2.2 m-85 -63.21 -39.24 94.08 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-N 115.88 -0.6 . . . . 1.0 110.17 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 70.2 mt . . . . . 0 N--CA 1.472 0.628 0 CA-C-O 117.698 -1.144 . . . . 1.0 109.338 -179.32 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 7.0 mtpm? . . . . . 0 N--CA 1.47 0.565 0 CA-C-O 120.722 0.296 . . . . 1.0 110.994 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 68.6 p -125.89 163.07 23.74 Favored 'General case' 0 N--CA 1.48 1.045 0 CA-C-O 121.786 0.803 . . . . 1.0 110.353 -179.259 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -122.13 153.17 16.81 Favored Glycine 0 N--CA 1.479 1.565 0 CA-C-N 115.147 -0.933 . . . . 1.0 110.883 -179.696 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 28.2 pt -114.45 140.47 35.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 CA-C-O 121.869 0.842 . . . . 1.0 110.076 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.511 ' H ' ' HA ' ' A' ' 31' ' ' ASN . 2.2 t -90.82 132.04 36.41 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 CA-C-N 115.083 -0.962 . . . . 1.0 109.315 -179.666 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 31.9 m120 -59.53 114.66 2.82 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 120.397 -0.521 . . . . 1.0 110.35 179.329 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 40.6 t -53.49 -19.51 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 CA-C-O 121.397 0.618 . . . . 1.0 110.448 -179.676 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.5 m -49.42 109.28 0.25 Allowed 'General case' 0 CA--C 1.545 0.769 0 CA-C-N 115.642 -0.708 . . . . 1.0 110.873 179.339 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 7.9 m 61.67 -125.42 0.81 Allowed 'General case' 0 CA--C 1.543 0.699 0 CA-C-N 116.582 -0.281 . . . . 1.0 110.606 -179.18 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 89.0 p -152.28 158.68 43.13 Favored 'General case' 0 N--CA 1.478 0.936 0 CA-C-O 120.97 0.414 . . . . 1.0 110.666 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 51.5 tp -123.05 133.44 54.32 Favored 'General case' 0 N--CA 1.486 1.345 0 CA-C-O 121.578 0.704 . . . . 1.0 110.212 179.596 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 14.9 p-10 -84.63 143.48 29.22 Favored 'General case' 0 CA--C 1.535 0.394 0 CA-C-N 115.432 -0.804 . . . . 1.0 109.982 179.404 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 45.2 t -96.4 117.54 40.95 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 N-CA-C 109.424 -0.584 . . . . 1.0 109.424 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 81.3 mtt85 -84.97 165.63 17.44 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 109.774 -0.454 . . . . 1.0 109.774 179.675 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 38.0 t -95.85 -18.28 20.48 Favored 'General case' 0 N--CA 1.483 1.184 0 CA-C-N 115.972 -0.558 . . . . 1.0 110.516 179.468 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 32.9 t -153.36 -164.63 1.95 Allowed 'General case' 0 N--CA 1.479 0.986 0 CA-C-N 116.246 -0.434 . . . . 1.0 111.089 -179.806 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -83.72 47.33 1.27 Allowed 'General case' 0 N--CA 1.477 0.919 0 CA-C-O 121.458 0.647 . . . . 1.0 110.234 -179.776 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 53.6 m -157.74 137.1 11.88 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-N 115.562 -0.745 . . . . 1.0 110.851 179.748 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.1 t -70.38 -32.09 69.62 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 115.939 -0.573 . . . . 1.0 110.448 179.701 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . 0.45 ' C ' ' H ' ' A' ' 23' ' ' LYS . 51.1 m -70.81 -2.58 15.31 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 116.42 -0.354 . . . . 1.0 110.683 -179.78 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . 0.535 ' O ' ' O ' ' A' ' 23' ' ' LYS . 59.8 p -76.71 21.07 0.21 Allowed 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 121.362 0.601 . . . . 1.0 110.563 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.535 ' O ' ' O ' ' A' ' 22' ' ' SER . 98.2 mttt 48.13 167.25 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.443 0 CA-C-N 115.653 -0.703 . . . . 1.0 111.565 -179.147 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.456 HG12 ' N ' ' A' ' 25' ' ' ILE . 25.9 t -89.56 168.92 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-O 121.563 0.697 . . . . 1.0 109.56 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.456 ' N ' HG12 ' A' ' 24' ' ' VAL . 43.5 pt -135.58 -22.64 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 CA-C-N 115.472 -0.785 . . . . 1.0 110.497 179.565 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.72 179.87 43.0 Favored Glycine 0 N--CA 1.462 0.419 0 N-CA-C 110.52 -1.032 . . . . 1.0 110.52 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 88.7 p -132.56 133.44 43.72 Favored 'General case' 0 N--CA 1.478 0.933 0 CA-C-O 121.282 0.563 . . . . 1.0 109.873 179.664 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -98.62 174.19 6.55 Favored 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 108.959 -0.756 . . . . 1.0 108.959 -179.468 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . 0.533 ' O ' ' O ' ' A' ' 30' ' ' GLY . 42.0 t -79.16 137.19 37.35 Favored 'General case' 0 CA--C 1.515 -0.367 0 CA-C-N 115.964 -0.562 . . . . 1.0 109.901 -179.189 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.533 ' O ' ' O ' ' A' ' 29' ' ' SER . . . -13.24 -107.45 0.0 OUTLIER Glycine 0 N--CA 1.512 3.715 0 CA-C-O 119.473 -0.626 . . . . 1.0 113.017 179.82 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . 0.511 ' HA ' ' H ' ' A' ' 6' ' ' VAL . 19.5 p-10 -77.73 79.22 4.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 117.569 0.684 . . . . 1.0 109.781 177.775 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 45.6 m -84.84 146.24 27.42 Favored 'General case' 0 N--CA 1.494 1.769 0 CA-C-N 115.961 -0.563 . . . . 1.0 109.82 179.293 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 55.8 mtpt -82.62 128.47 34.36 Favored 'General case' 0 N--CA 1.474 0.761 0 CA-C-N 116.035 -0.529 . . . . 1.0 110.116 179.157 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.9 m -144.48 127.0 10.72 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 CA-C-N 116.323 -0.399 . . . . 1.0 110.368 179.361 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 68.6 p -80.81 83.82 6.47 Favored 'General case' 0 N--CA 1.47 0.559 0 CA-C-O 121.289 0.566 . . . . 1.0 109.86 179.485 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.475 HG22 ' N ' ' A' ' 37' ' ' VAL . 81.3 mt -47.23 163.83 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.063 0 CA-C-N 115.641 -0.708 . . . . 1.0 110.54 179.787 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.475 ' N ' HG22 ' A' ' 36' ' ' ILE . 42.7 t -129.25 -94.18 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 N-CA-C 110.045 -0.354 . . . . 1.0 110.045 -179.229 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -102.12 -168.12 27.0 Favored Glycine 0 N--CA 1.474 1.227 0 N-CA-C 110.912 -0.875 . . . . 1.0 110.912 -179.568 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -130.29 140.68 50.65 Favored 'General case' 0 N--CA 1.485 1.275 0 CA-C-N 115.293 -0.453 . . . . 1.0 110.541 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 -153.21 114.02 4.09 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 116.084 -0.507 . . . . 1.0 110.207 -179.845 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 51.22 -116.4 4.54 Favored Glycine 0 CA--C 1.542 1.772 0 N-CA-C 111.634 -0.586 . . . . 1.0 111.634 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -117.41 25.07 10.7 Favored 'General case' 0 N--CA 1.488 1.453 0 C-N-CA 122.401 0.28 . . . . 1.0 110.429 179.493 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -145.64 157.08 44.01 Favored 'General case' 0 N--CA 1.48 1.074 0 CA-C-O 121.232 0.539 . . . . 1.0 110.405 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 13.8 p90 -141.72 176.18 9.12 Favored 'General case' 0 N--CA 1.482 1.131 0 CA-C-N 115.76 -0.654 . . . . 1.0 110.376 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 34.3 mtmm -97.06 149.35 22.05 Favored 'General case' 0 N--CA 1.479 0.987 0 CA-C-N 115.786 -0.643 . . . . 1.0 110.327 -179.117 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 26.3 pt -142.95 160.48 18.02 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 CA-C-O 121.949 0.88 . . . . 1.0 110.119 179.487 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -121.7 92.1 3.66 Favored 'General case' 0 N--CA 1.487 1.385 0 CA-C-N 115.084 -0.962 . . . . 1.0 109.608 -179.68 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 21.8 t80 -136.32 151.86 50.05 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-O 121.239 0.542 . . . . 1.0 110.398 179.82 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 46.9 mmtt 53.53 17.55 1.18 Allowed 'General case' 0 N--CA 1.479 1.02 0 CA-C-N 115.763 -0.653 . . . . 1.0 110.619 -179.586 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 72.81 -2.25 33.97 Favored Glycine 0 N--CA 1.467 0.713 0 N-CA-C 110.63 -0.988 . . . . 1.0 110.63 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 41.9 t -107.89 172.47 6.81 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 124.009 0.924 . . . . 1.0 110.489 -179.672 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 25.8 p-80 -106.77 142.26 36.69 Favored 'General case' 0 N--CA 1.482 1.125 0 CA-C-N 115.803 -0.635 . . . . 1.0 110.133 179.882 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -150.83 169.79 30.62 Favored Glycine 0 N--CA 1.472 1.08 0 N-CA-C 111.094 -0.802 . . . . 1.0 111.094 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 58.5 m-85 -133.53 145.81 50.47 Favored 'General case' 0 N--CA 1.48 1.04 0 CA-C-O 121.673 0.749 . . . . 1.0 110.33 179.655 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 3.5 m -146.16 147.98 17.63 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 CA-C-N 115.319 -0.855 . . . . 1.0 109.892 -179.7 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -66.44 147.21 53.62 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 115.204 -0.907 . . . . 1.0 110.477 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -82.4 -25.74 33.45 Favored 'General case' 0 N--CA 1.477 0.879 0 CA-C-N 116.166 -0.47 . . . . 1.0 110.44 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 4.2 tm-20 -56.68 -34.58 67.54 Favored 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 121.293 0.568 . . . . 1.0 110.738 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 26.1 m-85 -78.46 -4.92 50.87 Favored 'General case' 0 N--CA 1.483 1.188 0 CA-C-N 115.629 -0.714 . . . . 1.0 110.1 179.81 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 34.2 mm . . . . . 0 N--CA 1.487 1.393 0 CA-C-O 118.17 -0.919 . . . . 1.0 109.507 180.0 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 24.3 pttm . . . . . 0 N--CA 1.479 0.978 0 CA-C-O 121.298 0.57 . . . . 1.0 110.716 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 62.7 p -131.84 154.74 48.85 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-O 121.955 0.883 . . . . 1.0 109.84 -179.649 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -143.11 161.22 27.6 Favored Glycine 0 N--CA 1.461 0.341 0 N-CA-C 110.317 -1.113 . . . . 1.0 110.317 -179.663 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 74.1 mt -109.97 135.86 47.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 CA-C-O 121.691 0.758 . . . . 1.0 109.503 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 47.4 t -82.49 131.02 34.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.282 -0.872 . . . . 1.0 109.44 179.575 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 -60.09 109.64 1.02 Allowed 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 115.628 -0.715 . . . . 1.0 110.404 179.751 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 14.7 p -65.79 133.3 31.0 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 CA-C-N 116.028 -0.533 . . . . 1.0 110.234 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 88.0 p -170.51 -55.98 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 121.191 0.52 . . . . 1.0 110.138 179.599 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 68.5 m -148.79 -110.98 0.07 Allowed 'General case' 0 N--CA 1.477 0.891 0 CA-C-N 115.863 -0.608 . . . . 1.0 110.718 -179.471 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 39.7 t -135.29 142.95 45.97 Favored 'General case' 0 N--CA 1.473 0.713 0 CA-C-O 121.9 0.857 . . . . 1.0 110.51 -179.55 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -101.39 141.66 33.93 Favored 'General case' 0 N--CA 1.474 0.742 0 CA-C-O 122.21 1.005 . . . . 1.0 110.029 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 79.8 m-20 -93.13 123.17 36.21 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 114.708 -1.133 . . . . 1.0 109.523 -179.672 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 64.3 t -96.67 114.97 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 CA-C-N 115.603 -0.726 . . . . 1.0 109.089 -179.808 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -87.65 173.19 9.18 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-O 122.07 0.938 . . . . 1.0 109.585 179.095 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 88.8 p -97.52 -19.25 18.5 Favored 'General case' 0 N--CA 1.478 0.969 0 CA-C-N 114.974 -1.012 . . . . 1.0 110.292 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 88.9 p -149.41 -163.58 1.82 Allowed 'General case' 0 N--CA 1.475 0.823 0 CA-C-O 121.47 0.653 . . . . 1.0 110.824 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -101.3 53.61 0.83 Allowed 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 115.58 -0.736 . . . . 1.0 110.165 -179.79 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 46.4 t -138.89 137.34 36.42 Favored 'General case' 0 N--CA 1.479 1.023 0 CA-C-O 121.55 0.691 . . . . 1.0 110.744 179.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.2 t -67.42 -27.14 66.82 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 115.391 -0.822 . . . . 1.0 110.702 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 50.0 m -77.41 -7.51 56.24 Favored 'General case' 0 N--CA 1.469 0.508 0 CA-C-N 115.656 -0.702 . . . . 1.0 110.19 -179.854 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 34.8 t -65.77 124.89 23.65 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-O 120.987 0.422 . . . . 1.0 110.341 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -67.88 166.57 15.3 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.89 -0.595 . . . . 1.0 110.208 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 19.5 t -76.9 114.38 17.19 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.658 0 CA-C-O 121.662 0.744 . . . . 1.0 110.023 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 5.4 tt -96.88 -17.35 6.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.195 -0.911 . . . . 1.0 109.846 179.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -166.81 -162.12 17.62 Favored Glycine 0 N--CA 1.463 0.456 0 N-CA-C 110.721 -0.952 . . . . 1.0 110.721 -179.537 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 50.4 m -158.71 132.51 7.63 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.278 0.561 . . . . 1.0 109.936 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.2 tp -110.31 149.06 30.74 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-O 121.567 0.699 . . . . 1.0 109.907 179.614 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 45.7 p -91.15 159.89 15.85 Favored 'General case' 0 N--CA 1.469 0.483 0 CA-C-N 115.327 -0.851 . . . . 1.0 109.604 179.608 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -78.75 152.17 36.74 Favored Glycine 0 CA--C 1.529 0.934 0 N-CA-C 110.443 -1.063 . . . . 1.0 110.443 179.526 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 70.14 19.08 6.84 Favored 'General case' 0 N--CA 1.474 0.772 0 CA-C-O 120.887 0.375 . . . . 1.0 110.449 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 32.0 m -88.67 139.75 30.15 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-N 116.119 -0.491 . . . . 1.0 109.878 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 63.3 tttm -86.3 139.25 31.17 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.893 -0.594 . . . . 1.0 109.963 179.547 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 14.4 m -142.99 124.46 11.77 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.879 0 CA-C-N 115.687 -0.688 . . . . 1.0 110.2 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 62.1 p -79.89 87.76 5.32 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-O 121.355 0.598 . . . . 1.0 109.709 179.636 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.577 HG22 ' N ' ' A' ' 37' ' ' VAL . 63.0 mt -55.81 169.43 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.504 0 CA-C-O 121.66 0.743 . . . . 1.0 109.498 179.844 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.577 ' N ' HG22 ' A' ' 36' ' ' ILE . 0.2 OUTLIER -131.91 -96.0 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.055 0 CA-C-N 115.348 -0.842 . . . . 1.0 109.885 -179.156 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . 0.408 ' H ' HG23 ' A' ' 37' ' ' VAL . . . -99.4 -170.07 30.46 Favored Glycine 0 N--CA 1.465 0.62 0 N-CA-C 110.631 -0.987 . . . . 1.0 110.631 -179.566 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 13.5 mp0 -128.85 132.95 47.81 Favored 'General case' 0 N--CA 1.478 0.943 0 CA-C-N 114.651 -0.775 . . . . 1.0 110.224 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.41 ' O ' ' O ' ' A' ' 43' ' ' PHE . 44.3 tp10 -150.32 120.68 7.35 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-N 115.497 -0.774 . . . . 1.0 110.041 179.527 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 47.08 -122.65 7.17 Favored Glycine 0 CA--C 1.543 1.805 0 N-CA-C 111.509 -0.636 . . . . 1.0 111.509 179.779 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -114.03 22.32 14.0 Favored 'General case' 0 N--CA 1.481 1.106 0 C-N-CA 122.546 0.338 . . . . 1.0 110.251 178.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.41 ' O ' ' O ' ' A' ' 40' ' ' GLU . 77.7 m-85 -149.13 157.42 43.37 Favored 'General case' 0 N--CA 1.484 1.264 0 CA-C-O 121.6 0.714 . . . . 1.0 110.74 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' TYR . . . . . 0.458 ' N ' ' CD1' ' A' ' 44' ' ' TYR . 10.1 p90 -140.39 172.99 11.95 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 122.077 0.942 . . . . 1.0 109.939 -179.712 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -97.52 156.56 16.44 Favored 'General case' 0 N--CA 1.474 0.751 0 CA-C-N 114.905 -1.043 . . . . 1.0 109.97 -179.434 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 32.2 pt -147.41 161.7 7.9 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 CA-C-O 122.215 1.007 . . . . 1.0 109.884 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 18.6 mp0 -121.54 87.36 2.74 Favored 'General case' 0 N--CA 1.481 1.088 0 CA-C-N 114.748 -1.115 . . . . 1.0 109.844 -179.768 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -138.68 158.86 43.45 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-N 115.576 -0.738 . . . . 1.0 110.019 179.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . 0.404 ' C ' ' H ' ' A' ' 51' ' ' SER . 48.7 mtmt 52.92 18.47 1.08 Allowed 'General case' 0 CA--C 1.541 0.611 0 CA-C-N 115.626 -0.715 . . . . 1.0 110.811 179.801 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 67.97 -1.52 8.11 Favored Glycine 0 CA--C 1.532 1.1 0 N-CA-C 110.429 -1.068 . . . . 1.0 110.429 -179.181 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . 0.404 ' H ' ' C ' ' A' ' 49' ' ' LYS . 97.6 p -116.12 171.96 7.47 Favored 'General case' 0 N--CA 1.484 1.265 0 CA-C-O 121.994 0.902 . . . . 1.0 110.317 -179.859 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 96.3 m-70 -101.75 146.12 28.2 Favored 'General case' 0 N--CA 1.478 0.932 0 CA-C-N 115.006 -0.997 . . . . 1.0 110.09 -179.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -152.9 168.32 31.78 Favored Glycine 0 CA--C 1.531 1.041 0 N-CA-C 110.673 -0.971 . . . . 1.0 110.673 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 66.2 m-85 -134.61 150.16 50.66 Favored 'General case' 0 N--CA 1.486 1.37 0 CA-C-O 121.018 0.437 . . . . 1.0 110.608 179.601 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -155.19 155.84 5.45 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 CA-C-N 115.967 -0.561 . . . . 1.0 110.348 -179.808 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.69 130.38 44.02 Favored 'General case' 0 CA--C 1.545 0.78 0 CA-C-O 122.173 0.987 . . . . 1.0 109.861 179.049 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.46 -35.1 17.23 Favored 'General case' 0 N--CA 1.483 1.191 0 CA-C-N 114.86 -1.064 . . . . 1.0 110.177 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -58.33 -30.39 66.66 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.656 0.741 . . . . 1.0 110.371 -179.674 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 1.2 t80 -52.52 -19.8 2.51 Favored 'General case' 0 CA--C 1.537 0.465 0 CA-C-N 115.362 -0.835 . . . . 1.0 110.792 -179.806 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 69.8 mt . . . . . 0 C--O 1.221 -0.436 0 CA-C-O 118.0 -1.0 . . . . 1.0 108.761 -179.834 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 74.6 mmtt . . . . . 0 N--CA 1.471 0.593 0 CA-C-O 121.267 0.556 . . . . 1.0 110.753 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 69.8 p -131.55 158.59 40.55 Favored 'General case' 0 N--CA 1.472 0.659 0 CA-C-O 121.825 0.821 . . . . 1.0 110.136 -179.48 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -145.57 163.94 28.15 Favored Glycine 0 N--CA 1.468 0.812 0 N-CA-C 110.495 -1.042 . . . . 1.0 110.495 -179.556 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 3.7 mp -110.13 129.68 64.69 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 CA-C-O 121.287 0.565 . . . . 1.0 109.97 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 55.9 t -73.42 133.34 31.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.648 -0.706 . . . . 1.0 109.491 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ASN . . . . . 0.571 HD22 ' N ' ' A' ' 7' ' ' ASN . 1.0 OUTLIER -49.2 96.83 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.707 0 CA-C-N 115.768 -0.651 . . . . 1.0 110.694 179.604 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.5 t -63.37 -6.55 2.26 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.539 0 CA-C-N 115.749 -0.66 . . . . 1.0 110.008 -179.221 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.0 m -52.71 -49.87 64.5 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.087 -0.506 . . . . 1.0 110.69 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 93.0 p -149.96 169.37 21.33 Favored 'General case' 0 N--CA 1.472 0.652 0 CA-C-O 121.461 0.648 . . . . 1.0 110.524 179.385 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 89.1 p -78.93 150.34 32.11 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 115.523 -0.762 . . . . 1.0 109.707 -179.331 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.9 mp -118.96 145.48 45.76 Favored 'General case' 0 N--CA 1.49 1.543 0 CA-C-O 122.287 1.042 . . . . 1.0 110.08 -179.426 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 73.8 m-80 -96.49 146.62 24.64 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 114.701 -1.136 . . . . 1.0 110.003 179.693 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 22.4 t -94.57 104.78 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.936 0 CA-C-N 115.529 -0.76 . . . . 1.0 109.684 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 88.8 mtm180 -79.41 135.64 36.74 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.341 0.591 . . . . 1.0 109.761 179.821 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 38.9 t -63.43 -27.17 69.1 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 115.581 -0.736 . . . . 1.0 110.442 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 47.2 t -144.85 -176.66 5.16 Favored 'General case' 0 N--CA 1.479 0.998 0 CA-C-N 115.97 -0.559 . . . . 1.0 110.927 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.425 ' HB2' ' CD1' ' A' ' 43' ' ' PHE . . . -81.83 57.17 3.33 Favored 'General case' 0 N--CA 1.476 0.843 0 CA-C-N 115.774 -0.648 . . . . 1.0 110.235 -179.898 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 47.3 t -156.92 137.67 13.29 Favored 'General case' 0 N--CA 1.472 0.64 0 CA-C-O 121.203 0.525 . . . . 1.0 110.686 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.8 t -67.12 -32.97 74.46 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 115.756 -0.656 . . . . 1.0 110.629 179.62 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 89.4 p -69.35 -4.31 17.72 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 116.029 -0.532 . . . . 1.0 110.303 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 90.2 p -60.47 -172.02 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.539 0 CA-C-O 120.995 0.426 . . . . 1.0 110.25 179.53 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 5.5 mptt -116.57 148.16 41.15 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-O 121.234 0.54 . . . . 1.0 110.749 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 20.1 t -82.16 115.46 24.73 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 115.778 -0.646 . . . . 1.0 109.537 179.79 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 34.2 pt -96.43 -16.79 7.09 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.896 0 CA-C-N 115.706 -0.679 . . . . 1.0 109.891 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 179.53 165.77 34.17 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.71 -0.956 . . . . 1.0 110.71 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 50.7 m -117.54 135.55 53.87 Favored 'General case' 0 N--CA 1.484 1.268 0 CA-C-O 121.289 0.566 . . . . 1.0 109.918 179.61 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 3.5 tp -100.04 159.02 15.42 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-O 121.875 0.845 . . . . 1.0 109.141 -179.414 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 49.1 m -101.48 145.95 28.29 Favored 'General case' 0 N--CA 1.473 0.677 0 CA-C-N 115.208 -0.906 . . . . 1.0 110.106 -179.132 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -73.85 151.86 44.93 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.353 -1.099 . . . . 1.0 110.353 179.285 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 74.78 13.77 3.43 Favored 'General case' 0 N--CA 1.482 1.159 0 CA-C-O 120.525 0.202 . . . . 1.0 110.518 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 89.0 m -83.05 137.15 34.23 Favored 'General case' 0 N--CA 1.477 0.912 0 CA-C-O 121.12 0.486 . . . . 1.0 110.32 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -92.81 144.04 25.68 Favored 'General case' 0 N--CA 1.473 0.721 0 CA-C-N 115.806 -0.634 . . . . 1.0 109.989 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.4 p -154.77 139.81 10.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.748 -0.66 . . . . 1.0 109.91 179.872 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 68.9 p -83.4 83.36 7.9 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.877 -0.601 . . . . 1.0 109.637 179.217 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.539 HG22 ' N ' ' A' ' 37' ' ' VAL . 74.5 mt -48.49 167.0 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 CA-C-N 115.818 -0.628 . . . . 1.0 110.066 179.801 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.539 ' N ' HG22 ' A' ' 36' ' ' ILE . 40.8 t -128.07 -91.86 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 CA-C-N 116.22 -0.445 . . . . 1.0 110.087 -179.61 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -118.03 -155.54 10.06 Favored Glycine 0 N--CA 1.474 1.215 0 N-CA-C 110.863 -0.895 . . . . 1.0 110.863 -179.471 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -142.19 144.71 33.54 Favored 'General case' 0 N--CA 1.478 0.971 0 CA-C-N 115.059 -0.57 . . . . 1.0 110.281 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 38.3 tp10 -147.36 122.39 10.09 Favored 'General case' 0 N--CA 1.473 0.713 0 CA-C-N 115.74 -0.664 . . . . 1.0 109.986 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 54.71 -129.43 44.63 Favored Glycine 0 CA--C 1.53 0.995 0 N-CA-C 111.398 -0.681 . . . . 1.0 111.398 179.595 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -100.18 33.92 2.5 Favored 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 110.068 -0.345 . . . . 1.0 110.068 179.406 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.425 ' CD1' ' HB2' ' A' ' 18' ' ' ALA . 26.9 p90 -159.04 168.96 25.35 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-O 122.152 0.977 . . . . 1.0 110.083 179.321 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' TYR . . . . . 0.483 ' N ' ' CD1' ' A' ' 44' ' ' TYR . 3.3 p90 -129.63 163.92 25.01 Favored 'General case' 0 N--CA 1.481 1.107 0 CA-C-N 114.79 -1.095 . . . . 1.0 110.448 179.779 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 62.8 tttp -86.88 142.31 28.13 Favored 'General case' 0 N--CA 1.473 0.717 0 CA-C-N 115.341 -0.845 . . . . 1.0 109.771 -179.049 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 19.7 pt -141.32 156.51 21.54 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-O 122.083 0.944 . . . . 1.0 110.22 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -124.88 94.08 4.08 Favored 'General case' 0 N--CA 1.48 1.053 0 CA-C-N 114.844 -1.071 . . . . 1.0 109.971 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 22.8 t80 -128.47 147.5 50.67 Favored 'General case' 0 N--CA 1.476 0.875 0 CA-C-N 115.974 -0.557 . . . . 1.0 110.058 179.517 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 46.4 mtpt 54.11 17.56 1.47 Allowed 'General case' 0 CA--C 1.547 0.832 0 CA-C-N 115.908 -0.587 . . . . 1.0 110.497 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 72.18 1.78 51.01 Favored Glycine 0 N--CA 1.468 0.805 0 N-CA-C 110.6 -1.0 . . . . 1.0 110.6 -179.489 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 47.4 t -104.99 171.13 7.48 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 123.517 0.727 . . . . 1.0 110.2 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 49.4 p-80 -103.67 138.5 40.23 Favored 'General case' 0 N--CA 1.482 1.137 0 CA-C-N 115.618 -0.719 . . . . 1.0 110.484 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -150.75 166.76 30.36 Favored Glycine 0 N--CA 1.472 1.058 0 N-CA-C 110.782 -0.927 . . . . 1.0 110.782 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 33.4 m-85 -135.5 152.16 51.06 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-O 121.539 0.685 . . . . 1.0 110.194 179.456 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -150.39 151.16 12.91 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.953 0 CA-C-N 115.455 -0.793 . . . . 1.0 109.768 -179.089 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.56 125.64 24.61 Favored 'General case' 0 CA--C 1.54 0.561 0 CA-C-N 115.222 -0.899 . . . . 1.0 110.2 179.405 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 7.7 pttm -78.55 -31.18 47.32 Favored 'General case' 0 N--CA 1.473 0.681 0 CA-C-N 115.259 -0.882 . . . . 1.0 110.183 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -55.57 -35.45 65.76 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.061 -0.518 . . . . 1.0 110.401 -179.14 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.7 m-85 -60.47 -42.01 95.36 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 115.866 -0.606 . . . . 1.0 109.868 179.486 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 65.6 mt . . . . . 0 N--CA 1.476 0.831 0 CA-C-O 118.199 -0.905 . . . . 1.0 109.268 -179.359 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 41.1 ttp . . . . . 0 N--CA 1.489 1.499 0 N-CA-C 108.795 -0.817 . . . . 1.0 108.795 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 61.2 tttp -64.42 124.64 22.32 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 121.141 0.496 . . . . 1.0 110.131 -179.219 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 65.8 p -96.03 162.69 13.44 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.953 0.883 . . . . 1.0 109.759 179.738 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -101.6 155.89 18.89 Favored Glycine 0 N--CA 1.47 0.961 0 N-CA-C 110.454 -1.058 . . . . 1.0 110.454 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 69.0 mt -111.55 128.09 68.29 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.088 0 CA-C-O 121.502 0.668 . . . . 1.0 109.559 -179.939 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 24.4 t -68.48 132.05 33.13 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.335 0 CA-C-N 115.571 -0.741 . . . . 1.0 109.883 179.807 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . 0.418 ' O ' ' N ' ' A' ' 9' ' ' SER . 10.5 p-10 -55.77 109.18 0.53 Allowed 'General case' 0 CA--C 1.54 0.572 0 CA-C-N 116.112 -0.494 . . . . 1.0 110.411 179.659 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 15.1 t -66.4 72.28 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.495 0 CA-C-N 116.155 -0.475 . . . . 1.0 110.207 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.418 ' N ' ' O ' ' A' ' 7' ' ' ASN . 30.4 t -85.39 -104.59 0.06 Allowed 'General case' 0 CA--C 1.54 0.564 0 CA-C-N 115.92 -0.582 . . . . 1.0 109.916 179.798 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 97.0 p -157.29 -28.02 0.09 Allowed 'General case' 0 N--CA 1.478 0.967 0 CA-C-O 121.471 0.653 . . . . 1.0 111.11 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 44.4 t -153.87 145.31 23.13 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 115.539 -0.755 . . . . 1.0 110.703 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.424 HD13 ' N ' ' A' ' 13' ' ' ASN . 0.2 OUTLIER -155.16 121.55 5.28 Favored 'General case' 0 N--CA 1.467 0.413 0 C-N-CA 120.773 -0.371 . . . . 1.0 110.536 178.319 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . 0.424 ' N ' HD13 ' A' ' 12' ' ' LEU . 74.7 m-20 -89.23 134.09 34.18 Favored 'General case' 0 CA--C 1.531 0.243 0 CA-C-O 121.856 0.836 . . . . 1.0 109.809 179.453 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 33.9 t -103.84 128.36 57.18 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.028 0 CA-C-N 115.154 -0.93 . . . . 1.0 109.559 179.71 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 83.1 mtt-85 -97.43 179.75 4.76 Favored 'General case' 0 N--CA 1.471 0.602 0 CA-C-O 121.56 0.695 . . . . 1.0 110.046 179.426 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 24.4 p -104.86 -7.15 19.58 Favored 'General case' 0 N--CA 1.484 1.238 0 CA-C-N 115.373 -0.83 . . . . 1.0 110.36 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.447 ' C ' ' H ' ' A' ' 19' ' ' SER . 42.0 t -170.7 178.22 3.64 Favored 'General case' 0 N--CA 1.469 0.482 0 CA-C-O 121.264 0.554 . . . . 1.0 110.745 -179.772 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -72.97 40.4 0.09 Allowed 'General case' 0 N--CA 1.475 0.793 0 CA-C-N 115.82 -0.627 . . . . 1.0 110.664 179.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.447 ' H ' ' C ' ' A' ' 17' ' ' SER . 78.8 p -137.49 136.82 38.06 Favored 'General case' 0 N--CA 1.48 1.033 0 CA-C-O 121.52 0.676 . . . . 1.0 110.403 179.871 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 80.4 p -73.71 -27.98 61.48 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-N 115.427 -0.806 . . . . 1.0 110.21 179.784 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 97.2 p -65.34 -21.32 66.68 Favored 'General case' 0 N--CA 1.465 0.295 0 CA-C-N 116.335 -0.393 . . . . 1.0 110.242 -179.541 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 37.6 m -55.49 -29.36 58.66 Favored 'General case' 0 N--CA 1.472 0.639 0 CA-C-O 120.988 0.423 . . . . 1.0 110.284 179.138 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 25.5 tttm 71.14 -177.2 0.2 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.933 -0.576 . . . . 1.0 110.018 179.911 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 13.2 t -79.57 161.06 4.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 122.063 0.935 . . . . 1.0 109.512 179.335 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 35.0 pt -148.82 -22.43 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.471 0.615 0 CA-C-N 114.858 -1.065 . . . . 1.0 110.414 -179.766 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -173.52 164.62 36.33 Favored Glycine 0 CA--C 1.52 0.376 0 N-CA-C 110.673 -0.971 . . . . 1.0 110.673 -179.752 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 98.1 p -118.62 133.11 56.1 Favored 'General case' 0 N--CA 1.48 1.053 0 CA-C-O 121.91 0.862 . . . . 1.0 110.06 179.562 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.2 tp -101.6 155.48 18.07 Favored 'General case' 0 N--CA 1.473 0.725 0 CA-C-N 115.113 -0.948 . . . . 1.0 109.649 -179.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 57.6 m -93.2 143.06 26.62 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.144 -0.934 . . . . 1.0 109.919 -179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -74.83 155.65 48.37 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.149 -1.18 . . . . 1.0 110.149 179.442 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 8.0 t-20 69.67 16.84 7.91 Favored 'General case' 0 N--CA 1.475 0.784 0 CA-C-O 120.792 0.329 . . . . 1.0 110.381 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 83.3 m -88.06 141.95 28.17 Favored 'General case' 0 N--CA 1.471 0.581 0 CA-C-O 121.279 0.562 . . . . 1.0 109.957 179.993 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 37.9 ttpt -83.15 134.6 34.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 121.712 0.768 . . . . 1.0 110.029 179.555 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 5.2 m -140.96 123.42 15.24 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.575 0 CA-C-N 115.316 -0.856 . . . . 1.0 110.136 179.805 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.43 ' O ' ' C ' ' A' ' 36' ' ' ILE . 31.2 m -84.31 87.62 7.21 Favored 'General case' 0 N--CA 1.467 0.384 0 N-CA-C 109.661 -0.496 . . . . 1.0 109.661 179.117 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.614 HD12 ' H ' ' A' ' 36' ' ' ILE . 1.7 mp -34.49 145.66 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 CA-C-N 116.067 -0.515 . . . . 1.0 110.541 179.196 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -154.3 67.54 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 CA-C-N 115.974 -0.557 . . . . 1.0 109.829 -178.563 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 96.05 167.89 34.61 Favored Glycine 0 CA--C 1.503 -0.69 0 N-CA-C 110.567 -1.013 . . . . 1.0 110.567 178.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 1.3 pp20? -153.73 156.61 38.1 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.216 -0.492 . . . . 1.0 110.669 -178.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 42.9 tt0 -153.61 127.61 8.96 Favored 'General case' 0 CA--C 1.534 0.35 0 CA-C-N 116.022 -0.536 . . . . 1.0 110.505 179.229 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 59.54 -152.87 33.7 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.358 -0.697 . . . . 1.0 111.358 179.602 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -77.47 38.87 0.25 Allowed 'General case' 0 N--CA 1.467 0.378 0 N-CA-C 109.855 -0.424 . . . . 1.0 109.855 179.443 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 50.6 m-85 -151.37 159.14 44.42 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-O 121.804 0.812 . . . . 1.0 110.477 -179.769 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 1.3 m-85 -118.86 157.3 27.9 Favored 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 122.199 0.999 . . . . 1.0 110.238 179.668 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 84.4 tttt -99.81 144.33 29.0 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 114.854 -1.067 . . . . 1.0 109.854 179.95 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 28.8 pt -149.37 172.24 1.66 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 115.241 -0.891 . . . . 1.0 109.952 -179.576 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 77.4 tt0 -139.86 105.13 5.04 Favored 'General case' 0 N--CA 1.472 0.673 0 CA-C-N 115.143 -0.935 . . . . 1.0 110.333 179.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 27.1 t80 -139.7 163.71 31.87 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 115.592 -0.731 . . . . 1.0 110.187 179.269 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . 0.414 ' C ' ' H ' ' A' ' 51' ' ' SER . 18.5 mmtm 51.77 24.87 2.64 Favored 'General case' 0 CA--C 1.544 0.741 0 CA-C-N 115.57 -0.741 . . . . 1.0 111.06 179.623 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 74.0 -8.89 10.3 Favored Glycine 0 CA--C 1.528 0.883 0 N-CA-C 110.147 -1.181 . . . . 1.0 110.147 -179.623 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . 0.414 ' H ' ' C ' ' A' ' 49' ' ' LYS . 50.5 m -108.82 174.02 6.06 Favored 'General case' 0 N--CA 1.478 0.959 0 CA-C-O 122.07 0.938 . . . . 1.0 110.074 179.783 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 32.7 p80 -131.01 135.12 47.32 Favored 'General case' 0 N--CA 1.48 1.044 0 CA-C-N 114.971 -1.013 . . . . 1.0 110.331 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.03 154.55 25.98 Favored Glycine 0 N--CA 1.47 0.944 0 N-CA-C 110.652 -0.979 . . . . 1.0 110.652 179.537 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 55.6 m-85 -90.76 145.09 25.08 Favored 'General case' 0 N--CA 1.472 0.651 0 CA-C-O 121.485 0.66 . . . . 1.0 109.731 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 17.1 t -141.85 145.78 23.76 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 CA-C-N 115.582 -0.736 . . . . 1.0 110.365 -179.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.91 138.38 58.53 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.573 -0.74 . . . . 1.0 109.967 179.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 12.5 pttp -89.86 -25.13 21.18 Favored 'General case' 0 N--CA 1.475 0.809 0 CA-C-N 115.541 -0.754 . . . . 1.0 110.183 179.919 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 44.7 tp10 -65.95 -37.72 86.75 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.465 0.65 . . . . 1.0 110.509 -178.85 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 23.0 m-85 -68.89 -31.88 71.13 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 115.527 -0.76 . . . . 1.0 110.092 179.82 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 72.8 mt . . . . . 0 N--CA 1.467 0.42 0 CA-C-O 118.138 -0.934 . . . . 1.0 109.193 -179.486 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.5 mtt . . . . . 0 N--CA 1.488 1.443 0 N-CA-C 108.967 -0.753 . . . . 1.0 108.967 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -66.24 -20.23 66.05 Favored 'General case' 0 N--CA 1.472 0.628 0 CA-C-O 121.512 0.672 . . . . 1.0 110.591 -179.6 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 3.2 p -132.8 153.5 51.2 Favored 'General case' 0 N--CA 1.478 0.946 0 CA-C-N 115.469 -0.787 . . . . 1.0 110.166 -179.29 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -140.71 160.78 26.63 Favored Glycine 0 N--CA 1.468 0.797 0 N-CA-C 110.658 -0.977 . . . . 1.0 110.658 -179.931 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 12.5 pt -106.01 135.96 42.25 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.09 0 CA-C-O 121.287 0.565 . . . . 1.0 109.737 179.542 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.485 ' O ' ' N ' ' A' ' 8' ' ' VAL . 37.7 t -53.72 111.69 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 CA-C-N 115.62 -0.718 . . . . 1.0 109.926 -179.751 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 4.7 m120 -56.31 83.42 0.01 OUTLIER 'General case' 0 N--CA 1.472 0.649 0 CA-C-N 115.724 -0.671 . . . . 1.0 110.593 179.601 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.485 ' N ' ' O ' ' A' ' 6' ' ' VAL . 3.2 t 47.71 -126.25 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.554 1.134 0 CA-C-N 115.579 -0.737 . . . . 1.0 110.199 -179.791 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . 0.474 ' O ' ' O ' ' A' ' 8' ' ' VAL . 19.3 m 57.78 136.69 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.563 0 CA-C-N 115.687 -0.688 . . . . 1.0 110.72 179.659 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 48.9 m -54.41 -65.73 0.52 Allowed 'General case' 0 CA--C 1.533 0.301 0 CA-C-O 121.022 0.439 . . . . 1.0 110.652 -179.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 65.7 m -148.72 154.51 39.72 Favored 'General case' 0 N--CA 1.471 0.621 0 CA-C-O 121.798 0.809 . . . . 1.0 110.505 179.599 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -102.21 142.68 33.06 Favored 'General case' 0 N--CA 1.485 1.301 0 CA-C-N 115.233 -0.894 . . . . 1.0 109.977 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -85.18 99.53 11.14 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.072 -0.967 . . . . 1.0 109.477 -179.492 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 17.6 m -80.66 135.5 25.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 N-CA-C 108.686 -0.857 . . . . 1.0 108.686 -179.458 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 67.2 mtm180 -117.85 -176.48 3.05 Favored 'General case' 0 N--CA 1.476 0.852 0 CA-C-N 115.13 -0.941 . . . . 1.0 110.234 -179.247 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 67.0 p -89.88 -20.61 23.19 Favored 'General case' 0 N--CA 1.477 0.892 0 CA-C-N 115.333 -0.849 . . . . 1.0 110.519 -179.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.645 ' C ' ' H ' ' A' ' 19' ' ' SER . 60.9 p -176.28 -173.17 0.53 Allowed 'General case' 0 N--CA 1.473 0.718 0 CA-C-O 121.681 0.753 . . . . 1.0 110.414 -179.649 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.81 17.24 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.375 0 CA-C-N 115.343 -0.844 . . . . 1.0 111.586 178.654 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . 0.645 ' H ' ' C ' ' A' ' 17' ' ' SER . 70.0 m -100.87 97.83 8.39 Favored 'General case' 0 N--CA 1.48 1.038 0 CA-C-N 115.352 -0.84 . . . . 1.0 110.169 179.533 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 2.9 m -64.37 -4.29 3.72 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-N 115.685 -0.689 . . . . 1.0 110.15 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 85.7 p -97.89 -3.53 38.39 Favored 'General case' 0 N--CA 1.473 0.699 0 CA-C-N 116.001 -0.545 . . . . 1.0 110.719 -179.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 78.1 p -77.36 -4.96 47.81 Favored 'General case' 0 N--CA 1.472 0.632 0 N-CA-C 110.022 -0.362 . . . . 1.0 110.022 179.331 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 33.7 tttt 66.05 -163.27 0.24 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 121.094 0.473 . . . . 1.0 110.167 179.606 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 24.8 t -94.22 158.16 2.95 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 CA-C-O 122.193 0.997 . . . . 1.0 109.28 179.753 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 47.7 pt -137.67 -20.58 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.479 1.005 0 CA-C-N 114.852 -1.067 . . . . 1.0 110.496 179.966 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.471 ' CA ' ' HZ1' ' A' ' 49' ' ' LYS . . . -158.44 -153.89 6.95 Favored Glycine 0 N--CA 1.466 0.64 0 N-CA-C 110.689 -0.964 . . . . 1.0 110.689 -179.441 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . 0.681 ' H ' ' HZ3' ' A' ' 49' ' ' LYS . 93.2 p -159.17 148.65 18.69 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 121.322 0.582 . . . . 1.0 110.372 179.644 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.6 tp -122.3 154.43 37.6 Favored 'General case' 0 N--CA 1.481 1.106 0 CA-C-O 121.624 0.726 . . . . 1.0 110.311 179.763 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 90.9 p -103.33 159.92 15.14 Favored 'General case' 0 N--CA 1.477 0.901 0 CA-C-N 115.39 -0.823 . . . . 1.0 110.25 179.749 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -79.65 168.11 52.31 Favored Glycine 0 N--CA 1.476 1.352 0 N-CA-C 110.537 -1.025 . . . . 1.0 110.537 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 66.2 m-20 56.32 20.87 4.94 Favored 'General case' 0 N--CA 1.477 0.877 0 CA-C-O 120.929 0.395 . . . . 1.0 110.759 -179.976 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 29.6 m -89.94 150.42 22.17 Favored 'General case' 0 N--CA 1.473 0.693 0 CA-C-O 121.401 0.619 . . . . 1.0 109.828 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 50.9 tttp -103.25 150.6 23.57 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 115.548 -0.751 . . . . 1.0 110.275 -179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 6.4 p -157.36 145.56 10.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.687 -0.688 . . . . 1.0 109.858 179.553 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 90.4 m -106.09 106.33 16.79 Favored 'General case' 0 N--CA 1.481 1.095 0 N-CA-C 109.428 -0.582 . . . . 1.0 109.428 178.544 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.459 ' O ' HG13 ' A' ' 37' ' ' VAL . 11.7 mm -42.35 134.86 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 CA-C-N 116.502 -0.317 . . . . 1.0 111.2 179.283 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.459 HG13 ' O ' ' A' ' 36' ' ' ILE . 3.2 m -159.51 90.24 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.069 0 CA-C-O 121.986 0.898 . . . . 1.0 110.518 -178.052 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 109.63 115.06 3.7 Favored Glycine 0 N--CA 1.481 1.657 0 CA-C-N 115.114 -0.948 . . . . 1.0 110.824 179.178 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.546 ' CD ' ' H ' ' A' ' 39' ' ' GLU . 0.5 OUTLIER -105.13 132.62 51.12 Favored 'General case' 0 N--CA 1.48 1.033 0 N-CA-C 109.245 -0.65 . . . . 1.0 109.245 -178.817 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 79.8 tt0 -151.31 102.85 2.95 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.837 -0.62 . . . . 1.0 109.883 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.432 ' C ' ' H ' ' A' ' 43' ' ' PHE . . . 57.12 -149.21 31.39 Favored Glycine 0 CA--C 1.533 1.16 0 N-CA-C 111.226 -0.749 . . . . 1.0 111.226 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -74.56 17.56 0.2 Allowed 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 120.926 -0.31 . . . . 1.0 110.455 179.082 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.432 ' H ' ' C ' ' A' ' 41' ' ' GLY . 38.3 m-85 -133.56 158.13 43.95 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-O 121.853 0.835 . . . . 1.0 110.215 -179.53 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' TYR . . . . . 0.441 ' CD2' ' CG2' ' A' ' 36' ' ' ILE . 2.8 m-85 -127.04 165.22 19.88 Favored 'General case' 0 N--CA 1.473 0.692 0 CA-C-O 122.621 1.2 . . . . 1.0 109.839 179.618 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 23.9 ttpp -107.96 129.58 55.1 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-N 114.465 -1.243 . . . . 1.0 110.004 -179.736 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 45.5 pt -122.18 170.05 12.81 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.396 0 CA-C-O 122.302 1.048 . . . . 1.0 110.045 179.458 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 6.4 pt-20 -131.1 102.2 5.91 Favored 'General case' 0 N--CA 1.482 1.164 0 CA-C-N 114.702 -1.135 . . . . 1.0 109.778 -179.441 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.3 OUTLIER -138.93 160.35 39.95 Favored 'General case' 0 N--CA 1.47 0.575 0 CA-C-O 121.432 0.634 . . . . 1.0 109.829 179.561 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . 0.681 ' HZ3' ' H ' ' A' ' 27' ' ' SER . 43.3 mtmt 50.35 26.65 2.36 Favored 'General case' 0 CA--C 1.546 0.811 0 CA-C-N 115.595 -0.73 . . . . 1.0 111.369 -179.906 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 67.07 6.74 40.19 Favored Glycine 0 N--CA 1.474 1.227 0 N-CA-C 110.465 -1.054 . . . . 1.0 110.465 -179.418 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 85.7 p -117.35 175.45 5.61 Favored 'General case' 0 N--CA 1.485 1.303 0 C-N-CA 124.228 1.011 . . . . 1.0 110.506 -179.631 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 27.3 p-80 -114.29 135.51 53.99 Favored 'General case' 0 N--CA 1.486 1.368 0 CA-C-N 115.18 -0.918 . . . . 1.0 110.331 -179.956 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -140.08 166.08 25.8 Favored Glycine 0 N--CA 1.472 1.059 0 N-CA-C 110.988 -0.845 . . . . 1.0 110.988 179.724 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 58.2 m-85 -130.35 136.5 49.17 Favored 'General case' 0 N--CA 1.483 1.196 0 CA-C-O 121.904 0.859 . . . . 1.0 110.11 179.692 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 26.0 t -143.28 150.2 17.77 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.641 0 CA-C-N 115.145 -0.934 . . . . 1.0 110.175 -179.895 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -67.64 127.49 32.97 Favored 'General case' 0 CA--C 1.538 0.496 0 CA-C-N 115.481 -0.781 . . . . 1.0 109.812 179.424 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 11.5 pttm -74.91 -20.81 59.54 Favored 'General case' 0 N--CA 1.476 0.853 0 CA-C-N 115.251 -0.886 . . . . 1.0 110.095 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 76.5 tt0 -65.41 -37.47 87.06 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 121.461 0.648 . . . . 1.0 110.399 -178.817 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 27.3 m-85 -74.08 -33.61 63.7 Favored 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 115.609 -0.723 . . . . 1.0 109.897 179.754 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 62.6 mt . . . . . 0 N--CA 1.471 0.613 0 CA-C-O 118.096 -0.954 . . . . 1.0 109.051 -179.033 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.9 mtm . . . . . 0 N--CA 1.49 1.537 0 N-CA-C 108.706 -0.85 . . . . 1.0 108.706 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 55.1 mtpt -63.69 -23.53 67.41 Favored 'General case' 0 N--CA 1.468 0.436 0 CA-C-O 121.382 0.61 . . . . 1.0 110.434 -179.647 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 46.0 p -137.11 160.43 38.99 Favored 'General case' 0 N--CA 1.473 0.709 0 CA-C-O 121.719 0.771 . . . . 1.0 110.458 -179.681 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -138.01 155.51 23.33 Favored Glycine 0 N--CA 1.471 0.995 0 N-CA-C 110.659 -0.977 . . . . 1.0 110.659 -179.861 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 15.6 pt -98.24 137.26 26.29 Favored 'Isoleucine or valine' 0 N--CA 1.476 0.83 0 CA-C-O 121.676 0.75 . . . . 1.0 109.209 179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.571 ' O ' ' C ' ' A' ' 7' ' ' ASN . 22.0 t -83.01 142.98 12.83 Favored 'Isoleucine or valine' 0 CA--C 1.513 -0.46 0 CA-C-N 115.366 -0.834 . . . . 1.0 109.566 -179.827 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . 0.571 ' C ' ' O ' ' A' ' 6' ' ' VAL . 42.9 t30 8.72 -109.27 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.125 0 CA-C-N 116.243 -0.435 . . . . 1.0 111.859 -179.602 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 22.0 t -143.02 -52.25 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.292 0 CA-C-O 120.715 0.293 . . . . 1.0 110.434 177.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 40.7 t -170.14 77.75 0.09 Allowed 'General case' 0 N--CA 1.472 0.641 0 CA-C-O 120.855 0.359 . . . . 1.0 110.618 -179.544 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 49.3 m -160.52 168.46 25.01 Favored 'General case' 0 N--CA 1.472 0.66 0 CA-C-N 116.052 -0.522 . . . . 1.0 110.679 -179.803 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 41.8 t -90.38 130.82 36.42 Favored 'General case' 0 N--CA 1.473 0.682 0 CA-C-O 121.304 0.573 . . . . 1.0 110.104 179.585 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 9.8 mp -100.94 164.35 11.86 Favored 'General case' 0 N--CA 1.479 1.002 0 CA-C-O 122.73 1.252 . . . . 1.0 109.41 179.409 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 84.9 m-20 -93.4 118.24 31.06 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-N 114.253 -1.339 . . . . 1.0 109.989 -179.614 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 20.6 t -101.9 107.58 21.94 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.308 0 N-CA-C 110.173 -0.306 . . . . 1.0 110.173 179.773 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 31.9 mtm180 -82.42 -173.14 4.41 Favored 'General case' 0 N--CA 1.478 0.971 0 CA-C-O 121.297 0.57 . . . . 1.0 110.345 179.441 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 17.6 t -95.17 -23.69 17.17 Favored 'General case' 0 N--CA 1.48 1.057 0 CA-C-N 115.675 -0.693 . . . . 1.0 111.085 -179.738 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.401 ' O ' ' HB3' ' A' ' 18' ' ' ALA . 28.7 t 175.86 38.85 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.645 0 CA-C-O 121.182 0.515 . . . . 1.0 111.214 -179.717 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.401 ' HB3' ' O ' ' A' ' 17' ' ' SER . . . 76.07 45.39 0.12 Allowed 'General case' 0 N--CA 1.483 1.192 0 CA-C-N 115.834 -0.621 . . . . 1.0 110.55 -179.782 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 70.5 m -129.83 117.28 19.95 Favored 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 115.84 -0.618 . . . . 1.0 110.795 179.832 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 24.9 m -64.06 -29.12 70.28 Favored 'General case' 0 N--CA 1.475 0.794 0 CA-C-N 116.067 -0.515 . . . . 1.0 109.995 179.347 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 55.0 m -68.45 -22.38 64.58 Favored 'General case' 0 CA--C 1.537 0.442 0 CA-C-N 116.121 -0.49 . . . . 1.0 110.508 -179.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 45.9 t -70.18 -39.07 75.48 Favored 'General case' 0 N--CA 1.475 0.8 0 CA-C-O 121.429 0.633 . . . . 1.0 110.528 179.128 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.451 ' HG2' ' H ' ' A' ' 24' ' ' VAL . 5.0 ttmm 80.43 -170.58 0.04 OUTLIER 'General case' 0 N--CA 1.485 1.305 0 CA-C-N 115.612 -0.722 . . . . 1.0 109.703 179.957 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.451 ' H ' ' HG2' ' A' ' 23' ' ' LYS . 24.9 t -83.76 105.51 13.35 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.494 0 CA-C-N 115.852 -0.613 . . . . 1.0 109.873 179.746 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 40.0 pt -94.12 -19.61 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 CA-C-N 115.789 -0.641 . . . . 1.0 110.489 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -145.22 -163.95 10.42 Favored Glycine 0 N--CA 1.478 1.492 0 N-CA-C 110.99 -0.844 . . . . 1.0 110.99 -179.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 45.4 t -160.87 130.24 4.84 Favored 'General case' 0 N--CA 1.47 0.549 0 C-N-CA 120.65 -0.42 . . . . 1.0 109.958 179.594 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 4.9 tp -109.52 153.32 24.27 Favored 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 121.342 0.591 . . . . 1.0 109.947 -179.937 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 61.4 m -91.3 149.93 21.53 Favored 'General case' 0 N--CA 1.472 0.628 0 CA-C-N 115.696 -0.684 . . . . 1.0 110.037 -179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -74.7 148.68 38.79 Favored Glycine 0 CA--C 1.528 0.849 0 N-CA-C 110.481 -1.048 . . . . 1.0 110.481 179.612 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 12.1 t-20 64.82 41.06 5.18 Favored 'General case' 0 N--CA 1.471 0.589 0 CA-C-O 121.024 0.44 . . . . 1.0 110.52 -179.763 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 34.7 m -106.96 127.43 53.44 Favored 'General case' 0 N--CA 1.489 1.484 0 CA-C-N 115.95 -0.568 . . . . 1.0 110.356 179.554 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 98.1 mttt -76.68 147.05 37.71 Favored 'General case' 0 N--CA 1.469 0.478 0 CA-C-O 121.231 0.538 . . . . 1.0 109.822 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.3 p -157.28 148.08 10.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-N 115.706 -0.679 . . . . 1.0 110.35 -179.421 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 68.4 p -86.06 84.28 7.55 Favored 'General case' 0 N--CA 1.473 0.689 0 CA-C-N 116.111 -0.495 . . . . 1.0 110.031 179.228 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.577 HG22 ' N ' ' A' ' 37' ' ' VAL . 69.4 mt -50.53 171.57 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 CA-C-N 116.37 -0.377 . . . . 1.0 110.216 -179.862 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.577 ' N ' HG22 ' A' ' 36' ' ' ILE . 39.1 t -139.29 -92.42 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.298 0 CA-C-N 116.547 -0.297 . . . . 1.0 110.668 -179.482 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -118.45 -172.58 15.6 Favored Glycine 0 N--CA 1.487 2.04 0 N-CA-C 111.052 -0.819 . . . . 1.0 111.052 -179.172 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 5.5 pt-20 -113.86 111.84 22.38 Favored 'General case' 0 N--CA 1.483 1.19 0 CA-C-O 123.331 1.539 . . . . 1.0 109.623 179.359 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.497 ' N ' ' O ' ' A' ' 43' ' ' PHE . 3.1 tm-20 -104.07 96.41 6.64 Favored 'General case' 0 N--CA 1.485 1.286 0 CA-C-N 113.676 -1.602 . . . . 1.0 109.214 179.026 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.423 ' O ' ' HB3' ' A' ' 42' ' ' ALA . . . 30.61 56.31 0.25 Allowed Glycine 0 N--CA 1.503 3.11 0 CA-C-N 114.806 -1.088 . . . . 1.0 113.141 179.64 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . 0.423 ' HB3' ' O ' ' A' ' 41' ' ' GLY . . . 76.46 30.41 0.65 Allowed 'General case' 0 N--CA 1.489 1.494 0 CA-C-N 115.18 -0.51 . . . . 1.0 111.188 -178.438 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.497 ' O ' ' N ' ' A' ' 40' ' ' GLU . 75.1 m-85 -153.86 159.41 41.79 Favored 'General case' 0 N--CA 1.496 1.864 0 CA-C-N 116.194 -0.457 . . . . 1.0 111.005 179.774 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' TYR . . . . . 0.428 ' CD1' ' N ' ' A' ' 44' ' ' TYR . 15.2 p90 -143.89 165.98 26.21 Favored 'General case' 0 N--CA 1.488 1.435 0 CA-C-O 120.893 0.377 . . . . 1.0 110.407 179.398 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 68.4 mttm -88.2 159.52 18.12 Favored 'General case' 0 N--CA 1.471 0.591 0 N-CA-C 109.551 -0.537 . . . . 1.0 109.551 -179.433 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 38.4 pt -146.97 154.38 11.91 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.563 0 CA-C-N 115.902 -0.59 . . . . 1.0 110.308 -179.367 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 72.7 mt-10 -110.33 84.28 1.9 Allowed 'General case' 0 N--CA 1.479 1.009 0 CA-C-N 115.911 -0.586 . . . . 1.0 109.67 179.501 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 7.7 t80 -119.56 137.04 54.09 Favored 'General case' 0 N--CA 1.486 1.352 0 CA-C-N 116.036 -0.529 . . . . 1.0 110.149 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 96.2 mttt 47.49 27.47 0.97 Allowed 'General case' 0 N--CA 1.481 1.09 0 CA-C-N 115.907 -0.588 . . . . 1.0 111.149 -179.297 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 67.44 23.26 73.49 Favored Glycine 0 N--CA 1.472 1.039 0 N-CA-C 110.824 -0.91 . . . . 1.0 110.824 179.965 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 92.1 p -128.4 166.02 19.5 Favored 'General case' 0 N--CA 1.482 1.136 0 CA-C-O 121.722 0.772 . . . . 1.0 110.826 -178.787 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 96.4 m-70 -94.31 153.66 17.89 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-N 115.344 -0.844 . . . . 1.0 110.382 -179.407 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -158.09 166.31 34.03 Favored Glycine 0 N--CA 1.473 1.118 0 N-CA-C 110.748 -0.941 . . . . 1.0 110.748 -179.821 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 69.5 m-85 -133.38 142.1 48.22 Favored 'General case' 0 N--CA 1.484 1.233 0 CA-C-N 115.552 -0.324 . . . . 1.0 110.417 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -147.78 147.29 17.4 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.404 0 CA-C-O 121.366 0.603 . . . . 1.0 109.816 -179.167 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -69.69 143.22 53.2 Favored 'General case' 0 CA--C 1.533 0.323 0 CA-C-N 115.642 -0.708 . . . . 1.0 110.017 -179.452 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 9.6 mtmp? -87.31 -32.81 19.46 Favored 'General case' 0 N--CA 1.48 1.073 0 CA-C-N 116.006 -0.543 . . . . 1.0 110.218 179.645 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 43.5 tt0 -52.58 -39.77 61.92 Favored 'General case' 0 N--CA 1.472 0.634 0 N-CA-C 110.227 -0.286 . . . . 1.0 110.227 -179.412 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 7.4 m-85 -48.4 -25.09 1.46 Allowed 'General case' 0 N--CA 1.48 1.069 0 CA-C-N 116.386 -0.37 . . . . 1.0 110.591 179.152 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 69.9 mt . . . . . 0 N--CA 1.476 0.861 0 CA-C-O 117.781 -1.104 . . . . 1.0 108.656 179.739 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 71.3 mtp . . . . . 0 N--CA 1.494 1.731 0 N-CA-C 109.391 -0.596 . . . . 1.0 109.391 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -62.88 -40.93 99.05 Favored 'General case' 0 N--CA 1.471 0.607 0 CA-C-O 121.812 0.815 . . . . 1.0 110.678 -179.57 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 51.7 p -115.73 156.89 25.16 Favored 'General case' 0 N--CA 1.479 1.003 0 CA-C-N 115.132 -0.94 . . . . 1.0 110.228 -179.8 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -91.4 148.98 19.57 Favored Glycine 0 N--CA 1.468 0.777 0 N-CA-C 110.36 -1.096 . . . . 1.0 110.36 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 65.7 mt -104.33 126.75 59.02 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.112 0 CA-C-O 121.607 0.718 . . . . 1.0 109.131 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 28.8 t -91.47 129.49 42.1 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-N 115.402 -0.817 . . . . 1.0 109.692 179.532 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 62.5 m-80 -49.27 125.64 11.31 Favored 'General case' 0 CA--C 1.545 0.762 0 CA-C-N 116.085 -0.507 . . . . 1.0 110.54 179.315 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 32.6 t -51.28 -62.27 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.474 0.733 0 CA-C-N 115.905 -0.589 . . . . 1.0 110.473 -179.451 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 58.9 m -62.91 153.93 31.87 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-O 121.179 0.514 . . . . 1.0 109.988 179.611 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER 69.54 -171.8 0.18 Allowed 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 115.856 -0.611 . . . . 1.0 110.157 -179.873 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 42.6 t -150.32 154.17 37.38 Favored 'General case' 0 N--CA 1.473 0.697 0 CA-C-O 121.548 0.69 . . . . 1.0 110.366 179.91 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.584 HD11 ' CG ' ' A' ' 59' ' ' TYR . 4.5 mm? -99.68 135.28 41.33 Favored 'General case' 0 N--CA 1.478 0.94 0 CA-C-O 122.062 0.934 . . . . 1.0 109.989 -179.42 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 20.3 p-10 -90.76 129.27 36.86 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.009 -0.996 . . . . 1.0 109.674 -179.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 41.0 t -92.02 103.38 14.51 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.548 0 CA-C-N 115.664 -0.698 . . . . 1.0 109.336 -179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 90.8 mtt-85 -81.97 151.57 27.11 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 121.434 0.635 . . . . 1.0 109.893 179.244 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 39.8 t -71.99 -21.63 61.54 Favored 'General case' 0 N--CA 1.467 0.422 0 CA-C-N 115.582 -0.735 . . . . 1.0 110.433 179.535 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 48.9 m -163.73 174.94 11.02 Favored 'General case' 0 N--CA 1.474 0.758 0 CA-C-N 116.014 -0.539 . . . . 1.0 110.682 -179.522 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -70.6 56.48 0.17 Allowed 'General case' 0 N--CA 1.474 0.744 0 CA-C-N 115.792 -0.64 . . . . 1.0 110.42 179.502 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 49.1 m -140.65 130.02 23.84 Favored 'General case' 0 N--CA 1.481 1.089 0 CA-C-O 121.532 0.682 . . . . 1.0 110.577 179.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 3.7 t -66.31 -31.66 72.59 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-N 115.476 -0.784 . . . . 1.0 110.425 179.755 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 95.7 p -73.85 -4.81 37.14 Favored 'General case' 0 N--CA 1.469 0.507 0 CA-C-N 115.976 -0.557 . . . . 1.0 110.244 -179.787 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 43.1 t -58.9 -173.82 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 120.952 0.406 . . . . 1.0 110.41 179.493 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 67.9 mttm -127.58 161.52 28.63 Favored 'General case' 0 N--CA 1.478 0.974 0 CA-C-O 121.747 0.784 . . . . 1.0 110.286 -179.768 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.2 t -89.42 108.99 19.81 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.429 0 CA-C-N 115.283 -0.871 . . . . 1.0 109.694 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 45.9 pt -85.72 -17.01 9.69 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.538 0 CA-C-N 115.597 -0.729 . . . . 1.0 110.187 179.728 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 175.32 174.73 42.17 Favored Glycine 0 N--CA 1.461 0.319 0 N-CA-C 110.942 -0.863 . . . . 1.0 110.942 -179.455 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 42.6 t -142.52 137.58 30.31 Favored 'General case' 0 N--CA 1.475 0.798 0 CA-C-O 121.775 0.798 . . . . 1.0 110.528 179.604 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -99.8 171.87 7.61 Favored 'General case' 0 N--CA 1.475 0.782 0 CA-C-N 115.303 -0.862 . . . . 1.0 109.206 -179.671 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 56.7 m -89.96 155.13 19.32 Favored 'General case' 0 N--CA 1.469 0.524 0 CA-C-N 115.085 -0.961 . . . . 1.0 110.298 -179.225 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -74.97 150.76 41.47 Favored Glycine 0 CA--C 1.523 0.535 0 N-CA-C 110.117 -1.193 . . . . 1.0 110.117 179.397 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 22.9 t30 74.83 17.71 2.79 Favored 'General case' 0 N--CA 1.48 1.04 0 CA-C-O 120.798 0.332 . . . . 1.0 110.572 179.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 59.4 m -87.86 132.39 34.21 Favored 'General case' 0 N--CA 1.478 0.975 0 CA-C-O 121.236 0.541 . . . . 1.0 110.042 -179.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 26.9 mtpp -82.61 144.62 30.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 121.638 0.732 . . . . 1.0 109.677 179.738 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 16.9 m -147.63 130.47 7.87 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.451 0 CA-C-N 115.319 -0.855 . . . . 1.0 109.863 -179.91 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.411 ' O ' ' C ' ' A' ' 36' ' ' ILE . 30.7 m -86.39 89.05 7.75 Favored 'General case' 0 CA--C 1.515 -0.388 0 N-CA-C 109.098 -0.704 . . . . 1.0 109.098 179.463 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.438 HD12 ' H ' ' A' ' 36' ' ' ILE . 3.5 mp -34.47 146.94 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.504 2.253 0 CA-C-N 116.372 -0.377 . . . . 1.0 111.579 179.345 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 4.7 t -143.45 62.55 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.084 0 CA-C-O 121.05 0.452 . . . . 1.0 110.333 -178.669 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 108.61 166.57 20.94 Favored Glycine 0 N--CA 1.465 0.624 0 N-CA-C 110.462 -1.055 . . . . 1.0 110.462 179.75 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 16.4 pt-20 -142.21 147.25 36.24 Favored 'General case' 0 N--CA 1.476 0.842 0 CA-C-N 114.824 -0.688 . . . . 1.0 110.15 -179.747 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 44.4 tt0 -154.37 125.84 7.47 Favored 'General case' 0 N--CA 1.466 0.35 0 CA-C-N 115.704 -0.68 . . . . 1.0 110.162 179.453 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 50.33 -112.46 1.55 Allowed Glycine 0 CA--C 1.535 1.312 0 N-CA-C 111.398 -0.681 . . . . 1.0 111.398 179.442 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -115.37 22.63 13.08 Favored 'General case' 0 N--CA 1.482 1.143 0 N-CA-C 109.911 -0.403 . . . . 1.0 109.911 179.151 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.407 ' C ' ' NZ ' ' A' ' 57' ' ' LYS . 54.5 m-85 -143.37 153.88 43.15 Favored 'General case' 0 N--CA 1.477 0.884 0 CA-C-O 122.012 0.91 . . . . 1.0 110.365 179.845 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' TYR . . . . . 0.43 ' N ' ' CD1' ' A' ' 44' ' ' TYR . 11.8 p90 -134.67 169.17 17.72 Favored 'General case' 0 N--CA 1.473 0.687 0 CA-C-O 122.146 0.974 . . . . 1.0 110.04 -179.481 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.462 ' NZ ' ' CD2' ' A' ' 52' ' ' HIS . 63.3 tttm -95.58 151.85 18.96 Favored 'General case' 0 N--CA 1.467 0.419 0 CA-C-N 114.902 -1.045 . . . . 1.0 109.918 -179.328 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 18.1 pt -143.91 162.05 15.66 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 CA-C-O 122.156 0.979 . . . . 1.0 110.021 179.39 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -125.25 96.78 4.96 Favored 'General case' 0 N--CA 1.479 1.017 0 CA-C-N 114.818 -1.083 . . . . 1.0 110.108 179.276 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 39.2 t80 -135.73 152.79 51.5 Favored 'General case' 0 N--CA 1.47 0.541 0 CA-C-N 115.718 -0.674 . . . . 1.0 109.968 179.287 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 63.5 mttt 56.69 10.86 0.78 Allowed 'General case' 0 N--CA 1.475 0.819 0 CA-C-N 115.812 -0.631 . . . . 1.0 110.84 179.629 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 81.35 0.03 88.44 Favored Glycine 0 N--CA 1.472 1.1 0 N-CA-C 110.264 -1.134 . . . . 1.0 110.264 -179.573 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 49.4 m -110.98 172.97 6.56 Favored 'General case' 0 N--CA 1.482 1.153 0 C-N-CA 123.902 0.881 . . . . 1.0 110.167 179.922 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' HIS . . . . . 0.462 ' CD2' ' NZ ' ' A' ' 45' ' ' LYS . 30.7 m170 -107.16 145.54 32.43 Favored 'General case' 0 N--CA 1.481 1.093 0 CA-C-N 115.35 -0.841 . . . . 1.0 110.023 -179.747 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -152.06 170.92 31.42 Favored Glycine 0 N--CA 1.464 0.501 0 N-CA-C 110.9 -0.88 . . . . 1.0 110.9 -179.382 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 80.1 m-85 -132.38 146.23 51.81 Favored 'General case' 0 N--CA 1.482 1.13 0 CA-C-O 121.518 0.675 . . . . 1.0 110.258 179.219 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 36.4 t -143.64 147.59 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.754 0 CA-C-N 115.451 -0.795 . . . . 1.0 110.277 -179.936 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -68.75 153.12 44.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.547 -0.751 . . . . 1.0 110.216 179.641 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . 0.407 ' NZ ' ' C ' ' A' ' 43' ' ' PHE . 65.4 mttp -89.99 -22.82 21.73 Favored 'General case' 0 N--CA 1.478 0.961 0 CA-C-N 115.709 -0.678 . . . . 1.0 110.586 179.874 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -52.38 -35.99 52.83 Favored 'General case' 0 CA--C 1.537 0.478 0 CA-C-O 121.068 0.461 . . . . 1.0 110.488 -179.146 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.584 ' CG ' HD11 ' A' ' 12' ' ' LEU . 24.4 m-85 -64.04 -30.18 71.27 Favored 'General case' 0 N--CA 1.475 0.823 0 CA-C-N 115.905 -0.589 . . . . 1.0 110.477 178.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 63.5 mt . . . . . 0 N--CA 1.47 0.542 0 CA-C-O 118.119 -0.943 . . . . 1.0 108.609 -179.577 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 65.8 mtt . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 108.807 -0.812 . . . . 1.0 108.807 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 25.9 ttpp -65.04 148.91 50.79 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.531 -0.759 . . . . 1.0 110.112 -179.551 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 53.9 p -118.31 144.79 45.58 Favored 'General case' 0 N--CA 1.474 0.727 0 CA-C-O 121.695 0.76 . . . . 1.0 110.475 179.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -97.58 154.25 20.31 Favored Glycine 0 N--CA 1.476 1.322 0 N-CA-C 110.038 -1.225 . . . . 1.0 110.038 -179.795 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 65.7 mt -106.07 125.26 61.66 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.086 0 CA-C-O 121.239 0.543 . . . . 1.0 109.555 179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 45.0 t -74.55 133.48 31.45 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.324 0 CA-C-N 115.788 -0.642 . . . . 1.0 109.479 179.61 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 9.4 m120 -62.13 109.27 1.25 Allowed 'General case' 0 CA--C 1.537 0.444 0 CA-C-N 115.735 -0.666 . . . . 1.0 110.113 179.363 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 7.3 p -55.61 -19.33 5.91 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.549 0 CA-C-N 116.035 -0.529 . . . . 1.0 110.435 179.515 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 49.5 m -52.08 105.97 0.13 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.158 -0.473 . . . . 1.0 110.422 -179.373 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 80.9 p 60.42 -122.38 0.97 Allowed 'General case' 0 CA--C 1.548 0.882 0 CA-C-N 116.062 -0.517 . . . . 1.0 110.448 -180.0 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 47.7 t -151.98 156.57 40.29 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-O 121.379 0.609 . . . . 1.0 110.083 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -104.24 136.46 43.8 Favored 'General case' 0 N--CA 1.479 1.016 0 CA-C-O 121.817 0.818 . . . . 1.0 110.323 -179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 72.5 m-80 -92.31 133.97 35.35 Favored 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.199 -0.909 . . . . 1.0 109.269 -179.623 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 59.3 t -93.19 105.75 17.17 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.529 0 CA-C-N 115.104 -0.953 . . . . 1.0 109.37 -179.658 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 88.9 mtt-85 -81.32 148.55 29.33 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-O 121.487 0.661 . . . . 1.0 109.922 179.305 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 87.6 p -73.14 -19.41 61.14 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 115.606 -0.724 . . . . 1.0 110.019 179.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 87.1 p -162.17 172.85 15.13 Favored 'General case' 0 N--CA 1.474 0.752 0 CA-C-O 121.179 0.514 . . . . 1.0 110.798 -179.585 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -71.47 57.45 0.26 Allowed 'General case' 0 N--CA 1.474 0.767 0 CA-C-N 115.789 -0.641 . . . . 1.0 110.49 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 55.8 m -143.93 130.43 20.01 Favored 'General case' 0 N--CA 1.481 1.105 0 CA-C-N 115.71 -0.677 . . . . 1.0 110.492 -179.961 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 57.8 p -65.72 -26.61 67.83 Favored 'General case' 0 N--CA 1.468 0.435 0 CA-C-N 115.827 -0.624 . . . . 1.0 110.226 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 49.4 m -71.07 -8.02 50.49 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 116.063 -0.517 . . . . 1.0 110.256 179.685 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 61.2 m -67.0 132.08 47.17 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-O 121.388 0.614 . . . . 1.0 110.01 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -72.48 169.58 16.13 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.615 -0.72 . . . . 1.0 110.123 179.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 21.7 t -90.16 112.58 24.95 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.377 0 CA-C-O 121.807 0.813 . . . . 1.0 109.754 179.751 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 2.1 pp -85.18 -27.19 6.54 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.451 0 CA-C-N 115.146 -0.934 . . . . 1.0 109.761 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 173.15 -171.84 44.73 Favored Glycine 0 N--CA 1.465 0.583 0 N-CA-C 111.398 -0.681 . . . . 1.0 111.398 -179.423 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 95.4 p -151.92 145.23 24.73 Favored 'General case' 0 N--CA 1.472 0.672 0 CA-C-O 121.895 0.855 . . . . 1.0 110.449 179.208 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -102.31 -179.11 3.89 Favored 'General case' 0 N--CA 1.483 1.204 0 CA-C-N 115.166 -0.925 . . . . 1.0 109.28 -179.662 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 96.8 p -91.66 144.63 25.33 Favored 'General case' 0 N--CA 1.469 0.519 0 CA-C-N 115.145 -0.934 . . . . 1.0 110.197 -179.646 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -75.13 157.96 50.5 Favored Glycine 0 N--CA 1.461 0.343 0 N-CA-C 110.212 -1.155 . . . . 1.0 110.212 179.566 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 8.7 t30 69.46 20.82 7.08 Favored 'General case' 0 N--CA 1.48 1.042 0 CA-C-O 120.707 0.289 . . . . 1.0 110.485 -179.971 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 85.7 m -88.99 137.16 32.57 Favored 'General case' 0 N--CA 1.478 0.962 0 CA-C-O 121.413 0.625 . . . . 1.0 110.433 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 14.3 mptt -86.93 144.51 26.92 Favored 'General case' 0 N--CA 1.471 0.593 0 CA-C-O 122.069 0.938 . . . . 1.0 109.814 179.771 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 5.7 p -153.75 138.14 9.48 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.423 0 CA-C-N 114.898 -1.046 . . . . 1.0 109.806 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 60.9 p -82.46 84.32 7.23 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.784 -0.644 . . . . 1.0 109.62 178.694 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.432 HG22 ' N ' ' A' ' 37' ' ' VAL . 88.6 mt -43.02 160.06 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.31 0 CA-C-N 115.657 -0.701 . . . . 1.0 110.243 179.428 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.432 ' N ' HG22 ' A' ' 36' ' ' ILE . 43.3 t -123.34 -92.5 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.472 0.638 0 CA-C-N 115.882 -0.599 . . . . 1.0 109.698 -179.745 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -114.89 -159.15 12.27 Favored Glycine 0 N--CA 1.466 0.653 0 CA-C-O 122.318 0.954 . . . . 1.0 110.861 -179.278 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . 0.461 ' N ' ' NZ ' ' A' ' 45' ' ' LYS . 1.0 OUTLIER -143.66 147.93 35.04 Favored 'General case' 0 N--CA 1.467 0.392 0 CA-C-N 114.707 -0.747 . . . . 1.0 110.61 -179.524 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -154.64 124.5 6.65 Favored 'General case' 0 N--CA 1.47 0.558 0 CA-C-N 115.929 -0.578 . . . . 1.0 110.345 179.319 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 53.3 -150.15 11.71 Favored Glycine 0 CA--C 1.532 1.149 0 N-CA-C 111.139 -0.784 . . . . 1.0 111.139 179.834 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -84.9 30.37 0.58 Allowed 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 110.151 -0.314 . . . . 1.0 110.151 179.431 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 72.4 m-85 -145.69 153.37 40.92 Favored 'General case' 0 N--CA 1.477 0.909 0 CA-C-O 121.784 0.802 . . . . 1.0 110.529 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 1.7 m-85 -109.68 148.87 30.59 Favored 'General case' 0 N--CA 1.48 1.032 0 CA-C-O 122.556 1.169 . . . . 1.0 110.099 179.468 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.461 ' NZ ' ' N ' ' A' ' 39' ' ' GLU . 35.4 mtmm -87.98 140.73 29.2 Favored 'General case' 0 CA--C 1.518 -0.281 0 CA-C-N 114.485 -1.234 . . . . 1.0 109.508 -179.677 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 39.9 pt -149.86 173.41 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.358 0 CA-C-N 114.594 -1.185 . . . . 1.0 109.688 -179.128 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 42.6 tt0 -146.61 108.14 4.29 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 115.74 -0.664 . . . . 1.0 110.225 178.94 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 54.6 t80 -139.08 162.35 35.15 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.739 -0.664 . . . . 1.0 110.054 179.76 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 19.2 tttp 59.18 16.49 4.91 Favored 'General case' 0 CA--C 1.546 0.818 0 CA-C-N 115.55 -0.75 . . . . 1.0 110.9 179.838 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 77.85 -2.1 65.64 Favored Glycine 0 N--CA 1.477 1.403 0 N-CA-C 110.171 -1.171 . . . . 1.0 110.171 -179.357 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 49.2 m -114.95 176.29 5.12 Favored 'General case' 0 N--CA 1.49 1.55 0 C-N-CA 124.278 1.031 . . . . 1.0 110.486 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 25.9 p80 -105.36 141.01 37.62 Favored 'General case' 0 N--CA 1.482 1.15 0 CA-C-N 115.464 -0.789 . . . . 1.0 110.064 -179.447 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.68 165.8 27.92 Favored Glycine 0 N--CA 1.463 0.435 0 N-CA-C 110.525 -1.03 . . . . 1.0 110.525 -179.718 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 81.2 m-85 -130.37 145.43 51.8 Favored 'General case' 0 N--CA 1.483 1.217 0 CA-C-O 121.527 0.68 . . . . 1.0 110.001 179.538 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 41.3 t -145.92 149.75 16.06 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.453 0 CA-C-O 121.904 0.859 . . . . 1.0 109.427 -179.723 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.402 ' O ' ' CD1' ' A' ' 59' ' ' TYR . . . -60.71 153.44 24.11 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 114.986 -1.006 . . . . 1.0 110.164 178.952 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 15.8 pttp -102.89 -31.34 10.31 Favored 'General case' 0 N--CA 1.482 1.167 0 CA-C-N 115.442 -0.799 . . . . 1.0 111.763 178.9 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 14.6 pt-20 -64.53 -31.82 73.19 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 121.444 0.64 . . . . 1.0 111.022 -179.176 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . 0.402 ' CD1' ' O ' ' A' ' 56' ' ' ALA . 0.6 OUTLIER -62.7 -4.12 1.88 Allowed 'General case' 0 CA--C 1.549 0.918 0 CA-C-N 115.476 -0.783 . . . . 1.0 110.138 -179.888 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 85.1 mt . . . . . 0 N--CA 1.477 0.888 0 N-CA-C 108.13 -1.063 . . . . 1.0 108.13 -179.163 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 15.5 ptp . . . . . 0 N--CA 1.492 1.642 0 N-CA-C 109.435 -0.58 . . . . 1.0 109.435 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -63.84 -79.8 0.03 OUTLIER 'General case' 0 N--CA 1.475 0.785 0 CA-C-O 121.432 0.634 . . . . 1.0 110.563 -179.759 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 20.2 p -137.78 151.26 47.96 Favored 'General case' 0 N--CA 1.489 1.479 0 CA-C-N 115.549 -0.75 . . . . 1.0 110.353 -179.738 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -96.8 142.78 16.36 Favored Glycine 0 N--CA 1.474 1.217 0 N-CA-C 110.625 -0.99 . . . . 1.0 110.625 179.776 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 75.1 mt -109.24 141.56 24.18 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.177 0 CA-C-O 121.224 0.535 . . . . 1.0 109.95 -179.618 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 2.8 t -116.56 115.86 50.39 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.348 0 CA-C-O 116.812 -1.566 . . . . 1.0 110.682 178.083 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 80.4 m-20 -82.48 146.3 29.33 Favored 'General case' 0 CA--C 1.535 0.4 0 CA-C-N 120.098 1.317 . . . . 1.0 109.06 177.638 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 13.9 p -50.14 139.01 5.41 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.943 0 CA-C-N 116.314 -0.403 . . . . 1.0 111.126 179.289 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 79.2 p -168.59 -78.88 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.844 0 CA-C-O 120.843 0.354 . . . . 1.0 111.141 -179.26 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 97.6 p -131.15 -133.74 0.2 Allowed 'General case' 0 N--CA 1.485 1.287 0 CA-C-N 116.068 -0.515 . . . . 1.0 110.516 -179.105 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 98.3 p -138.85 153.76 48.36 Favored 'General case' 0 N--CA 1.477 0.925 0 CA-C-O 121.312 0.577 . . . . 1.0 110.238 -179.795 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -140.3 128.27 22.09 Favored 'General case' 0 N--CA 1.49 1.553 0 CA-C-O 121.733 0.778 . . . . 1.0 109.715 179.875 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 19.3 p30 -92.96 144.08 25.61 Favored 'General case' 0 N--CA 1.473 0.704 0 CA-C-N 115.298 -0.865 . . . . 1.0 110.06 -179.853 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 93.9 t -97.79 128.45 49.15 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.996 0 CA-C-O 121.879 0.847 . . . . 1.0 108.894 179.173 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 89.5 mtt-85 -99.55 -167.74 1.51 Allowed 'General case' 0 N--CA 1.473 0.702 0 CA-C-N 115.187 -0.915 . . . . 1.0 110.162 -179.744 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 60.1 p -130.8 33.16 4.26 Favored 'General case' 0 N--CA 1.474 0.735 0 C-N-CA 123.017 0.527 . . . . 1.0 110.611 -179.413 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . 0.48 ' OG ' ' N ' ' A' ' 18' ' ' ALA . 6.9 t 175.8 -177.95 0.13 Allowed 'General case' 0 N--CA 1.48 1.027 0 CA-C-O 121.632 0.729 . . . . 1.0 110.507 -179.92 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.48 ' N ' ' OG ' ' A' ' 17' ' ' SER . . . -97.11 42.97 1.08 Allowed 'General case' 0 N--CA 1.488 1.448 0 CA-C-N 115.285 -0.87 . . . . 1.0 110.182 179.511 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 44.3 t -130.63 138.18 49.97 Favored 'General case' 0 N--CA 1.489 1.477 0 CA-C-N 115.106 -0.952 . . . . 1.0 110.902 -179.96 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 80.1 p -74.73 -8.75 57.37 Favored 'General case' 0 N--CA 1.475 0.821 0 CA-C-N 116.227 -0.442 . . . . 1.0 110.569 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 66.7 m -99.36 -6.58 27.57 Favored 'General case' 0 N--CA 1.486 1.333 0 CA-C-N 116.201 -0.454 . . . . 1.0 111.069 -179.072 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 13.9 t -66.48 133.95 51.46 Favored 'General case' 0 N--CA 1.473 0.72 0 CA-C-N 115.962 -0.563 . . . . 1.0 110.843 -179.414 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 38.3 ttmt -59.89 155.67 15.99 Favored 'General case' 0 N--CA 1.475 0.793 0 CA-C-N 116.031 -0.531 . . . . 1.0 110.622 -179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 6.8 p -83.94 144.56 9.68 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.193 0 CA-C-O 121.176 0.513 . . . . 1.0 110.503 -179.68 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 40.1 pt -121.87 -10.26 8.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 CA-C-N 115.813 -0.631 . . . . 1.0 110.34 179.266 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 179.35 -171.56 43.42 Favored Glycine 0 N--CA 1.467 0.759 0 N-CA-C 111.111 -0.796 . . . . 1.0 111.111 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 96.7 p -157.25 151.0 24.33 Favored 'General case' 0 N--CA 1.475 0.797 0 CA-C-N 115.642 -0.279 . . . . 1.0 110.559 179.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 2.2 pp -117.23 167.78 10.9 Favored 'General case' 0 N--CA 1.485 1.32 0 C-N-CA 123.076 0.55 . . . . 1.0 110.507 179.907 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 90.9 p -112.74 160.02 18.37 Favored 'General case' 0 N--CA 1.482 1.17 0 CA-C-N 115.718 -0.673 . . . . 1.0 110.537 -179.491 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.467 ' O ' ' HB2' ' A' ' 31' ' ' ASN . . . -83.75 76.06 2.29 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 110.901 -0.88 . . . . 1.0 110.901 179.41 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.467 ' HB2' ' O ' ' A' ' 30' ' ' GLY . 22.1 t-20 164.61 16.3 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.843 0 C-N-CA 123.287 0.635 . . . . 1.0 110.242 -179.566 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 36.4 m -109.84 147.47 33.27 Favored 'General case' 0 N--CA 1.486 1.337 0 C-N-CA 123.424 0.69 . . . . 1.0 111.046 -179.458 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 22.2 pttp -90.25 148.77 22.7 Favored 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 122.602 0.361 . . . . 1.0 110.209 178.532 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.6 m -143.21 126.04 13.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 CA-C-O 120.829 0.347 . . . . 1.0 110.296 179.587 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . 0.542 ' O ' HG23 ' A' ' 35' ' ' THR . 9.8 t -82.79 85.47 7.07 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 121.445 0.641 . . . . 1.0 110.619 179.674 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 85.6 mt -51.16 157.23 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.488 0 CA-C-N 115.546 -0.752 . . . . 1.0 110.165 179.742 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 39.6 t -127.4 -97.86 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.482 1.129 0 CA-C-N 115.947 -0.569 . . . . 1.0 110.003 -179.076 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -99.49 -178.42 31.2 Favored Glycine 0 N--CA 1.472 1.036 0 N-CA-C 110.937 -0.865 . . . . 1.0 110.937 -179.773 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 47.1 mt-10 -135.16 141.8 46.0 Favored 'General case' 0 N--CA 1.483 1.193 0 CA-C-O 120.984 0.421 . . . . 1.0 110.204 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 16.1 pt-20 -155.38 134.84 12.48 Favored 'General case' 0 CA--C 1.539 0.524 0 CA-C-N 116.001 -0.545 . . . . 1.0 110.378 -179.985 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 48.56 -113.14 1.4 Allowed Glycine 0 CA--C 1.547 2.051 0 CA-C-N 115.947 -0.57 . . . . 1.0 111.707 179.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -122.49 24.7 9.16 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 110.049 -0.352 . . . . 1.0 110.049 179.23 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 54.9 m-85 -145.07 156.18 43.76 Favored 'General case' 0 N--CA 1.47 0.554 0 CA-C-O 121.301 0.572 . . . . 1.0 110.296 -179.474 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 22.6 p90 -131.67 162.87 29.38 Favored 'General case' 0 N--CA 1.488 1.458 0 CA-C-N 115.684 -0.689 . . . . 1.0 110.452 179.712 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -88.58 160.39 17.45 Favored 'General case' 0 N--CA 1.476 0.829 0 CA-C-N 116.037 -0.528 . . . . 1.0 110.159 -179.372 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 34.4 pt -145.75 153.17 13.74 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.209 0 CA-C-O 121.312 0.577 . . . . 1.0 110.504 -179.632 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 80.8 mm-40 -95.75 58.73 1.99 Allowed 'General case' 0 N--CA 1.481 1.113 0 CA-C-N 115.668 -0.696 . . . . 1.0 110.069 179.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 77.8 t80 -78.94 117.54 20.11 Favored 'General case' 0 N--CA 1.474 0.727 0 CA-C-N 115.603 -0.726 . . . . 1.0 109.915 179.805 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 47.2 mmtm 45.58 33.21 1.32 Allowed 'General case' 0 CA--C 1.557 1.24 0 CA-C-O 121.276 0.56 . . . . 1.0 111.415 -179.629 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 68.19 21.74 74.03 Favored Glycine 0 N--CA 1.482 1.736 0 N-CA-C 111.373 -0.691 . . . . 1.0 111.373 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 28.9 t -115.98 171.65 7.65 Favored 'General case' 0 N--CA 1.491 1.604 0 C-N-CA 123.332 0.653 . . . . 1.0 110.878 -179.186 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -96.77 136.85 36.73 Favored 'General case' 0 N--CA 1.479 0.995 0 CA-C-N 115.942 -0.572 . . . . 1.0 110.229 -179.856 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -148.2 163.13 28.9 Favored Glycine 0 N--CA 1.479 1.522 0 N-CA-C 110.993 -0.843 . . . . 1.0 110.993 -179.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . 0.451 ' CD1' ' N ' ' A' ' 17' ' ' SER . 82.2 m-85 -133.83 138.01 45.39 Favored 'General case' 0 N--CA 1.483 1.184 0 CA-C-O 121.483 0.659 . . . . 1.0 110.544 -179.744 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 42.8 t -144.23 151.22 16.16 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.291 0 CA-C-N 115.501 -0.772 . . . . 1.0 110.1 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -79.55 113.53 17.77 Favored 'General case' 0 N--CA 1.474 0.747 0 CA-C-N 115.785 -0.643 . . . . 1.0 110.502 179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 19.3 pttp -74.23 -28.44 61.24 Favored 'General case' 0 N--CA 1.476 0.871 0 CA-C-O 120.812 0.339 . . . . 1.0 110.512 -179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -55.11 -45.18 75.5 Favored 'General case' 0 N--CA 1.477 0.876 0 CA-C-N 116.234 -0.439 . . . . 1.0 111.014 -179.297 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 22.9 m-85 -63.0 -35.02 78.81 Favored 'General case' 0 N--CA 1.477 0.893 0 N-CA-C 110.003 -0.369 . . . . 1.0 110.003 178.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 74.4 mt . . . . . 0 N--CA 1.479 1.01 0 CA-C-O 118.133 -0.937 . . . . 1.0 109.253 -179.48 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 21.2 ptt? . . . . . 0 N--CA 1.484 1.229 0 N-CA-C 108.835 -0.802 . . . . 1.0 108.835 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -134.3 153.45 51.87 Favored 'General case' 0 N--CA 1.479 1.006 0 CA-C-O 121.817 0.818 . . . . 1.0 110.181 179.776 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 73.3 p -123.14 144.59 49.24 Favored 'General case' 0 N--CA 1.48 1.054 0 CA-C-N 115.161 -0.927 . . . . 1.0 110.314 -179.796 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -95.64 151.77 20.11 Favored Glycine 0 CA--C 1.527 0.838 0 N-CA-C 110.229 -1.149 . . . . 1.0 110.229 179.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 4.0 mp -103.56 124.89 58.11 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.342 0 N-CA-C 109.493 -0.558 . . . . 1.0 109.493 179.99 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 21.3 t -66.67 120.09 13.24 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.554 0 CA-C-N 115.7 -0.682 . . . . 1.0 109.845 179.91 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 18.2 p-10 -59.63 102.28 0.14 Allowed 'General case' 0 CA--C 1.539 0.537 0 CA-C-O 121.029 0.443 . . . . 1.0 110.479 179.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 8.2 p -64.27 -2.85 1.08 Allowed 'Isoleucine or valine' 0 N--CA 1.468 0.45 0 CA-C-N 115.951 -0.568 . . . . 1.0 110.721 -179.914 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 41.3 m -45.89 -56.71 5.08 Favored 'General case' 0 N--CA 1.474 0.766 0 CA-C-N 115.743 -0.662 . . . . 1.0 111.445 -179.87 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 50.0 m -148.56 179.41 7.83 Favored 'General case' 0 N--CA 1.477 0.907 0 CA-C-N 115.61 -0.723 . . . . 1.0 110.277 179.216 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 45.1 t -84.75 140.31 31.35 Favored 'General case' 0 N--CA 1.473 0.712 0 CA-C-N 115.479 -0.782 . . . . 1.0 110.249 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.2 mm? -111.6 140.65 46.04 Favored 'General case' 0 N--CA 1.485 1.29 0 CA-C-O 122.232 1.015 . . . . 1.0 109.935 -179.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 72.6 m-80 -82.67 126.7 32.65 Favored 'General case' 0 N--CA 1.451 -0.407 0 CA-C-N 114.805 -1.089 . . . . 1.0 109.476 179.663 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 6.4 t -102.09 125.86 56.21 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.138 0 CA-C-N 115.229 -0.896 . . . . 1.0 110.181 -179.763 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -91.83 179.62 5.57 Favored 'General case' 0 N--CA 1.486 1.348 0 CA-C-O 121.582 0.706 . . . . 1.0 110.238 179.039 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 1.4 m -92.65 -22.61 19.35 Favored 'General case' 0 N--CA 1.489 1.508 0 CA-C-N 115.435 -0.802 . . . . 1.0 110.282 179.837 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 45.5 p -176.74 -178.13 0.85 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 122.175 0.988 . . . . 1.0 110.032 -179.162 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -82.15 82.27 7.76 Favored 'General case' 0 N--CA 1.47 0.562 0 CA-C-N 114.852 -1.067 . . . . 1.0 109.689 179.182 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 65.5 p -167.25 154.68 8.92 Favored 'General case' 0 N--CA 1.466 0.339 0 CA-C-O 121.565 0.698 . . . . 1.0 110.332 179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 26.3 m -75.1 -25.32 58.44 Favored 'General case' 0 N--CA 1.47 0.542 0 CA-C-N 115.398 -0.819 . . . . 1.0 110.639 179.311 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 99.5 p -63.08 -22.93 67.19 Favored 'General case' 0 N--CA 1.471 0.602 0 C-N-CA 120.597 -0.441 . . . . 1.0 110.408 -178.423 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 26.5 t -96.96 141.79 29.7 Favored 'General case' 0 N--CA 1.472 0.66 0 N-CA-C 109.652 -0.499 . . . . 1.0 109.652 178.41 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 24.9 tttm -163.24 109.9 1.16 Allowed 'General case' 0 N--CA 1.474 0.754 0 CA-C-O 122.077 0.942 . . . . 1.0 110.029 179.638 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.3 t 62.06 135.92 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.519 0 CA-C-N 115.032 -0.986 . . . . 1.0 110.24 -179.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 1.3 pp -152.57 -17.14 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.478 0.963 0 CA-C-N 115.93 -0.577 . . . . 1.0 110.326 -179.387 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 163.27 -166.91 37.32 Favored Glycine 0 CA--C 1.522 0.469 0 N-CA-C 110.359 -1.096 . . . . 1.0 110.359 -178.247 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 93.9 p -145.11 140.44 28.03 Favored 'General case' 0 N--CA 1.481 1.121 0 CA-C-N 114.882 -0.659 . . . . 1.0 110.591 179.782 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 1.9 pp -102.17 122.41 44.1 Favored 'General case' 0 N--CA 1.491 1.58 0 CA-C-O 121.587 0.708 . . . . 1.0 109.392 179.987 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 51.0 m -44.69 131.62 6.75 Favored 'General case' 0 N--CA 1.484 1.233 0 CA-C-N 115.476 -0.784 . . . . 1.0 111.082 -178.654 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -68.08 165.87 45.14 Favored Glycine 0 CA--C 1.521 0.449 0 N-CA-C 111.354 -0.699 . . . . 1.0 111.354 -178.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 13.8 m-80 65.1 20.66 12.08 Favored 'General case' 0 N--CA 1.471 0.624 0 CA-C-O 120.954 0.407 . . . . 1.0 110.455 179.654 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 91.8 m -97.67 145.54 26.21 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-N 115.994 -0.548 . . . . 1.0 109.735 179.48 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 98.0 mttt -86.27 139.3 31.14 Favored 'General case' 0 N--CA 1.473 0.682 0 CA-C-N 115.77 -0.65 . . . . 1.0 110.143 179.428 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 9.8 m -142.49 124.99 13.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 CA-C-N 115.675 -0.693 . . . . 1.0 110.118 179.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 60.0 p -89.93 90.78 8.31 Favored 'General case' 0 N--CA 1.471 0.584 0 CA-C-N 115.917 -0.583 . . . . 1.0 109.813 179.185 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 3.5 mp -36.75 147.17 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.498 1.94 0 CA-C-N 115.768 -0.651 . . . . 1.0 111.517 179.669 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 4.7 t -141.68 61.47 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.37 0 CA-C-O 121.239 0.543 . . . . 1.0 110.522 -178.485 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . 107.83 160.55 20.83 Favored Glycine 0 N--CA 1.471 1.005 0 N-CA-C 110.711 -0.956 . . . . 1.0 110.711 179.435 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 74.7 mt-10 -135.46 140.72 45.08 Favored 'General case' 0 N--CA 1.487 1.383 0 CA-C-O 121.161 0.505 . . . . 1.0 110.261 179.703 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 5.7 tm-20 -148.95 121.87 8.77 Favored 'General case' 0 N--CA 1.477 0.875 0 CA-C-N 115.837 -0.619 . . . . 1.0 110.346 -179.595 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 50.41 -114.17 2.44 Favored Glycine 0 CA--C 1.543 1.783 0 N-CA-C 111.16 -0.776 . . . . 1.0 111.16 179.651 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -113.62 26.82 10.05 Favored 'General case' 0 N--CA 1.486 1.342 0 C-N-CA 122.609 0.364 . . . . 1.0 110.724 179.431 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 74.9 m-85 -146.9 156.34 43.0 Favored 'General case' 0 N--CA 1.476 0.841 0 CA-C-O 121.721 0.772 . . . . 1.0 110.487 179.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' TYR . . . . . 0.4 ' CD1' ' N ' ' A' ' 44' ' ' TYR . 15.0 p90 -140.45 172.67 12.4 Favored 'General case' 0 N--CA 1.473 0.72 0 CA-C-N 115.336 -0.847 . . . . 1.0 110.121 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 24.0 mtpp -101.32 151.83 21.42 Favored 'General case' 0 N--CA 1.478 0.944 0 CA-C-N 115.225 -0.898 . . . . 1.0 110.281 -179.282 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 38.9 pt -139.55 152.97 23.29 Favored 'Isoleucine or valine' 0 N--CA 1.474 0.757 0 CA-C-N 115.59 -0.732 . . . . 1.0 110.596 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 4.3 tm-20 -113.45 86.82 2.47 Favored 'General case' 0 N--CA 1.485 1.288 0 CA-C-N 115.323 -0.853 . . . . 1.0 109.872 179.236 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 22.6 t80 -139.65 158.46 44.08 Favored 'General case' 0 N--CA 1.469 0.505 0 CA-C-O 121.209 0.528 . . . . 1.0 110.566 179.391 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 33.8 mtmt 50.29 20.83 0.7 Allowed 'General case' 0 N--CA 1.476 0.859 0 CA-C-N 115.847 -0.615 . . . . 1.0 110.447 179.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 71.55 -3.32 18.04 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.799 -0.92 . . . . 1.0 110.799 -179.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 44.0 t -117.38 173.97 6.4 Favored 'General case' 0 N--CA 1.474 0.765 0 C-N-CA 124.119 0.968 . . . . 1.0 110.644 -179.431 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' HIS . . . . . 0.508 ' CD2' ' H ' ' A' ' 52' ' ' HIS . 6.8 p80 -112.37 153.54 27.11 Favored 'General case' 0 N--CA 1.481 1.094 0 CA-C-N 115.467 -0.788 . . . . 1.0 109.955 -179.587 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -145.06 165.55 27.71 Favored Glycine 0 N--CA 1.471 0.994 0 N-CA-C 110.711 -0.956 . . . . 1.0 110.711 179.851 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 77.0 m-85 -130.54 139.67 50.48 Favored 'General case' 0 N--CA 1.486 1.351 0 CA-C-O 121.119 0.485 . . . . 1.0 110.268 -179.887 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 4.2 p -158.91 158.84 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.001 0 CA-C-N 115.92 -0.582 . . . . 1.0 110.25 179.754 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -59.66 134.13 56.74 Favored 'General case' 0 CA--C 1.541 0.609 0 CA-C-O 121.191 0.519 . . . . 1.0 110.397 179.721 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -91.06 -35.97 14.31 Favored 'General case' 0 N--CA 1.483 1.198 0 CA-C-N 115.712 -0.676 . . . . 1.0 110.258 -179.831 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 10.7 pt-20 -56.73 -28.47 61.09 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-O 121.099 0.476 . . . . 1.0 110.633 -179.454 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 2.2 m-85 -63.21 -39.24 94.08 Favored 'General case' 0 N--CA 1.471 0.588 0 CA-C-N 115.88 -0.6 . . . . 1.0 110.17 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 70.2 mt . . . . . 0 N--CA 1.472 0.628 0 CA-C-O 117.698 -1.144 . . . . 1.0 109.338 -179.32 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 25.7 mmt . . . . . 0 N--CA 1.492 1.638 0 N-CA-C 108.938 -0.764 . . . . 1.0 108.938 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 7.0 mtpm? 52.43 98.09 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.565 0 CA-C-N 115.897 -0.592 . . . . 1.0 110.994 -179.553 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 68.6 p -125.89 163.07 23.74 Favored 'General case' 0 N--CA 1.48 1.045 0 CA-C-O 121.786 0.803 . . . . 1.0 110.353 -179.259 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -122.13 153.17 16.81 Favored Glycine 0 N--CA 1.479 1.565 0 CA-C-N 115.147 -0.933 . . . . 1.0 110.883 -179.696 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 28.2 pt -114.45 140.47 35.11 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.901 0 CA-C-O 121.869 0.842 . . . . 1.0 110.076 179.684 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.511 ' H ' ' HA ' ' A' ' 31' ' ' ASN . 2.2 t -90.82 132.04 36.41 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.599 0 CA-C-N 115.083 -0.962 . . . . 1.0 109.315 -179.666 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 31.9 m120 -59.53 114.66 2.82 Favored 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 120.397 -0.521 . . . . 1.0 110.35 179.329 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 40.6 t -53.49 -19.51 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.626 0 CA-C-O 121.397 0.618 . . . . 1.0 110.448 -179.676 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.5 m -49.42 109.28 0.25 Allowed 'General case' 0 CA--C 1.545 0.769 0 CA-C-N 115.642 -0.708 . . . . 1.0 110.873 179.339 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 7.9 m 61.67 -125.42 0.81 Allowed 'General case' 0 CA--C 1.543 0.699 0 CA-C-N 116.582 -0.281 . . . . 1.0 110.606 -179.18 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 89.0 p -152.28 158.68 43.13 Favored 'General case' 0 N--CA 1.478 0.936 0 CA-C-O 120.97 0.414 . . . . 1.0 110.666 179.919 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 51.5 tp -123.05 133.44 54.32 Favored 'General case' 0 N--CA 1.486 1.345 0 CA-C-O 121.578 0.704 . . . . 1.0 110.212 179.596 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 14.9 p-10 -84.63 143.48 29.22 Favored 'General case' 0 CA--C 1.535 0.394 0 CA-C-N 115.432 -0.804 . . . . 1.0 109.982 179.404 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 45.2 t -96.4 117.54 40.95 Favored 'Isoleucine or valine' 0 N--CA 1.482 1.133 0 N-CA-C 109.424 -0.584 . . . . 1.0 109.424 179.894 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 81.3 mtt85 -84.97 165.63 17.44 Favored 'General case' 0 C--N 1.329 -0.326 0 N-CA-C 109.774 -0.454 . . . . 1.0 109.774 179.675 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 38.0 t -95.85 -18.28 20.48 Favored 'General case' 0 N--CA 1.483 1.184 0 CA-C-N 115.972 -0.558 . . . . 1.0 110.516 179.468 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 32.9 t -153.36 -164.63 1.95 Allowed 'General case' 0 N--CA 1.479 0.986 0 CA-C-N 116.246 -0.434 . . . . 1.0 111.089 -179.806 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -83.72 47.33 1.27 Allowed 'General case' 0 N--CA 1.477 0.919 0 CA-C-O 121.458 0.647 . . . . 1.0 110.234 -179.776 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 53.6 m -157.74 137.1 11.88 Favored 'General case' 0 N--CA 1.476 0.834 0 CA-C-N 115.562 -0.745 . . . . 1.0 110.851 179.748 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.1 t -70.38 -32.09 69.62 Favored 'General case' 0 N--CA 1.47 0.57 0 CA-C-N 115.939 -0.573 . . . . 1.0 110.448 179.701 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . 0.45 ' C ' ' H ' ' A' ' 23' ' ' LYS . 51.1 m -70.81 -2.58 15.31 Favored 'General case' 0 N--CA 1.466 0.359 0 CA-C-N 116.42 -0.354 . . . . 1.0 110.683 -179.78 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . 0.535 ' O ' ' O ' ' A' ' 23' ' ' LYS . 59.8 p -76.71 21.07 0.21 Allowed 'General case' 0 N--CA 1.478 0.965 0 CA-C-O 121.362 0.601 . . . . 1.0 110.563 179.935 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.535 ' O ' ' O ' ' A' ' 22' ' ' SER . 98.2 mttt 48.13 167.25 0.0 OUTLIER 'General case' 0 N--CA 1.488 1.443 0 CA-C-N 115.653 -0.703 . . . . 1.0 111.565 -179.147 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.456 HG12 ' N ' ' A' ' 25' ' ' ILE . 25.9 t -89.56 168.92 1.45 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.496 0 CA-C-O 121.563 0.697 . . . . 1.0 109.56 179.36 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.456 ' N ' HG12 ' A' ' 24' ' ' VAL . 43.5 pt -135.58 -22.64 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 CA-C-N 115.472 -0.785 . . . . 1.0 110.497 179.565 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 171.72 179.87 43.0 Favored Glycine 0 N--CA 1.462 0.419 0 N-CA-C 110.52 -1.032 . . . . 1.0 110.52 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 88.7 p -132.56 133.44 43.72 Favored 'General case' 0 N--CA 1.478 0.933 0 CA-C-O 121.282 0.563 . . . . 1.0 109.873 179.664 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -98.62 174.19 6.55 Favored 'General case' 0 N--CA 1.477 0.903 0 N-CA-C 108.959 -0.756 . . . . 1.0 108.959 -179.468 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . 0.533 ' O ' ' O ' ' A' ' 30' ' ' GLY . 42.0 t -79.16 137.19 37.35 Favored 'General case' 0 CA--C 1.515 -0.367 0 CA-C-N 115.964 -0.562 . . . . 1.0 109.901 -179.189 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.533 ' O ' ' O ' ' A' ' 29' ' ' SER . . . -13.24 -107.45 0.0 OUTLIER Glycine 0 N--CA 1.512 3.715 0 CA-C-O 119.473 -0.626 . . . . 1.0 113.017 179.82 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . 0.511 ' HA ' ' H ' ' A' ' 6' ' ' VAL . 19.5 p-10 -77.73 79.22 4.22 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 117.569 0.684 . . . . 1.0 109.781 177.775 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 45.6 m -84.84 146.24 27.42 Favored 'General case' 0 N--CA 1.494 1.769 0 CA-C-N 115.961 -0.563 . . . . 1.0 109.82 179.293 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 55.8 mtpt -82.62 128.47 34.36 Favored 'General case' 0 N--CA 1.474 0.761 0 CA-C-N 116.035 -0.529 . . . . 1.0 110.116 179.157 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 15.9 m -144.48 127.0 10.72 Favored 'Isoleucine or valine' 0 N--CA 1.481 1.115 0 CA-C-N 116.323 -0.399 . . . . 1.0 110.368 179.361 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 68.6 p -80.81 83.82 6.47 Favored 'General case' 0 N--CA 1.47 0.559 0 CA-C-O 121.289 0.566 . . . . 1.0 109.86 179.485 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.475 HG22 ' N ' ' A' ' 37' ' ' VAL . 81.3 mt -47.23 163.83 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.063 0 CA-C-N 115.641 -0.708 . . . . 1.0 110.54 179.787 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.475 ' N ' HG22 ' A' ' 36' ' ' ILE . 42.7 t -129.25 -94.18 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.483 1.178 0 N-CA-C 110.045 -0.354 . . . . 1.0 110.045 -179.229 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -102.12 -168.12 27.0 Favored Glycine 0 N--CA 1.474 1.227 0 N-CA-C 110.912 -0.875 . . . . 1.0 110.912 -179.568 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 11.0 pt-20 -130.29 140.68 50.65 Favored 'General case' 0 N--CA 1.485 1.275 0 CA-C-N 115.293 -0.453 . . . . 1.0 110.541 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 43.8 tt0 -153.21 114.02 4.09 Favored 'General case' 0 N--CA 1.469 0.521 0 CA-C-N 116.084 -0.507 . . . . 1.0 110.207 -179.845 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 51.22 -116.4 4.54 Favored Glycine 0 CA--C 1.542 1.772 0 N-CA-C 111.634 -0.586 . . . . 1.0 111.634 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -117.41 25.07 10.7 Favored 'General case' 0 N--CA 1.488 1.453 0 C-N-CA 122.401 0.28 . . . . 1.0 110.429 179.493 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 41.4 m-85 -145.64 157.08 44.01 Favored 'General case' 0 N--CA 1.48 1.074 0 CA-C-O 121.232 0.539 . . . . 1.0 110.405 179.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' TYR . . . . . . . . . . . . . 13.8 p90 -141.72 176.18 9.12 Favored 'General case' 0 N--CA 1.482 1.131 0 CA-C-N 115.76 -0.654 . . . . 1.0 110.376 179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 34.3 mtmm -97.06 149.35 22.05 Favored 'General case' 0 N--CA 1.479 0.987 0 CA-C-N 115.786 -0.643 . . . . 1.0 110.327 -179.117 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 26.3 pt -142.95 160.48 18.02 Favored 'Isoleucine or valine' 0 N--CA 1.471 0.624 0 CA-C-O 121.949 0.88 . . . . 1.0 110.119 179.487 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -121.7 92.1 3.66 Favored 'General case' 0 N--CA 1.487 1.385 0 CA-C-N 115.084 -0.962 . . . . 1.0 109.608 -179.68 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 21.8 t80 -136.32 151.86 50.05 Favored 'General case' 0 N--CA 1.479 1.018 0 CA-C-O 121.239 0.542 . . . . 1.0 110.398 179.82 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 46.9 mmtt 53.53 17.55 1.18 Allowed 'General case' 0 N--CA 1.479 1.02 0 CA-C-N 115.763 -0.653 . . . . 1.0 110.619 -179.586 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 72.81 -2.25 33.97 Favored Glycine 0 N--CA 1.467 0.713 0 N-CA-C 110.63 -0.988 . . . . 1.0 110.63 -179.831 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 41.9 t -107.89 172.47 6.81 Favored 'General case' 0 N--CA 1.477 0.905 0 C-N-CA 124.009 0.924 . . . . 1.0 110.489 -179.672 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 25.8 p-80 -106.77 142.26 36.69 Favored 'General case' 0 N--CA 1.482 1.125 0 CA-C-N 115.803 -0.635 . . . . 1.0 110.133 179.882 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -150.83 169.79 30.62 Favored Glycine 0 N--CA 1.472 1.08 0 N-CA-C 111.094 -0.802 . . . . 1.0 111.094 -179.739 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 58.5 m-85 -133.53 145.81 50.47 Favored 'General case' 0 N--CA 1.48 1.04 0 CA-C-O 121.673 0.749 . . . . 1.0 110.33 179.655 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 3.5 m -146.16 147.98 17.63 Favored 'Isoleucine or valine' 0 N--CA 1.48 1.034 0 CA-C-N 115.319 -0.855 . . . . 1.0 109.892 -179.7 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -66.44 147.21 53.62 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 115.204 -0.907 . . . . 1.0 110.477 -179.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -82.4 -25.74 33.45 Favored 'General case' 0 N--CA 1.477 0.879 0 CA-C-N 116.166 -0.47 . . . . 1.0 110.44 179.856 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 4.2 tm-20 -56.68 -34.58 67.54 Favored 'General case' 0 N--CA 1.477 0.899 0 CA-C-O 121.293 0.568 . . . . 1.0 110.738 -179.63 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 26.1 m-85 -78.46 -4.92 50.87 Favored 'General case' 0 N--CA 1.483 1.188 0 CA-C-N 115.629 -0.714 . . . . 1.0 110.1 179.81 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 34.2 mm . . . . . 0 N--CA 1.487 1.393 0 CA-C-O 118.17 -0.919 . . . . 1.0 109.507 180.0 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.45 ' C ' ' H ' ' A' ' 3' ' ' THR . 28.4 ttt . . . . . 0 N--CA 1.499 2.011 0 CA-C-O 121.554 0.692 . . . . 1.0 109.297 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 24.3 pttm -77.44 26.81 0.16 Allowed 'General case' 0 N--CA 1.479 0.978 0 CA-C-N 115.45 -0.795 . . . . 1.0 110.716 -179.913 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . 0.45 ' H ' ' C ' ' A' ' 1' ' ' MET . 62.7 p -131.84 154.74 48.85 Favored 'General case' 0 N--CA 1.469 0.522 0 CA-C-O 121.955 0.883 . . . . 1.0 109.84 -179.649 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -143.11 161.22 27.6 Favored Glycine 0 N--CA 1.461 0.341 0 N-CA-C 110.317 -1.113 . . . . 1.0 110.317 -179.663 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 74.1 mt -109.97 135.86 47.68 Favored 'Isoleucine or valine' 0 N--CA 1.479 1.004 0 CA-C-O 121.691 0.758 . . . . 1.0 109.503 -179.634 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 47.4 t -82.49 131.02 34.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.282 -0.872 . . . . 1.0 109.44 179.575 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 -60.09 109.64 1.02 Allowed 'General case' 0 CA--C 1.538 0.517 0 CA-C-N 115.628 -0.715 . . . . 1.0 110.404 179.751 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 14.7 p -65.79 133.3 31.0 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 CA-C-N 116.028 -0.533 . . . . 1.0 110.234 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 88.0 p -170.51 -55.98 0.02 OUTLIER 'General case' 0 N--CA 1.466 0.335 0 CA-C-O 121.191 0.52 . . . . 1.0 110.138 179.599 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 68.5 m -148.79 -110.98 0.07 Allowed 'General case' 0 N--CA 1.477 0.891 0 CA-C-N 115.863 -0.608 . . . . 1.0 110.718 -179.471 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 39.7 t -135.29 142.95 45.97 Favored 'General case' 0 N--CA 1.473 0.713 0 CA-C-O 121.9 0.857 . . . . 1.0 110.51 -179.55 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 4.5 mm? -101.39 141.66 33.93 Favored 'General case' 0 N--CA 1.474 0.742 0 CA-C-O 122.21 1.005 . . . . 1.0 110.029 -179.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 79.8 m-20 -93.13 123.17 36.21 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 114.708 -1.133 . . . . 1.0 109.523 -179.672 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 64.3 t -96.67 114.97 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.499 0 CA-C-N 115.603 -0.726 . . . . 1.0 109.089 -179.808 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -87.65 173.19 9.18 Favored 'General case' 0 CA--C 1.532 0.26 0 CA-C-O 122.07 0.938 . . . . 1.0 109.585 179.095 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 88.8 p -97.52 -19.25 18.5 Favored 'General case' 0 N--CA 1.478 0.969 0 CA-C-N 114.974 -1.012 . . . . 1.0 110.292 -179.811 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 88.9 p -149.41 -163.58 1.82 Allowed 'General case' 0 N--CA 1.475 0.823 0 CA-C-O 121.47 0.653 . . . . 1.0 110.824 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -101.3 53.61 0.83 Allowed 'General case' 0 N--CA 1.484 1.227 0 CA-C-N 115.58 -0.736 . . . . 1.0 110.165 -179.79 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 46.4 t -138.89 137.34 36.42 Favored 'General case' 0 N--CA 1.479 1.023 0 CA-C-O 121.55 0.691 . . . . 1.0 110.744 179.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.2 t -67.42 -27.14 66.82 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-N 115.391 -0.822 . . . . 1.0 110.702 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 50.0 m -77.41 -7.51 56.24 Favored 'General case' 0 N--CA 1.469 0.508 0 CA-C-N 115.656 -0.702 . . . . 1.0 110.19 -179.854 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 34.8 t -65.77 124.89 23.65 Favored 'General case' 0 CA--C 1.534 0.332 0 CA-C-O 120.987 0.422 . . . . 1.0 110.341 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 97.7 mttt -67.88 166.57 15.3 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.89 -0.595 . . . . 1.0 110.208 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 19.5 t -76.9 114.38 17.19 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.658 0 CA-C-O 121.662 0.744 . . . . 1.0 110.023 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 5.4 tt -96.88 -17.35 6.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.195 -0.911 . . . . 1.0 109.846 179.763 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -166.81 -162.12 17.62 Favored Glycine 0 N--CA 1.463 0.456 0 N-CA-C 110.721 -0.952 . . . . 1.0 110.721 -179.537 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 50.4 m -158.71 132.51 7.63 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 121.278 0.561 . . . . 1.0 109.936 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 5.2 tp -110.31 149.06 30.74 Favored 'General case' 0 N--CA 1.474 0.768 0 CA-C-O 121.567 0.699 . . . . 1.0 109.907 179.614 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 45.7 p -91.15 159.89 15.85 Favored 'General case' 0 N--CA 1.469 0.483 0 CA-C-N 115.327 -0.851 . . . . 1.0 109.604 179.608 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -78.75 152.17 36.74 Favored Glycine 0 CA--C 1.529 0.934 0 N-CA-C 110.443 -1.063 . . . . 1.0 110.443 179.526 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 70.14 19.08 6.84 Favored 'General case' 0 N--CA 1.474 0.772 0 CA-C-O 120.887 0.375 . . . . 1.0 110.449 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 32.0 m -88.67 139.75 30.15 Favored 'General case' 0 N--CA 1.477 0.919 0 CA-C-N 116.119 -0.491 . . . . 1.0 109.878 -179.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 63.3 tttm -86.3 139.25 31.17 Favored 'General case' 0 N--CA 1.465 0.308 0 CA-C-N 115.893 -0.594 . . . . 1.0 109.963 179.547 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 14.4 m -142.99 124.46 11.77 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.879 0 CA-C-N 115.687 -0.688 . . . . 1.0 110.2 179.854 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 62.1 p -79.89 87.76 5.32 Favored 'General case' 0 N--CA 1.468 0.465 0 CA-C-O 121.355 0.598 . . . . 1.0 109.709 179.636 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.577 HG22 ' N ' ' A' ' 37' ' ' VAL . 63.0 mt -55.81 169.43 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.469 0.504 0 CA-C-O 121.66 0.743 . . . . 1.0 109.498 179.844 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.577 ' N ' HG22 ' A' ' 36' ' ' ILE . 0.2 OUTLIER -131.91 -96.0 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.48 1.055 0 CA-C-N 115.348 -0.842 . . . . 1.0 109.885 -179.156 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . 0.408 ' H ' HG23 ' A' ' 37' ' ' VAL . . . -99.4 -170.07 30.46 Favored Glycine 0 N--CA 1.465 0.62 0 N-CA-C 110.631 -0.987 . . . . 1.0 110.631 -179.566 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 13.5 mp0 -128.85 132.95 47.81 Favored 'General case' 0 N--CA 1.478 0.943 0 CA-C-N 114.651 -0.775 . . . . 1.0 110.224 -179.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.41 ' O ' ' O ' ' A' ' 43' ' ' PHE . 44.3 tp10 -150.32 120.68 7.35 Favored 'General case' 0 N--CA 1.471 0.609 0 CA-C-N 115.497 -0.774 . . . . 1.0 110.041 179.527 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 47.08 -122.65 7.17 Favored Glycine 0 CA--C 1.543 1.805 0 N-CA-C 111.509 -0.636 . . . . 1.0 111.509 179.779 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -114.03 22.32 14.0 Favored 'General case' 0 N--CA 1.481 1.106 0 C-N-CA 122.546 0.338 . . . . 1.0 110.251 178.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.41 ' O ' ' O ' ' A' ' 40' ' ' GLU . 77.7 m-85 -149.13 157.42 43.37 Favored 'General case' 0 N--CA 1.484 1.264 0 CA-C-O 121.6 0.714 . . . . 1.0 110.74 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' TYR . . . . . 0.458 ' N ' ' CD1' ' A' ' 44' ' ' TYR . 10.1 p90 -140.39 172.99 11.95 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-O 122.077 0.942 . . . . 1.0 109.939 -179.712 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -97.52 156.56 16.44 Favored 'General case' 0 N--CA 1.474 0.751 0 CA-C-N 114.905 -1.043 . . . . 1.0 109.97 -179.434 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 32.2 pt -147.41 161.7 7.9 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 CA-C-O 122.215 1.007 . . . . 1.0 109.884 -179.941 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 18.6 mp0 -121.54 87.36 2.74 Favored 'General case' 0 N--CA 1.481 1.088 0 CA-C-N 114.748 -1.115 . . . . 1.0 109.844 -179.768 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 0.2 OUTLIER -138.68 158.86 43.45 Favored 'General case' 0 N--CA 1.471 0.605 0 CA-C-N 115.576 -0.738 . . . . 1.0 110.019 179.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . 0.404 ' C ' ' H ' ' A' ' 51' ' ' SER . 48.7 mtmt 52.92 18.47 1.08 Allowed 'General case' 0 CA--C 1.541 0.611 0 CA-C-N 115.626 -0.715 . . . . 1.0 110.811 179.801 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 67.97 -1.52 8.11 Favored Glycine 0 CA--C 1.532 1.1 0 N-CA-C 110.429 -1.068 . . . . 1.0 110.429 -179.181 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . 0.404 ' H ' ' C ' ' A' ' 49' ' ' LYS . 97.6 p -116.12 171.96 7.47 Favored 'General case' 0 N--CA 1.484 1.265 0 CA-C-O 121.994 0.902 . . . . 1.0 110.317 -179.859 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 96.3 m-70 -101.75 146.12 28.2 Favored 'General case' 0 N--CA 1.478 0.932 0 CA-C-N 115.006 -0.997 . . . . 1.0 110.09 -179.828 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -152.9 168.32 31.78 Favored Glycine 0 CA--C 1.531 1.041 0 N-CA-C 110.673 -0.971 . . . . 1.0 110.673 -179.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 66.2 m-85 -134.61 150.16 50.66 Favored 'General case' 0 N--CA 1.486 1.37 0 CA-C-O 121.018 0.437 . . . . 1.0 110.608 179.601 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 7.5 p -155.19 155.84 5.45 Favored 'Isoleucine or valine' 0 N--CA 1.473 0.707 0 CA-C-N 115.967 -0.561 . . . . 1.0 110.348 -179.808 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -63.69 130.38 44.02 Favored 'General case' 0 CA--C 1.545 0.78 0 CA-C-O 122.173 0.987 . . . . 1.0 109.861 179.049 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -88.46 -35.1 17.23 Favored 'General case' 0 N--CA 1.483 1.191 0 CA-C-N 114.86 -1.064 . . . . 1.0 110.177 -179.984 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 14.0 pt-20 -58.33 -30.39 66.66 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 121.656 0.741 . . . . 1.0 110.371 -179.674 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 1.2 t80 -52.52 -19.8 2.51 Favored 'General case' 0 CA--C 1.537 0.465 0 CA-C-N 115.362 -0.835 . . . . 1.0 110.792 -179.806 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 69.8 mt . . . . . 0 C--O 1.221 -0.436 0 CA-C-O 118.0 -1.0 . . . . 1.0 108.761 -179.834 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 28.0 ttt . . . . . 0 N--CA 1.492 1.63 0 N-CA-C 109.218 -0.66 . . . . 1.0 109.218 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 74.6 mmtt 51.76 92.09 0.02 OUTLIER 'General case' 0 N--CA 1.471 0.593 0 CA-C-O 121.267 0.556 . . . . 1.0 110.753 179.466 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' THR . . . . . . . . . . . . . 69.8 p -131.55 158.59 40.55 Favored 'General case' 0 N--CA 1.472 0.659 0 CA-C-O 121.825 0.821 . . . . 1.0 110.136 -179.48 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -145.57 163.94 28.15 Favored Glycine 0 N--CA 1.468 0.812 0 N-CA-C 110.495 -1.042 . . . . 1.0 110.495 -179.556 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ILE . . . . . . . . . . . . . 3.7 mp -110.13 129.68 64.69 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.88 0 CA-C-O 121.287 0.565 . . . . 1.0 109.97 -179.697 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 55.9 t -73.42 133.34 31.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 115.648 -0.706 . . . . 1.0 109.491 179.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ASN . . . . . 0.571 HD22 ' N ' ' A' ' 7' ' ' ASN . 1.0 OUTLIER -49.2 96.83 0.01 OUTLIER 'General case' 0 N--CA 1.473 0.707 0 CA-C-N 115.768 -0.651 . . . . 1.0 110.694 179.604 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 10.5 t -63.37 -6.55 2.26 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.539 0 CA-C-N 115.749 -0.66 . . . . 1.0 110.008 -179.221 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' SER . . . . . . . . . . . . . 50.0 m -52.71 -49.87 64.5 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 116.087 -0.506 . . . . 1.0 110.69 -179.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' SER . . . . . . . . . . . . . 93.0 p -149.96 169.37 21.33 Favored 'General case' 0 N--CA 1.472 0.652 0 CA-C-O 121.461 0.648 . . . . 1.0 110.524 179.385 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 89.1 p -78.93 150.34 32.11 Favored 'General case' 0 N--CA 1.474 0.729 0 CA-C-N 115.523 -0.762 . . . . 1.0 109.707 -179.331 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.9 mp -118.96 145.48 45.76 Favored 'General case' 0 N--CA 1.49 1.543 0 CA-C-O 122.287 1.042 . . . . 1.0 110.08 -179.426 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ASN . . . . . . . . . . . . . 73.8 m-80 -96.49 146.62 24.64 Favored 'General case' 0 N--CA 1.469 0.518 0 CA-C-N 114.701 -1.136 . . . . 1.0 110.003 179.693 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 22.4 t -94.57 104.78 16.17 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.936 0 CA-C-N 115.529 -0.76 . . . . 1.0 109.684 -179.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . . . . . . . . . 88.8 mtm180 -79.41 135.64 36.74 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 121.341 0.591 . . . . 1.0 109.761 179.821 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' SER . . . . . . . . . . . . . 38.9 t -63.43 -27.17 69.1 Favored 'General case' 0 N--CA 1.466 0.373 0 CA-C-N 115.581 -0.736 . . . . 1.0 110.442 -179.989 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 47.2 t -144.85 -176.66 5.16 Favored 'General case' 0 N--CA 1.479 0.998 0 CA-C-N 115.97 -0.559 . . . . 1.0 110.927 179.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.425 ' HB2' ' CD1' ' A' ' 43' ' ' PHE . . . -81.83 57.17 3.33 Favored 'General case' 0 N--CA 1.476 0.843 0 CA-C-N 115.774 -0.648 . . . . 1.0 110.235 -179.898 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 47.3 t -156.92 137.67 13.29 Favored 'General case' 0 N--CA 1.472 0.64 0 CA-C-O 121.203 0.525 . . . . 1.0 110.686 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 4.8 t -67.12 -32.97 74.46 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 115.756 -0.656 . . . . 1.0 110.629 179.62 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' SER . . . . . . . . . . . . . 89.4 p -69.35 -4.31 17.72 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 116.029 -0.532 . . . . 1.0 110.303 -179.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' SER . . . . . . . . . . . . . 90.2 p -60.47 -172.02 0.02 OUTLIER 'General case' 0 N--CA 1.47 0.539 0 CA-C-O 120.995 0.426 . . . . 1.0 110.25 179.53 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 5.5 mptt -116.57 148.16 41.15 Favored 'General case' 0 N--CA 1.484 1.256 0 CA-C-O 121.234 0.54 . . . . 1.0 110.749 -179.826 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 20.1 t -82.16 115.46 24.73 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.3 0 CA-C-N 115.778 -0.646 . . . . 1.0 109.537 179.79 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . . . . . . . . . 34.2 pt -96.43 -16.79 7.09 Favored 'Isoleucine or valine' 0 N--CA 1.477 0.896 0 CA-C-N 115.706 -0.679 . . . . 1.0 109.891 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 179.53 165.77 34.17 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.71 -0.956 . . . . 1.0 110.71 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' SER . . . . . . . . . . . . . 50.7 m -117.54 135.55 53.87 Favored 'General case' 0 N--CA 1.484 1.268 0 CA-C-O 121.289 0.566 . . . . 1.0 109.918 179.61 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 3.5 tp -100.04 159.02 15.42 Favored 'General case' 0 N--CA 1.477 0.915 0 CA-C-O 121.875 0.845 . . . . 1.0 109.141 -179.414 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' SER . . . . . . . . . . . . . 49.1 m -101.48 145.95 28.29 Favored 'General case' 0 N--CA 1.473 0.677 0 CA-C-N 115.208 -0.906 . . . . 1.0 110.106 -179.132 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -73.85 151.86 44.93 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.353 -1.099 . . . . 1.0 110.353 179.285 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 74.78 13.77 3.43 Favored 'General case' 0 N--CA 1.482 1.159 0 CA-C-O 120.525 0.202 . . . . 1.0 110.518 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' THR . . . . . . . . . . . . . 89.0 m -83.05 137.15 34.23 Favored 'General case' 0 N--CA 1.477 0.912 0 CA-C-O 121.12 0.486 . . . . 1.0 110.32 -179.911 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' LYS . . . . . . . . . . . . . 67.7 mttm -92.81 144.04 25.68 Favored 'General case' 0 N--CA 1.473 0.721 0 CA-C-N 115.806 -0.634 . . . . 1.0 109.989 179.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' VAL . . . . . . . . . . . . . 7.4 p -154.77 139.81 10.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.748 -0.66 . . . . 1.0 109.91 179.872 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' THR . . . . . . . . . . . . . 68.9 p -83.4 83.36 7.9 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.877 -0.601 . . . . 1.0 109.637 179.217 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.539 HG22 ' N ' ' A' ' 37' ' ' VAL . 74.5 mt -48.49 167.0 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 CA-C-N 115.818 -0.628 . . . . 1.0 110.066 179.801 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.539 ' N ' HG22 ' A' ' 36' ' ' ILE . 40.8 t -128.07 -91.86 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.479 0.99 0 CA-C-N 116.22 -0.445 . . . . 1.0 110.087 -179.61 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' GLY . . . . . . . . . . . . . . . -118.03 -155.54 10.06 Favored Glycine 0 N--CA 1.474 1.215 0 N-CA-C 110.863 -0.895 . . . . 1.0 110.863 -179.471 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' GLU . . . . . . . . . . . . . 37.1 tt0 -142.19 144.71 33.54 Favored 'General case' 0 N--CA 1.478 0.971 0 CA-C-N 115.059 -0.57 . . . . 1.0 110.281 -179.933 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 38.3 tp10 -147.36 122.39 10.09 Favored 'General case' 0 N--CA 1.473 0.713 0 CA-C-N 115.74 -0.664 . . . . 1.0 109.986 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 54.71 -129.43 44.63 Favored Glycine 0 CA--C 1.53 0.995 0 N-CA-C 111.398 -0.681 . . . . 1.0 111.398 179.595 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ALA . . . . . . . . . . . . . . . -100.18 33.92 2.5 Favored 'General case' 0 N--CA 1.474 0.734 0 N-CA-C 110.068 -0.345 . . . . 1.0 110.068 179.406 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.425 ' CD1' ' HB2' ' A' ' 18' ' ' ALA . 26.9 p90 -159.04 168.96 25.35 Favored 'General case' 0 N--CA 1.468 0.43 0 CA-C-O 122.152 0.977 . . . . 1.0 110.083 179.321 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' TYR . . . . . 0.483 ' N ' ' CD1' ' A' ' 44' ' ' TYR . 3.3 p90 -129.63 163.92 25.01 Favored 'General case' 0 N--CA 1.481 1.107 0 CA-C-N 114.79 -1.095 . . . . 1.0 110.448 179.779 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 62.8 tttp -86.88 142.31 28.13 Favored 'General case' 0 N--CA 1.473 0.717 0 CA-C-N 115.341 -0.845 . . . . 1.0 109.771 -179.049 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ILE . . . . . . . . . . . . . 19.7 pt -141.32 156.51 21.54 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.467 0 CA-C-O 122.083 0.944 . . . . 1.0 110.22 179.727 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 5.6 pt-20 -124.88 94.08 4.08 Favored 'General case' 0 N--CA 1.48 1.053 0 CA-C-N 114.844 -1.071 . . . . 1.0 109.971 179.99 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' TYR . . . . . . . . . . . . . 22.8 t80 -128.47 147.5 50.67 Favored 'General case' 0 N--CA 1.476 0.875 0 CA-C-N 115.974 -0.557 . . . . 1.0 110.058 179.517 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' LYS . . . . . . . . . . . . . 46.4 mtpt 54.11 17.56 1.47 Allowed 'General case' 0 CA--C 1.547 0.832 0 CA-C-N 115.908 -0.587 . . . . 1.0 110.497 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 72.18 1.78 51.01 Favored Glycine 0 N--CA 1.468 0.805 0 N-CA-C 110.6 -1.0 . . . . 1.0 110.6 -179.489 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' SER . . . . . . . . . . . . . 47.4 t -104.99 171.13 7.48 Favored 'General case' 0 N--CA 1.479 0.996 0 C-N-CA 123.517 0.727 . . . . 1.0 110.2 179.878 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' HIS . . . . . . . . . . . . . 49.4 p-80 -103.67 138.5 40.23 Favored 'General case' 0 N--CA 1.482 1.137 0 CA-C-N 115.618 -0.719 . . . . 1.0 110.484 179.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . -150.75 166.76 30.36 Favored Glycine 0 N--CA 1.472 1.058 0 N-CA-C 110.782 -0.927 . . . . 1.0 110.782 -179.885 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' TYR . . . . . . . . . . . . . 33.4 m-85 -135.5 152.16 51.06 Favored 'General case' 0 N--CA 1.479 1.008 0 CA-C-O 121.539 0.685 . . . . 1.0 110.194 179.456 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -150.39 151.16 12.91 Favored 'Isoleucine or valine' 0 N--CA 1.478 0.953 0 CA-C-N 115.455 -0.793 . . . . 1.0 109.768 -179.089 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -62.56 125.64 24.61 Favored 'General case' 0 CA--C 1.54 0.561 0 CA-C-N 115.222 -0.899 . . . . 1.0 110.2 179.405 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' LYS . . . . . . . . . . . . . 7.7 pttm -78.55 -31.18 47.32 Favored 'General case' 0 N--CA 1.473 0.681 0 CA-C-N 115.259 -0.882 . . . . 1.0 110.183 -179.838 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' GLU . . . . . . . . . . . . . 79.7 tt0 -55.57 -35.45 65.76 Favored 'General case' 0 N--CA 1.468 0.433 0 CA-C-N 116.061 -0.518 . . . . 1.0 110.401 -179.14 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' TYR . . . . . . . . . . . . . 10.7 m-85 -60.47 -42.01 95.36 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 115.866 -0.606 . . . . 1.0 109.868 179.486 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 65.6 mt . . . . . 0 N--CA 1.476 0.831 0 CA-C-O 118.199 -0.905 . . . . 1.0 109.268 -179.359 . . . . . . . . 0 0 . 1 stop_ save_